

10/598,302

=> d his

(FILE 'HOME' ENTERED AT 12:28:07 ON 14 SEP 2010)

FILE 'REGISTRY' ENTERED AT 12:28:24 ON 14 SEP 2010

L1 STRUCTURE UPLOADED
L2 50 S L1
L3 16879 S L1 SSS FUL
L4 STRUCTURE UPLOADED
L5 2459 S L4 FUL SUB=L3
L6 STRUCTURE UPLOADED
L7 116 S L6 FUL SUB=L3
L8 STRUCTURE UPLOADED
L9 3677 S L8 FUL SUB=L3

FILE 'CAPLUS' ENTERED AT 12:41:26 ON 14 SEP 2010

FILE 'REGISTRY' ENTERED AT 12:42:31 ON 14 SEP 2010

L10 STRUCTURE UPLOADED
L11 2352 S L10 FUL SUB=L3

FILE 'CAPLUS' ENTERED AT 12:43:31 ON 14 SEP 2010

L12 20 S L11
L13 18 S L12 NOT (2010/SO OR 2009/SO OR 2008/SO OR 2007/SO)

FILE 'REGISTRY' ENTERED AT 12:51:59 ON 14 SEP 2010

L14 1574 S L11 AND CAPLUS/LC
L15 778 S L11 NOT L14
L16 68 S L7 AND CAPLUS/LC
L17 48 S L7 NOT L16

FILE 'CAPLUS' ENTERED AT 13:01:37 ON 14 SEP 2010

L18 2 S L7

FILE 'REGISTRY' ENTERED AT 13:02:51 ON 14 SEP 2010

L19 1730 S L5 AND CAPLUS/LC
L20 729 S L5 NOT L19

FILE 'CAPLUS' ENTERED AT 13:08:42 ON 14 SEP 2010

L21 151 S L5
L22 ANALYZE L21 1- RN HIT : 1730 TERMS

FILE 'REGISTRY' ENTERED AT 13:09:19 ON 14 SEP 2010

L23 1 S 110857-22-2/RN
L24 1 S 90047-53-3/RN
L25 2457 S L5 NOT (L23 OR L24)

FILE 'CAPLUS' ENTERED AT 13:11:19 ON 14 SEP 2010


L26 112 S L25
L27 107 S L26 NOT (2010/SO OR 2009/SO OR 2008/SO OR 2007/SO OR 2006/SO)

=> d l4

L4 HAS NO ANSWERS

L4 STR

10/598,302



1

G1 O,S,N,[@1]

Structure attributes must be viewed using STN Express query preparation.

=> d ibib abs hitstr total

L27 ANSWER 1 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:846114 CAPLUS

DOCUMENT NUMBER: 151:92851

TITLE: Method using lifespan-altering compounds for altering the lifespan of eukaryotic organisms, and screening for such compounds

INVENTOR(S): Goldfarb, David Scott

PATENT ASSIGNEE(S): University of Rochester, USA

SOURCE: U.S. Pat. Appl. Publ., 57pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 20

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090163545	A1	20090625	US 2008-341615	20081222
US 20090163545	A1	20090625	US 2008-341615	20081222
AU 2008345225	A1	20090709	AU 2008-345225	20081222
CA 2709784	A1	20090709	CA 2008-2709784	20081222
EP 2219646	A2	20100825	EP 2008-867410	20081222

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS

PRIORITY APPLN. INFO.:

US 2008-23801P P 20080125

US 2007-16362P P 20071221

US 2008-341615 20081222

WO 2008-US88016 W 20081222

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


AB The invention discloses a method for altering the lifespan of a eukaryotic organism. The method comprises the steps of providing a lifespan-altering compound, and administering an effective amount of the compound to a eukaryotic organism, such that the lifespan of the organism is altered. In one embodiment, the compound is identified using the DeaD assay. [This abstract record is one of 20 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 75428-30-7

RL: PAC (Pharmacological activity); BIOL (Biological study)
(method using lifespan-altering compds. for altering lifespan of eukaryotic organisms, and screening for such compds.)

RN 75428-30-7 CAPLUS

CN 2H-3-Benzazepin-2-one, 1,3,4,5-tetrahydro-7,8,9-trimethoxy-3-methyl- (CA INDEX NAME)



L27 ANSWER 2 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:798386 CAPLUS
 DOCUMENT NUMBER: 151:124006
 TITLE: Preparation of oxadiazole derivatives active on
 sphingosine-1-phosphate (S1P)
 INVENTOR(S): Demont, Emmanuel Hubert; Heer, Jag Paul; Heightman,
 Thomas Daniel; Hurst, David Nigel; Johnson,
 Christopher Norbert; Skidmore, John; Wall, Ian David;
 Witherington, Jason
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl., 127pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009080725	A1	20090702	WO 2008-EP67965	20081219
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2008339988	A1	20090702	AU 2008-339988	20081219
CA 2710130	A1	20090702	CA 2008-2710130	20081219
AR 69916	A1	20100303	AR 2008-105590	20081219
EP 2222669	A1	20100901	EP 2008-864021	20081219
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS			
US 20100174065	A1	20100708	US 2009-360886	20090128
PRIORITY APPLN. INFO.:			GB 2007-25120	A 20071221
			GB 2008-21918	A 20081201
			WO 2008-EP67965	W 20081219

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 151:124006

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I [A = Ph, 5-6 membered heteroaryl; R1 is up to 2 substituents selected from halo, alkoxy, fluoroalkyl, etc.; R2 = H, halo, alkyl; B = II-IV; R3 = H or (CH₂)₁₋₄CO₂H; R4 = H or alkyl optionally interrupted by oxygen], useful in the treatment of various disorders, in particular lupus erythematosus, were prepared E.g., a multi-step synthesis

of V.HCl, starting from 7-amino-2,3,4,5-tetrahydro-1H-2-benzazepin-1-one, was given. Exemplified compound I were tested in S1P1 GTPγS assay (data given). Pharmaceutical compns. containing compound I are also disclosed.


IT 873446-59-4, tert-Butyl 6-hydroxy-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of oxadiazole derivs. active on sphingosine-1-phosphate (S1P))

RN 873446-59-4 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-6-hydroxy-, 1,1-dimethylethyl ester (CA INDEX NAME)




IT 864262-40-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of oxadiazole derivs. active on sphingosine-1-phosphate (S1P))

RN 864262-40-8 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-6-[(trifluoromethyl)sulfonyl]oxy-, 1,1-dimethylethyl ester (CA INDEX NAME)



REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 3 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:292055 CAPLUS

DOCUMENT NUMBER: 150:329638

TITLE: 1,2,4,5-Tetrahydro-3H-benzazepine-amide derivatives as HCN channel blockers and their preparation, pharmaceutical compositions and use in the treatment of diseases

INVENTOR(S): Peglione, Jean-Louis; Goument, Bertrand; Dessinges, Aimee; Caignard, Pascal; Vilaine, Jean-Paul; Thollon, Catherine; Villeneuve, Nicole; Chimenti, Stefano

PATENT ASSIGNEE(S): Les Laboratoires Servier, Fr.

SOURCE: U.S. Pat. Appl. Publ., 30pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090069296	A1	20090312	US 2008-283110	20080909
FR 2920773	A1	20090313	FR 2007-6346	20070911
FR 2920773	B1	20091023		
SG 151172	A1	20090430	SG 2008-6160	20080820
PH 1200800294	A	20100301	PH 2008-1200800294	20080820
IN 2008DE01992	A	20090424	IN 2008-DE1992	20080822
AU 2008207585	A1	20090326	AU 2008-207585	20080828
MX 2008011164	A	20090310	MX 2008-11164	20080901
CA 2639349	A1	20090311	CA 2008-2639349	20080902
JP 2009108032	A	20090521	JP 2008-227956	20080905
AR 68386	A1	20091111	AR 2008-103906	20080909
KR 2009027164	A	20090316	KR 2008-89213	20080910
NZ 571143	A	20100430	NZ 2008-571143	20080910
CN 101386594	A	20090318	CN 2008-10213550	20080911
EP 2036892	A1	20090318	EP 2008-290851	20080911
EP 2036892	B1	20100310		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS				
BR 2008004091	A2	20090505	BR 2008-4091	20080911
WO 2009066041	A2	20090528	WO 2008-FR1268	20080911
WO 2009066041	A3	20091217		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AT 460401	T	20100315	AT 2008-290851	20080911
PT 2036892	E	20100510	PT 2008-290851	20080911
ES 2342511	T3	20100707	ES 2008-290851	20080911

PRIORITY APPLN. INFO.: FR 2007-6346 A 20070911
 ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 150:329638
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The invention relates to compds. of formula I and their racemic forms, optical isomers, addition salts of pharmaceutically acceptable acids. The invention also relates to medicinal products containing the same, which are hyperpolarization-activated cyclic nucleotide-gated (HCN) blockers and useful in treating various pathologies. Compds. of formula I wherein R1 is H, C3-7 cycloalkyl, benzyl and (un)substituted (un)branched (un)saturated C1-6 alkyl; R2-R5 are independently H, OH, Me, -OSO2R10, -OCOR10 and (un)substituted (un)branched (un)saturated C1-6 alkoxy; R2R3 or R3R4 or R4R5 may taken together to form -O(CH2)1-2O-, -OCH=CHO- and -OCH=CH-; R6-R9 are independently H and (un)branched (un)saturated C1-6 alkoxy; R6R7, or R7R8 or R8R9 may together to form -O(CH2)1-2O-; R10 is (un)branched C1-C6 alkoxy, NH2 and derivs., and (un)substituted (un)branched C1-6 alkyl; A is X0-1; X is O, NH and CH2; B is (CH2)1-2; D is (CH2)0-1; and their racemic forms, optical isomers, addition salts of pharmaceutically acceptable acids thereof, are claimed. Example compound II•fumarate was prepared by following a given procedure. All the invention compds. were evaluated for their HCN channel blocking activity. From the assay, it was determined that II exhibited an IC50 value of 0.4 μ M.

IT 1132074-27-1P 1132074-30-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of tetrahydrobenzazepine-amide derivs. as HCN channel blockers useful in the treatment of diseases)

RN 1132074-27-1 CAPLUS

CN 1-Propanone, 3-[[[(7R)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl)methyl]methylamino]-1-(1,2,4,5-tetrahydro-6,7,8-trimethoxy-3H-3-benzazepin-3-yl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 1132074-30-6 CAPLUS


CN 1-Propanone, 3-[[[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl)methyl]methylamino]-1-(1,2,4,5-tetrahydro-6,7,8-trimethoxy-3H-3-benzazepin-3-yl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

IT 1132079-27-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (starting material; preparation of tetrahydrobenzazepine-amide derivs. as
 HCN channel blockers useful in the treatment of diseases)
 RN 1132079-27-6 CAPLUS
 CN 2-Propen-1-one, 1-(1,2,4,5-tetrahydro-6,7,8-trimethoxy-3H-3-benzazepin-3-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)

L27 ANSWER 4 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:529900 CAPLUS

DOCUMENT NUMBER: 148:538288

TITLE: Preparation of fused bicyclic derivatives of
2,4-diaminopyrimidine as ALK and c-Met kinase
inhibitorsINVENTOR(S): Ahmed, Gulzar; Bohnstedt, Adolph; Breslin, Henry
Joseph; Burke, Jason; Curry, Matthew A.; Diebold,
James L.; Dorsey, Bruce; Dugan, Benjamin J.; Feng,
Daming; Gingrich, Diane E.; Guo, Tao; Ho, Koc-Kan;
Learn, Keith S.; Lisko, Joseph G.; Liu, Rong-Qiang;
Mesaros, Eugen F.; Milkiewicz, Karen; Ott, Gregory R.;
Parrish, Jonathan; Theroff, Jay P.; Thieu, Tho V.;
Tripathy, Rabindranath; Underiner, Theodore L.;
Wagner, Jason C.; Weinberg, Linda; Wells, Gregory J.;
You, Ming; Zificsak, Craig A.PATENT ASSIGNEE(S): Cephalon, Inc., USA; Pharmacoepia Drug Discovery, Inc.
SOURCE: PCT Int. Appl., 1297 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008051547	A1	20080502	WO 2007-US22496	20071023
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2007309427	A1	20080502	AU 2007-309427	20071023
CA 2669111	A1	20080502	CA 2007-2669111	20071023
AR 63527	A1	20090128	AR 2007-104687	20071023
JP 2010507665	T	20100311	JP 2009-534629	20071023
EP 2222647	A1	20100901	EP 2007-861484	20071023
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR				
US 20090221555	A1	20090903	US 2009-162851	20090113
MX 2009004426	A	20090812	MX 2009-4426	20090423
CN 101535276	A	20090916	CN 2007-80039464	20090423
PRIORITY APPLN. INFO.:			US 2006-853562P	P 20061023
			WO 2007-US22496	W 20071023

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 148:538288

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I and II [R1 = H, halo, NO₂, OH and derivs., aryl, alkyl, etc.; R2 = (un)substituted alk(en/yn)yl, (hetero)aryl, R3-R5 = independently H, CO₂H and derivs., NH₂ and derivs., OCHF₂, etc.; A1-A5 = independently (CH₂)₁₋₂ and derivs., CO, NH and derivs., S, SO, SO₂, O, with provisos; with the exception of specified compds.; and their pharmaceutically acceptable salts] were prepared as ALK and c-Met kinase inhibitors for treating proliferative disorders. Thus, nitration of 1,3,4,5-tetrahydrobenzo[b]azepin-2-one with HNO₃/H₂SO₄, alkylation with Me iodide, reduction of the nitro intermediate and amination of 2-[(2,5-dichloropyrimidin-4-yl)amino]-N-methylbenzamide gave benzazepinylaminopyrimidine III. III inhibited ALK and C-Met kinases with IC₅₀ < 0.1 μM.

IT 1022956-90-6P, 2-[[5-Chloro-2-[(3-ethyl-7-methoxy-2,3,4,5-tetrahydro-1H-benzo[d]azepin-6-yl)amino]pyrimidin-4-yl]amino]-N-methylbenzenesulfonamide 1022956-92-8P, 2-[[2-[(9-Amino-3-ethyl-8-methoxy-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)amino]-5-chloropyrimidin-4-yl]amino]-N-methylbenzamide 1022962-21-5P, 2-[[5-Chloro-2-[(1,3-diethyl-6-methoxy-2-oxo-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)amino]pyrimidin-4-yl]amino]-N-methylbenzamide 1022962-35-1P, 2-[[5-Chloro-2-[(3-ethyl-9-methoxy-2,3,4,5-tetrahydro-1H-benzo[d]azepin-6-yl)amino]pyrimidin-4-yl]amino]-N-methylbenzamide 1022962-47-5P, N-[(1R,2R)-2-[[5-Chloro-2-[(3-ethyl-9-methoxy-2,3,4,5-tetrahydro-1H-benzo[d]azepin-6-yl)amino]pyrimidin-4-yl]amino]cyclohexyl]methanesulfonamide 1022965-83-8P, 1022965-91-8P, N-[2-[[5-Chloro-2-[(3-ethyl-6-methoxy-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)amino]pyrimidin-4-yl]amino]phenyl]methanesulfonamide 1022965-94-1P, 2-[[5-Chloro-2-[(3-ethyl-6-methoxy-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)amino]pyrimidin-4-yl]amino]-N-methylbenzamide 1022966-39-7P, 1022966-48-8P, rel-(1S,2S,3R,4R)-3-[[5-Chloro-2-[[7-methoxy-3-(2-methoxyethyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-6-yl]amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide 1022966-52-4P, 5-Chloro-N-[7-methoxy-3-(2-methoxyethyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-6-yl]-N'-[2-methoxy-4-(morpholin-4-yl)phenyl]pyrimidine-2,4-diamine 1022967-59-4P, 9-[[5-Chloro-4-[[2-methoxy-4-(morpholin-4-yl)phenyl]amino]pyrimidin-2-yl]amino]-3-ethyl-8-methoxy-1,3,4,5-tetrahydrobenzo[d]azepin-2-one 1022967-63-0P, 2-[[5-Chloro-2-[(3-ethyl-7-methoxy-4-oxo-2,3,4,5-tetrahydro-1H-benzo[d]azepin-6-yl)amino]pyrimidin-4-yl]amino]-N-ethylbenzamide


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of fused bicyclic derivs. of 2,4-diaminopyrimidine as ALK and c-Met kinase inhibitors)

RN 1022956-90-6 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[(3-ethyl-2,3,4,5-tetrahydro-7-methoxy-1H-3-benzazepin-6-yl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

10/598,302




RN 1022956-92-8 CAPLUS

CN Benzamide, 2-[[2-[(9-amino-3-ethyl-2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1022962-21-5 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[(1,3-diethyl-2,3,4,5-tetrahydro-6-methoxy-2-oxo-1H-3-benzazepin-7-yl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 1022962-35-1 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[(3-ethyl-2,3,4,5-tetrahydro-9-methoxy-1H-3-benzazepin-6-yl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 1022962-47-5 CAPLUS

CN Methanesulfonamide, N-[(1R,2R)-2-[[5-chloro-2-[(3-ethyl-2,3,4,5-tetrahydro-9-methoxy-1H-3-benzazepin-6-yl)amino]-4-pyrimidinyl]amino]cyclohexyl]-(CA INDEX NAME)


Absolute stereochemistry.



RN 1022965-83-8 CAPLUS

CN Methanesulfonamide, N-[(1R,2R)-2-[[5-chloro-2-[(3-ethyl-2,3,4,5-tetrahydro-6-methoxy-1H-3-benzazepin-7-yl)amino]-4-pyrimidinyl]amino]cyclohexyl]-(CA INDEX NAME)


Absolute stereochemistry.



10/598,302


RN 1022965-91-8 CAPLUS

CN Methanesulfonamide, N-[2-[[5-chloro-2-[(3-ethyl-2,3,4,5-tetrahydro-6-methoxy-1H-3-benzazepin-7-yl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 1022965-94-1 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[(3-ethyl-2,3,4,5-tetrahydro-6-methoxy-1H-3-benzazepin-7-yl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 1022966-39-7 CAPLUS

CN Methanesulfonamide, N-[(1R,2R)-2-[[5-chloro-2-[[2,3,4,5-tetrahydro-7-methoxy-3-(2-methoxyethyl)-1H-3-benzazepin-6-yl]amino]-4-pyrimidinyl]amino]cyclohexyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1022966-48-8 CAPLUS


10/598,302

CN Bicyclo[2.2.1]hept-5-ene-2-carboxamide,
3-[[5-chloro-2-[[2,3,4,5-tetrahydro-7-methoxy-3-(2-methoxyethyl)-1H-3-
benzazepin-6-yl]amino]-4-pyrimidinyl]amino]-, (1R,2R,3S,4S)-rel- (CA
INDEX NAME)


Relative stereochemistry.



RN 1022966-52-4 CAPLUS
CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-methoxy-4-(4-morpholinyl)phenyl]-N2-
[2,3,4,5-tetrahydro-7-methoxy-3-(2-methoxyethyl)-1H-3-benzazepin-6-yl]-
(CA INDEX NAME)




RN 1022967-59-4 CAPLUS
CN 2H-3-Benzazepin-2-one, 9-[[5-chloro-4-[[2-methoxy-4-(4-
morpholinyl)phenyl]amino]-2-pyrimidinyl]amino]-3-ethyl-1,3,4,5-tetrahydro-
8-methoxy- (CA INDEX NAME)



RN 1022967-63-0 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[(3-ethyl-2,3,4,5-tetrahydro-7-methoxy-4-oxo-1H-3-benzazepin-6-yl)amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




IT 1022956-76-8P, 7-Methoxy-9-nitro-2,3,4,5-tetrahydro-1H-benzo[d]azepine 1022956-87-1P, (3-Ethyl-8-methoxy-2,3,4,5-tetrahydro-1H-benzo[d]azepin-6-yl)amine
 1022956-96-2P, 7-Methoxy-6,8-dinitro-2,3,4,5-tetrahydro-1H-benzo[d]azepine 1022962-43-1P, (3-Ethyl-9-methoxy-2,3,4,5-tetrahydro-1H-benzo[d]azepin-6-yl)amine
 1022966-27-3P, 2,2,2-Trifluoro-1-(7-methoxy-6-nitro-1,2,4,5-tetrahydrobenzo[d]azepin-3-yl)ethanone 1022966-42-2P, 7-Methoxy-3-(2-methoxyethyl)-6-nitro-2,3,4,5-tetrahydro-1H-benzo[d]azepine
 1022966-45-5P, [8-Methoxy-3-(2-methoxyethyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-6-yl]amine 1022966-65-9P, 9-Amino-3-(3-dimethylaminopropyl)-8-methoxy-1,3,4,5-tetrahydrobenzo[d]azepin-2-one
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of fused bicyclic derivs. of 2,4-diaminopyrimidine as ALK and c-Met kinase inhibitors)

RN 1022956-76-8 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-8-methoxy-6-nitro- (CA INDEX NAME)

10/598,302




RN 1022956-87-1 CAPLUS

CN 1H-3-Benzazepin-6-amine, 3-ethyl-2,3,4,5-tetrahydro-8-methoxy- (CA INDEX NAME)




RN 1022956-96-2 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-6,8-dinitro- (CA INDEX NAME)




RN 1022962-43-1 CAPLUS

CN 1H-3-Benzazepin-6-amine, 3-ethyl-2,3,4,5-tetrahydro-9-methoxy- (CA INDEX NAME)




RN 1022966-27-3 CAPLUS


CN Ethanone, 2,2,2-trifluoro-1-(1,2,4,5-tetrahydro-7-methoxy-6-nitro-3H-3-benzazepin-3-yl)- (CA INDEX NAME)




RN 1022966-42-2 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-3-(2-methoxyethyl)-6-nitro-
(CA INDEX NAME)

RN 1022966-45-5 CAPLUS

CN 1H-3-Benzazepin-6-amine, 2,3,4,5-tetrahydro-8-methoxy-3-(2-methoxyethyl)-
(CA INDEX NAME)

RN 1022966-65-9 CAPLUS

CN 2H-3-Benzazepin-2-one, 9-amino-3-[3-(dimethylamino)propyl]-1,3,4,5-tetrahydro-8-methoxy-
(CA INDEX NAME)


IT 1022962-25-9, 7-Amino-1,3-diethyl-6-methoxy-1,3,4,5-tetrahydrobenzo[d]azepin-2-one 1022962-39-5,
3-Ethyl-6-methoxy-9-nitro-2,3,4,5-tetrahydro-1H-benzo[d]azepine
1022965-87-2, (3-Ethyl-6-methoxy-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)amine 1022966-55-7,
[7-Methoxy-3-(2-methoxyethyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-6-yl]amine
RL: RCT (Reactant); RACT (Reactant or reagent)

10/598,302

(preparation of fused bicyclic derivs. of 2,4-diaminopyrimidine as ALK and c-Met kinase inhibitors)


RN 1022962-25-9 CAPLUS

CN 2H-3-Benzazepin-2-one, 7-amino-1,3-diethyl-1,3,4,5-tetrahydro-6-methoxy-
(CA INDEX NAME)




RN 1022962-39-5 CAPLUS

CN 1H-3-Benzazepine, 3-ethyl-2,3,4,5-tetrahydro-6-methoxy-9-nitro- (CA INDEX
NAME)




RN 1022965-87-2 CAPLUS

CN 1H-3-Benzazepin-7-amine, 3-ethyl-2,3,4,5-tetrahydro-6-methoxy- (CA INDEX
NAME)




RN 1022966-55-7 CAPLUS

CN 1H-3-Benzazepin-6-amine, 2,3,4,5-tetrahydro-7-methoxy-3-(2-methoxyethyl)-
(CA INDEX NAME)




10/598,302

IT 1022966-92-2P, 3-Ethyl-8-methoxy-9-nitro-1,3,4,5-tetrahydrobenzo[d]azepin-2-one 1022967-67-4P, 8-Methoxy-9-nitro-1,3,4,5-tetrahydrobenzo[d]azepin-2-one
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of fused bicyclic derivs. of 2,4-diaminopyrimidine as ALK and c-Met kinase inhibitors)
RN 1022966-92-2 CAPLUS
CN 2H-3-Benzazepin-2-one, 3-ethyl-1,3,4,5-tetrahydro-8-methoxy-9-nitro- (CA INDEX NAME)



RN 1022967-67-4 CAPLUS
CN 2H-3-Benzazepin-2-one, 1,3,4,5-tetrahydro-8-methoxy-9-nitro- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 5 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2007:1237132 CAPLUS

DOCUMENT NUMBER: 147:502375

TITLE: Benzylphthalazinone derivs. as histamine-H1 and histamine-H3 antagonists and their preparation, pharmaceutical compositions and use in the treatment of allergic diseases

INVENTOR(S): Gore, Paul Martin; Hancock, Ashley Paul; Hodgson, Simon Teanby; Kindon, Leanda Jane; Procopiou, Panayiotis Alexandrou

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 148 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007122156	A1	20071101	WO 2007-EP53773	20070418
WO 2007122156	A9	20080124		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2007242842	A1	20071101	AU 2007-242842	20070418
CA 2649029	A1	20071101	CA 2007-2649029	20070418
US 20080039444	A1	20080214	US 2007-736602	20070418
AR 60535	A1	20080625	AR 2007-101668	20070418
EP 2007735	A1	20081231	EP 2007-728235	20070418
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
JP 2009534351	T	20090924	JP 2009-505878	20070418
JP 4489143	B2	20100623		
IN 2008KN04143	A	20090306	IN 2008-KN4143	20081013
ZA 2008008770	A	20091230	ZA 2008-8770	20081014
MX 2008013406	A	20081104	MX 2008-13406	20081017
NO 2008004363	A	20081117	NO 2008-4363	20081017
US 20090105225	A1	20090423	US 2008-297458	20081017
KR 2009007604	A	20090119	KR 2008-728456	20081120
CN 101472899	A	20090701	CN 2007-80023232	20081222
PRIORITY APPLN. INFO.:			GB 2006-7839	A 20060420
			GB 2007-6160	A 20070329
			GB 2007-6176	A 20070329
			WO 2007-EP53773	W 20070418

OTHER SOURCE(S): MARPAT 147:502375

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to compds. of formula I and salts thereof, processes for their preparation, compns. containing them and their use in the treatment of

various disorders, such as allergic rhinitis. Compds. of formula I wherein A is N and CH; R1 and R2 are independently halo, C1-6 alkyl(oxy), OH and CF3; y and z are independently 0-2; R3 is C1-3 alkylamines, substituted (methyl)-cyclic amines; and their salts thereof, are claimed. Example compound II was prepared by amination of 4-[(4-chlorophenyl)methyl]-2-[[(2R)-1-(4-{4-[(3-chloropropyl)oxy]phenyl}butyl)-2-pyrrolidinyl]methyl]-1(2H)-phthalazinone with hexamethylenimine. All the invention compds. were evaluated for their H1 and H3 receptor antagonistic activity. From the assays, it was determined that compound II exhibited an average PKi (PKb) at H1 of approx.

7.8 and

at H3 of approx. 9.6.


IT 955360-18-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of benzylphthalazinone derivs. as H1 and H3 antagonists useful in the treatment of allergic diseases)

RN 955360-18-6 CAPLUS

CN 1H-3-Benzazepine-7-carboxaldehyde,
3-cyclobutyl-2,3,4,5-tetrahydro-6-hydroxy- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 6 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2007:259940 CAPLUS

DOCUMENT NUMBER: 146:295788

TITLE: Preparation of 6-N-linked heterocycle-substituted
2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT_{2C}
receptor agonistsINVENTOR(S): Briner, Karin; Camp, Anne Marie; Cornell, Alan;
Mazanetz, Michael Philip; Rothhaar, Roger Ryan;
Victor, Frantz; Williams, Andrew Caerwyn; Zhang, Deyi

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 84 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007028132	A2	20070308	WO 2006-US34431	20060901
WO 2007028132	A3	20070607		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
CA 2619450	A1	20070308	CA 2006-2619450	20060901
EP 1924578	A2	20080528	EP 2006-802905	20060901
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
JP 2009507038	T	20090219	JP 2008-529361	20060901
US 20080214520	A1	20080904	US 2008-995212	20080110
PRIORITY APPLN. INFO.:			US 2005-713504P	P 20050901
			WO 2006-US34431	W 20060901


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 146:295788; MARPAT 146:295788

GI



- AB The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of formula I (wherein R1 is H, F, or (C1-C3)alkyl; R2, R3, and R4 are each independently H, Me, or Et; R5 is H, F, Me, or Et; R6 is substituted N-containing heterocycle; R7 is H, halo, CN, (C1-C3)alkyl, etc.; R8 is H, halo, CN, -SCF3, or OH; R9 is H, halo, CN, -CF3, -SCF3, OH, etc.) as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety. Example compound II was prepared by reacting III with 2,4-pentanedione to form the desired pyrazole compound, followed by removal of the protecting group. Although assays for measuring 5-HT2C receptor agonist activity are described in detail, no specific biol. data is given for I.
- IT 927829-51-4, 7-Chloro-3-(2,2,2-trifluoroacetyl)-6-[[3-(2-methyl-1,3-dioxolan-2-yl)propyl]amino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of 6-N-linked heterocycle-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists for treating various disorders)
- RN 927829-51-4 CAPLUS
- CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[3-(2-methyl-1,3-dioxolan-2-yl)propyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




IT 488838-92-2P, 6-Methoxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine 488838-93-3P, 6-Hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine 488838-94-4P, 3-(2,2,2-Trifluoroacetyl)-6-[(trifluoromethylsulfonyl)oxy]-2,3,4,5-tetrahydro-1H-benzo[d]azepine 847199-06-8P, 6-Methoxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine hydrochloride 847199-07-9P, 7-Chloro-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine 847199-08-0P, 7-Chloro-3-(2,2,2-trifluoroacetyl)-6-[(trifluoromethylsulfonyl)oxy]-2,3,4,5-tetrahydro-1H-benzo[d]azepine 864262-43-1P, 3-tert-Butoxycarbonyl-7-chloro-6-hydroxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine 864262-72-6P, 6-Hydroxy-7-iodo-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine 864262-73-7P, 7-Iodo-3-(2,2,2-trifluoroacetyl)-6-[(trifluoromethylsulfonyl)oxy]-2,3,4,5-tetrahydro-1H-benzo[d]azepine 864262-74-8P, 3-(2,2,2-Trifluoroacetyl)-6-[(trifluoromethylsulfonyl)oxy]-7-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine 864262-75-9P, 9-Bromo-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine 864262-76-0P, 6-Acetoxy-9-bromo-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine 864262-77-1P, 7-Acetyl-9-bromo-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine 864262-78-2P, 7-Acetyl-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine 864262-79-3P, 7-Ethyl-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine 864262-80-6P, 7-Ethyl-3-(2,2,2-trifluoroacetyl)-6-[(trifluoromethylsulfonyl)oxy]-2,3,4,5-tetrahydro-1H-benzo[d]azepine 927829-26-3P, 3-tert-Butoxycarbonyl-7-chloro-6-(2-benzhydrylidenehydrazino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine 927829-29-6P, 3-tert-Butoxycarbonyl-7-chloro-6-[(trifluoromethylsulfonyl)oxy]-2,3,4,5-tetrahydro-1H-benzo[d]azepine 927829-38-7P, 7-Chloro-6-(3-hydroxy-2,2-dimethylpropylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine 927829-40-1P, 7-Chloro-6-[[2,2-dimethyl-3-[(tetrahydropyran-2-yl)oxy]propyl]amino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine 927829-46-7P, 7-Chloro-3-(2,2,2-trifluoroacetyl)-6-[[3-(2-phenyl-[1,3]dioxolan-2-yl)propyl]amino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 6-N-linked heterocycle-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT_{2C} receptor agonists for treating various disorders)


RN 488838-92-2 CAPLUS

CN Ethanone, 2,2,2-trifluoro-1-(1,2,4,5-tetrahydro-6-methoxy-3H-3-benzazepin-3-yl)- (CA INDEX NAME)




RN 488838-93-3 CAPLUS

CN Ethanone, 2,2,2-trifluoro-1-(1,2,4,5-tetrahydro-6-hydroxy-3H-3-benzazepin-3-yl)- (CA INDEX NAME)




RN 488838-94-4 CAPLUS

CN Methanesulfonic acid, 1,1,1-trifluoro-, 2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl ester (CA INDEX NAME)




RN 847199-06-8 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-6-methoxy-, hydrochloride (1:1) (CA INDEX NAME)




● HCl


RN 847199-07-9 CAPLUS
 CN Ethanone, 1-(7-chloro-1,2,4,5-tetrahydro-6-hydroxy-3H-3-benzazepin-3-yl)-
 2,2,2-trifluoro- (CA INDEX NAME)



RN 847199-08-0 CAPLUS
 CN Methanesulfonic acid, 1,1,1-trifluoro-,
 7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl
 ester (CA INDEX NAME)




RN 864262-43-1 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-chloro-1,2,4,5-tetrahydro-6-hydroxy-, 1,1-dimethylethyl ester (CA INDEX
 NAME)




RN 864262-72-6 CAPLUS

CN Ethanone, 2,2,2-trifluoro-1-(1,2,4,5-tetrahydro-6-hydroxy-7-iodo-3H-3-benzazepin-3-yl)- (CA INDEX NAME)




RN 864262-73-7 CAPLUS

CN Methanesulfonic acid, 1,1,1-trifluoro-, 2,3,4,5-tetrahydro-7-iodo-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl ester (CA INDEX NAME)




RN 864262-74-8 CAPLUS

CN Methanesulfonic acid, 1,1,1-trifluoro-, 2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-7-(trifluoromethyl)-1H-3-benzazepin-6-yl ester (CA INDEX NAME)




RN 864262-75-9 CAPLUS

CN Ethanone, 1-(6-bromo-1,2,4,5-tetrahydro-9-hydroxy-3H-3-benzazepin-3-yl)-2,2,2-trifluoro- (CA INDEX NAME)




RN 864262-76-0 CAPLUS

CN Ethanone, 1-[6-(acetyloxy)-9-bromo-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 864262-77-1 CAPLUS


CN Ethanone, 1-(7-acetyl-9-bromo-1,2,4,5-tetrahydro-6-hydroxy-3H-3-benzazepin-3-yl)-2,2,2-trifluoro- (CA INDEX NAME)



10/598,302


RN 864262-78-2 CAPLUS

CN Ethanone, 1-(7-acetyl-1,2,4,5-tetrahydro-6-hydroxy-3H-3-benzazepin-3-yl)-
2,2,2-trifluoro- (CA INDEX NAME)




RN 864262-79-3 CAPLUS

CN Ethanone, 1-(7-ethyl-1,2,4,5-tetrahydro-6-hydroxy-3H-3-benzazepin-3-yl)-
2,2,2-trifluoro- (CA INDEX NAME)



RN 864262-80-6 CAPLUS


CN Methanesulfonic acid, 1,1,1-trifluoro-,
7-ethyl-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl
ester (CA INDEX NAME)




RN 927829-26-3 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-6-[2-(diphenylmethylene)hydrazinyl]-1,2,4,5-tetrahydro-,
1,1-dimethylethyl ester (CA INDEX NAME)


10/598,302




RN 927829-29-6 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-1,2,4,5-tetrahydro-6-[[(trifluoromethyl)sulfonyl]oxy]-,
1,1-dimethylethyl ester (CA INDEX NAME)



RN 927829-38-7 CAPLUS
CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[(3-hydroxy-2,2-dimethylpropyl)amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 927829-40-1 CAPLUS
CN Ethanone, 1-[7-chloro-6-[[2,2-dimethyl-3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 927829-46-7 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[3-(2-phenyl-1,3-dioxolan-2-yl)propyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



OS.CITING REF COUNT: 1

THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L27 ANSWER 7 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2007:259776 CAPLUS

DOCUMENT NUMBER: 146:316790

TITLE: Preparation of 6-substituted
2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C
receptor agonistsINVENTOR(S): Allen, John Gordon; Briner, Karin; Camp, Anne Marie;
Cases-Thomas, Manuel Javier; Hoying, Richard Charles;
Martinez-Grau, Maria Angeles; Mazanetz, Michael
Philip; Pokrovskaja, Natalia; Rathmell, Richard
Edmund; Rothhaar, Roger Ryan; Sapmaz, Selma; Williams,
Andrew Caerwyn

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 108pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007028131	A1	20070308	WO 2006-US34430	20060901
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006287160	A1	20070308	AU 2006-287160	20060901
CA 2619287	A1	20070308	CA 2006-2619287	20060901
EP 1926712	A1	20080604	EP 2006-802904	20060901
EP 1926712	B1	20090729		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2009507037	T	20090219	JP 2008-529360	20060901
AT 437859	T	20090815	AT 2006-802904	20060901
PT 1926712	E	20091006	PT 2006-802904	20060901
ES 2328408	T3	20091112	ES 2006-802904	20060901
US 20080207897	A1	20080828	US 2008-995344	20080111
MX 2008002180	A	20080422	MX 2008-2180	20080214
CN 101253153	A	20080827	CN 2006-80031892	20080229
PRIORITY APPLN. INFO.:			US 2005-713584P	P 20050901
			WO 2006-US34430	W 20060901

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 146:316790

GI



AB Title compds. I [R1 = H, F, alkyl; R2-4 independently = H, Me, or Et; R5 = H, F, Me, or Et; R6 = substituted alkyne, alkene, or (un)substituted aryl, etc.; R7 = H, halo, CN, (un)substituted alkyl, etc.; R8 = H, halo, CN, etc.; R9 = H, CF₃, OH, etc.], and their pharmaceutically acceptable salts, are prepared and disclosed as 5-HT_{2C} receptor agonists. Thus, e.g., II·H₂O₂C(CH₂)₂CO₂H was prepared by coupling of 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine (preparation given) with 3-biphenylboronic acid followed by exposure to succinic acid. Selected compds. of the invention were found to be highly potent and selective agonists of the 5-HT_{2C} receptor with EC₅₀'s typically ≤ 200 nM. As 5-HT_{2C} receptor agonists, I should prove useful in treated of obesity, obsessive/compulsive disorder, depression, and anxiety.

IT 928829-29-2P 928829-35-0P 928829-60-1P
 928829-72-5P 928829-88-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of tetrahydro-1H-benzo[d]azepines as 5-HT_{2C} receptor agonists)


RN 928829-29-2 CAPLUS

CN 2-Imidazolidinone, 1-[4-(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)-3-butyn-1-yl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928829-28-1

CMF C17 H20 Cl N3 O




CM 2

CRN 87-69-4

10/598,302

CMF C4 H6 O6

Absolute stereochemistry.




RN 928829-35-0 CAPLUS

CN 2,4-Imidazolidinedione, 3-[3-(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)-2-propyn-1-yl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928829-34-9

CMF C16 H16 Cl N3 O2




CM 2

CRN 87-69-4

CMF C4 H6 O6


Absolute stereochemistry.



RN 928829-60-1 CAPLUS


CN Cyclopentanecarboxamide, N-[4-(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)-3-butyln-1-yl]- (CA INDEX NAME)

10/598,302



RN 928829-72-5 CAPLUS

CN Cyclopentanecarboxamide, N-[5-(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)-4-pentyn-1-yl]- (CA INDEX NAME)




RN 928829-88-3 CAPLUS

CN Cyclopentanecarboxamide, N-[3-(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)-2-propyn-1-yl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928829-87-2

CMF C19 H23 Cl N2 O




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



IT 928829-18-9P 928829-23-6P 928829-42-9P
 928829-47-4P 928829-52-1P 928829-56-5P
 928829-64-5P 928829-69-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of tetrahydro-1H-benzo[d]azepines as 5-HT_{2C} receptor agonists)


RN 928829-18-9 CAPLUS

CN Propanamide, N-[3-(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)-2-propyn-1-yl]-2,2-dimethyl-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928829-17-8

CMF C18 H23 Cl N2 O




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 928829-23-6 CAPLUS


CN Butanamide, N-[3-(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)-2-propyn-1-yl]-3,3-dimethyl-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

10/598,302

CM 1

CRN 928829-22-5

CMF C19 H25 Cl N2 O




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.




RN 928829-42-9 CAPLUS

CN 2,4-Imidazolidinedione, 3-[5-(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)-4-pentyn-1-yl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928829-41-8

CMF C18 H20 Cl N3 O2




CM 2


10/598,302

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.




RN 928829-47-4 CAPLUS
CN Propanamide, N-[4-(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)-3-butyn-1-yl]-2,2-dimethyl- (CA INDEX NAME)



RN 928829-52-1 CAPLUS
CN Carbamic acid, N-[4-(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)-3-butyn-1-yl]-, 1,1-dimethylethyl ester, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928829-51-0
CMF C19 H25 Cl N2 O2




CM 2

CRN 87-69-4
CMF C4 H6 O6


Absolute stereochemistry.

10/598,302




RN 928829-56-5 CAPLUS

CN Carbamic acid, N-[5-(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)-4-pentyn-1-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 928829-64-5 CAPLUS

CN Butanamide, N-[4-(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)-3-butyn-1-yl]-3,3-dimethyl- (CA INDEX NAME)



RN 928829-69-0 CAPLUS

CN Propanamide, N-[5-(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)-4-pentyn-1-yl]-2,2-dimethyl- (CA INDEX NAME)




IT 864265-66-7

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists)

10/598,302

RN 864265-66-7 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-6-ethynyl-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX
NAME)




IT 488838-92-2P 488838-93-3P 488838-94-4P
847199-06-8P 847199-07-9P 847199-08-0P
864265-68-9P 864265-69-0P 928830-32-4P
928830-33-5P 928830-34-6P 928830-41-5P
928830-43-7P 928830-44-8P 928830-45-9P
928830-46-0P 928830-51-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of tetrahydro-1H-benzo[d]azepines as 5-HT_{2C} receptor agonists)

RN 488838-92-2 CAPLUS
CN Ethanone, 2,2,2-trifluoro-1-(1,2,4,5-tetrahydro-6-methoxy-3H-3-benzazepin-
3-yl)- (CA INDEX NAME)




RN 488838-93-3 CAPLUS
CN Ethanone, 2,2,2-trifluoro-1-(1,2,4,5-tetrahydro-6-hydroxy-3H-3-benzazepin-
3-yl)- (CA INDEX NAME)




RN 488838-94-4 CAPLUS
CN Methanesulfonic acid, 1,1,1-trifluoro-,
2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl ester
(CA INDEX NAME)

10/598,302




RN 847199-06-8 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-6-methoxy-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 847199-07-9 CAPLUS
CN Ethanone, 1-(7-chloro-1,2,4,5-tetrahydro-6-hydroxy-3H-3-benzazepin-3-yl)-2,2,2-trifluoro- (CA INDEX NAME)




RN 847199-08-0 CAPLUS
CN Methanesulfonic acid, 1,1,1-trifluoro-, 7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl ester (CA INDEX NAME)

10/598,302




RN 864265-68-9 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[2-(2-pyridinyl)ethynyl]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 864265-69-0 CAPLUS


CN 3H-3-Benzazepine-3-carboxylic acid, 7-chloro-1,2,4,5-tetrahydro-6-[2-(2-thiazolyl)ethynyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 928830-32-4 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-(2-phenylethynyl)-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)


10/598,302




RN 928830-33-5 CAPLUS
CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-(2-phenylethynyl)- (CA INDEX NAME)



RN 928830-34-6 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 7-chloro-1,2,4,5-tetrahydro-6-(2-phenylethynyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 928830-41-5 CAPLUS
CN Ethanone, 2,2,2-trifluoro-1-[1,2,4,5-tetrahydro-6-(2-phenylethynyl)-3H-3-benzazepin-3-yl]- (CA INDEX NAME)




RN 928830-43-7 CAPLUS
CN Propanamide, N-[3-[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]-2-propyn-1-yl]-2,2-dimethyl- (CA INDEX NAME)

10/598,302




RN 928830-44-8 CAPLUS

CN Propanamide, N-[4-[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]-3-butyn-1-yl]-2,2-dimethyl- (CA INDEX NAME)



RN 928830-45-9 CAPLUS


CN 3H-3-Benzazepine-3-carboxylic acid, 7-chloro-1,2,4,5-tetrahydro-6-[4-(2-oxo-1-imidazolidinyl)-1-butyn-1-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 928830-46-0 CAPLUS


CN Cyclopentanecarboxamide, N-[5-[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]-4-pentyn-1-yl]- (CA INDEX NAME)

10/598,302



RN 928830-51-7 CAPLUS

CN Cyclopentanecarboxamide, N-[3-[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]-2-propyn-1-yl]- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 8 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2007:259428 CAPLUS

DOCUMENT NUMBER: 146:316789

TITLE: Preparation of
6-substituted-2,3,4,5-tetrahydro-1H-benzo[d]azepines
as 5-HT_{2C} receptor agonistsINVENTOR(S): Allen, John Gordon; Briner, Karin; Galka, Christopher
Stanley; Hoying, Richard Charles; Martinez-Grau, Maria
Angeles; Miyashiro, Julie; Pokrovskaja, Natalia;
Reinhard, Matthew Robert

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 141pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007028082	A1	20070308	WO 2006-US34334	20060901
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
CA 2619566	A1	20070308	CA 2006-2619566	20060901
EP 1924560	A1	20080528	EP 2006-802858	20060901
EP 1924560	B1	20090805		
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
JP 2009508818	T	20090305	JP 2008-529335	20060901
AT 438627	T	20090815	AT 2006-802858	20060901
PT 1924560	E	20091023	PT 2006-802858	20060901
ES 2328520	T3	20091113	ES 2006-802858	20060901
US 20080255092	A1	20081016	US 2008-996457	20080122
PRIORITY APPLN. INFO.:			US 2005-713495P	P 20050901
			WO 2006-US34334	W 20060901

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 146:316789

GI



AB Title compds. I [R1 = H, F, alkyl; R2-4 independently = H, Me, or Et; R5 = H, F, Me, or Et; R6 = substituted (C0-3)alkyl-X-(C1-3)alkyl wherein X = S, O, NH, NMe; R7 = H, halo, CN, (un)substituted alkyl, etc.; R8 = H, halo, CN, etc.; R9 = H, CF₃, OH, etc.], and their pharmaceutically acceptable salts, are prepared and disclosed as 5-HT_{2C} receptor agonists. Thus, e.g., II·HO₂C(CH₂)₂CO₂H was prepared by coupling of 6-aminomethyl-3-tert-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine (preparation given) with 2-bromopyridine followed by deprotection and exposure to succinic acid. Selected compds. of the invention were found to be highly potent and selective agonists of the 5-HT_{2C} receptor with EC₅₀'s typically ≤ 250 nM. As 5-HT_{2C} receptor agonists, I should prove useful in treated of obesity, obsessive/compulsive disorder, depression, and anxiety.


IT 488838-92-2P 488838-93-3P 847199-06-8P
847199-07-9P 847199-08-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation tetrahydro-1H-benzo[d]azepines as 5-HT_{2C} receptor agonists)

RN 488838-92-2 CAPLUS


CN Ethanone, 2,2,2-trifluoro-1-(1,2,4,5-tetrahydro-6-methoxy-3H-3-benzazepin-3-yl)- (CA INDEX NAME)




RN 488838-93-3 CAPLUS

CN Ethanone, 2,2,2-trifluoro-1-(1,2,4,5-tetrahydro-6-hydroxy-3H-3-benzazepin-3-yl)- (CA INDEX NAME)

10/598,302




RN 847199-06-8 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-6-methoxy-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 847199-07-9 CAPLUS
CN Ethanone, 1-(7-chloro-1,2,4,5-tetrahydro-6-hydroxy-3H-3-benzazepin-3-yl)-2,2,2-trifluoro- (CA INDEX NAME)



RN 847199-08-0 CAPLUS
CN Methanesulfonic acid, 1,1,1-trifluoro-, 7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl ester (CA INDEX NAME)

10/598,302



OS.CITING REF COUNT: 1

THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

REFERENCE COUNT: 9

THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 9 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2007:258026 CAPLUS

DOCUMENT NUMBER: 146:316788

TITLE: Preparation of

6-arylalkylamino-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT_{2C} receptor agonists

INVENTOR(S): Briner, Karin; Adeva Bartolome, Marta; Cases-Thomas, Manuel Javier; Galka, Christopher Stanley; Marcos Llorente, Alicia; Martinez-Grau, Maria Angeles; Mazanetz, Michael Philip; O'Toole, John Cunningham; Rathmell, Richard Edmund; Reinhard, Matthew Robert; Sapmaz, Selma; Williams, Andrew Caerwyn

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 245 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007028083	A2	20070308	WO 2006-US34335	20060901
WO 2007028083	A3	20070518		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2006287202	A1	20070308	AU 2006-287202	20060901
CA 2619448	A1	20070308	CA 2006-2619448	20060901
EP 1924561	A2	20080528	EP 2006-802859	20060901
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
JP 2009507034	T	20090219	JP 2008-529336	20060901
BR 2006015048	A2	20100330	BR 2006-15048	20060901
US 20080269196	A1	20081030	US 2008-996751	20080125
MX 2008002989	A	20080409	MX 2008-2989	20080229
CN 101258131	A	20080903	CN 2006-80032235	20080303
IN 2008DN02535	A	20080808	IN 2008-DN2535	20080326
PRIORITY APPLN. INFO.:			EP 2005-380191	A 20050901
			US 2005-731081P	P 20051028
			WO 2006-US34335	W 20060901

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 146:316788

GI



AB Title compds. I [R1 = H, F, alkyl; R2-4 independently = H, Me, or Et; R5 = H, F, Me, or Et; R6 = substituted amine; R7 = H, halo, CN, (un)substituted alkyl, etc.; R8 = H, halo, CN, etc.; R9 = H, CF₃, OH, etc.], and their pharmaceutically acceptable salts, are prepared and disclosed as 5-HT_{2C} receptor agonists. Thus, e.g., II·HO₂C(CH₂)₂CO₂H was prepared by condensation of 6-(4-acetylbenzylamino)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (preparation given) with O-methylhydroxylamine hydrochloride followed by deprotection and exposure to succinic acid. Selected compds. of the invention were found to be highly potent with EC₅₀'s typically ≤ 250 nM. As 5-HT_{2C} receptor agonists, I should prove useful in treated of obesity, obsessive/compulsive disorder, depression, and anxiety.

IT 928644-43-3P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of arylalkylaminotetrahydrobenzo[d]azepines as 5-HT_{2C} receptor agonists)

RN 928644-43-3 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[6-[(3,3-dimethylcyclohexyl)oxy]-3-pyridinyl]methyl]-2,3,4,5-tetrahydro-, (-)- (CA INDEX NAME)

Rotation (-).



IT	928643-51-0P	928643-57-6P	928643-61-2P
	928643-79-2P	928645-17-4P	928645-25-4P
	928645-31-2P	928645-63-0P	928645-70-9P
	928645-90-3P	928646-10-0P	928646-22-4P
	928646-26-8P	928646-30-4P	928646-34-8P
	928646-62-2P	928646-66-6P	928646-76-8P
	928646-79-1P	928646-83-7P	928646-87-1P
	928647-11-4P	928647-16-9P	928647-24-9P
	928647-32-9P	928647-42-1P	928647-46-5P
	928647-50-1P	928647-54-5P	928647-57-8P
	928647-90-9P	928647-92-1P	928647-96-5P
	928648-03-7P	928648-07-1P	928648-11-7P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of arylalkylaminotetrahydrobenzo[d]azepines as 5-HT_{2C} receptor agonists)

RN 928643-51-0 CAPLUS


CN Ethanone, 1-[4-[[[7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]-, O-methyloxime (CA INDEX NAME)

10/598,302



RN 928643-57-6 CAPLUS


CN 1-Butanone, 1-[4-[[4-(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]-3-methyl-, oxime (CA INDEX NAME)



RN 928643-61-2 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-[[4-[2-(methylamino)-4-thiazolyl]phenyl]methyl]- (CA INDEX NAME)

10/598,302



RN 928643-79-2 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[4-
[(cyclopentylthio)methyl]phenyl]methyl]-2,3,4,5-tetrahydro- (CA INDEX
NAME)



RN 928645-17-4 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[5-(cyclohexyloxy)-2-
pyridinyl]methyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)

10/598,302



RN 928645-25-4 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[5-[(3,3-dimethylcyclohexyl)oxy]-2-pyridinyl]methyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 928645-31-2 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[6-[(1E)-2-cyclohexylethenyl]-3-pyridinyl]methyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)

Double bond geometry as shown.


PAGE 1-A



PAGE 2-A




RN 928645-63-0 CAPLUS
 CN Ethanone, 2-[4-[[7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]-1-cyclohexyl- (CA INDEX NAME)



RN 928645-70-9 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-[[4-(4-morpholinylmethyl)phenyl]methyl]- (CA INDEX NAME)



RN 928645-90-3 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-[[4-(1-piperidinylmethyl)phenyl]methyl]- (CA INDEX NAME)

10/598,302



RN 928646-10-0 CAPLUS


CN 1,4-Benzenedimethanamine, N1-(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)-N4-cyclohexyl- (CA INDEX NAME)



RN 928646-22-4 CAPLUS


CN 1,4-Benzenedimethanamine, N4-(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)-N1-methyl-N1-(1-methylethyl)- (CA INDEX NAME)

10/598,302



RN 928646-26-8 CAPLUS


CN 2,5-Pyridinedimethanamine, N2-(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)-N5-cyclohexyl- (CA INDEX NAME)



RN 928646-30-4 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-[[6-(1-piperidinylmethyl)-3-pyridinyl]methyl]- (CA INDEX NAME)

10/598,302



RN 928646-34-8 CAPLUS


CN Propanamide, N-[4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]-2,2-dimethyl- (CA INDEX NAME)



RN 928646-62-2 CAPLUS


CN Propanamide, N-[4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]-N,N,2-trimethyl- (CA INDEX NAME)

10/598,302



RN 928646-66-6 CAPLUS


CN Cyclohexanecarboxamide, N-[4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]- (CA INDEX NAME)



RN 928646-76-8 CAPLUS


CN Propanamide, N-[[4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]methyl]-2,2-dimethyl- (CA INDEX NAME)

10/598,302



RN 928646-79-1 CAPLUS


CN Cyclopropanecarboxamide, N-[[4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]methyl]- (CA INDEX NAME)



RN 928646-83-7 CAPLUS


CN Propanamide, N-[2-[4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]ethyl]-2,2-dimethyl]- (CA INDEX NAME)

10/598,302



RN 928646-87-1 CAPLUS

CN Benzeneacetamide, 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-(1-methylethyl)- (CA INDEX NAME)




RN 928647-11-4 CAPLUS

CN Benzeneacetamide, 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).

10/598,302



RN 928647-16-9 CAPLUS


CN Benzenepropanamide, 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 928647-24-9 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[6-[[[(2,2-dimethylpropyl)sulfonyl]methyl]-3-pyridinyl]methyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)

10/598,302



RN 928647-32-9 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[4-[[2,2-dimethylpropyl)sulfonyl]methyl]phenyl]methyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 928647-42-1 CAPLUS


CN 2-Butanone, 1-[[4-[[7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]thio]-3,3-dimethyl- (CA INDEX NAME)

10/598,302



RN 928647-46-5 CAPLUS


CN Acetamide, 2-[[4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]thio]-N-(2,2-dimethylpropyl)- (CA INDEX NAME)



RN 928647-50-1 CAPLUS


CN 2-Butanone, 1-[[5-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-2-pyridinyloxy]-3,3-dimethyl]- (CA INDEX NAME)

10/598,302



RN 928647-54-5 CAPLUS


CN Acetamide, 2-[[5-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-2-pyridinyl]oxy]-N-(2,2-dimethylpropyl)- (CA INDEX NAME)




RN 928647-57-8 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[4-[5-[(cyclopropylmethyl)amino]-3-isothiazolyl]phenyl]methyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 928647-90-9 CAPLUS
 CN Cyclopropanecarboxamide, N-[4-[4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl) amino]methyl]phenyl]-2-thiazolyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 928647-92-1 CAPLUS
 CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[4-[1-(cyclopropylmethyl)-1H-pyrazol-3-yl]phenyl]methyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 928647-96-5 CAPLUS
 CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[4-[6-[(cyclopropylmethyl)amino]-4-pyrimidinyl]phenyl]methyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)

10/598,302




RN 928648-03-7 CAPLUS

CN 1-Butanone, 1-[5-[4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]-2-thienyl]-3,3-dimethyl- (CA INDEX NAME)




RN 928648-07-1 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[6-[(2,2-dimethylpropyl)sulfonyl]-3-pyridinyl]methyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 928648-11-7 CAPLUS

CN Ethanone, 1-[4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]-2-[(2,2,2-trifluoroethyl)thio]- (CA INDEX NAME)



IT	928643-52-1P	928643-54-3P	928643-56-5P
	928643-58-7P	928643-60-1P	928643-62-3P
	928643-64-5P	928643-66-7P	928643-68-9P
	928643-70-3P	928643-72-5P	928643-74-7P
	928643-76-9P	928643-80-5P	928643-86-1P
	928643-94-1P	928643-98-5P	928644-02-4P
	928644-08-0P	928644-13-7P	928644-18-2P
	928644-23-9P	928644-29-5P	928644-35-3P
	928644-44-4P	928644-51-3P	928644-59-1P
	928644-69-3P	928644-77-3P	928644-84-2P
	928644-92-2P	928644-97-7P	928645-02-7P
	928645-08-3P	928645-13-0P	928645-18-5P
	928645-21-0P	928645-26-5P	928645-32-3P

928645-37-8P	928645-44-7P	928645-50-5P
928645-56-1P	928645-64-1P	928645-71-0P
928645-78-7P	928645-85-6P	928645-91-4P
928645-98-1P	928646-03-1P	928646-08-6P
928646-11-1P	928646-15-5P	928646-19-9P
928646-23-5P	928646-27-9P	928646-31-5P
928646-35-9P	928646-39-3P	928646-44-0P
928646-49-5P	928646-54-2P	928646-59-7P
928646-63-3P	928646-67-7P	928646-71-3P
928646-74-6P	928646-77-9P	928646-80-4P
928646-84-8P	928646-88-2P	928646-92-8P
928646-96-2P	928647-00-1P	928647-05-6P
928647-09-0P	928647-12-5P	928647-17-0P
928647-21-6P	928647-25-0P	928647-29-4P
928647-33-0P	928647-38-5P	928647-43-2P
928647-47-6P	928647-51-2P	928647-55-6P
928647-58-9P	928647-61-4P	928647-64-7P
928647-66-9P	928647-69-2P	928647-71-6P
928647-74-9P	928647-77-2P	928647-79-4P
928647-81-8P	928647-83-0P	928647-86-3P
928647-88-5P	928647-91-0P	928647-93-2P
928647-95-4P	928647-97-6P	928647-99-8P
928648-02-6P	928648-04-8P	928648-08-2P
928648-12-8P		

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylalkylaminotetrahydrobenzo[d]azepines as 5-HT_{2C} receptor agonists)

RN 928643-52-1 CAPLUS


CN Butanedioic acid, compd. with 1-[4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]ethanone O-methyloxime (1:1) (CA INDEX NAME)

CM 1

CRN 928643-51-0

CMF C20 H24 Cl N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928643-54-3 CAPLUS


CN Butanedioic acid, compd. with 1-[4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]ethanone O-ethyloxime (1:1) (CA INDEX NAME)

CM 1

CRN 928643-53-2

CMF C21 H26 Cl N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928643-56-5 CAPLUS


CN Butanedioic acid, compd. with 1-[4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]ethanone 1-[O-(2-methylpropyl)oxime]
(1:1) (CA INDEX NAME)

CM 1

CRN 928643-55-4

CMF C23 H30 Cl N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928643-58-7 CAPLUS


CN Butanedioic acid, compd. with 1-[4-[[3-methyl-1-(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]-3-methyl-1-butanone oxime (1:1) (CA INDEX NAME)

CM 1

CRN 928643-57-6

CMF C22 H28 Cl N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928643-60-1 CAPLUS


CN Butanedioic acid, compd. with 1-[4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]-3-methyl-1-butanone O-methyloxime (1:1) (CA INDEX NAME)

CM 1

CRN 928643-59-8

CMF C23 H30 Cl N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928643-62-3 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-[2-(methylamino)-4-thiazolyl]phenyl]methyl]-1H-3-benzazepin-6-amine (1:1)
(CA INDEX NAME)

CM 1

CRN 928643-61-2

CMF C21 H23 Cl N4 S


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928643-64-5 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[[4-[2-(ethylamino)-4-thiazolyl]phenyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1)
(CA INDEX NAME)

CM 1

CRN 928643-63-4

CMF C22 H25 Cl N4 S


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928643-66-7 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-[2-[(1-methylethyl)amino]-4-thiazolyl]phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 928643-65-6

CMF C23 H27 Cl N4 S


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928643-68-9 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-[2-(propylamino)-4-thiazolyl]phenyl]methyl]-1H-3-benzazepin-6-amine (1:1)
(CA INDEX NAME)

CM 1

CRN 928643-67-8

CMF C23 H27 Cl N4 S


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928643-70-3 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-[2-(1-piperidinyl)-4-thiazolyl]phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 928643-69-0

CMF C25 H29 Cl N4 S


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928643-72-5 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[[4-[2-[(cyclopropylmethyl)amino]-4-thiazolyl]phenyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1


CRN 928643-71-4

CMF C24 H27 Cl N4 S

PAGE 1-A




PAGE 2-A



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928643-74-7 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-[2-[(2-methylpropyl)amino]-4-thiazolyl]phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 928643-73-6

10/598,302


CMF C24 H29 Cl N4 S



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928643-76-9 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-[[4-[2-(methylamino)-4-oxazolyl]phenyl]methyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928643-75-8

CMF C21 H23 Cl N4 O

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 928643-80-5 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[4-
[(cyclopentylthio)methyl]phenyl]methyl]-2,3,4,5-tetrahydro-,
(2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928643-79-2

CMF C23 H29 Cl N2 S

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 928643-86-1 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[4-
[(cyclohexylthio)methyl]phenyl]methyl]-2,3,4,5-tetrahydro-,
(2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928643-85-0

CMF C24 H31 Cl N2 S

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 928643-94-1 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[5-[(cyclopentylthio)methyl]-2-pyridinyl]methyl]-2,3,4,5-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928643-93-0

CMF C22 H28 Cl N3 S

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 928643-98-5 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[5-[(cyclohexylthio)methyl]-2-pyridinyl]methyl]-2,3,4,5-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928643-97-4

CMF C23 H30 Cl N3 S

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 928644-02-4 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-[[5-[[[(1-methylethyl)thio]methyl]-2-pyridinyl]methyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928644-01-3

CMF C20 H26 Cl N3 S

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 928644-08-0 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-[[5-[[(2-methylpropyl)thio]methyl]-2-pyridinyl]methyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928644-07-9

CMF C21 H28 Cl N3 S

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 928644-13-7 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[6-[[[(2,2-dimethylpropyl)thio]methyl]-3-pyridinyl]methyl]-2,3,4,5-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928644-12-6

CMF C22 H30 Cl N3 S

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 928644-18-2 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[4-[[[(3,3-dimethylcyclohexyl)thio]methyl]phenyl]methyl]-2,3,4,5-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928644-17-1

CMF C26 H35 Cl N2 S

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 928644-23-9 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[4-[(3,3-dimethylcyclohexyl)thio]phenyl]methyl]-2,3,4,5-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928644-22-8

CMF C25 H33 Cl N2 S

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 928644-29-5 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[6-[(3,3-dimethylcyclohexyl)thio]-3-pyridinyl]methyl]-2,3,4,5-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928644-28-4

CMF C24 H32 Cl N3 S

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 928644-35-3 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[6-[[[(1,1-dimethylethyl)thio]methyl]-3-pyridinyl]methyl]-2,3,4,5-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928644-34-2

CMF C21 H28 Cl N3 S

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 928644-44-4 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[6-[(3,3-dimethylcyclohexyl)oxy]-3-pyridinyl]methyl]-2,3,4,5-tetrahydro-, (-)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)


CM 1

CRN 928644-43-3

CMF C24 H32 Cl N3 O

Rotation (-).

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 928644-51-3 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[6-[(3,3-dimethylcyclohexyl)oxy]-3-pyridinyl]methyl]-2,3,4,5-tetrahydro-, (+)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)


CM 1

CRN 928644-50-2

CMF C24 H32 Cl N3 O

Rotation (+).

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 928644-59-1 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[6-[(cyclopentylthio)methyl]-3-pyridinyl]methyl]-2,3,4,5-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928644-58-0

CMF C22 H28 Cl N3 S

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 928644-69-3 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[6-[(cyclohexylthio)methyl]-3-pyridinyl]methyl]-2,3,4,5-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928644-68-2

CMF C23 H30 Cl N3 S

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 928644-77-3 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[6-(cyclohexyloxy)-3-pyridinyl]methyl]-2,3,4,5-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928644-76-2

CMF C22 H28 Cl N3 O

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 928644-84-2 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[6-[(4,4-dimethylcyclohexyl)oxy]-3-pyridinyl]methyl]-2,3,4,5-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928644-83-1

CMF C24 H32 Cl N3 O

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 928644-92-2 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[6-[[[(1,1-dimethylethyl)sulfonyl]methyl]-3-pyridinyl]methyl]-2,3,4,5-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928644-91-1

CMF C21 H28 Cl N3 O2 S


10/598,302



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.




RN 928644-97-7 CAPLUS
CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-[[6-[(1-methylethoxy)methyl]-3-pyridinyl]methyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928644-96-6
CMF C20 H26 Cl N3 O

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 928645-02-7 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[6-[(2,2-dimethylpropoxy)methyl]-3-pyridinyl]methyl]-2,3,4,5-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928645-01-6

CMF C22 H30 Cl N3 O

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 928645-08-3 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[6-[(cyclopentyloxy)methyl]-3-pyridinyl]methyl]-2,3,4,5-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928645-07-2

CMF C22 H28 Cl N3 O

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 928645-13-0 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[6-[(cyclohexyloxy)methyl]-3-pyridinyl]methyl]-2,3,4,5-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928645-12-9

CMF C23 H30 Cl N3 O

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 928645-18-5 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[[5-(cyclohexyloxy)-2-pyridinyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 928645-17-4

CMF C22 H28 Cl N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928645-21-0 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[[5-(cycloheptyloxy)-2-pyridinyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 928645-20-9

CMF C23 H30 Cl N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928645-26-5 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[[5-[(3,3-dimethylcyclohexyl)oxy]-2-pyridinyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 928645-25-4

CMF C24 H32 Cl N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928645-32-3 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-N-[[6-[(1E)-2-cyclohexylethenyl]-3-pyridinyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)


CM 1

CRN 928645-31-2


CMF C24 H30 Cl N3

Double bond geometry as shown.

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-15-6

CMF C4 H6 O4

 $\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 928645-37-8 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-N-[[5-[(1E)-2-cyclohexylethenyl]-2-pyridinyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)


CM 1

10/598,302


CRN 928645-36-7
CMF C24 H30 Cl N3

Double bond geometry as shown.

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-15-6
CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 928645-44-7 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-N-[[6-[(1Z)-2-cyclohexylethenyl]-3-pyridinyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA

10/598,302


INDEX NAME)

CM 1

CRN 928645-43-6

CMF C24 H30 Cl N3

Double bond geometry as shown.



CM 2

CRN 110-15-6

CMF C4 H6 O4

$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 928645-50-5 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-N-[[5-[(1Z)-2-cyclohexylethenyl]-2-pyridinyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)


CM 1

CRN 928645-49-2

CMF C24 H30 Cl N3

Double bond geometry as shown.

10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 928645-56-1 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[4-[(1Z)-2-cyclohexylethenyl]phenyl]methyl]-2,3,4,5-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)


CM 1

CRN 928645-55-0

CMF C25 H31 Cl N2

Double bond geometry as shown.

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 928645-64-1 CAPLUS


CN Ethanone, 2-[4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]-1-cyclohexyl-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928645-63-0

CMF C25 H31 Cl N2 O

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 928645-71-0 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-(4-morpholinylmethyl)phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 928645-70-9

CMF C22 H28 Cl N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928645-78-7 CAPLUS

CN Butanedioic acid, compd. with N1-(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)-N4-[(1R)-2,2,2-trifluoro-1-methylethyl]-1,4-benzenedimethanamine (1:1) (CA INDEX NAME)


CM 1

CRN 928645-77-6

CMF C21 H25 Cl F3 N3

Absolute stereochemistry. Rotation (-).

10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 928645-85-6 CAPLUS


CN Butanedioic acid, compd. with N1-(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)-N4-(2,2,2-trifluoroethyl)-1,4-benzenedimethanamine (1:1)
(CA INDEX NAME)

CM 1

CRN 928645-84-5

CMF C20 H23 Cl F3 N3


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928645-91-4 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-(1-piperidinylmethyl)phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 928645-90-3

CMF C23 H30 Cl N3


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928645-98-1 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-(1-pyrrolidinylmethyl)phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 928645-97-0

CMF C22 H28 Cl N3


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928646-03-1 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[[4-[(hexahydro-1H-azepin-1-yl)methyl]phenyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1)
(CA INDEX NAME)

CM 1

CRN 928646-02-0

CMF C24 H32 Cl N3


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928646-08-6 CAPLUS


CN Butanedioic acid, compd. with N1-(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)-N4-(2,2,2-trifluoro-1-methylethyl)-1,4-benzenedimethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 928646-07-5

CMF C21 H25 Cl F3 N3


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928646-11-1 CAPLUS


CN Butanedioic acid, compd. with N1-(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)-N4-cyclohexyl-1,4-benzenedimethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 928646-10-0

CMF C24 H32 Cl N3


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928646-15-5 CAPLUS


CN Butanedioic acid, compd. with N1-(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)-N4-(2-methylpropyl)-1,4-benzenedimethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 928646-14-4

CMF C22 H30 Cl N3


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4




RN 928646-19-9 CAPLUS

CN Butanedioic acid, compd. with N1-(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)-N4-(1-methylethyl)-1,4-benzenedimethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 928646-18-8

CMF C21 H28 Cl N3



10/598,302

CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H


RN 928646-23-5 CAPLUS

CN Butanedioic acid, compd. with N4-(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)-N1-methyl-N1-(1-methylethyl)-1,4-benzenedimethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 928646-22-4

CMF C22 H30 Cl N3



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 928646-27-9 CAPLUS


CN Butanedioic acid, compd. with N2-(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)-N5-cyclohexyl-2,5-pyridinedimethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 928646-26-8

10/598,302

CMF C23 H31 Cl N4



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 928646-31-5 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[6-(1-piperidinylmethyl)-3-pyridinyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 928646-30-4

CMF C22 H29 Cl N4


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928646-35-9 CAPLUS


CN Butanedioic acid, compd. with N-[4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]-2,2-dimethylpropanamide (1:1) (CA INDEX NAME)

CM 1

CRN 928646-34-8

CMF C22 H28 Cl N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928646-39-3 CAPLUS


CN Butanedioic acid, compd. with N-[4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]cyclopropanecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 928646-38-2

CMF C21 H24 Cl N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928646-44-0 CAPLUS


CN Butanedioic acid, compd. with N-[4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]-1-methylcyclopropanecarboxamide (1:1)
(CA INDEX NAME)

CM 1

CRN 928646-43-9

CMF C22 H26 Cl N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928646-49-5 CAPLUS


CN Butanedioic acid, compd. with N-[4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]-2,2,3,3-tetramethylcyclopropanecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 928646-48-4

CMF C25 H32 Cl N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928646-54-2 CAPLUS

CN Butanedioic acid, (1R,2R)-compd. with
N-[4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]-2-methylcyclopropanecarboxamide (1:1) (CA INDEX NAME)


CM 1

CRN 928646-53-1

CMF C22 H26 Cl N3 O

Absolute stereochemistry.


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928646-59-7 CAPLUS

CN Butanedioic acid, (1S,2S)-compd. with
N-[4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl) amino]methyl]phenyl]-2-methylcyclopropanecarboxamide (1:1) (CA INDEX NAME)


CM 1

CRN 928646-58-6

CMF C22 H26 Cl N3 O

Absolute stereochemistry.


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928646-63-3 CAPLUS


CN Butanedioic acid, compd. with N-[4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]-N,2,2-trimethylpropanamide (1:1) (CA INDEX NAME)

CM 1

CRN 928646-62-2

CMF C23 H30 Cl N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928646-67-7 CAPLUS


CN Butanedioic acid, compd. with N-[4-[[[7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl]amino]methyl]phenyl]cyclohexanecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 928646-66-6

CMF C24 H30 Cl N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928646-71-3 CAPLUS


CN Butanedioic acid, compd. with N-[4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]cyclopentanecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 928646-70-2

CMF C23 H28 Cl N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928646-74-6 CAPLUS


CN Butanedioic acid, compd. with N-[4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]cycloheptanecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 928646-73-5

CMF C25 H32 Cl N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928646-77-9 CAPLUS


CN Propanamide, N-[[4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]methyl]-2,2-dimethyl-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928646-76-8

CMF C23 H30 Cl N3 O


10/598,302



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.




RN 928646-80-4 CAPLUS
CN Butanedioic acid, compd. with N-[[4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]methyl]cyclopropanecarboxamide (1:1)
(CA INDEX NAME)

CM 1

CRN 928646-79-1
CMF C22 H26 Cl N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928646-84-8 CAPLUS


CN Propanamide, N-[2-[4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]ethyl]-2,2-dimethyl-,
(2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928646-83-7

CMF C24 H32 Cl N3 O

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 928646-88-2 CAPLUS


CN Benzeneacetamide, 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-(1-methylethyl)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928646-87-1

CMF C22 H28 Cl N3 O

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 928646-92-8 CAPLUS


CN Benzeneacetamide, 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-(2,2-dimethylpropyl)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928646-91-7

CMF C24 H32 Cl N3 O

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 928646-96-2 CAPLUS


CN Ethanone, 2-[4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]-1-(1-pyrrolidinyl)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928646-95-1

CMF C23 H28 Cl N3 O

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 928647-00-1 CAPLUS


CN Benzeneacetamide, 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-(2,2-dimethylpropyl)-alpha-methyl-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928646-99-5

CMF C25 H34 Cl N3 O

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 928647-05-6 CAPLUS


CN Benzeneacetamide, 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-(cyclohexylmethyl)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1


CRN 928647-04-5

CMF C26 H34 Cl N3 O

PAGE 1-A




PAGE 2-A



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 928647-09-0 CAPLUS
CN Benzeneacetamide, 4-[[7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-


10/598,302

yl)amino]methyl]-N-(3,3-dimethylbutyl)-, (2R,3R)-2,3-dihydroxybutanedioate
(1:1) (CA INDEX NAME)

CM 1

CRN 928647-08-9

CMF C25 H34 Cl N3 O




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 928647-12-5 CAPLUS

CN Benzeneacetamide, 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)


CM 1

CRN 928647-11-4

CMF C22 H25 Cl F3 N3 O

Absolute stereochemistry. Rotation (-).

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 928647-17-0 CAPLUS


CN Benzenepropanamide, 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-(1,1-dimethylethyl)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928647-16-9

CMF C24 H32 Cl N3 O

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 928647-21-6 CAPLUS


CN Benzenepropanamide, 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-(2,2-dimethylpropyl)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928647-20-5

CMF C25 H34 Cl N3 O

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 928647-25-0 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[[6-[[[(2,2-dimethylpropyl)sulfonyl]methyl]-3-pyridinyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 928647-24-9

CMF C22 H30 Cl N3 O2 S


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928647-29-4 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[[6-[(cyclohexylsulfonyl)methyl]-3-pyridinyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 928647-28-3

CMF C23 H30 Cl N3 O2 S


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928647-33-0 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[[4-[[[(2,2-dimethylpropyl)sulfonyl]methyl]phenyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 928647-32-9

CMF C23 H31 Cl N2 O2 S


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928647-38-5 CAPLUS


CN Butanedioic acid, compd. with S-[4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl] N,N-dimethylcarbamothioate (1:1) (CA INDEX NAME)

CM 1

CRN 928647-37-4

CMF C20 H24 Cl N3 O S


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928647-43-2 CAPLUS


CN 2-Butanone, 1-[[4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]thio]-3,3-dimethyl-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928647-42-1

CMF C23 H29 Cl N2 O S

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 928647-47-6 CAPLUS


CN Acetamide, 2-[[4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]thio]-N-(2,2-dimethylpropyl)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928647-46-5

CMF C24 H32 Cl N3 O S

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 928647-51-2 CAPLUS


CN 2-Butanone, 1-[[5-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-2-pyridinyl]oxy]-3,3-dimethyl-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928647-50-1

CMF C22 H28 Cl N3 O2

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 928647-55-6 CAPLUS


CN Acetamide, 2-[[5-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-2-pyridinyl]oxy]-N-(2,2-dimethylpropyl)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928647-54-5

CMF C23 H31 Cl N4 O2

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.





RN 928647-58-9 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-N-[[4-[5-[(cyclopropylmethyl)amino]-3-isothiazolyl]phenyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 928647-57-8

CMF C24 H27 Cl N4 S



CM 2

CRN 110-15-6

CMF C4 H6 O4

 $\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 928647-61-4 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-[2-[(2,2,2-trifluoroethyl)amino]-4-thiazolyl]phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 928647-60-3

10/598,302

CMF C22 H22 Cl F3 N4 S



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 928647-64-7 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-[2-[(3-methylbutyl)amino]-4-thiazolyl]phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 928647-63-6

CMF C25 H31 Cl N4 S


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928647-66-9 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[[4-[2-[(2,2-dimethylpropyl)amino]-4-thiazolyl]phenyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 928647-65-8

CMF C25 H31 Cl N4 S

10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H



RN 928647-69-2 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-N-[[4-[2-[(cyclopentylmethyl)amino]-4-thiazolyl]phenyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 928647-68-1

CMF C26 H31 Cl N4 S



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 928647-71-6 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-N-[[4-[2-[(cyclohexylmethyl)amino]-4-thiazolyl]phenyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)


CM 1

CRN 928647-70-5


10/598,302

CMF C27 H33 Cl N4 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 928647-74-9 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[[4-[2-[(cyclopropylmethyl)amino]-5-methyl-4-thiazolyl]phenyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1


10/598,302

CRN 928647-73-8
CMF C25 H29 Cl N4 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-15-6
CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 928647-77-2 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-[2-[[(1R)-2,2,2-trifluoro-1-methylethyl]amino]-4-thiazolyl]phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)


10/598,302

CM 1

CRN 928647-76-1

CMF C23 H24 Cl F3 N4 S

Absolute stereochemistry. Rotation (-).



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 928647-79-4 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-[2-[[(1S)-2,2,2-trifluoro-1-methylethyl]amino]-4-thiazolyl]phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)


CM 1

CRN 928647-78-3

CMF C23 H24 Cl F3 N4 S

Absolute stereochemistry. Rotation (+).


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928647-81-8 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-[2-[(phenylmethyl)amino]-4-thiazolyl]phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 928647-80-7

CMF C27 H27 Cl N4 S

10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 928647-83-0 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-[2-[(3,3,3-trifluoropropyl)amino]-4-thiazolyl]phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 928647-82-9

CMF C23 H24 Cl F3 N4 S

10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H



RN 928647-86-3 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-N-[[5-[2-[(cyclopropylmethyl)amino]-4-thiazolyl]-2-pyridinyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 928647-85-2

CMF C23 H26 Cl N5 S



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 928647-88-5 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-N-[[6-[2-[(cyclopropylmethyl)amino]-4-thiazolyl]-3-pyridinyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepine-6-amine (1:1) (CA INDEX NAME)


CM 1

CRN 928647-87-4


10/598,302

CMF C23 H26 Cl N5 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 928647-91-0 CAPLUS


CN Butanedioic acid, compd. with N-[4-[4-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]-2-thiazolyl]cyclopropanecarboxamide (1:1) (CA INDEX NAME)

CM 1


10/598,302

CRN 928647-90-9
CMF C24 H25 Cl N4 O S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-15-6
CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 928647-93-2 CAPLUS
CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[4-[1-(cyclopropylmethyl)-1H-pyrazol-3-yl]phenyl]methyl]-2,3,4,5-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)


10/598,302

CM 1


CRN 928647-92-1

CMF C24 H27 Cl N4

PAGE 1-A



PAGE 2-A




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.

10/598,302




RN 928647-95-4 CAPLUS
CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[4-[3-[(cyclopropylmethyl)amino]-1H-pyrazol-1-yl]phenyl]methyl]-2,3,4,5-tetrahydro-,
(2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1


CRN 928647-94-3

CMF C24 H28 Cl N5

PAGE 1-A



PAGE 2-A




10/598,302

CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.




RN 928647-97-6 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-N-[[4-[6-[(cyclopropylmethyl)amino]-4-pyrimidinyl]phenyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 928647-96-5


CMF C25 H28 Cl N5



CM 2

CRN 110-15-6

CMF C4 H6 O4




10/598,302

RN 928647-99-8 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-N-[[4-[4-[(cyclopropylmethyl)amino]-2-pyrimidinyl]phenyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 928647-98-7
CMF C25 H28 Cl N5



CM 2

CRN 110-15-6
CMF C4 H6 O4


HO₂C-CH₂-CH₂-CO₂H

RN 928648-02-6 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-N-[[4-[2-[(cyclopropylmethyl)amino]-4-pyrimidinyl]phenyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 928648-01-5
CMF C25 H28 Cl N5

10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 928648-04-8 CAPLUS


CN 1-Butanone, 1-[5-[4-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]-2-thienyl]-3,3-dimethyl-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928648-03-7

CMF C27 H31 Cl N2 O S

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 928648-08-2 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[[6-[(2,2-dimethylpropyl)sulfonyl]-3-pyridinyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 928648-07-1

CMF C21 H28 Cl N3 O2 S


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4




RN 928648-12-8 CAPLUS

CN Ethanone, 1-[4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]-2-[(2,2,2-trifluoroethyl)thio]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 928648-11-7

CMF C21 H22 Cl F3 N2 O S




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



IT 928650-66-2P 928650-67-3P

RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of arylalkylaminotetrahydrobenzo[d]azepines as 5-HT_{2C} receptor agonists)

RN 928650-66-2 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]phenyl]-2-methyl-, (1R,2R)- (CA INDEX NAME)

Absolute stereochemistry.


10/598,302



RN 928650-67-3 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]phenyl]-2-methyl-, (1S,2S)- (CA INDEX NAME)

Absolute stereochemistry.



IT	488838-92-2P	488838-93-3P	847199-06-8P
	847199-07-9P	847199-08-0P	864264-32-4P
	864264-35-7P	928644-34-2P	928647-37-4P


928648-20-8P	928649-25-6P	928649-26-7P
928649-61-0P	928649-62-1P	928650-44-6P
928650-45-7P	928650-46-8P	928650-47-9P
928650-48-0P	928650-49-1P	928650-50-4P
928650-51-5P	928650-52-6P	928650-53-7P
928650-54-8P	928650-55-9P	928650-56-0P
928650-57-1P	928650-58-2P	928650-59-3P
928650-60-6P	928650-61-7P	928650-62-8P
928650-63-9P	928650-64-0P	928650-65-1P
928650-68-4P	928650-69-5P	928650-70-8P
928650-71-9P	928650-72-0P	928650-73-1P
928650-74-2P	928650-75-3P	928650-76-4P
928650-77-5P	928650-78-6P	928650-79-7P
928650-80-0P	928650-81-1P	928650-82-2P
928650-83-3P	928650-84-4P	928650-85-5P
928650-86-6P	928650-87-7P	928650-88-8P
928650-89-9P	928650-90-2P	928650-91-3P
928650-92-4P	928650-93-5P	

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of arylalkylaminotetrahydrobenzo[d]azepines as 5-HT_{2C} receptor agonists)


RN 488838-92-2 CAPLUS

CN Ethanone, 2,2,2-trifluoro-1-(1,2,4,5-tetrahydro-6-methoxy-3H-3-benzazepin-3-yl)- (CA INDEX NAME)




RN 488838-93-3 CAPLUS

CN Ethanone, 2,2,2-trifluoro-1-(1,2,4,5-tetrahydro-6-hydroxy-3H-3-benzazepin-3-yl)- (CA INDEX NAME)




RN 847199-06-8 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-6-methoxy-, hydrochloride (1:1) (CA INDEX NAME)




● HCl


RN 847199-07-9 CAPLUS
CN Ethanone, 1-(7-chloro-1,2,4,5-tetrahydro-6-hydroxy-3H-3-benzazepin-3-yl)-
2,2,2-trifluoro- (CA INDEX NAME)



RN 847199-08-0 CAPLUS
CN Methanesulfonic acid, 1,1,1-trifluoro-,
7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl
ester (CA INDEX NAME)




RN 864264-32-4 CAPLUS
CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[4-(2-methyl-1,3-dioxolan-2-yl)phenyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 864264-35-7 CAPLUS


CN Ethanone, 1-[6-[[[(4-acetylphenyl)methyl]amino]-7-chloro-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 928644-34-2 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[6-[[[(1,1-dimethylethyl)thio]methyl]-3-pyridinyl]methyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)

10/598,302




RN 928647-37-4 CAPLUS

CN Carbamothioic acid, N,N-dimethyl-,
S-[4-[[[7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl]amino]methyl]phenyl] ester (CA INDEX NAME)




RN 928648-20-8 CAPLUS

CN 1-Butanone, 1-[4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]phenyl]-3-methyl- (CA INDEX NAME)




RN 928649-25-6 CAPLUS

CN Carbamic acid, N-[4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 928649-26-7 CAPLUS

CN Ethanone, 1-[6-[[[(4-aminophenyl)methyl]amino]-7-chloro-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 928649-61-0 CAPLUS
 CN Carbamothioic acid, N,N-dimethyl-,
 S-[4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-
 benzazepin-6-yl]amino]methyl]phenyl] ester (CA INDEX NAME)




RN 928649-62-1 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-chloro-6-[[[4-[(dimethylamino)carbonyl]thio]phenyl]methyl]amino]-
 1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)

10/598,302




RN 928650-44-6 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[4-[1-(methoxyimino)ethyl]phenyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 928650-45-7 CAPLUS

CN 1-Butanone, 1-[4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]phenyl]-3-methyl-, 1-oxime (CA INDEX NAME)



RN 928650-46-8 CAPLUS


CN Ethanone, 1-[[7-chloro-1,2,4,5-tetrahydro-6-[[[4-[2-(methanimino)-4-thiazolyl]phenyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 928650-47-9 CAPLUS


CN Ethanone, 1-[[7-chloro-1,2,4,5-tetrahydro-6-[[[4-[2-(methanimino)-4-oxazolyl]phenyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)

10/598,302




RN 928650-48-0 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[[4-[(cyclopentylthio)methyl]phenyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 928650-49-1 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[[5-[(cyclopentylthio)methyl]-2-pyridinyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 928650-50-4 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[[6-[(2,2-dimethylpropyl)thio]methyl]-3-pyridinyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 928650-51-5 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[[6-[(1,1-dimethylethyl)thio]methyl]-3-pyridinyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 928650-52-6 CAPLUS
 CN Ethanone, 1-[7-chloro-6-[[[6-[(3,3-dimethylcyclohexyl)oxy]-3-pyridinyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 928650-53-7 CAPLUS
 CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[6-[(1-methylethoxy)methyl]-3-pyridinyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)

10/598,302




RN 928650-54-8 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[[5-(cyclohexyloxy)-2-pyridinyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 928650-55-9 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[[5-[(3,3-dimethylcyclohexyl)oxy]-2-pyridinyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)





RN 928650-56-0 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[[6-[(1E)-2-cyclohexylethenyl]-3-pyridinyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)


Double bond geometry as shown.

PAGE 1-A






RN 928650-57-1 CAPLUS
 CN Ethanone, 1-[7-chloro-6-[[[4-(2-cyclohexyl-2-oxoethyl)phenyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 928650-58-2 CAPLUS
 CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[4-(4-morpholinylmethyl)phenyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)

10/598,302




RN 928650-59-3 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[4-(1-piperidinylmethyl)phenyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 928650-60-6 CAPLUS

CN Carbamic acid, N-[[[4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]phenyl]methyl]-N-cyclohexyl-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 928650-61-7 CAPLUS


CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[4-[[methyl(1-methylethyl)amino]methyl]phenyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 928650-62-8 CAPLUS


CN Acetamide, N-[[[6-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]-3-pyridinyl]methyl]-N-cyclohexyl-2,2,2-trifluoro- (CA INDEX NAME)

10/598,302



RN 928650-63-9 CAPLUS


CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[6-(1-piperidinylmethyl)-3-pyridinyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 928650-64-0 CAPLUS

10/598,302


CN Propanamide, N-[4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]phenyl]-2,2-dimethyl- (CA INDEX NAME)



RN 928650-65-1 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]phenyl]-2-methyl-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 928650-68-4 CAPLUS

CN Propanamide, N-[4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]phenyl]-N,2,2-trimethyl- (CA INDEX NAME)


10/598,302

NAME)



RN 928650-69-5 CAPLUS

CN Cyclohexanecarboxamide, N-[4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]phenyl]- (CA INDEX NAME)




RN 928650-70-8 CAPLUS

CN Propanamide, N-[[[4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]phenyl]methyl]-2,2-

10/598,302


dimethyl- (CA INDEX NAME)



RN 928650-71-9 CAPLUS

CN Cyclopropanecarboxamide, N-[[4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]phenyl]methyl]- (CA INDEX NAME)


PAGE 1-A






RN 928650-72-0 CAPLUS

CN Propanamide, N-[2-[4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]phenyl]ethyl]-2,2-dimethyl- (CA INDEX NAME)



RN 928650-73-1 CAPLUS

CN Benzeneacetamide, 4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]-N-(1-methylethyl)- (CA INDEX NAME)




10/598,302

RN 928650-74-2 CAPLUS


CN Benzeneacetamide, 4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 928650-75-3 CAPLUS


CN Benzenepropanamide, 4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]-N-(1,1-dimethylethyl)- (CA INDEX NAME)



10/598,302


RN 928650-76-4 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[[6-[[(2,2-dimethylpropyl)sulfonyl]methyl]-3-pyridinyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 928650-77-5 CAPLUS


CN Ethanone, 1-[7-chloro-6-[[[4-[[(2,2-dimethylpropyl)sulfonyl]methyl]phenyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 928650-78-6 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 7-chloro-6-[[[4-[[(3,3-dimethyl-2-oxobutyl)thio]phenyl]methyl]amino]-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)


10/598,302




RN 928650-79-7 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-1,2,4,5-tetrahydro-6-[[[4-[(2-methoxy-2-
oxoethyl)thio]phenyl]methyl]amino]-, 1,1-dimethylethyl ester (CA INDEX
NAME)




RN 928650-80-0 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-6-[[[4-[[2-[(2,2-dimethylpropyl)amino]-2-
oxoethyl]thio]phenyl]methyl]amino]-1,2,4,5-tetrahydro-, 1,1-dimethylethyl
ester (CA INDEX NAME)



RN 928650-81-1 CAPLUS
 CN 2-Butanone, 1-[[5-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]-2-pyridinyl]oxy]-3,3-dimethyl- (CA INDEX NAME)





RN 928650-82-2 CAPLUS
 CN Acetamide, 2-[[5-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]-2-pyridinyl]oxy]-N-(2,2-dimethylpropyl)- (CA INDEX NAME)



RN 928650-83-3 CAPLUS
 CN Ethanone, 1-[7-chloro-6-[[[4-[5-[(cyclopropylmethyl)amino]-3-isothiazolyl]phenyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)


PAGE 1-A





RN 928650-84-4 CAPLUS


CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[4-[2-[(2,2,2-trifluoroethyl)amino]-4-thiazolyl]phenyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 928650-85-5 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[4-[2-[(3-methylbutyl)amino]-4-thiazolyl]phenyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)


10/598,302




RN 928650-86-6 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[[5-[2-[(cyclopropylmethyl)amino]-4-thiazolyl]-2-pyridinyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 928650-87-7 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]phenyl]-2-thiazolyl]-
(CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 928650-88-8 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[[4-[1-(cyclopropylmethyl)-1H-pyrazol-3-


10/598,302

yl]phenyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 928650-89-9 CAPLUS


CN Ethanone, 1-[7-chloro-6-[[[4-[6-[(cyclopropylmethyl)amino]-4-pyrimidinyl]phenyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)

10/598,302




RN 928650-90-2 CAPLUS

CN 1-Butanone, 1-[5-[4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]phenyl]-2-thienyl]-3,3-dimethyl- (CA INDEX NAME)




RN 928650-91-3 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[[6-[(2,2-dimethylpropyl)sulfonyl]-3-pyridinyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 928650-92-4 CAPLUS


CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[4-[2-[(2,2,2-trifluoroethyl)thio]methyl]-1,3-dioxolan-2-yl]phenyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 928650-93-5 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[4-[2-[(2,2,2-trifluoroethyl)thio]acetyl]phenyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)

10/598,302



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L27 ANSWER 10 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2006:735083 CAPLUS

DOCUMENT NUMBER: 145:167261

TITLE: Preparation of
2-phenoxy-N-(1,3,4-thiadiazol-2-yl)pyridin-3-amine
derivatives and related compounds as P2Y1 receptor
inhibitors for the treatment of thromboembolic
disorders

INVENTOR(S): Sutton, James C.; Pi, Zulan; Ruel, Rejean; L'Heureux,
Alexandre; Thibeault, Carl; Lam, Patrick Y. S.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 295 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006078621	A2	20060727	WO 2006-US1535	20060117
WO 2006078621	A3	20061005		
WO 2006078621	A9	20080619		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2006206611	A1	20060727	AU 2006-206611	20060117
US 20060173002	A1	20060803	US 2006-333050	20060117
US 7645778	B2	20100112		
JP 2008527043	T	20080724	JP 2007-552205	20060117
EP 1954696	A2	20080813	EP 2006-733718	20060117
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, HR, MK			
AR 53011	A1	20070418	AR 2006-100185	20060118
MX 2007008434	A	20070725	MX 2007-8434	20070711
NO 2007003665	A	20071018	NO 2007-3665	20070717
IN 2007DN05767	A	20070817	IN 2007-DN5767	20070725
KR 2007100894	A	20071012	KR 2007-718794	20070817
CN 101142212	A	20080312	CN 2006-80008886	20070919
US 20100093689	A1	20100415	US 2009-619702	20091117
PRIORITY APPLN. INFO.:			US 2005-645285P	P 20050119
			US 2005-749317P	P 20051209
			US 2006-333050	A3 20060117
			WO 2006-US1535	W 20060117


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 145:167261; MARPAT 145:167261

GI




- AB Title compds. I [A = (un)substituted 5-6 membered heteroaryl; X = NH or NMe; Y = O or S; R1 = (un)substituted carbocycle or heterocycle], and their pharmaceutically acceptable salts, are prepared and disclosed as selective inhibitors of the human P2Y1 receptor. Thus, e.g., II was prepared by conversion of 2-(2-tert-butylphenoxy)-3-aminopyridine (preparation given) to the isothiocyanate derivative, then the thiosemicarbazide derivative which undergoes cyclocondensation with benzoyl chloride. I in P2Y1 binding assays have demonstrated K_i values of $\leq 10 \mu\text{M}$, thereby confirming they act to modulate P2Y1 activity. The invention also provides for various pharmaceutical compns. of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.
- IT 143620-35-3, 2,3,4,5-Tetrahydro-1H-benzo[d]azepin-6-ol
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of 2-phenoxy-N-(1,3,4-thiadiazol-2-yl)pyridin-3-amine derivs. and related compound as P2Y1 receptor inhibitors for the treatment of thromboembolic disorders)
- RN 143620-35-3 CAPLUS
- CN 1H-3-Benzazepin-6-ol, 2,3,4,5-tetrahydro- (CA INDEX NAME)



- IT 901308-92-7P, 3-Neopentyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-6-ol
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 2-phenoxy-N-(1,3,4-thiadiazol-2-yl)pyridin-3-amine derivs. and related compound as P2Y1 receptor inhibitors for the treatment of thromboembolic disorders)
- RN 901308-92-7 CAPLUS
- CN 1H-3-Benzazepin-6-ol, 3-(2,2-dimethylpropyl)-2,3,4,5-tetrahydro- (CA INDEX NAME)

10/598,302



OS.CITING REF COUNT:	7	THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
REFERENCE COUNT:	4	THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 11 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2006:31589 CAPLUS

DOCUMENT NUMBER: 144:128979

TITLE: Preparation of fused benzazepines having affinity for the dopamine D3 receptor

INVENTOR(S): Bonanomi, Giorgio; Cardullo, Francesca; Damiani, Federica; Gentile, Gabriella; Hamprecht, Dieter; Micheli, Fabrizio; Tarsi, Luca

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 51 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006002928	A1	20060112	WO 2005-EP7069	20050629
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1773844	A1	20070418	EP 2005-760843	20050629
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV			
JP 2008504332	T	20080214	JP 2007-518542	20050629
US 20080269195	A1	20081030	US 2007-571051	20071217
PRIORITY APPLN. INFO.:			GB 2004-14795	A 20040701
			WO 2005-EP7069	W 20050629

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 144:128979; MARPAT 144:128979

GI



AB The title compds. I [A = 5-6 membered heteroaryl, 5-6 membered heterocyclyl; m = 0-3; R1 = halo, oxo, hydroxy, etc.; R2, R3 = H, Me; q = 2-4; W1, W2 = N, CH, C(alkyl); R4 = H, alkyl; R5 = Z, (CR10R11)tZ; Z = alkyl, haloalkyl, cycloalkyl, etc.; R10, R11 = H, alkyl; t = 1-4; or (CR10R11)t forms cycloalkylene linker], useful in medicine, for example for the treatment of schizophrenia or drug dependency, were prepared E.g., the compound II.HCl was prepared from 2-methyl-7,8,9,10-6H-[1,3]oxazolo[4,5-g][3]benzazepine and 5-{5-[(3-chloropropyl)thio]-4-methyl-4H-1,2,4-triazol-3-yl}-2-methylquinoline (preps. given). The pharmaceutical composition comprising the compound I is disclosed.

IT 36688-74-1P 873446-51-6P 873446-52-7P


873446-59-4P 873446-60-7P 873446-61-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of fused benzazepines having affinity for the dopamine D3 receptor)


RN 36688-74-1 CAPLUS

CN 2H-3-Benzazepin-2-one, 1,3,4,5-tetrahydro-9-methoxy- (CA INDEX NAME)




RN 873446-51-6 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-hydroxy-6-nitro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 873446-52-7 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 6-amino-1,2,4,5-tetrahydro-7-hydroxy-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 873446-59-4 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-6-hydroxy-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 873446-60-7 CAPLUS


CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-6-hydroxy-7-nitro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 873446-61-8 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 7-amino-1,2,4,5-tetrahydro-6-hydroxy-, 1,1-dimethylethyl ester (CA INDEX NAME)

10/598,302



OS.CITING REF COUNT: 6

THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD
(6 CITINGS)

REFERENCE COUNT: 3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 12 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:979618 CAPLUS

DOCUMENT NUMBER: 143:286301

TITLE: Preparation of 6-substituted
2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT_{2c}
receptor agonistsINVENTOR(S): Allen, John Gordon; Briner, Karin; Cohen, Michael
Philip; Galka, Christopher Stanley; Hellman, Sarah
Lynne; Martinez-Grau, Maria Angeles; Reinhard, Matthew
Robert; Rodriguez, Michael John; Rothhaar, Roger Ryan;
Tidwell, Michael Wade; Victor, Frantz; Williams,
Andrew Caerwyn; Zhang, Deyi; Boyd, Steven Armen;
Conway, Richard Gerard; Deo, Arundhati S.; Lee,
Wai-Man; Siedem, Christopher Stephen; Singh, Ajay

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 595 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005082859	A1	20050909	WO 2005-US5418	20050218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005217602	A1	20050909	AU 2005-217602	20050218
CA 2556390	A1	20050909	CA 2005-2556390	20050218
EP 1720836	A1	20061115	EP 2005-723397	20050218
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 1934088	A	20070321	CN 2005-80005788	20050218
BR 2005007986	A	20070724	BR 2005-7986	20050218
JP 2007523951	T	20070823	JP 2007-500906	20050218
NZ 549009	A	20100827	NZ 2005-549009	20050218
AR 48242	A1	20060412	AR 2005-100686	20050224
ZA 2006006580	A	20080227	ZA 2006-6580	20060807
MX 2006009671	A	20061211	MX 2006-9671	20060824
IN 2006KN02479	A	20070525	IN 2006-KN2479	20060831
NO 2006004277	A	20061122	NO 2006-4277	20060921
KR 2007001200	A	20070103	KR 2006-7019634	20060922
KR 848411	B1	20080728		
US 20090099155	A1	20090416	US 2008-598302	20080609
PRIORITY APPLN. INFO.:			US 2004-547681P	P 20040225
			WO 2005-US5418	W 20050218

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 143:286301; MARPAT 143:286301
GI



AB The title compds. I [R1 = H, F, alkyl; R2-R4 = H, Me, Et; R5 = H, F, Me, Et; R6 = C.tplbond.CR10, OR12, SR14, substituted NH2; R7 = H, halo, CN, etc.; R8 = H, halo, CN, SCF3; R9 = H, halo, CN, etc.; R10 = CF3, alkyl, fluoroalkyl, etc.; R12 = pyridylalkyl, thiazolylalkyl, etc.; R13 = cycloalkylalkyl, alkoxy, fluoroalkoxy, etc.; R14 = tetrahydropyranyl, tetrahydrofuranyl, etc.], useful as selective 5-HT_{2c} receptor agonists for the treatment of 5-HT_{2c} associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety, were prepared. Thus, reacting 3-tert-butoxycarbonyl-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine (preparation given) with 3-phenyl-1-propyne followed by deprotection afforded 85% II.HCl. Representative compds. I are found to have excellent affinity for the 5-HT_{2c} receptor, with K_i's typically less than or equal to about 200 nM.

IT 864255-28-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(8; preparation of 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT_{2c} receptor agonists)

RN 864255-28-7 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[(1R)-1-(4-methylphenyl)ethyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)


CM 1

CRN 864255-27-6

CMF C19 H23 Cl N2

Absolute stereochemistry. Rotation (+).

10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4

$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

IT 864255-24-3P 864255-79-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(8prepn. of 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT_{2c} receptor agonists)

RN 864255-24-3 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-N-[1-(3-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)


CM 1

CRN 864255-23-2

CMF C18 H20 Cl2 N2

Rotation (+).

10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4

$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$


RN 864255-79-8 CAPLUS

CN Butanedioic acid, compd. with 5-[[2-(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-2,2-dimethyl-3(2H)-benzofuranone (1:1) (CA INDEX NAME)

CM 1

CRN 864255-78-7

CMF C21 H23 Cl N2 O2



CM 2

CRN 110-15-6

10/598,302

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

IT 1044693-90-4 1044693-92-6 1044693-96-0


1044693-99-3

RL: PRPH (Prophetic)

(Preparation of 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT_{2c} receptor agonists)

RN 1044693-90-4 CAPLUS

CN Benzenecarbothioamide, 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-(1,1-dimethylethyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 1044693-92-6 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-6-[[(2,6-difluorophenyl)methyl]thio]-2,3,4,5-tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)


10/598,302



● HCl

RN 1044693-96-0 CAPLUS


CN Ethanone, 2-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]-1-(4-fluorophenyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 1044693-99-3 CAPLUS

CN 1H-3-Benzazepin-6-amine, 2,3,4,5-tetrahydro-7-propyl-N-(2-thienylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

IT 864254-88-6P 864256-84-8P 864256-85-9P
 864257-09-0P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2c receptor agonists)
 RN 864254-88-6 CAPLUS
 CN Butanedioic acid, compd. with 7-chloro-N-[1-(3-fluorophenyl)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)
 CM 1
 CRN 864254-87-5
 CMF C18 H20 Cl F N2




CM 2
 CRN 110-15-6
 CMF C4 H6 O4

10/598,302



RN 864256-84-8 CAPLUS


CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[2,2,2-trifluoro-1-(2-pyridinyl)ethyl]thio]-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl

RN 864256-85-9 CAPLUS


CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[1-(2-pyridinyl)propyl]thio]-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl

RN 864257-09-0 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[(2-pyridinylmethyl)thio]-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl

IT	864251-52-5P	864251-53-6P	864251-54-7P
	864251-55-8P	864251-57-0P	864251-59-2P
	864251-61-6P	864251-62-7P	864251-63-8P
	864251-64-9P	864251-65-0P	864251-66-1P
	864251-67-2P	864251-69-4P	864251-71-8P
	864251-72-9P	864251-73-0P	864251-74-1P
	864251-75-2P	864251-77-4P	864251-79-6P
	864251-80-9P	864251-81-0P	864251-82-1P
	864251-83-2P	864251-84-3P	864251-85-4P
	864251-86-5P	864251-87-6P	864251-88-7P
	864251-89-8P	864251-90-1P	864251-91-2P
	864251-92-3P	864251-93-4P	864251-94-5P
	864251-95-6P	864251-96-7P	864251-97-8P
	864251-98-9P	864251-99-0P	864252-00-6P
	864252-01-7P	864252-02-8P	864252-03-9P
	864252-04-0P	864252-06-2P	864252-07-3P
	864252-08-4P	864252-09-5P	864252-10-8P
	864252-11-9P	864252-12-0P	864252-13-1P
	864252-14-2P	864252-15-3P	864252-16-4P
	864252-17-5P	864252-18-6P	864252-19-7P
	864252-21-1P	864252-23-3P	864252-25-5P
	864252-27-7P	864252-29-9P	864252-31-3P
	864252-33-5P	864252-34-6P	864252-35-7P
	864252-36-8P	864252-37-9P	864252-38-0P
	864252-39-1P	864252-40-4P	864252-41-5P
	864252-42-6P	864252-43-7P	864252-44-8P
	864252-45-9P	864252-47-1P	864252-49-3P
	864252-51-7P	864252-53-9P	864252-55-1P
	864252-57-3P	864252-59-5P	864252-61-9P
	864252-62-0P	864252-63-1P	864252-64-2P
	864252-65-3P	864252-66-4P	864252-68-6P
	864252-70-0P	864252-72-2P	864252-74-4P
	864252-76-6P	864252-78-8P	864252-80-2P
	864252-82-4P	864252-84-6P	864252-86-8P
	864252-88-0P	864252-90-4P	864252-92-6P
	864252-94-8P	864252-95-9P	864252-96-0P
	864252-98-2P	864253-00-9P	864253-02-1P
	864253-04-3P	864253-06-5P	864253-08-7P

864253-10-1P	864253-12-3P	864253-14-5P
864253-16-7P	864253-18-9P	864253-20-3P
864253-22-5P	864253-24-7P	864253-25-8P
864253-27-0P	864253-29-2P	864253-31-6P
864253-33-8P	864253-34-9P	864253-36-1P
864253-37-2P	864253-39-4P	864253-41-8P
864253-42-9P	864253-44-1P	864253-45-2P
864253-46-3P	864253-47-4P	864253-49-6P
864253-51-0P	864253-53-2P	864253-55-4P
864253-57-6P	864253-58-7P	864253-59-8P
864253-61-2P	864253-62-3P	864253-63-4P
864253-64-5P	864253-65-6P	864253-66-7P
864253-67-8P	864253-68-9P	864253-69-0P
864253-71-4P	864253-74-7P	864253-76-9P
864253-78-1P	864253-80-5P	864253-81-6P
864253-82-7P	864253-84-9P	864253-85-0P
864253-86-1P	864253-87-2P	864253-88-3P
864253-89-4P	864253-90-7P	864253-91-8P
864253-93-0P	864253-95-2P	864253-97-4P
864253-99-6P	864254-01-3P	864254-03-5P
864254-05-7P	864254-07-9P	864254-09-1P
864254-11-5P	864254-13-7P	864254-15-9P
864254-17-1P	864254-19-3P	864254-21-7P
864254-23-9P	864254-25-1P	864254-27-3P
864254-29-5P	864254-31-9P	864254-33-1P
864254-35-3P	864254-36-4P	864254-37-5P
864254-39-7P	864254-41-1P	864254-43-3P
864254-45-5P	864254-47-7P	864254-49-9P
864254-51-3P	864254-53-5P	864254-55-7P
864254-57-9P	864254-58-0P	864254-60-4P
864254-62-6P	864254-64-8P	864254-66-0P
864254-68-2P	864254-70-6P	864254-72-8P
864254-74-0P	864254-76-2P	864254-78-4P
864254-80-8P	864254-82-0P	864254-84-2P
864254-86-4P	864254-90-0P	864254-92-2P
864254-94-4P	864254-96-6P	864254-98-8P
864255-00-5P	864255-02-7P	864255-04-9P
864255-06-1P	864255-08-3P	864255-10-7P
864255-12-9P	864255-14-1P	864255-16-3P
864255-18-5P	864255-20-9P	


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT_{2c} receptor agonists)

RN 864251-52-5 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-6-(3-phenyl-1-propyn-1-yl)-, hydrochloride (1:1) (CA INDEX NAME)

10/598,302




● HCl

RN 864251-53-6 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-6-(4-phenyl-1-butyn-1-yl)-,
hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 864251-54-7 CAPLUS
CN 1H-3-Benzazepine, 6-(3-cyclopentyl-1-propyn-1-yl)-2,3,4,5-tetrahydro-,
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 864251-55-8 CAPLUS
CN 1H-3-Benzazepine, 6-(3-cyclohexyl-1-propyn-1-yl)-2,3,4,5-tetrahydro-,
hydrochloride (1:1) (CA INDEX NAME)

10/598,302



● HCl


RN 864251-57-0 CAPLUS

CN Butanedioic acid, compd. with 6-(3,3-dimethyl-1-butyn-1-yl)-2,3,4,5-tetrahydro-1H-3-benzazepine (1:1) (CA INDEX NAME)

CM 1

CRN 864251-56-9

CMF C16 H21 N



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864251-59-2 CAPLUS


CN Butanedioic acid, compd. with 6-(3,3-dimethyl-1-butyn-1-yl)-7-fluoro-2,3,4,5-tetrahydro-1H-3-benzazepine (1:1) (CA INDEX NAME)

CM 1

CRN 864251-58-1

CMF C16 H20 F N


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4




RN 864251-61-6 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-6-[(4-fluorophenyl)methoxy]-2,3,4,5-tetrahydro-1H-3-benzazepine (1:1) (CA INDEX NAME)

CM 1

CRN 864251-60-5


CMF C17 H17 Cl F N O



CM 2

CRN 110-15-6


CMF C4 H6 O4



RN 864251-62-7 CAPLUS

10/598,302


CN Benzonitrile, 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)oxy]methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 864251-63-8 CAPLUS

CN Ethanone, 2-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)oxy]-1-(4-fluorophenyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 864251-64-9 CAPLUS


CN Benzenesulfonamide, 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)oxy]methyl]-N-methyl-, hydrochloride (1:1) (CA INDEX NAME)

10/598,302



● HCl


RN 864251-65-0 CAPLUS
CN Benzenesulfonamide, 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)oxy]methyl]-N-ethyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 864251-66-1 CAPLUS
CN Benzenesulfonamide, 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)oxy]methyl]-N-(2-fluoroethyl)-, hydrochloride (1:1) (CA INDEX NAME)

10/598,302



● HCl

RN 864251-67-2 CAPLUS
CN 1H-3-Benzazepine, 7-chloro-9-fluoro-6-[(4-fluorophenyl)methoxy]-2,3,4,5-tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 864251-69-4 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-6-(2-pyridinylmethoxy)-1H-3-benzazepine (1:1) (CA INDEX NAME)

CM 1

CRN 864251-68-3

10/598,302

CMF C16 H17 Cl N2 O



CM 2

CRN 110-15-6

CMF C4 H6 O4

$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$


RN 864251-71-8 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-6-(3-pyridinylmethoxy)-1H-3-benzazepine (2:1) (CA INDEX NAME)

CM 1

CRN 864251-70-7

CMF C16 H17 Cl N2 O



CM 2

CRN 110-15-6


10/598,302

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864251-72-9 CAPLUS


CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-(2-thiazolylmethoxy)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 864251-73-0 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-(5-thiazolylmethoxy)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 864251-74-1 CAPLUS


CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[(5-methyl-3-isoxazolyl)methoxy]-, hydrochloride (1:1) (CA INDEX NAME)

10/598,302



● HCl

RN 864251-75-2 CAPLUS
CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[(1-methyl-1H-pyrazol-3-yl)methoxy]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 864251-77-4 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-6-[3-(methylthio)propoxy]-1H-3-benzazepine (1:1) (CA INDEX NAME)

CM 1

CRN 864251-76-3
CMF C14 H20 Cl N O S


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4




RN 864251-79-6 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-6-[4-(methylthio)butoxy]-1H-3-benzazepine (1:1) (CA INDEX NAME)

CM 1

CRN 864251-78-5


CMF C15 H22 Cl N O S



CM 2

CRN 110-15-6


CMF C4 H6 O4



RN 864251-80-9 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[3-(2-pyridinyl)propoxy]-, hydrochloride (1:?) (CA INDEX NAME)


10/598,302



● x HCl

RN 864251-81-0 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[2-(4-methyl-5-thiazolyl)ethoxy]-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 864251-82-1 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[2-(2-pyridinyl)ethoxy]-, hydrochloride (1:?) (CA INDEX NAME)


10/598,302



●x HCl

RN 864251-83-2 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[3-(3-pyridinyl)propoxy]-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 864251-84-3 CAPLUS

CN 1H-3-Benzazepine, 6-[3-(1H-benzimidazol-2-yl)propoxy]-7-chloro-2,3,4,5-tetrahydro-, hydrochloride (1:?) (CA INDEX NAME)


10/598,302



●_x HCl

RN 864251-85-4 CAPLUS


CN Benzamide, N-[2-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)oxy]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 864251-86-5 CAPLUS

CN Benzamide, 4-chloro-N-[2-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)oxy]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 864251-87-6 CAPLUS


CN Benzamide, 3-chloro-N-[2-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)oxy]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 864251-88-7 CAPLUS


CN Benzamide, 2-chloro-N-[2-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)oxy]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)

10/598,302



RN 864251-89-8 CAPLUS


CN Benzamide, N-[2-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)oxy]ethyl]-4-fluoro-, hydrochloride (1:1) (CA INDEX NAME)




RN 864251-90-1 CAPLUS

CN 4-Pyridinecarboxamide, N-[2-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)oxy]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)

10/598,302




RN 864251-91-2 CAPLUS
CN Cyclopropanecarboxamide, N-[2-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)oxy]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 864251-92-3 CAPLUS
CN 1-Pyrrolidinecarboxamide, N-[2-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)oxy]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)

10/598,302



RN 864251-93-4 CAPLUS


CN Cyclohexanecarboxamide, N-[2-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)oxy]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 864251-94-5 CAPLUS

CN Carbamic acid, [3-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)oxy]propyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)


10/598,302



● HCl

RN 864251-95-6 CAPLUS


CN Benzamide, N-[3-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)oxy]propyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 864251-96-7 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)oxy]propyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 864251-97-8 CAPLUS
 CN Carbamic acid, [4-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)oxy]butyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 864251-98-9 CAPLUS
 CN Benzamide, N-[4-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)oxy]butyl]-, hydrochloride (1:1) (CA INDEX NAME)


10/598,302



● HCl

RN 864251-99-0 CAPLUS

CN Benzamide, N-[2-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)oxy]ethyl]-2-fluoro-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 864252-00-6 CAPLUS


CN 2-Pyridinecarboxamide, N-[2-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)oxy]ethyl]-, hydrochloride (1:?) (CA INDEX NAME)

10/598,302



RN 864252-01-7 CAPLUS


CN 3-Pyridinecarboxamide, N-[2-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)oxy]ethyl]-, hydrochloride (1:?) (CA INDEX NAME)



RN 864252-02-8 CAPLUS

CN Urea, N-[2-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)oxy]ethyl]-N'-phenyl-, hydrochloride (1:1) (CA INDEX NAME)


10/598,302



● HCl

RN 864252-03-9 CAPLUS


CN Urea, N-[3-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)oxy]propyl]-N'-phenyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 864252-04-0 CAPLUS

CN Urea, N-[4-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)oxy]butyl]-N'-phenyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 864252-06-2 CAPLUS


10/598,302

CN Butanedioic acid, compd. with methyl
4-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)oxy]butanoate (1:1)
(CA INDEX NAME)

CM 1

CRN 864252-05-1


CMF C15 H20 Cl N O3



CM 2


CRN 110-15-6

CMF C4 H6 O4



RN 864252-07-3 CAPLUS


CN Benzamide, N-[2-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]ethyl]-, hydrochloride (1:?) (CA INDEX NAME)



●_x HCl


RN 864252-08-4 CAPLUS

CN Benzamide, N-[2-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]ethyl]-2-fluoro-, hydrochloride (1:?) (CA INDEX NAME)



RN 864252-09-5 CAPLUS

CN Benzamide, N-[3-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]propyl]-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 864252-10-8 CAPLUS

CN Benzamide, N-[3-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]propyl]-2-fluoro-, hydrochloride (1:?) (CA INDEX NAME)


10/598,302



●x HCl

RN 864252-11-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[2-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]ethyl]-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 864252-12-0 CAPLUS

CN Urea, N-[3-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]propyl]-N'-phenyl-, hydrochloride (1:?) (CA INDEX NAME)


10/598,302



●x HCl

RN 864252-13-1 CAPLUS


CN 1H-3-Benzazepin-6-amine, 2,3,4,5-tetrahydro-N-(2-phenoxycarbonyl)-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 864252-14-2 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-(2-phenylethyl)-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 864252-15-3 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[2-(3-fluorophenyl)ethyl]-2,3,4,5-tetrahydro-, hydrochloride (1:?) (CA INDEX NAME)


10/598,302



● x HCl

RN 864252-16-4 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-(2-thiazolylmethyl)-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 864252-17-5 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-[(2-methyl-4-thiazolyl)methyl]-, hydrochloride (1:?) (CA INDEX NAME)


10/598,302



● x HCl

RN 864252-18-6 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-[2-(2-pyridinyl)ethyl]-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 864252-19-7 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-[2-(2-thienyl)ethyl]-, hydrochloride (1:?) (CA INDEX NAME)

10/598,302



● x HCl


RN 864252-21-1 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-N-(2-ethoxyethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864252-20-0


CMF C14 H21 Cl N2 O



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864252-23-3 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-(2-propoxyethyl)-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)


CM 1

CRN 864252-22-2

CMF C15 H23 Cl N2 O

10/598,302

n-PrO-CH₂-CH₂-NH



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864252-25-5 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[2-(1-methylethoxy)ethyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864252-24-4

CMF C15 H23 Cl N2 O

i-PrO-CH₂-CH₂-NH



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864252-27-7 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[2-(phenylmethoxy)ethyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864252-26-6

CMF C19 H23 Cl N2 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864252-29-9 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[(1R)-1-methyl-2-(phenylmethoxy)ethyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864252-28-8

CMF C20 H25 Cl N2 O


Absolute stereochemistry.



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864252-31-3 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[(1R)-1-methyl-2-phenoxyethyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

10/598,302

CRN 864252-30-2
CMF C19 H23 Cl N2 O

Absolute stereochemistry.



CM 2

CRN 110-15-6
CMF C4 H6 O4


$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 864252-33-5 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-N-[(1R)-2-[(4-fluorophenyl)methoxy]-1-methylethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864252-32-4
CMF C20 H24 Cl F N2 O

Absolute stereochemistry.



CM 2

CRN 110-15-6


10/598,302

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864252-34-6 CAPLUS


CN 1H-3-Benzazepin-6-amine, N-[(2-fluorophenyl)methyl]-2,3,4,5-tetrahydro-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 864252-35-7 CAPLUS


CN 1H-3-Benzazepin-6-amine, N-[(2,6-difluorophenyl)methyl]-2,3,4,5-tetrahydro-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 864252-36-8 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[(2-fluorophenyl)methyl]-2,3,4,5-tetrahydro-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 864252-37-9 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[(3-fluorophenyl)methyl]-2,3,4,5-tetrahydro-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 864252-38-0 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-, hydrochloride (1:?) (CA INDEX NAME)


10/598,302



● x HCl

RN 864252-39-1 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[(2,3-difluorophenyl)methyl]-2,3,4,5-tetrahydro-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 864252-40-4 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[(3,4-difluorophenyl)methyl]-2,3,4,5-tetrahydro-, hydrochloride (1:?) (CA INDEX NAME)


10/598,302



●x HCl

RN 864252-41-5 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[(3,5-difluorophenyl)methyl]-2,3,4,5-tetrahydro-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 864252-42-6 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-[(3,4,5-trifluorophenyl)methyl]-, hydrochloride (1:?) (CA INDEX NAME)


10/598,302



●x HCl

RN 864252-43-7 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-[[3-(trifluoromethyl)phenyl]methyl]-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 864252-44-8 CAPLUS

CN 1H-3-Benzazepin-6-amine, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7-chloro-2,3,4,5-tetrahydro-, hydrochloride (1:?) (CA INDEX NAME)


10/598,302



●x HCl

RN 864252-45-9 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-2,3,4,5-tetrahydro-, hydrochloride
(1:?) (CA INDEX NAME)



●x HCl

RN 864252-47-1 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[[4-(1,1-dimethylethyl)phenyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine
(1:1) (CA INDEX NAME)

CM 1

CRN 864252-46-0

CMF C21 H27 Cl N2


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4




RN 864252-49-3 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-N-[[3-(1,1-dimethylethyl)phenyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864252-48-2

CMF C21 H27 Cl N2



CM 2

10/598,302


CRN 110-15-6
CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864252-51-7 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-(trifluoromethoxy)phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864252-50-6
CMF C18 H18 Cl F3 N2 O



CM 2

CRN 110-15-6
CMF C4 H6 O4


HO₂C-CH₂-CH₂-CO₂H

RN 864252-53-9 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-N-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864252-52-8
CMF C18 H17 Cl F4 N2


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4




RN 864252-55-1 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-N-[(4-fluoro-3-methoxyphenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1)
(CA INDEX NAME)

CM 1

CRN 864252-54-0

CMF C18 H20 Cl F N2 O



10/598,302

CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H


RN 864252-57-3 CAPLUS

CN Butanedioic acid, compd. with N-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864252-56-2

CMF C23 H23 Cl N2



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864252-59-5 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[(4-phenoxyphenyl)methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864252-58-4

CMF C23 H23 Cl N2 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4




RN 864252-61-9 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-(methylsulfonyl)phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864252-60-8

CMF C18 H21 Cl N2 O2 S



10/598,302

CM 2


CRN 110-15-6

CMF C4 H6 O4

$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 864252-62-0 CAPLUS

CN Benzonitrile, 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]- (CA INDEX NAME)



RN 864252-63-1 CAPLUS


CN Butanedioic acid, compd. with 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]benzonitrile (1:1) (CA INDEX NAME)

CM 1

CRN 864252-62-0

CMF C18 H18 Cl N3


10/598,302



CM 2


CRN 110-15-6

CMF C4 H6 O4



RN 864252-64-2 CAPLUS

CN 1H-3-Benzazepin-6-amine, N-([1,1'-biphenyl]-3-ylmethyl)-7-chloro-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 864252-65-3 CAPLUS


CN Butanedioic acid, compd. with N-([1,1'-biphenyl]-3-ylmethyl)-7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864252-64-2

CMF C23 H23 Cl N2

10/598,302




CM 2

CRN 110-15-6
CMF C4 H6 O4

$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 864252-66-4 CAPLUS
CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[(4-chlorophenyl)methyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 864252-68-6 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-N-[(3-chlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1


CRN 864252-67-5
CMF C17 H18 Cl2 N2

10/598,302



CM 2


CRN 110-15-6
CMF C4 H6 O4



RN 864252-70-0 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-N-[(3-chloro-4-fluorophenyl)methyl]-
2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864252-69-7
CMF C17 H17 Cl2 F N2



CM 2

CRN 110-15-6

10/598,302

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H


RN 864252-72-2 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-N-[(2-chloro-4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864252-71-1

CMF C17 H17 Cl2 F N2



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864252-74-4 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[(3-methoxyphenyl)methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864252-73-3

CMF C18 H21 Cl N2 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4




RN 864252-76-6 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-N-[(2-fluoro-4-methylphenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864252-75-5

CMF C18 H20 Cl F N2



CM 2

CRN 110-15-6

10/598,302

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H


RN 864252-78-8 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[3-(trifluoromethoxy)phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864252-77-7

CMF C18 H18 Cl F3 N2 O



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864252-80-2 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[(3-chloro-4-methoxyphenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864252-79-9

CMF C18 H20 Cl2 N2 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4




RN 864252-82-4 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-(phenylmethoxy)phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864252-81-3

CMF C24 H25 Cl N2 O



10/598,302

CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H


RN 864252-84-6 CAPLUS

CN Butanedioic acid, compd. with 1-[4-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenoxy]-3,3-dimethyl-2-butanone (1:1) (CA INDEX NAME)

CM 1

CRN 864252-83-5

CMF C23 H29 Cl N2 O2



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864252-86-8 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[[4-(2,2-dimethylpropoxy)phenyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864252-85-7

10/598,302


CMF C22 H29 Cl N2 O



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864252-88-0 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[[4-(2-cyclohexylethoxy)phenyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1


CRN 864252-87-9

CMF C25 H33 Cl N2 O

PAGE 1-A




PAGE 2-A



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864252-90-4 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-(1H-pyrazol-1-yl)phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864252-89-1

CMF C20 H21 Cl N4


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864252-92-6 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-(3-pyridinyloxy)phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864252-91-5

CMF C22 H22 Cl N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864252-94-8 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-[(phenylmethyl)thio]phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864252-93-7

CMF C24 H25 Cl N2 S


10/598,302



CM 2


CRN 110-15-6

CMF C4 H6 O4



RN 864252-95-9 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[(2-fluoro-4-phenoxyphenyl)methyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 864252-96-0 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[2-fluoro-4-(3-fluorophenoxy)phenyl]methyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)

10/598,302




RN 864252-98-2 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-N-[[4-(2-fluorophenoxy)phenyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864252-97-1

CMF C23 H22 Cl F N2 O



CM 2

10/598,302


CRN 110-15-6
CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864253-00-9 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-N-[[4-(3-fluorophenoxy)phenyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864252-99-3
CMF C23 H22 Cl F N2 O



CM 2

CRN 110-15-6
CMF C4 H6 O4


HO₂C-CH₂-CH₂-CO₂H

RN 864253-02-1 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-N-[[4-(4-fluorophenoxy)phenyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1


10/598,302

CRN 864253-01-0
CMF C23 H22 Cl F N2 O



CM 2

CRN 110-15-6
CMF C4 H6 O4




RN 864253-04-3 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-N-[[4-(3-chlorophenoxy)phenyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864253-03-2
CMF C23 H22 Cl2 N2 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864253-06-5 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[[4-(3,5-difluorophenoxy)phenyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864253-05-4

CMF C23 H21 Cl F2 N2 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864253-08-7 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-(4-methylphenoxy)phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864253-07-6

CMF C24 H25 Cl N2 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864253-10-1 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-(3-methylphenoxy)phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864253-09-8

CMF C24 H25 Cl N2 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864253-12-3 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-(2-methylphenoxy)phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864253-11-2

CMF C24 H25 Cl N2 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864253-14-5 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-[3-(1-methylethyl)phenoxy]phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864253-13-4

CMF C26 H29 Cl N2 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864253-16-7 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-[2-(1-methylethyl)phenoxy]phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864253-15-6

CMF C26 H29 Cl N2 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864253-18-9 CAPLUS


CN Butanedioic acid, compd. with 2-[4-[[[7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl]amino]methyl]phenoxy]benzonitrile (1:1) (CA INDEX NAME)

CM 1

CRN 864253-17-8

CMF C24 H22 Cl N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864253-20-3 CAPLUS


CN Butanedioic acid, compd. with 3-[4-[[[7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl]amino]methyl]phenoxy]benzonitrile (1:1) (CA INDEX NAME)

CM 1

CRN 864253-19-0

CMF C24 H22 Cl N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864253-22-5 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-[2-(trifluoromethyl)phenoxy]phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864253-21-4

CMF C24 H22 Cl F3 N2 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864253-24-7 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-[3-(trifluoromethyl)phenoxy]phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864253-23-6

CMF C24 H22 Cl F3 N2 O


10/598,302



CM 2

CRN 110-15-6


CMF C4 H6 O4



RN 864253-25-8 CAPLUS

CN Benzonitrile, 3-[[4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenoxy]methyl]- (CA INDEX NAME)

10/598,302



RN 864253-27-0 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864253-26-9

CMF C24 H24 Cl F N2 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864253-29-2 CAPLUS


CN Butanedioic acid, compd. with 2-[4-[[[7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl]amino]methyl]phenoxy]-1-phenylethanone (1:1) (CA INDEX NAME)

CM 1

CRN 864253-28-1

CMF C25 H25 Cl N2 O2


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864253-31-6 CAPLUS


CN Butanedioic acid, compd. with 2-[4-[[[7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl]amino]methyl]phenoxy]-1-(4-fluorophenyl)ethanone (1:1)
(CA INDEX NAME)

CM 1


CRN 864253-30-5

CMF C25 H24 Cl F N2 O2

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-15-6

CMF C4 H6 O4

 $\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 864253-33-8 CAPLUS

CN Butanedioic acid, compd. with 2-[4-[[4-(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenoxy]-1-(1-piperidinyl)ethanone (1:1) (CA INDEX NAME)


CM 1

CRN 864253-32-7


10/598,302

CMF C24 H30 Cl N3 O2

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-15-6


CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864253-34-9 CAPLUS

CN 2-Butanone, 1-[2-chloro-4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenoxy]-3,3-dimethyl- (CA INDEX NAME)

10/598,302




RN 864253-36-1 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-N-[[3-chloro-4-(phenylmethoxy)phenyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864253-35-0


CMF C24 H24 Cl2 N2 O



CM 2

CRN 110-15-6


CMF C4 H6 O4



10/598,302

RN 864253-37-2 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-[[4-(1-phenylethoxy)phenyl]methyl]- (CA INDEX NAME)



RN 864253-39-4 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-(1-phenylethoxy)phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864253-38-3

CMF C25 H27 Cl N2 O

Rotation (+).



10/598,302

CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864253-41-8 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-(1-phenylethoxy)phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864253-40-7

CMF C₂₅ H₂₇ Cl N₂ O

Rotation (-).



CM 2

CRN 110-15-6


CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864253-42-9 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[4-(3,3-dimethylbutoxy)phenyl]methyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)

10/598,302




RN 864253-44-1 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[4-(cyclohexylmethoxy)phenyl]methyl]-2,3,4,5-tetrahydro-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 864253-43-0

CMF C24 H31 Cl N2 O




CM 2

CRN 75-75-2


CMF C H4 O3 S

10/598,302



RN 864253-45-2 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-[[3-(1-pyrrolidinyl)phenyl]methyl]- (CA INDEX NAME)




RN 864253-46-3 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[3-(1-pyrrolidinyl)phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864253-45-2

CMF C21 H26 Cl N3




CM 2

CRN 110-15-6


CMF C4 H6 O4

10/598,302



RN 864253-47-4 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-[(4-methoxyphenyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 864253-49-6 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-(2,2,3,3-tetrafluoropropoxy)phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864253-48-5

CMF C20 H21 Cl F4 N2 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4




RN 864253-51-0 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-(2,2,3,3,3-pentafluoropropoxy)phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864253-50-9

CMF C20 H20 Cl F5 N2 O



10/598,302

CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H


RN 864253-53-2 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-(2,2,2-trifluoro-1,1-dimethylethoxy)phenyl]methyl]-1H-3-benzazepin-6-amine (1:1)
(CA INDEX NAME)

CM 1

CRN 864253-52-1

CMF C21 H24 Cl F3 N2 O



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864253-55-4 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-(2,2,2-trifluoro-1-methylethoxy)phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)


CM 1

CRN 864253-54-3

10/598,302

CMF C20 H22 Cl F3 N2 O

Rotation (-).



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864253-57-6 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-(2,2,2-trifluoro-1-methylethoxy)phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)


CM 1

CRN 864253-56-5

CMF C20 H22 Cl F3 N2 O

Rotation (+).


10/598,302



CM 2


CRN 110-15-6

CMF C4 H6 O4



RN 864253-58-7 CAPLUS

CN Ethanone, 1-[4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]- (CA INDEX NAME)



RN 864253-59-8 CAPLUS


CN Butanedioic acid, compd. with 1-[4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]ethanone (1:1) (CA INDEX NAME)

10/598,302

CM 1

CRN 864253-58-7


CMF C19 H21 Cl N2 O



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864253-61-2 CAPLUS


CN Butanedioic acid, compd. with 1-[3-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]ethanone (1:1) (CA INDEX NAME)

CM 1

CRN 864253-60-1


CMF C19 H21 Cl N2 O

10/598,302




CM 2

CRN 110-15-6
CMF C4 H6 O4



RN 864253-62-3 CAPLUS
CN Ethanone, 1-[4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]-, oxime (CA INDEX NAME)




RN 864253-63-4 CAPLUS
CN Butanedioic acid, compd. with 1-[4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]ethanone oxime (1:1) (CA INDEX NAME)

CM 1

CRN 864253-62-3

10/598,302


CMF C19 H22 Cl N3 O



CM 2


CRN 110-15-6

CMF C4 H6 O4



RN 864253-64-5 CAPLUS

CN Methanone, [4-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]phenyl- (CA INDEX NAME)



RN 864253-65-6 CAPLUS


10/598,302

CN Butanedioic acid, compd. with [4-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]phenylmethanone (1:1) (CA INDEX NAME)

CM 1

CRN 864253-64-5

CMF C24 H23 Cl N2 O



CM 2

CRN 110-15-6


CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864253-66-7 CAPLUS

CN Methanone, [4-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]phenyl-, oxime (CA INDEX NAME)

10/598,302




RN 864253-67-8 CAPLUS

CN Butanedioic acid, compd. with [4-[[7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl]amino]methyl]phenyl]phenylmethanone oxime (1:1) (CA INDEX NAME)

CM 1

CRN 864253-66-7

CMF C24 H24 Cl N3 O




CM 2

CRN 110-15-6


CMF C4 H6 O4

10/598,302



RN 864253-68-9 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-[[4-(4-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 864253-69-0 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-(4-pyridinyl)phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864253-68-9

CMF C22 H22 Cl N3



10/598,302

CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H


RN 864253-71-4 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-(2-pyridinyl)phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864253-70-3

CMF C22 H22 Cl N3



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864253-74-7 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-(1,2,3-thiadiazol-4-yl)phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864253-73-6

CMF C19 H19 Cl N4 S


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864253-76-9 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-(2-methyl-4-thiazolyl)phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864253-75-8

CMF C21 H22 Cl N3 S

10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4


$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 864253-78-1 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[4-(4,5-dihydro-5-phenyl-1H-imidazol-2-yl)phenyl]methyl]-2,3,4,5-tetrahydro-, hydrochloride (1:?), (-)- (CA INDEX NAME)

Rotation (-).

10/598,302




RN 864253-80-5 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-(1-methyl-1H-imidazol-2-yl)phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864253-79-2

CMF C21 H23 Cl N4



CM 2

CRN 110-15-6


10/598,302

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864253-81-6 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[4-(ethylsulfonyl)phenyl]methyl]-
2,3,4,5-tetrahydro-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 864253-82-7 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-[[4-[(1-
methylethyl)sulfonyl]phenyl]methyl]-, hydrochloride (1:?) (CA INDEX NAME)

10/598,302



● x HCl


RN 864253-84-9 CAPLUS

CN Butanedioic acid, compd. with methyl
4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-
yl)amino]methyl]benzoate (1:1) (CA INDEX NAME)

CM 1

CRN 864253-83-8

CMF C19 H21 Cl N2 O2




CM 2

10/598,302

CRN 110-15-6
CMF C4 H6 O4

$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$


RN 864253-85-0 CAPLUS
CN Benzoic acid, 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl

RN 864253-86-1 CAPLUS
CN Benzamide, 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-methyl-, hydrochloride (1:?) (CA INDEX NAME)


10/598,302



● x HCl

RN 864253-87-2 CAPLUS

CN Benzamide, 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N,N-dimethyl-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 864253-88-3 CAPLUS


CN Benzamide, 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-(1-methylethyl)-, hydrochloride (1:?) (CA INDEX NAME)

10/598,302



●x HCl


RN 864253-89-4 CAPLUS
CN Benzamide, 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-(1,1-dimethylethyl)-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl


RN 864253-90-7 CAPLUS
CN Benzamide, 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-(1,1-dimethylethyl)-2-fluoro-, hydrochloride (1:?) (CA INDEX NAME)

10/598,302



● x HCl

RN 864253-91-8 CAPLUS
CN Benzamide, 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-2-fluoro-N-methyl-N-propyl-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl


RN 864253-93-0 CAPLUS
CN Butanedioic acid, compd. with 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-cyclohexyl-2-fluorobenzamide (1:1) (CA INDEX NAME)

10/598,302

CM 1

CRN 864253-92-9


CMF C24 H29 Cl F N3 O



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864253-95-2 CAPLUS


CN Butanedioic acid, compd. with 4-[[7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl]amino]methyl]-N-(2,2,2-trifluoroethyl)benzamide (1:1) (CA INDEX NAME)

CM 1

CRN 864253-94-1

CMF C20 H21 Cl F3 N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864253-97-4 CAPLUS


CN Butanedioic acid, compd. with 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl) amino]methyl]-N-(3,3,3-trifluoropropyl)benzamide (1:1)
(CA INDEX NAME)

CM 1

CRN 864253-96-3

CMF C21 H23 Cl F3 N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864253-99-6 CAPLUS


CN Butanedioic acid, compd. with 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl) amino]methyl]-N-(2,2,3,3,3-pentafluoropropyl)benzamide (1:1) (CA INDEX NAME)

CM 1

CRN 864253-98-5

CMF C21 H21 Cl F5 N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864254-01-3 CAPLUS


CN Butanedioic acid, compd. with 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-(2,2,2-trifluoro-1-methylethyl)benzamide (1:1) (CA INDEX NAME)

CM 1

CRN 864254-00-2

CMF C21 H23 Cl F3 N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864254-03-5 CAPLUS


CN Butanedioic acid, compd. with 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-(3,3,3-trifluoro-1-methylpropyl)benzamide (1:1) (CA INDEX NAME)

CM 1

CRN 864254-02-4

CMF C22 H25 Cl F3 N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864254-05-7 CAPLUS


CN Butanedioic acid, compd. with 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-cyclopentylbenzamide (1:1) (CA INDEX NAME)

CM 1

CRN 864254-04-6

CMF C23 H28 Cl N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864254-07-9 CAPLUS


CN Butanedioic acid, compd. with 4-[[7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl]amino]methyl]-N-cyclohexylbenzamide (1:1) (CA INDEX NAME)

CM 1

CRN 864254-06-8

CMF C24 H30 Cl N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864254-09-1 CAPLUS


CN Butanedioic acid, compd. with 4-[[[7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl]amino]methyl]-N-cycloheptylbenzamide (1:1) (CA INDEX NAME)

CM 1

CRN 864254-08-0

CMF C25 H32 Cl N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864254-11-5 CAPLUS


CN Butanedioic acid, compd. with 4-[[7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl]amino]methyl]-N-(phenylmethyl)benzamide (1:1) (CA INDEX NAME)

CM 1

CRN 864254-10-4

CMF C25 H26 Cl N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864254-13-7 CAPLUS


CN Butanedioic acid, compd. with 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-[(3,4-difluorophenyl)methyl]benzamide (1:1) (CA INDEX NAME)

CM 1


CRN 864254-12-6

CMF C25 H24 Cl F2 N3 O

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864254-15-9 CAPLUS


CN Butanedioic acid, compd. with 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl) amino]methyl]-N- (1-methyl-1-phenylethyl) benzamide (1:1)
(CA INDEX NAME)

CM 1

CRN 864254-14-8

10/598,302


CMF C27 H30 Cl N3 O



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864254-17-1 CAPLUS


CN Butanedioic acid, compd. with 4-[[7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl]amino]methyl]-N-(1-methyl-2-phenylethyl)benzamide (1:1)
(CA INDEX NAME)

CM 1

CRN 864254-16-0

CMF C27 H30 Cl N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864254-19-3 CAPLUS


CN Butanedioic acid, compd. with 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-(4-methylphenyl)benzamide (1:1) (CA INDEX NAME)

CM 1


CRN 864254-18-2

CMF C25 H26 Cl N3 O

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864254-21-7 CAPLUS

CN Butanedioic acid, compd. with N-(4-chlorophenyl)-4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]benzamide (1:1) (CA INDEX NAME)


CM 1

CRN 864254-20-6


10/598,302

CMF C24 H23 Cl2 N3 O

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H


RN 864254-23-9 CAPLUS

CN Butanedioic acid, compd. with 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-(tetrahydro-2H-pyran-4-yl)benzamide (1:1)
(CA INDEX NAME)

CM 1

10/598,302

CRN 864254-22-8
CMF C23 H28 Cl N3 O2



CM 2

CRN 110-15-6
CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H


RN 864254-25-1 CAPLUS
CN Butanedioic acid, compd. with (-)-4-[[[7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl]amino]methyl]-N-(2,2,2-trifluoro-1-methylethyl)benzamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 864254-24-0
CMF C21 H23 Cl F3 N3 O

Rotation (-).


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864254-27-3 CAPLUS

CN Butanedioic acid, compd. with (+)-4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-(2,2,2-trifluoro-1-methylethyl)benzamide (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 864254-26-2

CMF C21 H23 Cl F3 N3 O

Rotation (+).


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864254-29-5 CAPLUS

CN Butanedioic acid, compd. with (+)-4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-(3,3,3-trifluoro-1-methylpropyl)benzamide (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 864254-28-4

CMF C22 H25 Cl F3 N3 O

Rotation (+).


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864254-31-9 CAPLUS

CN Butanedioic acid, compd. with (-)-4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-(3,3,3-trifluoro-1-methylpropyl)benzamide (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 864254-30-8

CMF C22 H25 Cl F3 N3 O

Rotation (-).

10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864254-33-1 CAPLUS

CN Butanedioic acid, compd. with 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-[(1R)-1-phenylethyl]benzamide (1:1) (CA INDEX NAME)


CM 1

CRN 864254-32-0

CMF C26 H28 Cl N3 O

Absolute stereochemistry. Rotation (+).


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864254-35-3 CAPLUS

CN Butanedioic acid, compd. with 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-[(1S)-1-phenylethyl]benzamide (1:1) (CA INDEX NAME)


CM 1

CRN 864254-34-2

CMF C26 H28 Cl N3 O

Absolute stereochemistry. Rotation (-).

10/598,302



CM 2

CRN 110-15-6


CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H


RN 864254-36-4 CAPLUS

CN Benzamide, 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-[2-(2-thienyl)ethyl]- (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 864254-37-5 CAPLUS
 CN Butanedioic acid, compd. with 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl) amino]methyl]-N-[2-(2-thienyl)ethyl]benzamide (1:1) (CA INDEX NAME)

CM 1

CRN 864254-36-4
 CMF C24 H26 Cl N3 O S



CM 2

CRN 110-15-6

CMF C4 H6 O4

 $\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 864254-39-7 CAPLUS

CN Butanedioic acid, compd. with 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl) amino]methyl]-N-(2-thienylmethyl)benzamide (1:1) (CA INDEX NAME)


CM 1

CRN 864254-38-6


10/598,302

CMF C23 H24 Cl N3 O S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864254-41-1 CAPLUS


CN Butanedioic acid, compd. with 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-(2-pyridinylmethyl)benzamide (1:1) (CA INDEX NAME)

CM 1


10/598,302

CRN 864254-40-0
CMF C24 H25 Cl N4 O

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-15-6
CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864254-43-3 CAPLUS
CN Butanedioic acid, compd. with 4-[[[7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl]amino]methyl]-N-[[3-(trifluoromethyl)-2-pyridinyl]methyl]benzamide (1:1) (CA INDEX NAME)

10/598,302


benzazepin-6-yl]amino]methyl]-N-[[4-(trifluoromethyl)-2-pyridinyl]methyl]benzamide (1:1) (CA INDEX NAME)

CM 1


CRN 864254-44-4

CMF C25 H24 Cl F3 N4 O

PAGE 1-A




PAGE 2-A



CM 2

CRN 110-15-6

CMF C4 H6 O4



10/598,302


RN 864254-47-7 CAPLUS
CN Butanedioic acid, compd. with 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-[[5-(trifluoromethyl)-2-pyridinyl]methyl]benzamide (1:1) (CA INDEX NAME)

CM 1


CRN 864254-46-6

CMF C25 H24 Cl F3 N4 O

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-15-6

CMF C4 H6 O4

10/598,302



RN 864254-49-9 CAPLUS


CN Butanedioic acid, compd. with 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-[(3-fluoro-2-pyridinyl)methyl]benzamide (1:1) (CA INDEX NAME)

CM 1


CRN 864254-48-8

CMF C24 H24 Cl F N4 O

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-15-6

10/598,302

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864254-51-3 CAPLUS


CN Butanedioic acid, compd. with 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl) amino]methyl]-N-[(5-fluoro-2-pyridinyl)methyl]benzamide (1:1) (CA INDEX NAME)

CM 1


CRN 864254-50-2

CMF C24 H24 Cl F N4 O

PAGE 1-A



PAGE 2-A



CM 2

10/598,302

CRN 110-15-6
CMF C4 H6 O4


HO₂C—CH₂—CH₂—CO₂H

RN 864254-53-5 CAPLUS
CN Butanedioic acid, compd. with 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-[(6-fluoro-2-pyridinyl)methyl]benzamide (1:1) (CA INDEX NAME)


CM 1

CRN 864254-52-4
CMF C₂₄ H₂₄ Cl F N₄ O

PAGE 1-A



PAGE 2-A



10/598,302

CM 2

CRN 110-15-6

CMF C4 H6 O4

$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 864254-55-7 CAPLUS


CN Butanedioic acid, compd. with 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-[2-(3-pyridinyl)ethyl]benzamide (1:1) (CA INDEX NAME)


CM 1

CRN 864254-54-6

CMF C25 H27 Cl N4 O

PAGE 1-A






CM 2

CRN 110-15-6

CMF C4 H6 O4




RN 864254-57-9 CAPLUS

CN Butanedioic acid, compd. with 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl) amino]methyl]-N-[2-(4-pyridinyl)ethyl]benzamide (1:1) (CA INDEX NAME)


CM 1

CRN 864254-56-8

CMF C25 H27 Cl N4 O




PAGE 2-A



CM 2

CRN 110-15-6


CMF C4 H6 O4





RN 864254-58-0 CAPLUS

CN Benzamide, 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-[2-(2-pyridinyl)ethyl]-, hydrochloride (1:?) (CA INDEX NAME)

PAGE 1-A






RN 864254-60-4 CAPLUS
 CN Butanedioic acid, compd. with [4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]1-piperidinylmethanone (1:1) (CA INDEX NAME)


CM 1

CRN 864254-59-1
 CMF C23 H28 Cl N3 O



CM 2

CRN 110-15-6
 CMF C4 H6 O4



RN 864254-62-6 CAPLUS


10/598,302

CN Butanedioic acid, compd. with 5-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl) amino]methyl]-N-cyclohexyl-2-pyridinecarboxamide (1:1)
(CA INDEX NAME)

CM 1

CRN 864254-61-5

CMF C23 H29 Cl N4 O



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864254-64-8 CAPLUS


CN Butanedioic acid, compd. with 5-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl) amino]methyl]-N-[(4-fluorophenyl)methyl]-2-pyridinecarboxamide (1:1) (CA INDEX NAME)

CM 1


CRN 864254-63-7

CMF C24 H24 Cl F N4 O

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-15-6

CMF C4 H6 O4

 $\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 864254-66-0 CAPLUS

 CN Butanedioic acid, compd. with 7-chloro-N-[(1S)-1-(4-fluorophenyl)ethyl]-
 2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)


CM 1

CRN 864254-65-9

CMF C18 H20 Cl F N2

10/598,302

Absolute stereochemistry. Rotation (-).



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864254-68-2 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-N-[(1R)-1-(4-fluorophenyl)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)


CM 1

CRN 864254-67-1

CMF C18 H20 Cl F N2

Absolute stereochemistry. Rotation (+).

10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4

$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 864254-70-6 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[1-(2-fluorophenyl)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864254-69-3

CMF C18 H20 Cl F N2

Rotation (+).



10/598,302

CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864254-72-8 CAPLUS


CN Butanedioic acid, compd. with 4-[1-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]ethyl]benzonitrile (1:1) (CA INDEX NAME)

CM 1

CRN 864254-71-7

CMF C19 H20 Cl N3

Rotation (+).



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864254-74-0 CAPLUS

CN Butanedioic acid, compd. with 4-[1-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]ethyl]benzonitrile (1:1) (CA INDEX NAME)


CM 1

CRN 864254-73-9

CMF C19 H20 Cl N3

10/598,302

Rotation (-).



CM 2

CRN 110-15-6

CMF C4 H6 O4

$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 864254-76-2 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[1-(2,3-difluorophenyl)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864254-75-1

CMF C18 H19 Cl F2 N2

Rotation (+).



10/598,302

CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864254-78-4 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[1-(2,3-difluorophenyl)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864254-77-3

CMF C18 H19 Cl F2 N2

Rotation (-).



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864254-80-8 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-N-[1-(2,4-difluorophenyl)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)


CM 1

CRN 864254-79-5

CMF C18 H19 Cl F2 N2

Rotation (+).

10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4

$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 864254-82-0 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[1-(2,4-difluorophenyl)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864254-81-9

CMF C18 H19 Cl F2 N2

Rotation (-).



10/598,302

CM 2

CRN 110-15-6

CMF C4 H6 O4

$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 864254-84-2 CAPLUS


CN Butanedioic acid, compd. with N-[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864254-83-1

CMF C20 H19 Cl F6 N2

Rotation (-).



CM 2

CRN 110-15-6

CMF C4 H6 O4

$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 864254-86-4 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-[1-[2-(trifluoromethoxy)phenyl]ethyl]-, ethanedioate (1:1), (+)- (CA INDEX NAME)


CM 1

CRN 864254-85-3

CMF C19 H20 Cl F3 N2 O

10/598,302


Rotation (+).



CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 864254-90-0 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[1-(3-fluorophenyl)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864254-89-7

CMF C18 H20 Cl F N2

Rotation (+).



10/598,302

CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864254-92-2 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[1-(3-fluorophenyl)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864254-91-1

CMF C18 H20 Cl F N2

Rotation (-).



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864254-94-4 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[1-(2-fluorophenyl)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864254-93-3

CMF C18 H20 Cl F N2

10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4

$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 864254-96-6 CAPLUS


CN Butanedioic acid, compd. with 3-[1-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]ethyl]benzonitrile (1:1) (CA INDEX NAME)

CM 1

CRN 864254-95-5

CMF C19 H20 Cl N3

Rotation (+).



CM 2

CRN 110-15-6

10/598,302

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864254-98-8 CAPLUS


CN Butanedioic acid, compd. with 3-[1-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]ethyl]benzonitrile (1:1) (CA INDEX NAME)

CM 1

CRN 864254-97-7

CMF C19 H20 Cl N3

Rotation (-).



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864255-00-5 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[(1S)-1-phenylethyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)


CM 1

CRN 864254-99-9

CMF C18 H21 Cl N2

Absolute stereochemistry. Rotation (-).


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864255-02-7 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[(1R)-1-phenylethyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864255-01-6

CMF C18 H21 Cl N2


Absolute stereochemistry. Rotation (+).



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864255-04-9 CAPLUS

10/598,302


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[1-[4-(trifluoromethyl)phenyl]ethyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864255-03-8

CMF C19 H20 Cl F3 N2

Rotation (+).



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864255-06-1 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864255-05-0

CMF C19 H20 Cl F3 N2

10/598,302



CM 2

CRN 110-15-6
CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H


RN 864255-08-3 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-N-[1-(3,4-difluorophenyl)ethyl]-
2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864255-07-2
CMF C18 H19 Cl F2 N2

Rotation (-).



CM 2

10/598,302

CRN 110-15-6
CMF C4 H6 O4


HO₂C—CH₂—CH₂—CO₂H

RN 864255-10-7 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-N-[1-(3,4-difluorophenyl)ethyl]-
2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864255-09-4
CMF C18 H19 Cl F2 N2

Rotation (+).



CM 2

CRN 110-15-6
CMF C4 H6 O4


HO₂C—CH₂—CH₂—CO₂H

RN 864255-12-9 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[1-(3,4,5-trifluorophenyl)ethyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864255-11-8
CMF C18 H18 Cl F3 N2


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4




RN 864255-14-1 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[1-(3-methoxyphenyl)ethyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864255-13-0

CMF C19 H23 Cl N2 O




CM 2

CRN 110-15-6

CMF C4 H6 O4

10/598,302




RN 864255-16-3 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[1-(4-methoxyphenyl)ethyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864255-15-2


CMF C19 H23 Cl N2 O



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864255-18-5 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[1-(4-phenoxyphenyl)ethyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)


CM 1

CRN 864255-17-4

CMF C24 H25 Cl N2 O

Rotation (+).


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864255-20-9 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[1-(4-phenoxyphenyl)ethyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864255-19-6

CMF C24 H25 Cl N2 O

Rotation (-).



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

IT	864255-21-0P	864255-22-1P	864255-26-5P
	864255-30-1P	864255-32-3P	864255-34-5P
	864255-36-7P	864255-37-8P	864255-38-9P
	864255-39-0P	864255-40-3P	864255-41-4P
	864255-42-5P	864255-43-6P	864255-44-7P
	864255-45-8P	864255-46-9P	864255-47-0P
	864255-49-2P	864255-51-6P	864255-53-8P
	864255-55-0P	864255-56-1P	864255-58-3P
	864255-60-7P	864255-62-9P	864255-64-1P
	864255-66-3P	864255-68-5P	864255-69-6P
	864255-71-0P	864255-73-2P	864255-75-4P
	864255-77-6P	864255-81-2P	864255-83-4P
	864255-84-5P	864255-85-6P	864255-86-7P
	864255-87-8P	864255-88-9P	864255-89-0P
	864255-90-3P	864255-92-5P	864255-94-7P
	864255-96-9P	864255-98-1P	864256-00-8P
	864256-02-0P	864256-03-1P	864256-05-3P
	864256-07-5P	864256-09-7P	864256-11-1P
	864256-13-3P	864256-15-5P	864256-16-6P
	864256-17-7P	864256-18-8P	864256-19-9P
	864256-21-3P	864256-23-5P	864256-25-7P
	864256-27-9P	864256-29-1P	864256-31-5P
	864256-33-7P	864256-35-9P	864256-37-1P
	864256-39-3P	864256-40-6P	864256-41-7P
	864256-43-9P	864256-44-0P	864256-45-1P
	864256-46-2P	864256-47-3P	864256-48-4P
	864256-49-5P	864256-50-8P	864256-51-9P
	864256-52-0P	864256-53-1P	864256-54-2P
	864256-55-3P	864256-56-4P	864256-57-5P
	864256-58-6P	864256-59-7P	864256-60-0P
	864256-62-2P	864256-63-3P	864256-64-4P
	864256-66-6P	864256-68-8P	864256-69-9P
	864256-70-2P	864256-71-3P	864256-72-4P
	864256-73-5P	864256-74-6P	864256-75-7P
	864256-76-8P	864256-78-0P	864256-79-1P
	864256-80-4P	864256-81-5P	864256-82-6P
	864256-83-7P	864256-87-1P	864256-89-3P
	864256-90-6P	864256-91-7P	864256-92-8P
	864256-93-9P	864256-95-1P	864256-96-2P
	864256-97-3P	864256-98-4P	864256-99-5P
	864257-00-1P	864257-01-2P	864257-02-3P
	864257-03-4P	864257-04-5P	864257-05-6P
	864257-06-7P	864257-08-9P	864257-11-4P
	864257-12-5P	864257-13-6P	864257-14-7P
	864257-16-9P	864257-17-0P	864257-18-1P
	864257-19-2P	864257-20-5P	864257-21-6P

864257-22-7P	864257-23-8P	864257-24-9P
864257-25-0P	864257-26-1P	864257-27-2P
864257-28-3P	864257-29-4P	864257-30-7P
864257-31-8P	864257-32-9P	864257-33-0P
864257-35-2P	864257-36-3P	864257-37-4P
864257-38-5P	864257-39-6P	864257-40-9P
864257-41-0P	864257-42-1P	864257-44-3P
864257-46-5P	864257-48-7P	864257-49-8P
864257-50-1P	864257-51-2P	864257-52-3P
864257-53-4P	864257-54-5P	864257-57-8P
864257-60-3P	864257-63-6P	864257-66-9P
864257-69-2P	864257-72-7P	864257-75-0P
864257-78-3P	864257-81-8P	864257-83-0P
864257-85-2P	864257-87-4P	864257-88-5P
864257-89-6P	864257-90-9P	864257-91-0P
864257-92-1P	864257-93-2P	864257-94-3P
864257-95-4P	864257-96-5P	864257-97-6P
864257-98-7P	864257-99-8P	864258-00-4P
864258-02-6P	864258-03-7P	864258-04-8P
864258-05-9P	864258-06-0P	864258-07-1P
864258-10-6P	864258-12-8P	864258-13-9P
864258-14-0P	864258-15-1P	864258-16-2P
864258-17-3P	864258-18-4P	864258-19-5P
864258-20-8P	864258-21-9P	864258-22-0P
864258-23-1P	864258-24-2P	864258-25-3P
864258-26-4P	864258-27-5P	864258-28-6P
864258-30-0P	864258-32-2P	864258-33-3P
864258-34-4P	864258-35-5P	864258-36-6P
864258-37-7P	864258-38-8P	864258-39-9P
864258-40-2P	864258-41-3P	864258-42-4P
864258-43-5P	864258-44-6P	864258-45-7P
864258-46-8P	864258-47-9P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT_{2c} receptor agonists)

RN 864255-21-0 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[1-(3-chloro-4-fluorophenyl)ethyl]-2,3,4,5-tetrahydro-, (-)- (CA INDEX NAME)

Rotation (-).

10/598,302




RN 864255-22-1 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-N-[1-(3-chloro-4-fluorophenyl)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864255-21-0
CMF C18 H19 Cl2 F N2

Rotation (-).



CM 2

CRN 110-15-6
CMF C4 H6 O4

10/598,302

HO₂C—CH₂—CH₂—CO₂H

RN 864255-26-5 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[1-(2-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864255-25-4

CMF C18 H20 Cl2 N2

Rotation (+).



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864255-30-1 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[(1S)-1-(4-methylphenyl)ethyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)


CM 1

CRN 864255-29-8

CMF C19 H23 Cl N2

Absolute stereochemistry. Rotation (-).

10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864255-32-3 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-N-[1-(3-chloro-4-fluorophenyl)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)


CM 1

CRN 864255-31-2

CMF C18 H19 Cl2 F N2

Rotation (+).

10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4

$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 864255-34-5 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[1-(3,5-difluorophenyl)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864255-33-4

CMF C18 H19 Cl F2 N2

Rotation (-).



10/598,302

CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864255-36-7 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[1-(3,5-difluorophenyl)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864255-35-6

CMF C18 H19 Cl F2 N2

Rotation (+).



CM 2

CRN 110-15-6


CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864255-37-8 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)


10/598,302



RN 864255-38-9 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-, (-)- (CA INDEX NAME)

Rotation (-).



RN 864255-39-0 CAPLUS

CN Butanedioic acid, compd. with (-)-7-chloro-N-[1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)


CM 1

CRN 864255-38-9

CMF C18 H20 Cl2 N2

Rotation (-).

10/598,302



CM 2

CRN 110-15-6


CMF C4 H6 O4

$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 864255-40-3 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-, (+)- (CA INDEX NAME)

Rotation (+).



RN 864255-41-4 CAPLUS

CN Butanedioic acid, compd. with (+)-7-chloro-N-[1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)


10/598,302

CM 1

CRN 864255-40-3

CMF C18 H20 Cl2 N2

Rotation (+).



CM 2

CRN 110-15-6


CMF C4 H6 O4

$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 864255-42-5 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[1-(2,5-difluorophenyl)ethyl]-2,3,4,5-tetrahydro-, (+)- (CA INDEX NAME)

Rotation (+).



10/598,302

RN 864255-43-6 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[1-(2,5-difluorophenyl)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864255-42-5

CMF C18 H19 Cl F2 N2

Rotation (+).



CM 2

CRN 110-15-6

CMF C4 H6 O4


HO₂C—CH₂—CH₂—CO₂H

RN 864255-44-7 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[1-(2,5-difluorophenyl)ethyl]-2,3,4,5-tetrahydro-, (-)- (CA INDEX NAME)

Rotation (-).

10/598,302



RN 864255-45-8 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[1-(2,5-difluorophenyl)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864255-44-7

CMF C18 H19 Cl F2 N2

Rotation (-).



CM 2

CRN 110-15-6

CMF C4 H6 O4


HO₂C-CH₂-CH₂-CO₂H

RN 864255-46-9 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[1-(3,5-difluoro-4-methoxyphenyl)ethyl]-2,3,4,5-tetrahydro-, (-)- (CA INDEX NAME)

10/598,302

Rotation (-).



RN 864255-47-0 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[1-(3,5-difluoro-4-methoxyphenyl)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864255-46-9

CMF C19 H21 Cl F2 N2 O

Rotation (-).




CM 2

CRN 110-15-6

CMF C4 H6 O4

10/598,302




RN 864255-49-2 CAPLUS
CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-[(1R)-1-(2-methylphenyl)ethyl]-, ethanedioate (1:1) (CA INDEX NAME)

CM 1


CRN 864255-48-1
CMF C19 H23 Cl N2

Absolute stereochemistry. Rotation (+).



CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 864255-51-6 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-N-[(1R)-2,3-dihydro-1H-inden-1-yl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864255-50-5
CMF C19 H21 Cl N2

Absolute stereochemistry. Rotation (+).

10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864255-53-8 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-(5-fluoro-2,3-dihydro-1H-inden-1-yl)-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864255-52-7

CMF C19 H20 Cl F N2

Rotation (+).



CM 2

CRN 110-15-6

CMF C4 H6 O4


HO₂C—CH₂—CH₂—CO₂H

10/598,302

RN 864255-55-0 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-N-(2,3-dihydro-3-benzofuranyl)-
2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)


CM 1

CRN 864255-54-9
CMF C18 H19 Cl N2 O




CM 2

CRN 110-15-6
CMF C4 H6 O4



RN 864255-56-1 CAPLUS
CN 1H-3-Benzazepin-6-amine, 7-chloro-N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 864255-58-3 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-methyl-N-(1-phenylethyl)-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

10/598,302

CRN 864255-57-2
CMF C19 H23 Cl N2

Rotation (-).



CM 2


CRN 110-15-6
CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864255-60-7 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-methyl-N-(phenylmethyl)-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864255-59-4
CMF C18 H21 Cl N2



CM 2

CRN 110-15-6
CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

10/598,302


RN 864255-62-9 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-N-[(3-fluorophenyl)methyl]-2,3,4,5-tetrahydro-N-methyl-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864255-61-8

CMF C18 H20 Cl F N2



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H


RN 864255-64-1 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-(1-phenylcyclopropyl)-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864255-63-0

CMF C19 H21 Cl N2



10/598,302

CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H


RN 864255-66-3 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-N-[1-(2,4-dichlorophenyl)cyclopropyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864255-65-2

CMF C19 H19 Cl3 N2



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864255-68-5 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[(2,3-dihydro-3-benzofuranyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864255-67-4

CMF C19 H21 Cl N2 O


10/598,302



CM 2


CRN 110-15-6

CMF C4 H6 O4



RN 864255-69-6 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[(2,3-dihydro-5-benzofuranyl)methyl]-
2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 864255-71-0 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[(2,3-dihydro-3-methyl-5-benzofuranyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864255-70-9

CMF C20 H23 Cl N2 O

10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4

$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$


RN 864255-73-2 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-N-[(2,3-dihydro-3-methyl-6-benzofuranyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864255-72-1

CMF C20 H23 Cl N2 O



CM 2

CRN 110-15-6

CMF C4 H6 O4


$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

10/598,302

RN 864255-75-4 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-N-[(2,3-dihydro-3,3-dimethyl-6-benzofuranyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864255-74-3
CMF C21 H25 Cl N2 O



CM 2


CRN 110-15-6
CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864255-77-6 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-N-[(2,3-dihydro-3,3-dimethyl-5-benzofuranyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864255-76-5
CMF C21 H25 Cl N2 O



10/598,302

CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H


RN 864255-81-2 CAPLUS

CN Butanedioic acid, compd. with 6-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl) amino]methyl]-2,2-dimethyl-3(2H)-benzofuranone (1:1) (CA INDEX NAME)

CM 1

CRN 864255-80-1

CMF C21 H23 Cl N2 O2



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864255-83-4 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[(3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-6-yl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864255-82-3


CMF C22 H27 Cl N2 O

10/598,302




CM 2

CRN 110-15-6
CMF C4 H6 O4



RN 864255-84-5 CAPLUS
CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-(2-naphthalenylmethyl)- (CA INDEX NAME)




RN 864255-85-6 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-(2-naphthalenylmethyl)-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864255-84-5
CMF C21 H21 Cl N2


10/598,302



CM 2


CRN 110-15-6

CMF C4 H6 O4



RN 864255-86-7 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-(6-quinolinylmethyl)-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 864255-87-8 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-(3-isoquinolinylmethyl)-, hydrochloride (1:?) (CA INDEX NAME)


10/598,302



● x HCl

RN 864255-88-9 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-(3-quinolinylmethyl)-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 864255-89-0 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-(2-quinolinylmethyl)-, hydrochloride (1:?) (CA INDEX NAME)


10/598,302



●x HCl

RN 864255-90-3 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-[(2-phenyl-5-benzoxazolyl)methyl]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 864255-92-5 CAPLUS


CN Butanedioic acid, compd. with N-(6-benzofuranylmethyl)-7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864255-91-4

CMF C19 H19 Cl N2 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4




RN 864255-94-7 CAPLUS

CN Butanedioic acid, compd. with N-(1,3-benzodioxol-4-ylmethyl)-7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864255-93-6


CMF C18 H19 Cl N2 O2



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864255-96-9 CAPLUS


10/598,302

CN Butanedioic acid, compd. with N-(1,3-benzodioxol-5-ylmethyl)-7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864255-95-8

CMF C18 H19 Cl N2 O2



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO2C-CH2-CH2-CO2H


RN 864255-98-1 CAPLUS

CN Butanedioic acid, compd. with N-(benzo[b]thien-4-ylmethyl)-7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864255-97-0

CMF C19 H19 Cl N2 S



10/598,302

CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H


RN 864256-00-8 CAPLUS

CN Butanedioic acid, compd. with N-(benzo[b]thien-6-ylmethyl)-7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864255-99-2

CMF C19 H19 Cl N2 S



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864256-02-0 CAPLUS


CN 1H-3-Benzazepin-6-amine, N-(6-benzothiazolylmethyl)-7-chloro-2,3,4,5-tetrahydro-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 864256-01-9


CMF C18 H18 Cl N3 S

10/598,302




CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 864256-03-1 CAPLUS
CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-(8-chloroquinolin-2-ylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)




●x HCl

RN 864256-05-3 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-N-[(2-cyclohexyl-6-benzothiazolyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1


10/598,302

CRN 864256-04-2
CMF C24 H28 Cl N3 S



CM 2


CRN 110-15-6
CMF C4 H6 O4



RN 864256-07-5 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[(2-phenyl-6-benzothiazolyl)methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864256-06-4
CMF C24 H22 Cl N3 S



CM 2

CRN 110-15-6

10/598,302

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H


RN 864256-09-7 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[2-(phenylmethyl)-6-benzothiazolyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864256-08-6

CMF C25 H24 Cl N3 S



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864256-11-1 CAPLUS


CN Butanedioic acid, compd. with N-(5-benzoxazolylmethyl)-7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864256-10-0

CMF C18 H18 Cl N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4




RN 864256-13-3 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[(1-methyl-1H-indol-4-yl)methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864256-12-2

CMF C20 H22 Cl N3




CM 2

CRN 110-15-6

CMF C4 H6 O4

10/598,302




RN 864256-15-5 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[(1-methyl-1H-indol-6-yl)methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864256-14-4


CMF C20 H22 Cl N3



CM 2

CRN 110-15-6


CMF C4 H6 O4



RN 864256-16-6 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-(2-pyridinylmethyl)-, hydrochloride (1:?) (CA INDEX NAME)


10/598,302



● x HCl

RN 864256-17-7 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-(4-pyridinylmethyl)-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 864256-18-8 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-[1-(4-pyridinyl)ethyl]- (CA INDEX NAME)

10/598,302




RN 864256-19-9 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[1-(4-pyridinyl)ethyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864256-18-8

CMF C17 H20 Cl N3



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H


RN 864256-21-3 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-N-[(5-fluoro-3-pyridinyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

10/598,302

CRN 864256-20-2
CMF C16 H17 Cl F N3



CM 2


CRN 110-15-6
CMF C4 H6 O4

$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 864256-23-5 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[6-(trifluoromethyl)-3-pyridinyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864256-22-4
CMF C17 H17 Cl F3 N3



10/598,302

CM 2

CRN 110-15-6
CMF C4 H6 O4


HO₂C—CH₂—CH₂—CO₂H

RN 864256-25-7 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-(trifluoromethyl)-3-pyridinyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864256-24-6
CMF C17 H17 Cl F3 N3



CM 2

CRN 110-15-6
CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H


RN 864256-27-9 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[6-(trifluoromethyl)-2-pyridinyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864256-26-8
CMF C17 H17 Cl F3 N3


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4




RN 864256-29-1 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-N-[(5-fluoro-2-pyridinyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864256-28-0

CMF C16 H17 Cl F N3




CM 2

CRN 110-15-6

CMF C4 H6 O4


10/598,302



RN 864256-31-5 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[5-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)


CM 1

CRN 864256-30-4
CMF C18 H19 Cl F3 N3 O



CM 2

CRN 110-15-6
CMF C4 H6 O4




RN 864256-33-7 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[5-(2,2,2-trifluoro-1,1-dimethylethoxy)-2-pyridinyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864256-32-6
CMF C20 H23 Cl F3 N3 O

10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864256-35-9 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[5-(2,2,2-trifluoro-1-methylethoxy)-2-pyridinyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864256-34-8

CMF C19 H21 Cl F3 N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864256-37-1 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[5-(2,2,2-trifluoro-1-methylethoxy)-2-pyridinyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)


CM 1

CRN 864256-36-0

CMF C19 H21 Cl F3 N3 O

Rotation (-).


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864256-39-3 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[5-(2,2,2-trifluoro-1-methylethoxy)-2-pyridinyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)


CM 1

CRN 864256-38-2

CMF C19 H21 Cl F3 N3 O

Rotation (+).


10/598,302



CM 2


CRN 110-15-6

CMF C4 H6 O4



RN 864256-40-6 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-[1-(2-thienyl)ethyl]- (CA INDEX NAME)




RN 864256-41-7 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[1-(2-thienyl)ethyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

10/598,302

CRN 864256-40-6
CMF C16 H19 Cl N2 S



CM 2

CRN 110-15-6
CMF C4 H6 O4


HO₂C-CH₂-CH₂-CO₂H

RN 864256-43-9 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[1-(2-thienyl)ethyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864256-42-8
CMF C16 H19 Cl N2 S

Rotation (+).




CM 2

10/598,302

CRN 110-15-6
CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H


RN 864256-44-0 CAPLUS
CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-[1-(5-methyl-2-thienyl)ethyl]- (CA INDEX NAME)



RN 864256-45-1 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[1-(5-methyl-2-thienyl)ethyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864256-44-0
CMF C17 H21 Cl N2 S



CM 2


10/598,302

CRN 110-15-6
CMF C4 H6 O4

$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 864256-46-2 CAPLUS
CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-[1-(5-phenyl-2-thienyl)ethyl]-, (+)- (CA INDEX NAME)

Rotation (+).




RN 864256-47-3 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[1-(5-phenyl-2-thienyl)ethyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864256-46-2
CMF C22 H23 Cl N2 S

Rotation (+).



10/598,302

CM 2

CRN 110-15-6


CMF C4 H6 O4

$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 864256-48-4 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-[1-(5-phenyl-2-thienyl)ethyl]-, (-)- (CA INDEX NAME)

Rotation (-).



RN 864256-49-5 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[1-(5-phenyl-2-thienyl)ethyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)


CM 1

CRN 864256-48-4

CMF C22 H23 Cl N2 S

Rotation (-).

10/598,302



CM 2


CRN 110-15-6

CMF C4 H6 O4

$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 864256-50-8 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-[1-(3-thienyl)ethyl]- (CA INDEX NAME)



RN 864256-51-9 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[1-(3-thienyl)ethyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864256-50-8

CMF C16 H19 Cl N2 S


10/598,302



CM 2


CRN 110-15-6

CMF C4 H6 O4



RN 864256-52-0 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-[(5-methyl-2-furanyl)methyl]-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 864256-53-1 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[3-(4-chlorophenyl)-5-isoxazolyl]methyl]-2,3,4,5-tetrahydro-, hydrochloride (1:?) (CA INDEX NAME)

10/598,302



RN 864256-54-2 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-[[3-(4-methoxyphenyl)-5-isoxazolyl]methyl]-, hydrochloride (1:?) (CA INDEX NAME)



RN 864256-55-3 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-(5-thiazolylmethyl)- (CA INDEX NAME)

10/598,302



RN 864256-56-4 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-3-pyridinyl- (CA INDEX NAME)




RN 864256-57-5 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-3-pyridinyl-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864256-56-4

CMF C15 H16 Cl N3



10/598,302

CM 2


CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864256-58-6 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7,9-dichloro-N-[(3,4-difluorophenyl)methyl]-
2,3,4,5-tetrahydro-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 864256-59-7 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-9-fluoro-N-[(3-fluorophenyl)methyl]-
2,3,4,5-tetrahydro- (CA INDEX NAME)




10/598,302

RN 864256-60-0 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-9-fluoro-N-[(3-fluorophenyl)methyl]-
2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864256-59-7
CMF C17 H17 Cl F2 N2



CM 2

CRN 110-15-6
CMF C4 H6 O4


HO₂C—CH₂—CH₂—CO₂H

RN 864256-62-2 CAPLUS
CN Butanedioic acid, compd. with 7-fluoro-N-[(4-fluorophenyl)methyl]-2,3,4,5-
tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864256-61-1
CMF C17 H18 F2 N2


10/598,302



CM 2


CRN 110-15-6

CMF C4 H6 O4



RN 864256-63-3 CAPLUS

CN 1H-3-Benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro-6-[(phenylmethyl)amino]- (CA INDEX NAME)



RN 864256-64-4 CAPLUS


CN Butanedioic acid, compd. with 2,3,4,5-tetrahydro-6-[(phenylmethyl)amino]-1H-3-benzazepine-7-carbonitrile (1:1) (CA INDEX NAME)

CM 1

CRN 864256-63-3

CMF C18 H19 N3


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4




RN 864256-66-6 CAPLUS

CN Butanedioic acid, compd. with 6-[[[4-fluorophenyl)methyl]amino]-2,3,4,5-tetrahydro-1H-3-benzazepine-7-carbonitrile (1:1) (CA INDEX NAME)

CM 1

CRN 864256-65-5


CMF C18 H18 F N3



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864256-68-8 CAPLUS


10/598,302

CN Butanedioic acid, compd. with 6-[[(2-fluorophenyl)methyl]amino]-2,3,4,5-tetrahydro-1H-3-benzazepine-7-carbonitrile (1:1) (CA INDEX NAME)

CM 1

CRN 864256-67-7

CMF C18 H18 F N3



CM 2


CRN 110-15-6

CMF C4 H6 O4

$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 864256-69-9 CAPLUS

CN 1H-3-Benzazepin-6-amine, N-[(3-fluorophenyl)methyl]-2,3,4,5-tetrahydro-7-(trifluoromethyl)- (CA INDEX NAME)



RN 864256-70-2 CAPLUS

CN Butanedioic acid, compd. with N-[(3-fluorophenyl)methyl]-2,3,4,5-tetrahydro-7-(trifluoromethyl)-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)


10/598,302

NAME)

CM 1

CRN 864256-69-9


CMF C18 H18 F4 N2



CM 2

CRN 110-15-6


CMF C4 H6 O4



RN 864256-71-3 CAPLUS

CN 1H-3-Benzazepin-6-amine, N-[(1S)-1-(4-fluorophenyl)ethyl]-2,3,4,5-tetrahydro-7-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




10/598,302

RN 864256-72-4 CAPLUS
CN Butanedioic acid, compd. with N-[(1S)-1-(4-fluorophenyl)ethyl]-2,3,4,5-tetrahydro-7-(trifluoromethyl)-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864256-71-3
CMF C19 H20 F4 N2

Absolute stereochemistry. Rotation (-).



CM 2


CRN 110-15-6
CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H


RN 864256-73-5 CAPLUS
CN 1H-3-Benzazepin-6-amine, 7-ethyl-N-[(1S)-1-(4-fluorophenyl)ethyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)

Absolute stereochemistry.

10/598,302




RN 864256-74-6 CAPLUS
CN 1H-3-Benzazepin-6-amine, 2,3,4,5-tetrahydro-7-propyl-N-(2-thienylmethyl)-, hydrochloride (1:?) (CA INDEX NAME)



●_x HCl


RN 864256-75-7 CAPLUS
CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[2-(1-methylethoxy)ethyl]thio]-, hydrochloride (1:1) (CA INDEX NAME)

10/598,302



● HCl

RN 864256-76-8 CAPLUS
CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[1-(2-pyridinyl)ethyl]thio]-, hydrochloride (1:?) (CA INDEX NAME)



●_x HCl

RN 864256-78-0 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-6-[[1-(2-pyridinyl)ethyl]thio]-1H-3-benzazepine (1:1) (CA INDEX NAME)


CM 1

CRN 864256-77-9

CMF C17 H19 Cl N2 S

Rotation (-).

10/598,302



CM 2

CRN 110-15-6


CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864256-79-1 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[1-(2-pyridinyl)ethyl]thio]-, hydrochloride (1:?), (-)- (CA INDEX NAME)

Rotation (-).




●_x HCl

RN 864256-80-4 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[1-(6-methyl-2-pyridinyl)ethyl]thio]-, hydrochloride (1:?) (CA INDEX NAME)

10/598,302




● x HCl

RN 864256-81-5 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[1-(1R)-1-(6-methyl-2-pyridinyl)ethyl]thio]-, hydrochloride (1:?) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 864256-82-6 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[1-(3-methyl-2-pyridinyl)ethyl]thio]-, hydrochloride (1:?) (CA INDEX NAME)

10/598,302




●x HCl

RN 864256-83-7 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[1-(3-methyl-2-pyridinyl)ethyl]thio]-, hydrochloride (1:1), (-)- (CA INDEX NAME)

Rotation (-).



●x HCl

RN 864256-87-1 CAPLUS


CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[1-(3-pyridazinyl)ethyl]thio]-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 864256-86-0

CMF C16 H18 Cl N3 S


10/598,302



CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 864256-89-3 CAPLUS


CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[1-(3-pyridazinyl)ethyl]thio]-, ethanedioate (1:1), (+)- (CA INDEX NAME)

CM 1

CRN 864256-88-2

CMF C16 H18 Cl N3 S

Rotation (+).




10/598,302

CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 864256-90-6 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[(3-pyridazinylmethyl)thio]-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 864256-91-7 CAPLUS


CN 1H-3-Benzazepine, 7-chloro-6-[[[6-chloro-3-pyridazinyl)methyl]thio]-2,3,4,5-tetrahydro-, hydrochloride (1:?) (CA INDEX NAME)

10/598,302



● x HCl


RN 864256-92-8 CAPLUS
CN 1H-3-Benzazepine, 7-chloro-6-[[[6-(2,2-dimethylpropoxy)-3-pyridazinyl]methyl]thio]-2,3,4,5-tetrahydro-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl

RN 864256-93-9 CAPLUS
CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[(2-thienylmethyl)thio]-, hydrochloride (1:1) (CA INDEX NAME)

10/598,302




● HCl

RN 864256-95-1 CAPLUS
CN 3-Thiophenecarbonitrile, 2-[1-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]ethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 864256-94-0
CMF C17 H17 Cl N2 S2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



10/598,302

RN 864256-96-2 CAPLUS


CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[(5-methyl-3-isoxazolyl)methyl]thio]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 864256-97-3 CAPLUS

CN 1H-3-Benzazepine, 7,9-dichloro-2,3,4,5-tetrahydro-6-[[(5-methyl-3-isoxazolyl)methyl]thio]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 864256-98-4 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[(2-methyl-4-thiazolyl)methyl]thio]-, hydrochloride (1:1) (CA INDEX NAME)


10/598,302



● HCl

RN 864256-99-5 CAPLUS

CN 1H-3-Benzazepine, 6-[[4-bromo-2-thienyl)methyl]thio]-7-chloro-2,3,4,5-tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 864257-00-1 CAPLUS

CN 3-Thiophenecarbonitrile, 5-[[7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl]thio]methyl]-, hydrochloride (1:1) (CA INDEX NAME)


10/598,302



● HCl

RN 864257-01-2 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[(1,2,4-oxadiazol-3-ylmethyl)thio]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 864257-02-3 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]thio]-, hydrochloride (1:?) (CA INDEX NAME)


10/598,302



●x HCl

RN 864257-03-4 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-6-[[[3-(1,1-dimethylethyl)-1,2,4-oxadiazol-5-yl]methyl]thio]-2,3,4,5-tetrahydro-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 864257-04-5 CAPLUS


CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[[3-(3-propyl-1,2,4-oxadiazol-5-yl)methyl]thio]-, hydrochloride (1:?) (CA INDEX NAME)

10/598,302



●x HCl


RN 864257-05-6 CAPLUS
CN 1H-3-Benzazepine, 7-chloro-6-[[[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]methyl]thio]-2,3,4,5-tetrahydro-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 864257-06-7 CAPLUS
CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]methyl]thio]-, hydrochloride (1:?) (CA INDEX NAME)


10/598,302



●x HCl

RN 864257-08-9 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[[2-[4-(trifluoromethyl)phenyl]-4-thiazolyl]methyl]thio]-, hydrochloride (1:?)
(CA INDEX NAME)



●x HCl

RN 864257-11-4 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-6-[(2-pyridinylmethyl)thio]-1H-3-benzazepine (1:1) (CA INDEX NAME)

CM 1

CRN 864257-10-3

10/598,302

CMF C16 H17 Cl N2 S



CM 2


CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864257-12-5 CAPLUS

CN 1H-3-Benzazepine, 7,9-dichloro-2,3,4,5-tetrahydro-6-[(2-pyridinylmethyl)thio]-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 864257-13-6 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-6-[[(2-fluorophenyl)methyl]thio]-2,3,4,5-tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)


10/598,302



● HCl

RN 864257-14-7 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[(3-pyridinylmethyl)thio]-, hydrochloride (1:?) (CA INDEX NAME)



●_x HCl

RN 864257-16-9 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-6-[[5-fluoro-2-pyridinyl)methyl]thio]-2,3,4,5-tetrahydro-1H-3-benzazepine (1:1) (CA INDEX NAME)

CM 1

CRN 864257-15-8

CMF C16 H16 Cl F N2 S

10/598,302



CM 2


CRN 110-15-6

CMF C4 H6 O4

$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 864257-17-0 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-6-[[[6-chloro-2-pyridinyl)methyl]thio]-2,3,4,5-tetrahydro-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 864257-18-1 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-6-[[[6-chloro-3-pyridinyl)methyl]thio]-2,3,4,5-tetrahydro-, hydrochloride (1:?) (CA INDEX NAME)


10/598,302



● x HCl

RN 864257-19-2 CAPLUS

CN 1H-3-Benzazepine, 6-[[5-bromo-2-pyridinyl)methyl]thio]-7-chloro-2,3,4,5-tetrahydro-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 864257-20-5 CAPLUS

CN 1H-3-Benzazepine, 6-[[3-bromo-2-pyridinyl)methyl]thio]-7-chloro-2,3,4,5-tetrahydro-, hydrochloride (1:?) (CA INDEX NAME)


10/598,302



● x HCl

RN 864257-21-6 CAPLUS

CN 1H-3-Benzazepine, 6-[[6-bromo-2-pyridinyl)methyl]thio]-7-chloro-2,3,4,5-tetrahydro-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 864257-22-7 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[3-methyl-2-pyridinyl)methyl]thio]-, hydrochloride (1:?) (CA INDEX NAME)


10/598,302



● x HCl

RN 864257-23-8 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 864257-24-9 CAPLUS

CN 2-Pyridinecarbonitrile, 5-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-, hydrochloride (1:?) (CA INDEX NAME)


10/598,302



●x HCl

RN 864257-25-0 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[[6-(trifluoromethyl)-2-pyridinyl]methyl]thio]-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 864257-26-1 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[[3-(trifluoromethyl)-2-pyridinyl]methyl]thio]-, hydrochloride (1:?) (CA INDEX NAME)


10/598,302



●x HCl

RN 864257-27-2 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[(2-quinolinylmethyl)thio]-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 864257-28-3 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[3-methoxy-2-pyridinyl)methyl]thio]-, hydrochloride (1:?) (CA INDEX NAME)


10/598,302



●x HCl

RN 864257-29-4 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[6-methoxy-2-pyridinyl)methyl]thio]-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 864257-30-7 CAPLUS


CN 1H-3-Benzazepine, 6-[[5-butyl-2-pyridinyl)methyl]thio]-7-chloro-2,3,4,5-tetrahydro-, hydrochloride (1:?) (CA INDEX NAME)

10/598,302



●x HCl


RN 864257-31-8 CAPLUS
CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[[5-(3-methylbutyl)-2-pyridinyl]methyl]thio]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 864257-32-9 CAPLUS
CN 1H-3-Benzazepine, 7-chloro-6-[[[5-(2,2-dimethylpropyl)-2-pyridinyl]methyl]thio]-2,3,4,5-tetrahydro-, hydrochloride (1:?) (CA INDEX NAME)


10/598,302



●x HCl

RN 864257-33-0 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-6-[[5-(2-(trimethylgermylmethyl)pyridin-2-yl)methyl]thio]-2,3,4,5-tetrahydro-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl


RN 864257-35-2 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-6-[[5-(2-(cyclopentylmethyl)pyridin-2-yl)methyl]thio]-2,3,4,5-tetrahydro-1H-3-benzazepine (1:1) (CA INDEX NAME)

CM 1


10/598,302

CRN 864257-34-1
CMF C21 H25 Cl N2 S




CM 2

CRN 110-15-6
CMF C4 H6 O4




RN 864257-36-3 CAPLUS
CN 1H-3-Benzazepine, 7-chloro-6-[[[5-(cyclohexylmethyl)-2-pyridinyl]methyl]thio]-2,3,4,5-tetrahydro-, hydrochloride (1:?) (CA INDEX NAME)

10/598,302



RN 864257-37-4 CAPLUS


CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[[5-(1-piperidinyl)-2-pyridinyl]methyl]thio]-, hydrochloride (1:?) (CA INDEX NAME)



RN 864257-38-5 CAPLUS


CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[[5-(1-pyrrolidinyl)-2-pyridinyl]methyl]thio]-, hydrochloride (1:?) (CA INDEX NAME)

10/598,302



●x HCl


RN 864257-39-6 CAPLUS
CN 1H-3-Benzazepine, 7-chloro-6-[[[5-(hexahydro-1H-azepin-1-yl)-2-pyridinyl]methyl]thio]-2,3,4,5-tetrahydro-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl


RN 864257-40-9 CAPLUS
CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[[6-(1-piperidiny1)-3-pyridinyl]methyl]thio]-, hydrochloride (1:?) (CA INDEX NAME)

10/598,302



RN 864257-41-0 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-6-[[[5-[2-(4-fluorophenyl)ethynyl]-2-pyridinyl]methyl]thio]-2,3,4,5-tetrahydro-, hydrochloride (1:?) (CA INDEX NAME)




RN 864257-42-1 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-6-[[[5-[(1Z)-2-(4-fluorophenyl)ethenyl]-2-pyridinyl]methyl]thio]-2,3,4,5-tetrahydro-, hydrochloride (1:?) (CA INDEX NAME)

Double bond geometry as shown.

10/598,302





RN 864257-44-3 CAPLUS

CN Butanedioic acid, compd. with 6-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-N-[[2-fluoro-4-(trifluoromethyl)phenyl]methyl]-3-pyridinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 864257-43-2

CMF C25 H22 Cl F4 N3 O S



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864257-46-5 CAPLUS


CN Butanedioic acid, compd. with 6-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-N-(2,2-dimethylpropyl)-3-pyridinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 864257-45-4

10/598,302

CMF C22 H28 Cl N3 O S



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864257-48-7 CAPLUS


CN Butanedioic acid, compd. with 6-[[[7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl]thio]methyl]-N-[(4-fluorophenyl)methyl]-3-pyridinecarboxamide (1:1) (CA INDEX NAME)

CM 1


CRN 864257-47-6

CMF C24 H23 Cl F N3 O S

PAGE 1-A




PAGE 2-A



CM 2

CRN 110-15-6


CMF C4 H6 O4




RN 864257-49-8 CAPLUS

CN 3-Pyridinecarboxamide, 6-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-N-(cyclohexylmethyl)-, hydrochloride (1:?) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl

RN 864257-50-1 CAPLUS
 CN 3-Pyridinecarboxamide, 6-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-N-(1,1-dimethylethyl)-, hydrochloride (1:?) (CA INDEX NAME)


10/598,302



● x HCl

RN 864257-51-2 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[[4-(trifluoromethoxy)phenyl]methyl]thio]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 864257-52-3 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-6-[[[2-chlorophenyl]methyl]thio]-2,3,4,5-tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)


10/598,302



● HCl

RN 864257-53-4 CAPLUS

CN Benzonitrile, 2-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 864257-54-5 CAPLUS

CN 1H-3-Benzazepine, 6-[[([1,1'-biphenyl]-4-ylmethyl)thio]-7-chloro-2,3,4,5-tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)

10/598,302




● HCl

RN 864257-57-8 CAPLUS
CN 1H-3-Benzazepine, 7-chloro-6-[[4-(4-fluorophenyl)methyl]thio]-2,3,4,5-tetrahydro-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 864257-56-7
CMF C17 H17 Cl F N S



CM 2

CRN 76-05-1
CMF C2 H F3 O2


10/598,302



RN 864257-60-3 CAPLUS
CN 1H-3-Benzazepine, 7-chloro-6-[[(4-chlorophenyl)methyl]thio]-2,3,4,5-tetrahydro-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 864257-59-0
CMF C17 H17 Cl2 N S



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 864257-63-6 CAPLUS
CN Benzonitrile, 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 864257-62-5
CMF C18 H17 Cl N2 S


10/598,302



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 864257-66-9 CAPLUS


CN 1H-3-Benzazepine, 7-chloro-6-[[(3,4-dichlorophenyl)methyl]thio]-2,3,4,5-tetrahydro-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 864257-65-8

CMF C17 H16 Cl3 N S


10/598,302



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 864257-69-2 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-6-[[3-chlorophenyl]methyl]thio]-2,3,4,5-tetrahydro-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 864257-68-1

CMF C17 H17 Cl2 N S




10/598,302

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 864257-72-7 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-6-[[(3-fluorophenyl)methyl]thio]-2,3,4,5-tetrahydro-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 864257-71-6


CMF C17 H17 Cl F N S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 864257-75-0 CAPLUS


CN 1H-3-Benzazepine, 7-chloro-6-[[(3,4-difluorophenyl)methyl]thio]-2,3,4,5-tetrahydro-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

10/598,302

CM 1

CRN 864257-74-9


CMF C17 H16 Cl F2 N S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 864257-78-3 CAPLUS


CN 1H-3-Benzazepine, 7-chloro-6-[[3,5-difluorophenyl)methyl]thio]-2,3,4,5-tetrahydro-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 864257-77-2

CMF C17 H16 Cl F2 N S


10/598,302



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 864257-81-8 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[(3,4,5-trifluorophenyl)methyl]thio]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 864257-80-7

CMF C17 H15 Cl F3 N S




10/598,302

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 864257-83-0 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[[3-(trifluoromethoxy)phenyl]methyl]thio]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 864257-82-9


CMF C18 H17 Cl F3 N O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 864257-85-2 CAPLUS

CN 1H-3-Benzazepine, 7,9-dichloro-6-[[[3-fluorophenyl]methyl]thio]-2,3,4,5-


10/598,302

tetrahydro-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 864257-84-1


CMF C17 H16 Cl2 F N S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 864257-87-4 CAPLUS


CN 1H-3-Benzazepine, 7,9-dichloro-2,3,4,5-tetrahydro-6-[(3,4,5-trifluorophenyl)methyl]thio]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 864257-86-3


CMF C17 H14 Cl2 F3 N S

10/598,302




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 864257-88-5 CAPLUS
CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[3-nitrophenyl)methyl]thio]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

10/598,302

RN 864257-89-6 CAPLUS


CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[[2-(trifluoromethoxy)phenyl]methyl]thio]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 864257-90-9 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[[3-phenoxyphenyl]methyl]thio]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 864257-91-0 CAPLUS

CN 1H-3-Benzazepine, 6-[[[3,5-bis(trifluoromethyl)phenyl]methyl]thio]-7-chloro-2,3,4,5-tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)


10/598,302



● HCl

RN 864257-92-1 CAPLUS

CN 1H-3-Benzazepine, 6-[[[3,5-bis(trifluoromethyl)phenyl]methyl]thio]-7,9-dichloro-2,3,4,5-tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 864257-93-2 CAPLUS


CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[[2-(trifluoromethyl)phenyl]methyl]thio]-, hydrochloride (1:1) (CA INDEX NAME)

10/598,302



● HCl


RN 864257-94-3 CAPLUS
CN Benzoic acid, 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 864257-95-4 CAPLUS
CN Benzoic acid, 3-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)


10/598,302



● HCl

RN 864257-96-5 CAPLUS

CN Benzoic acid, 2-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 864257-97-6 CAPLUS


CN Benzoic acid, 2-[[(7,9-dichloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)

10/598,302



● HCl


RN 864257-98-7 CAPLUS
CN Methanone, [4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]phenyl]phenyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 864257-99-8 CAPLUS
CN 2-Butanone, 1-[4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]phenoxy]-3,3-dimethyl- (CA INDEX NAME)

10/598,302




RN 864258-00-4 CAPLUS

CN Butanedioic acid, compd. with 1-[4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]phenoxy]-3,3-dimethyl-2-butanone (1:1) (CA INDEX NAME)

CM 1

CRN 864257-99-8

CMF C23 H28 Cl N O2 S



CM 2

CRN 110-15-6

CMF C4 H6 O4

10/598,302

HO₂C—CH₂—CH₂—CO₂H


RN 864258-02-6 CAPLUS

CN Butanedioic acid, compd. with 1-[2-chloro-4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]phenoxy]-3,3-dimethyl-2-butanone (1:1)
(CA INDEX NAME)

CM 1

CRN 864258-01-5

CMF C23 H27 Cl2 N O2 S



CM 2

CRN 110-15-6


CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864258-03-7 CAPLUS


CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[[4-[(methylsulfonyl)methyl]phenyl]methyl]thio]-, hydrochloride (1:1) (CA INDEX NAME)

10/598,302



● HCl


RN 864258-04-8 CAPLUS
CN 1H-3-Benzazepine, 7-chloro-6-[[[5-chloro-2-thienyl)methyl]thio]-2,3,4,5-tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 864258-05-9 CAPLUS
CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[(4-pyridinylmethyl)thio]-, hydrochloride (1:?) (CA INDEX NAME)


10/598,302



● x HCl

RN 864258-06-0 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[6-methyl-2-pyridinyl)methyl]thio]-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 864258-07-1 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-6-[[[3-fluoro-4-(3-methylbutyl)phenyl]methyl]thio]-2,3,4,5-tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)

10/598,302




● HCl

RN 864258-10-6 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-6-[[[4-(cyclohexylmethyl)-3-fluorophenyl]methyl]thio]-2,3,4,5-tetrahydro-1H-3-benzazepine (1:1) (CA INDEX NAME)

CM 1

CRN 864258-09-3
CMF C24 H29 Cl F N S



CM 2

10/598,302


CRN 110-15-6
CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864258-12-8 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-6-[[4-cyclohexyl-3-fluorophenyl)methyl]thio]-2,3,4,5-tetrahydro-1H-3-benzazepine (1:1) (CA INDEX NAME)

CM 1

CRN 864258-11-7
CMF C23 H27 Cl F N S




CM 2

CRN 110-15-6
CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864258-13-9 CAPLUS
CN 1H-3-Benzazepine, 7-chloro-6-[[2,5'-difluoro-2'-methoxy[1,1'-biphenyl]-4-yl)methyl]thio]-2,3,4,5-tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)


10/598,302



● HCl

RN 864258-14-0 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-6-[[[2'-chloro-2-fluoro[1,1'-biphenyl]-4-yl)methyl]thio]-2,3,4,5-tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 864258-15-1 CAPLUS


CN 1H-3-Benzazepine, 7-chloro-6-[[[3-fluoro-4-(1-piperidinyl)phenyl]methyl]thio]-2,3,4,5-tetrahydro-, hydrochloride (1:?) (CA INDEX NAME)

10/598,302



RN 864258-16-2 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-6-[[[3-fluoro-4-(1-pyrrolidinyl)phenyl]methyl]thio]-2,3,4,5-tetrahydro-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl


RN 864258-17-3 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-6-[[[3-fluoro-4-(hexahydro-1H-azepin-1-yl)phenyl]methyl]thio]-2,3,4,5-tetrahydro-, hydrochloride (1:?) (CA INDEX NAME)

10/598,302




RN 864258-18-4 CAPLUS
CN 1H-3-Benzazepine, 7-chloro-6-[[[4-chloro-3-(1-pyrrolidinyl)phenyl]methyl]thio]-2,3,4,5-tetrahydro-, hydrochloride (1:?)
(CA INDEX NAME)



●x HCl


RN 864258-19-5 CAPLUS
CN 1H-3-Benzazepine, 7-chloro-6-[[[4-(cyclohexylmethoxy)phenyl]methyl]thio]-2,3,4,5-tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)

10/598,302



RN 864258-20-8 CAPLUS


CN 1H-3-Benzazepine, 7-chloro-6-[[[4-(cycloheptyloxy)phenyl]methyl]thio]-
2,3,4,5-tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)



RN 864258-21-9 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-6-[[[4-(2,2-dimethylpropoxy)phenyl]methyl]thio]-
2,3,4,5-tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)


10/598,302



● HCl

RN 864258-22-0 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[[2-(methylsulfonyl)phenyl]methyl]thio]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 864258-23-1 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[[4-(methylsulfonyl)phenyl]methyl]thio]-, hydrochloride (1:1) (CA INDEX NAME)


10/598,302



● HCl

RN 864258-24-2 CAPLUS


CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[[4-[[3,3,3-trifluoro-2-methyl-2-(trifluoromethyl)propyl]sulfonyl]phenyl]methyl]thio]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 864258-25-3 CAPLUS


CN 1H-3-Benzazepine, 7-chloro-6-[[[4-[(2,2-dimethylpropyl)sulfonyl]phenyl]methyl]thio]-2,3,4,5-tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 864258-26-4 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[[4-[[3,3,3-trifluoro-2-methyl-2-(trifluoromethyl)propyl]sulfonyl]phenyl]methyl]thio]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 864258-27-5 CAPLUS


CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[[4-[[4-(trifluoromethyl)phenyl]sulfonyl]phenyl]methyl]thio]-, hydrochloride (1:1)

(CA INDEX NAME)



RN 864258-28-6 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-6-[[[4-
[(cyclohexylmethyl)sulfonyl]phenyl]methyl]thio]-2,3,4,5-tetrahydro-,
hydrochloride (1:1) (CA INDEX NAME)



RN 864258-30-0 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-6-[[[4-[(2,4-

10/598,302


difluorophenyl)methyl]sulfonyl]phenyl)methyl]thio]-2,3,4,5-tetrahydro-1H-3-benzazepine (1:1) (CA INDEX NAME)

CM 1


CRN 864258-29-7

CMF C24 H22 Cl F2 N O2 S2

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

10/598,302


RN 864258-32-2 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-6-[[[4-[[3,3,3-trifluoro-2-methyl-2-(trifluoromethyl)propyl]thio]phenyl]methyl]thio]-1H-3-benzazepine (1:1) (CA INDEX NAME)

CM 1

CRN 864258-31-1


CMF C22 H22 Cl F6 N S2



CM 2

CRN 110-15-6


CMF C4 H6 O4



RN 864258-33-3 CAPLUS


CN 1-Butanone, 1-[4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]phenyl]-3,3-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

10/598,302



RN 864258-34-4 CAPLUS

CN Benzonitrile, 2-[1-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)




RN 864258-35-5 CAPLUS

CN Benzonitrile, 2-[1-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]ethyl]-, hydrochloride (1:1), (-)- (CA INDEX NAME)


Rotation (-).

10/598,302



● HCl


RN 864258-36-6 CAPLUS
CN 1H-3-Benzazepine, 6-[[[4-(1-butyl-1H-pyrazol-5-yl)phenyl]methyl]thio]-7-chloro-2,3,4,5-tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 864258-37-7 CAPLUS
CN 1H-3-Benzazepine, 6-[[[4-(1-butyl-1H-pyrazol-3-yl)phenyl]methyl]thio]-7-chloro-2,3,4,5-tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)

10/598,302




RN 864258-38-8 CAPLUS
CN Benzamide, 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-N-(1,1-dimethylethyl)-2-fluoro-, hydrochloride (1:1) (CA INDEX NAME)



RN 864258-39-9 CAPLUS
CN Benzamide, 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-2-fluoro-N-propyl-, hydrochloride (1:1) (CA INDEX NAME)


10/598,302



● HCl

RN 864258-40-2 CAPLUS


CN Benzamide, 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-2-fluoro-N-(2-methylpropyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 864258-41-3 CAPLUS


CN Benzamide, 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-2-fluoro-N,N-dipropyl-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 864258-42-4 CAPLUS
 CN Benzamide, 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-2-fluoro-N-[(4-fluorophenyl)methyl]-, hydrochloride (1:1)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl


RN 864258-43-5 CAPLUS
 CN Benzamide, 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-N-cyclohexyl-2-fluoro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 864258-44-6 CAPLUS
 CN Methanone, [4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-2-fluorophenyl][2-(2-methylpropyl)-1-pyrrolidinyl]-, hydrochloride (1:1) (CA INDEX NAME)


10/598,302



RN 864258-45-7 CAPLUS
CN Methanone, [4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-2-fluorophenyl][3-(4-fluorophenyl)-1-pyrrolidinyl]-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A






● HCl

RN 864258-46-8 CAPLUS
 CN Benzamide, 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-2-fluoro-N-[(1S)-1-methylpropyl]-, hydrochloride (1:1)
 (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



● HCl

RN 864258-47-9 CAPLUS
 CN Benzamide, 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-2-fluoro-N-[(1R)-1-methylpropyl]-, hydrochloride (1:1)
 (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT	864258-48-0P	864258-49-1P	864258-50-4P
	864258-51-5P	864258-52-6P	864258-54-8P
	864258-56-0P	864258-58-2P	864258-60-6P
	864258-62-8P	864258-64-0P	864258-66-2P
	864258-68-4P	864258-70-8P	864258-72-0P
	864258-74-2P	864258-75-3P	864258-76-4P
	864258-77-5P	864258-78-6P	864258-79-7P
	864258-80-0P	864258-81-1P	864258-82-2P
	864258-83-3P	864258-84-4P	864258-85-5P
	864258-86-6P	864258-87-7P	864258-88-8P
	864258-89-9P	864258-90-2P	864258-91-3P
	864258-93-5P	864258-95-7P	864258-96-8P
	864258-97-9P	864258-98-0P	864258-99-1P
	864259-00-7P	864259-01-8P	864259-02-9P
	864259-03-0P	864259-04-1P	864259-05-2P
	864259-06-3P	864259-07-4P	864259-08-5P
	864259-09-6P	864259-11-0P	864259-13-2P
	864259-15-4P	864259-17-6P	864259-19-8P
	864259-21-2P	864259-23-4P	864259-25-6P
	864259-27-8P	864259-28-9P	864259-29-0P
	864259-30-3P	864259-31-4P	864259-32-5P
	864259-33-6P	864259-34-7P	864259-35-8P
	864259-36-9P	864259-37-0P	864259-38-1P
	864259-39-2P	864259-40-5P	864259-41-6P
	864259-42-7P	864259-43-8P	864259-44-9P
	864259-45-0P	864259-46-1P	864259-47-2P
	864259-48-3P	864259-49-4P	864259-50-7P
	864259-51-8P	864259-53-0P	864259-55-2P
	864259-57-4P	864259-58-5P	864259-59-6P
	864259-61-0P	864259-62-1P	864259-63-2P
	864259-64-3P	864259-65-4P	864259-66-5P
	864259-67-6P	864259-68-7P	864259-70-1P
	864259-71-2P	864259-72-3P	864259-74-5P
	864259-75-6P	864259-76-7P	864259-77-8P
	864259-78-9P	864259-79-0P	864259-81-4P
	864259-82-5P	864259-83-6P	864259-84-7P

864259-85-8P	864259-86-9P	864259-87-0P
864259-88-1P	864259-89-2P	864259-90-5P
864259-91-6P	864259-92-7P	864259-93-8P
864259-94-9P	864259-95-0P	864259-97-2P
864259-99-4P	864260-01-5P	864260-03-7P
864260-05-9P	864260-07-1P	864260-09-3P
864260-11-7P	864260-12-8P	864260-13-9P
864260-14-0P	864260-15-1P	864260-16-2P
864260-17-3P	864260-19-5P	864260-21-9P
864260-23-1P	864260-25-3P	864260-27-5P
864260-29-7P	864260-31-1P	864260-33-3P
864260-35-5P	864260-37-7P	864260-39-9P
864260-41-3P	864260-43-5P	864260-45-7P
864260-47-9P	864260-49-1P	864260-51-5P
864260-53-7P	864260-55-9P	864260-57-1P
864260-59-3P	864260-61-7P	864260-63-9P
864260-65-1P	864260-67-3P	864260-69-5P
864260-71-9P	864260-73-1P	864260-75-3P
864260-77-5P	864260-79-7P	864260-81-1P
864260-83-3P	864260-85-5P	864260-86-6P
864260-87-7P	864260-89-9P	864260-90-2P
864260-91-3P	864260-92-4P	864260-93-5P
864260-94-6P	864260-95-7P	864260-96-8P
864260-97-9P	864260-99-1P	864261-01-8P
864261-03-0P	864261-04-1P	864261-05-2P
864261-06-3P	864261-07-4P	864261-08-5P
864261-10-9P	864261-12-1P	864261-14-3P
864261-16-5P	864261-17-6P	864261-18-7P
864261-19-8P	864261-20-1P	864261-21-2P
864261-22-3P	864261-24-5P	864261-26-7P
864261-28-9P	864261-30-3P	864261-31-4P
864261-32-5P	864261-33-6P	864261-34-7P
864261-35-8P	864261-36-9P	864261-37-0P
864261-38-1P	864261-39-2P	864261-40-5P
864261-41-6P	864261-42-7P	864261-43-8P
864261-44-9P	864261-45-0P	864261-47-2P
864261-49-4P	864261-51-8P	864261-53-0P
864261-54-1P	864261-55-2P	864261-57-4P
864261-59-6P	864261-61-0P	864261-63-2P
864261-65-4P	864261-67-6P	864261-69-8P
864261-71-2P	864261-73-4P	864261-75-6P
864261-77-8P	864261-78-9P	


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT_{2c} receptor agonists)


RN 864258-48-0 CAPLUS

CN Benzamide, N-[(2-chlorophenyl)methyl]-4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-2-fluoro-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● HCl

RN 864258-49-1 CAPLUS
CN Benzamide, 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-2-fluoro-N-[[2-(trifluoromethyl)phenyl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● HCl

RN 864258-50-4 CAPLUS
 CN Benzamide, 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-2-fluoro-N-[[2-fluoro-4-(trifluoromethyl)phenyl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl


RN 864258-51-5 CAPLUS
 CN Benzamide, 4-[[[2-fluoro-N-[(1S)-1-(4-fluorophenyl)ethyl]-2-fluorophenyl]thio]methyl]-2-fluoro-N-[(1S)-1-(4-fluorophenyl)ethyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 864258-52-6 CAPLUS
 CN Benzamide, 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-2-fluoro-N-[(1R)-1-(4-fluorophenyl)ethyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 864258-54-8 CAPLUS
 CN Butanedioic acid, compd. with 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-2-fluoro-N-(2-methylpropyl)benzamide (1:1) (CA INDEX NAME)

10/598,302

CM 1

CRN 864258-53-7

CMF C22 H26 Cl F N2 O S



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864258-56-0 CAPLUS


CN Butanedioic acid, compd. with 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-N-cyclohexylbenzamide (1:1) (CA INDEX NAME)

CM 1

CRN 864258-55-9

CMF C24 H29 Cl N2 O S


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864258-58-2 CAPLUS


CN Butanedioic acid, compd. with 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-N-[[2-fluoro-4-(trifluoromethyl)phenyl]methyl]benzamide (1:1) (CA INDEX NAME)

CM 1


CRN 864258-57-1

CMF C26 H23 Cl F4 N2 O S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864258-60-6 CAPLUS

CN Butanedioic acid, compd. with N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-
 [[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]benzamide
 (1:1) (CA INDEX NAME)


CM 1

CRN 864258-59-3


10/598,302

CMF C27 H23 Cl F6 N2 O S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864258-62-8 CAPLUS


CN Butanedioic acid, compd. with 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-N-[[4-fluoro-2-(trifluoromethyl)phenyl]methyl]benzamide (1:1) (CA INDEX NAME)

CM 1


10/598,302

CRN 864258-61-7
CMF C26 H23 Cl F4 N2 O S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-15-6
CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864258-64-0 CAPLUS
CN Butanedioic acid, compd. with 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-N-[(1S)-1-cyclohexylethyl]benzamide (1:1)
(CA INDEX NAME)


10/598,302

CM 1

CRN 864258-63-9

CMF C26 H33 Cl N2 O S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 110-15-6

CMF C4 H6 O4

$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 864258-66-2 CAPLUS

CN Butanedioic acid, compd. with 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-N-[(1R)-1-cyclohexylethyl]benzamide (1:1)
(CA INDEX NAME)


CM 1

CRN 864258-65-1

CMF C26 H33 Cl N2 O S

Absolute stereochemistry. Rotation (-).

10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864258-68-4 CAPLUS

CN Butanedioic acid, compd. with 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-N-[(1R)-1-(4-fluorophenyl)ethyl]benzamide (1:1) (CA INDEX NAME)


CM 1

CRN 864258-67-3

CMF C26 H26 Cl F N2 O S

Absolute stereochemistry. Rotation (+).


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864258-70-8 CAPLUS

CN Butanedioic acid, compd. with 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-N-[(1S)-1-(4-fluorophenyl)ethyl]benzamide (1:1) (CA INDEX NAME)


CM 1

CRN 864258-69-5

CMF C26 H26 Cl F N2 O S

Absolute stereochemistry. Rotation (-).

10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864258-72-0 CAPLUS

CN Butanedioic acid, compd. with N-[(1R)-1-(4-chlorophenyl)ethyl]-4-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]benzamide (1:1)
(CA INDEX NAME)


CM 1

CRN 864258-71-9

CMF C26 H26 Cl2 N2 O S

Absolute stereochemistry. Rotation (-).

10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864258-74-2 CAPLUS

CN Butanedioic acid, compd. with N-[(1S)-1-(4-chlorophenyl)ethyl]-4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]benzamide (1:1)
(CA INDEX NAME)


CM 1

CRN 864258-73-1

CMF C26 H26 Cl2 N2 O S

Absolute stereochemistry. Rotation (+).


10/598,302



CM 2

CRN 110-15-6


CMF C4 H6 O4



RN 864258-75-3 CAPLUS

CN Benzamide, 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-N-(2,2-dimethylpropyl)-, hydrochloride (1:1) (CA INDEX NAME)


10/598,302



● HCl

RN 864258-76-4 CAPLUS

CN Benzamide, 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-N-(1,1-dimethylethyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl


RN 864258-77-5 CAPLUS

CN Benzamide, 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-N-(cyclohexylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● HCl

RN 864258-78-6 CAPLUS
 CN Benzamide, 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-N-[[4-(trifluoromethyl)phenyl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● HCl

RN	864258-79-7	CAPLUS
CN	Benzamide, 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-N-[(3,4-difluorophenyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)	

PAGE 1-A




PAGE 2-A




● HCl

RN 864258-80-0 CAPLUS
 CN Benzamide, 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-N-[(2,3,4-trifluorophenyl)methyl]-, hydrochloride (1:1)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl

RN 864258-81-1 CAPLUS
 CN Benzeneacetic acid, α -[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)


10/598,302



● HCl

RN 864258-82-2 CAPLUS


CN Benzeneethanol, β -[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 864258-83-3 CAPLUS

CN Acetic acid, 2-[(7,9-dichloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

10/598,302

RN 864258-84-4 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[[4-(phenylmethoxy)phenyl]methyl]thio]- (CA INDEX NAME)




RN 864258-85-5 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-6-[[[4-(phenylmethoxy)phenyl]methyl]thio]-1H-3-benzazepine (1:1) (CA INDEX NAME)

CM 1

CRN 864258-84-4

CMF C24 H24 Cl N O S




CM 2

CRN 110-15-6


CMF C4 H6 O4

10/598,302




RN 864258-86-6 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-6-[[(2-fluoro-4-phenoxyphenyl)methyl]thio]-
2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 864258-87-7 CAPLUS


CN Ethanone, 2-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]-1-(4-
fluorophenyl)- (CA INDEX NAME)



RN 864258-88-8 CAPLUS

CN Ethanol, 2-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]-,
hydrochloride (1:1) (CA INDEX NAME)


10/598,302



● HCl

RN 864258-89-9 CAPLUS


CN Butanoic acid, 4-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 864258-90-2 CAPLUS

CN Pentanoic acid, 5-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 864258-91-3 CAPLUS

CN Pentanoic acid, 5-[(7,9-dichloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)

10/598,302




● HCl

RN 864258-93-5 CAPLUS
CN Acetonitrile, 2-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]-,
2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 864258-92-4
CMF C12 H13 Cl N2 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 864258-95-7 CAPLUS
CN Acetonitrile, 2-[(7,9-dichloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]-,
2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 864258-94-6

10/598,302


CMF C12 H12 Cl2 N2 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 864258-96-8 CAPLUS

CN Propanenitrile, 2-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]-
, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 864258-97-9 CAPLUS

CN Butanenitrile, 2-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]-
, hydrochloride (1:1) (CA INDEX NAME)


10/598,302



● HCl

RN 864258-98-0 CAPLUS


CN Propanenitrile, 2-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]-2-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 864258-99-1 CAPLUS

CN Pentanenitrile, 5-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 864259-00-7 CAPLUS

CN Pentanenitrile, 5-[(7,9-dichloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-

10/598,302


yl)thio]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 864259-01-8 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[2-(2-pyridinyl)ethyl]thio]-, hydrochloride (1:?) (CA INDEX NAME)




●_x HCl

RN 864259-02-9 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-6-[[3-[[3-(1,1-dimethylethyl)-1,2,4-oxadiazol-5-yl]propyl]thio]-2,3,4,5-tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)

10/598,302




● HCl

RN 864259-03-0 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[(3S)-tetrahydro-3-furanyl]thio]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 864259-04-1 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[(3R)-tetrahydro-3-furanyl]thio]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


10/598,302



● HCl

RN 864259-05-2 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[(tetrahydro-2-furanyl)methyl]thio-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 864259-06-3 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[(tetrahydro-2H-pyran-2-yl)methyl]thio-, hydrochloride (1:1) (CA INDEX NAME)

10/598,302




● HCl

RN 864259-07-4 CAPLUS

CN 2(3H)-Furanone, 5-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]dihydro-, hydrochloride (1:1), (5S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




● HCl

RN 864259-08-5 CAPLUS

CN Butanamide, 4-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]-N,N-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

10/598,302




● HCl

RN 864259-09-6 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[3-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]propyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 864353-06-0
CMF C21 H21 Cl N2 O2 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2




10/598,302

RN 864259-11-0 CAPLUS
CN Benzamide, N-[3-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]propyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 864259-10-9
CMF C20 H23 Cl N2 O S



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 864259-13-2 CAPLUS
CN Urea, N-[3-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]propyl]-N'-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 864259-12-1
CMF C20 H24 Cl N3 O S



CM 2

10/598,302


CRN 76-05-1
CMF C2 H F3 O2



RN 864259-15-4 CAPLUS
CN Benzamide, N-[3-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]propyl]-4-(trifluoromethyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 864259-14-3
CMF C21 H22 Cl F3 N2 O S



CM 2

CRN 76-05-1
CMF C2 H F3 O2




10/598,302

RN 864259-17-6 CAPLUS
CN Benzamide, N-[3-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]propyl]-4-(1,1-dimethylethyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 864259-16-5
CMF C24 H31 Cl N2 O S



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 864259-19-8 CAPLUS
CN Carbamic acid, [2-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]ethyl]-, ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 864259-18-7
CMF C15 H21 Cl N2 O2 S


10/598,302



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 864259-21-2 CAPLUS

CN 4-Pyridinecarboxamide, N-[2-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]ethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 864259-20-1

CMF C18 H20 Cl N3 O S




10/598,302

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 864259-23-4 CAPLUS

CN Cyclopropanecarboxamide, N-[2-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]ethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 864259-22-3


CMF C16 H21 Cl N2 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




10/598,302

RN 864259-25-6 CAPLUS
CN Benzenesulfonamide, N-[2-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 864259-24-5
CMF C18 H21 Cl N2 O2 S2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 864259-27-8 CAPLUS
CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[3-(1H-pyrrol-1-yl)propyl]thio]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 864259-26-7
CMF C17 H21 Cl N2 S




10/598,302

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 864259-28-9 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, 2-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]ethyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 864259-29-0 CAPLUS


CN Cyclohexanecarboxylic acid, 2-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]ethyl ester, hydrochloride (1:1) (CA INDEX NAME)

10/598,302



RN 864259-30-3 CAPLUS


CN Benzenemethanol, 3-[[[7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl]thio]methyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 864259-31-4 CAPLUS


CN Benzenemethanol, 2-[[[7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl]thio]methyl]-, hydrochloride (1:1) (CA INDEX NAME)

10/598,302



● HCl


RN 864259-32-5 CAPLUS
CN Benzenemethanol, 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 864259-33-6 CAPLUS
CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[[4-(methoxymethyl)phenyl]methyl]thio]-, hydrochloride (1:1) (CA INDEX NAME)


10/598,302



● HCl

RN 864259-34-7 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[[3-(methoxymethyl)phenyl]methyl]thio]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 864259-35-8 CAPLUS


CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[[2-(methoxymethyl)phenyl]methyl]thio]-, hydrochloride (1:1) (CA INDEX NAME)

10/598,302




● HCl

RN 864259-36-9 CAPLUS
CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[(2-methoxyethyl)thio]-,
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 864259-37-0 CAPLUS
CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[(4-methoxybutyl)thio]-,
hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 864259-38-1 CAPLUS

10/598,302

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[(2-methoxy-1-phenylethyl)thio]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 864259-39-2 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[(2-methoxy-1-phenylethyl)thio]-, hydrochloride (1:1), (-)- (CA INDEX NAME)

Rotation (-).




● HCl

RN 864259-40-5 CAPLUS

CN 1H-3-Benzazepine, 6-[[4-(4-fluorophenyl)methyl]thio]-2,3,4,5-tetrahydro-7-methyl-, hydrochloride (1:1) (CA INDEX NAME)

CN 1H-3-Benzazepine-7-carbonitrile, 6-[[(4-fluorophenyl)methyl]thio]-2,3,4,5-tetrahydro- (CA INDEX NAME)




CN Butanedioic acid, compd. with 6-[[[4-fluorophenyl)methyl]thio]-2,3,4,5-tetrahydro-1H-3-benzazepine-7-carbonitrile (1:1) (CA INDEX NAME)

CRN 864259-41-6

CMF C18 H17 F N2 S


10/598,302



CM 2


CRN 110-15-6

CMF C4 H6 O4



RN 864259-43-8 CAPLUS

CN 1H-3-Benzazepine-7-carbonitrile, 6-[[1-(4-fluorophenyl)ethyl]thio]-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 864259-44-9 CAPLUS


CN Butanedioic acid, compd. with 6-[[1-(4-fluorophenyl)ethyl]thio]-2,3,4,5-tetrahydro-1H-3-benzazepine-7-carbonitrile (1:1) (CA INDEX NAME)

CM 1

CRN 864259-43-8

10/598,302


CMF C19 H19 F N2 S



CM 2


CRN 110-15-6

CMF C4 H6 O4



RN 864259-45-0 CAPLUS

CN Butanoic acid, 4-[(7-bromo-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]-, ethyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 864259-46-1 CAPLUS

CN Butanamide, 4-[(7-bromo-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]-N,N-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)


10/598,302



● HCl

RN 864259-47-2 CAPLUS


CN 1-Butanone, 4-[(7-bromo-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]-1-(1-pyrrolidinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 864259-48-3 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[3-[(7-bromo-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]propyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 864259-49-4 CAPLUS
 CN Propanoic acid, 2,2-dimethyl-, 2-[[2,3,4,5-tetrahydro-7-(trifluoromethyl)-1H-3-benzazepin-6-yl]thio]ethyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 864259-50-7 CAPLUS
 CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[2-(2-pyridinyl)ethynyl]- (CA INDEX NAME)

10/598,302




RN 864259-51-8 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-6-[2-(2-pyridinyl)ethynyl]-1H-3-benzazepine (1:1) (CA INDEX NAME)

CM 1

CRN 864259-50-7

CMF C17 H15 Cl N2



CM 2

CRN 110-15-6

CMF C4 H6 O4

$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 864259-53-0 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-6-[2-(3-pyridinyl)ethynyl]-1H-3-benzazepine (1:1) (CA INDEX NAME)

CM 1

CRN 864259-52-9

CMF C17 H15 Cl N2

10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H


RN 864259-55-2 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-6-[2-(4-pyridinyl)ethynyl]-1H-3-benzazepine (1:1) (CA INDEX NAME)

CM 1

CRN 864259-54-1

CMF C17 H15 Cl N2



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H


RN 864259-57-4 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-6-[2-(2-thienyl)ethynyl]-1H-3-benzazepine (1:1) (CA INDEX NAME)

CM 1

10/598,302

CRN 864259-56-3
CMF C16 H14 Cl N S




CM 2

CRN 110-15-6
CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H


RN 864259-58-5 CAPLUS
CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[2-(2-thiazolyl)ethynyl]-
(CA INDEX NAME)



RN 864259-59-6 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-6-[2-(2-thiazolyl)ethynyl]-1H-3-benzazepine (1:1) (CA INDEX NAME)

CM 1

CRN 864259-58-5
CMF C15 H13 Cl N2 S




10/598,302

CM 2

CRN 110-15-6

CMF C4 H6 O4




RN 864259-61-0 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-(3-pyridazinylethynyl)-,
(2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 864259-60-9

CMF C16 H14 Cl N3




CM 2

CRN 87-69-4

CMF C4 H6 O6


Absolute stereochemistry.



RN 864259-62-1 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-6-[2-(2-fluorophenyl)ethynyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)


10/598,302



RN 864259-63-2 CAPLUS
CN 1H-3-Benzazepine, 7-chloro-6-[(3-fluorophenyl)ethynyl]-2,3,4,5-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 864259-62-1
CMF C18 H15 Cl F N



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.




RN 864259-64-3 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-6-[2-(2-fluorophenyl)ethynyl]-2,3,4,5-tetrahydro-1H-3-benzazepine (1:1) (CA INDEX NAME)

CM 1

CRN 864259-62-1
CMF C18 H15 Cl F N


10/598,302



CM 2


CRN 110-15-6

CMF C4 H6 O4



RN 864259-65-4 CAPLUS

CN 2-Imidazolidinone, 1-[3-(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)-2-propyn-1-yl]-3-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 864259-66-5 CAPLUS


CN 2-Imidazolidinone, 1-[3-(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)-2-propyn-1-yl]-3-(1,1-dimethylethyl)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 864259-65-4

CMF C20 H26 Cl N3 O

10/598,302




CM 2

CRN 87-69-4


CMF C4 H6 O6

Absolute stereochemistry.



RN 864259-67-6 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[(2,4-difluorophenyl)methyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 864259-68-7 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[(2,4-difluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864259-67-6

10/598,302

CMF C17 H17 Cl F2 N2



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H


RN 864259-70-1 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-N-[(2,5-difluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864259-69-8

CMF C17 H17 Cl F2 N2




CM 2

10/598,302

CRN 110-15-6
CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H


RN 864259-71-2 CAPLUS
CN 1H-3-Benzazepin-6-amine, 7-chloro-N-(2,2-difluoro-2-phenylethyl)-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 864259-72-3 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-N-(2,2-difluoro-2-phenylethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864259-71-2
CMF C18 H19 Cl F2 N2



CM 2

CRN 110-15-6
CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H


RN 864259-74-5 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-N-[2,2-difluoro-2-(2-pyridinyl)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864259-73-4

10/598,302

CMF C17 H18 Cl F2 N3



CM 2


CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864259-75-6 CAPLUS

CN 1H-3-Benzazepin-6-amine, N-(1,2,3-benzothiadiazol-6-ylmethyl)-7-chloro-2,3,4,5-tetrahydro-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 864259-76-7 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[2-(cyclohexylmethyl)-6-benzothiazolyl]methyl]-2,3,4,5-tetrahydro-, hydrochloride (1:?) (CA INDEX NAME)


10/598,302

NAME)



RN 864259-77-8 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-[(2-phenyl-6-benzothiazolyl)methyl]-, hydrochloride (1:?) (CA INDEX NAME)



RN 864259-78-9 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-[[2-(2-methylpropyl)-5-benzothiazolyl]methyl]-, hydrochloride (1:?) (CA INDEX NAME)

10/598,302



●x HCl

RN 864259-79-0 CAPLUS
CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-[(3-phenylbenzo[b]thien-6-yl)methyl]-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 864259-81-4 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-N-[[4-(difluorophenylmethyl)phenyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864259-80-3
CMF C24 H23 Cl F2 N2


10/598,302



CM 2


CRN 110-15-6

CMF C4 H6 O4



RN 864259-82-5 CAPLUS

CN 1-Butanone, 1-[4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]-3,3-dimethyl- (CA INDEX NAME)



RN 864259-83-6 CAPLUS


CN Butanedioic acid, compd. with 1-[4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]-3,3-dimethyl-1-butanone (1:1) (CA INDEX NAME)

10/598,302

CM 1

CRN 864259-82-5


CMF C23 H29 Cl N2 O



CM 2

CRN 110-15-6


CMF C4 H6 O4



RN 864259-84-7 CAPLUS

CN 1-Butanone, 1-[4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-2-fluorophenyl]-3,3-dimethyl- (CA INDEX NAME)

10/598,302




RN 864259-85-8 CAPLUS

CN Butanedioic acid, compd. with 1-[4-[[[7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl]amino]methyl]-2-fluorophenyl]-3,3-dimethyl-1-butanone (1:1) (CA INDEX NAME)

CM 1

CRN 864259-84-7

CMF C23 H28 Cl F N2 O




CM 2

CRN 110-15-6


CMF C4 H6 O4

10/598,302



RN 864259-86-9 CAPLUS

CN 1-Butanone, 1-[4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-3-fluorophenyl]-3,3-dimethyl- (CA INDEX NAME)




RN 864259-87-0 CAPLUS

CN Butanedioic acid, compd. with 1-[4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-3-fluorophenyl]-3,3-dimethyl-1-butanone (1:1) (CA INDEX NAME)

CM 1

CRN 864259-86-9

CMF C23 H28 Cl F N2 O



10/598,302

CM 2


CRN 110-15-6

CMF C4 H6 O4

$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 864259-88-1 CAPLUS

CN 1-Butanone, 1-[2-chloro-4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]-3,3-dimethyl- (CA INDEX NAME)



RN 864259-89-2 CAPLUS


CN Butanedioic acid, compd. with 1-[2-chloro-4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]-3,3-dimethyl-1-butanone (1:1)
(CA INDEX NAME)

CM 1

CRN 864259-88-1

CMF C23 H28 Cl2 N2 O


10/598,302



CM 2


CRN 110-15-6

CMF C4 H6 O4



RN 864259-90-5 CAPLUS

CN 1-Butanone, 1-[3-chloro-4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]-3,3-dimethyl- (CA INDEX NAME)



RN 864259-91-6 CAPLUS

CN Butanedioic acid, compd. with 1-[3-chloro-4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]-3,3-dimethyl-1-butanone (1:1)


10/598,302

(CA INDEX NAME)

CM 1

CRN 864259-90-5

CMF C23 H28 Cl2 N2 O



CM 2

CRN 110-15-6


CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864259-92-7 CAPLUS

CN 1-Pentanone, 1-[4-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]-4,4-dimethyl- (CA INDEX NAME)

10/598,302




RN 864259-93-8 CAPLUS

CN Butanedioic acid, compd. with 1-[4-[[[7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl]amino]methyl]phenyl]-4,4-dimethyl-1-pentanone (1:1) (CA INDEX NAME)

CM 1

CRN 864259-92-7

CMF C24 H31 Cl N2 O



CM 2

CRN 110-15-6


CMF C4 H6 O4

10/598,302

HO₂C-CH₂-CH₂-CO₂H

RN 864259-94-9 CAPLUS

CN Methanone, [4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]cyclohexyl- (CA INDEX NAME)



RN 864259-95-0 CAPLUS


CN Butanedioic acid, compd. with [4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]cyclohexylmethanone (1:1) (CA INDEX NAME)

CM 1

CRN 864259-94-9

CMF C24 H29 Cl N2 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864259-97-2 CAPLUS


CN Butanedioic acid, compd. with 1-[4-[[2-cyclopentylethanone-1-yl]amino]methyl]phenyl]-7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepine (1:1) (CA INDEX NAME)

CM 1

CRN 864259-96-1

CMF C24 H29 Cl N2 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864259-99-4 CAPLUS


CN Butanedioic acid, compd. with 1-[4-[[7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl]amino]methyl]phenyl]-2-cyclohexylethanone (1:1) (CA INDEX NAME)

CM 1

CRN 864259-98-3

CMF C25 H31 Cl N2 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864260-01-5 CAPLUS


CN Butanedioic acid, compd. with 1-[5-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-2-pyridinyl]-3-methyl-1-butanone (1:1) (CA INDEX NAME)

CM 1

CRN 864260-00-4

CMF C21 H26 Cl N3 O

10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864260-03-7 CAPLUS


CN Butanedioic acid, compd. with 1-[5-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-2-pyridinyl]-3,3-dimethyl-1-butanone (1:1)
(CA INDEX NAME)

CM 1

CRN 864260-02-6

CMF C22 H28 Cl N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864260-05-9 CAPLUS


CN Butanedioic acid, compd. with 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-cycloheptyl-2-fluorobenzamide (1:1) (CA INDEX NAME)

CM 1

CRN 864260-04-8

CMF C25 H31 Cl F N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864260-07-1 CAPLUS


CN Benzamide, 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-cycloheptyl-3-fluoro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 864260-06-0

CMF C25 H31 Cl F N3 O

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 864260-09-3 CAPLUS


CN Benzamide, 2-chloro-4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-cycloheptyl-, (2R,3R)-2,3-dihydroxybutanedioate (1:1)
(CA INDEX NAME)

CM 1

CRN 864260-08-2

CMF C25 H31 Cl2 N3 O

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 864260-11-7 CAPLUS


CN Butanedioic acid, compd. with 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-cycloheptyl-2-methylbenzamide (1:1) (CA INDEX NAME)

CM 1

CRN 864260-10-6

CMF C26 H34 Cl N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4




RN 864260-12-8 CAPLUS

CN Benzamide, 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-2-fluoro-N-[(1R)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)

Absolute stereochemistry.

10/598,302




RN 864260-13-9 CAPLUS
CN Butanedioic acid, compd. with 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-2-fluoro-N-[(1R)-2,2,2-trifluoro-1-methylethyl]benzamide (1:1) (CA INDEX NAME)

CM 1

CRN 864260-12-8
CMF C21 H22 Cl F4 N3 O

Absolute stereochemistry.



CM 2

CRN 110-15-6


10/598,302

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864260-14-0 CAPLUS

CN Benzamide, 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-2-fluoro-N-(1-methylethyl)- (CA INDEX NAME)



RN 864260-15-1 CAPLUS


CN Butanedioic acid, compd. with 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-2-fluoro-N-(1-methylethyl)benzamide (1:1) (CA INDEX NAME)

CM 1

CRN 864260-14-0

CMF C21 H25 Cl F N3 O


10/598,302



CM 2


CRN 110-15-6

CMF C4 H6 O4



RN 864260-16-2 CAPLUS

CN Benzamide, 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-2-fluoro-N-propyl- (CA INDEX NAME)



RN 864260-17-3 CAPLUS

CN Benzamide, 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-2-fluoro-N-propyl-, (2R,3R)-2,3-dihydroxybutanedioate


10/598,302

(1:1) (CA INDEX NAME)

CM 1

CRN 864260-16-2

CMF C21 H25 Cl F N3 O




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 864260-19-5 CAPLUS


CN Benzamide, 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-(cyclohexylmethyl)-2-fluoro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1


CRN 864260-18-4

CMF C25 H31 Cl F N3 O

PAGE 1-A




PAGE 2-A



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 864260-21-9 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-N-[[6-(cyclohexylamino)-3-


10/598,302

pyridinyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA
INDEX NAME)

CM 1

CRN 864260-20-8

CMF C22 H29 Cl N4



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864260-23-1 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[[6-[(cyclohexylmethyl)amino]-3-pyridinyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA
INDEX NAME)

CM 1

CRN 864260-22-0

CMF C23 H31 Cl N4


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864260-25-3 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[6-[(phenylmethyl)amino]-3-pyridinyl]methyl]-1H-3-benzazepin-6-amine (1:1)
(CA INDEX NAME)

CM 1

CRN 864260-24-2

CMF C23 H25 Cl N4


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4




RN 864260-27-5 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-(2,2,3,3,3-pentafluoro-1-methylpropoxy)phenyl]methyl]-1H-3-benzazepin-6-amine (1:1)
(CA INDEX NAME)

CM 1

CRN 864260-26-4

CMF C21 H22 Cl F5 N2 O



10/598,302

CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864260-29-7 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-(2,2,3,3,3-pentafluoro-1-methylpropoxy)phenyl]methyl]-1H-3-benzazepin-6-amine (1:1)
(CA INDEX NAME)

CM 1

CRN 864260-28-6

CMF C21 H22 Cl F5 N2 O

Rotation (-).



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864260-31-1 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-(2,2,3,3,3-pentafluoro-1-methylpropoxy)phenyl]methyl]-1H-3-benzazepin-6-amine (1:1)

10/598,302


(CA INDEX NAME)

CM 1

CRN 864260-30-0

CMF C21 H22 Cl F5 N2 O

Rotation (+).



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864260-33-3 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[5-(2,2,3,3,3-pentafluoro-1-methylpropoxy)-2-pyridinyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864260-32-2

CMF C20 H21 Cl F5 N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864260-35-5 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[5-(2,2,3,3,3-pentafluoro-1-methylpropoxy)-2-pyridinyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)


CM 1

CRN 864260-34-4

CMF C20 H21 Cl F5 N3 O

Rotation (-).


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864260-37-7 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[5-(2,2,3,3,3-pentafluoro-1-methylpropoxy)-2-pyridinyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)


CM 1

CRN 864260-36-6

CMF C20 H21 Cl F5 N3 O

Rotation (+).


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864260-39-9 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-[[4-[(1-methylcyclohexyl)methoxy]phenyl]methyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 864260-38-8

CMF C25 H33 Cl N2 O

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 864260-41-3 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[4-(cyclopentyloxy)phenyl]methyl]-2,3,4,5-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 864260-40-2

CMF C22 H27 Cl N2 O

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 864260-43-5 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[3-chloro-4-(cyclopentyloxy)phenyl]methyl]-2,3,4,5-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 864260-42-4

CMF C22 H26 Cl2 N2 O

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 864260-45-7 CAPLUS


CN 1-Propanol, 3-[4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenoxy]-2,2-dimethyl-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 864260-44-6

CMF C22 H29 Cl N2 O2

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 864260-47-9 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[6-(3,3-dimethylbutoxy)-3-pyridinyl]methyl]-2,3,4,5-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 864260-46-8

CMF C22 H30 Cl N3 O

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 864260-49-1 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-[[4-[[[(tetrahydro-2H-pyran-4-yl)oxy]methyl]phenyl]methyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 864260-48-0

CMF C23 H29 Cl N2 O2

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 864260-51-5 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[4-(cyclohexyloxy)phenyl]methyl]-2,3,4,5-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 864260-50-4

CMF C23 H29 Cl N2 O

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 864260-53-7 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-[[4-[(tetrahydro-2H-pyran-4-yl)oxy]phenyl]methyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1)
(CA INDEX NAME)

CM 1

CRN 864260-52-6

CMF C22 H27 Cl N2 O2

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 864260-55-9 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[[4-[(3,3-dimethylcyclohexyl)oxy]phenyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864260-54-8

CMF C25 H33 Cl N2 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864260-57-1 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[[6-(cyclohexylthio)-3-pyridinyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864260-56-0

CMF C22 H28 Cl N3 S


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864260-59-3 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[6-[(1,1-dimethylethyl)thio]-3-pyridinyl]methyl]-2,3,4,5-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 864260-58-2

CMF C20 H26 Cl N3 S

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 864260-61-7 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[6-[(3,3-dimethylbutyl)thio]-3-pyridinyl]methyl]-2,3,4,5-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 864260-60-6

CMF C22 H30 Cl N3 S

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 864260-63-9 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[(6-ethoxy-3-pyridinyl)methyl]-2,3,4,5-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 864260-62-8

CMF C18 H22 Cl N3 O

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 864260-65-1 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[3-chloro-4-[(1,1-dimethylethyl)thio]phenyl]methyl]-2,3,4,5-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 864260-64-0

CMF C21 H26 Cl2 N2 S

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 864260-67-3 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[3-chloro-4-
[(cyclohexylmethyl)thio]phenyl]methyl]-2,3,4,5-tetrahydro-,
(2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 864260-66-2

CMF C24 H30 Cl2 N2 S

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 864260-69-5 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[4-
[(cyclohexylmethyl)thio]phenyl]methyl]-2,3,4,5-tetrahydro-,
(2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 864260-68-4

CMF C24 H31 Cl N2 S

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 864260-71-9 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[4-[(1,1-dimethylethoxy)methyl]phenyl]methyl]-2,3,4,5-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 864260-70-8

CMF C22 H29 Cl N2 O

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 864260-73-1 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[4-
[(cyclopentyloxy)methyl]phenyl]methyl]-2,3,4,5-tetrahydro-,
(2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 864260-72-0

CMF C23 H29 Cl N2 O

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 864260-75-3 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[4-
[(cyclohexyloxy)methyl]phenyl]methyl]-2,3,4,5-tetrahydro-,
(2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 864260-74-2

CMF C24 H31 Cl N2 O

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 864260-77-5 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[4-[(2,2-dimethylpropoxy)methyl]phenyl]methyl]-2,3,4,5-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 864260-76-4

CMF C23 H31 Cl N2 O

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 864260-79-7 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[4-(cyclohexylthio)phenyl]methyl]-2,3,4,5-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 864260-78-6

CMF C23 H29 Cl N2 S

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 864260-81-1 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[6-(cyclopentylthio)-3-pyridinyl]methyl]-2,3,4,5-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 864260-80-0

CMF C21 H26 Cl N3 S

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 864260-83-3 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[4-(cyclopentylthio)phenyl]methyl]-2,3,4,5-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 864260-82-2

CMF C22 H27 Cl N2 S

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 864260-85-5 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[(3-chloro-4-ethoxyphenyl)methyl]-
2,3,4,5-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX
NAME)

CM 1

CRN 864260-84-4

CMF C19 H22 Cl2 N2 O

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6


Absolute stereochemistry.



RN 864260-86-6 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[4-(cycloheptyloxy)phenyl]methyl]-
2,3,4,5-tetrahydro- (CA INDEX NAME)


10/598,302



RN 864260-87-7 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-N-[[4-(cycloheptyloxy)phenyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864260-86-6
CMF C24 H31 Cl N2 O



10/598,302

CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H


RN 864260-89-9 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-N-[[4-(cycloheptylthio)phenyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864260-88-8

CMF C24 H31 Cl N2 S



CM 2

CRN 110-15-6


CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864260-90-2 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[4-(cyclohexylmethyl)phenyl]methyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)

10/598,302




RN 864260-91-3 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-N-[[4-(cyclohexylmethyl)phenyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864260-90-2

CMF C24 H31 Cl N2



CM 2

CRN 110-15-6


10/598,302

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864260-92-4 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-[[4-(2-methylbutyl)phenyl]methyl]- (CA INDEX NAME)



RN 864260-93-5 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-(2-methylbutyl)phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864260-92-4

CMF C22 H29 Cl N2


10/598,302



CM 2


CRN 110-15-6

CMF C4 H6 O4



RN 864260-94-6 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[4-(3,3-dimethylbutyl)phenyl]methyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 864260-95-7 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[[4-(3,3-dimethylbutyl)phenyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

10/598,302

CM 1

CRN 864260-94-6


CMF C23 H31 Cl N2



CM 2


CRN 110-15-6

CMF C4 H6 O4



RN 864260-96-8 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[6-(3,3-dimethylbutyl)-3-pyridinyl]methyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 864260-97-9 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-N-[[6-(3,3-dimethylbutyl)-3-


10/598,302

pyridinyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA
INDEX NAME)

CM 1

CRN 864260-96-8

CMF C22 H30 Cl N3



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864260-99-1 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[[6-(cyclohexylmethyl)-3-pyridinyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA
INDEX NAME)

CM 1

CRN 864260-98-0

CMF C23 H30 Cl N3


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864261-01-8 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[[5-(3,3-dimethylbutyl)-2-pyridinyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864261-00-7

CMF C22 H30 Cl N3


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4




RN 864261-03-0 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-(1,3,3-trimethylbutyl)phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864261-02-9

CMF C24 H33 Cl N2



10/598,302

CM 2


CRN 110-15-6

CMF C4 H6 O4

$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 864261-04-1 CAPLUS


CN 1H-3-Benzazepine, 6-[(6-benzothiazolylmethyl)thio]-7-chloro-2,3,4,5-tetrahydro-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 864261-05-2 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[(2-phenyl-6-benzothiazolyl)methyl]thio]-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

10/598,302

RN 864261-06-3 CAPLUS


CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[[2-(phenylmethyl)-6-benzothiazolyl]methyl]thio]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 864261-07-4 CAPLUS

CN 1H-3-Benzazepine, 6-[(benzo[b]thien-6-ylmethyl)thio]-7-chloro-2,3,4,5-tetrahydro-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 864261-08-5 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[(1,3,4-thiadiazol-2-ylmethyl)thio]-, hydrochloride (1:1) (CA INDEX NAME)

10/598,302



● HCl


RN 864261-10-9 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-6-[(5-thiazolylmethyl)thio]-1H-3-benzazepine (1:1) (CA INDEX NAME)

CM 1

CRN 864261-09-6

CMF C14 H15 Cl N2 S2



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864261-12-1 CAPLUS

CN Butanedioic acid, compd. with 5-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-N-(cyclohexylmethyl)-2-thiazolamine (1:1)


10/598,302

(CA INDEX NAME)

CM 1

CRN 864261-11-0

CMF C21 H28 Cl N3 S2



CM 2

CRN 110-15-6

CMF C4 H6 O4

$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 864261-14-3 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-6-[[1-(2-thiazolyl)ethyl]thio]-1H-3-benzazepine (1:1) (CA INDEX NAME)


CM 1

CRN 864261-13-2

CMF C15 H17 Cl N2 S2

Rotation (-).

10/598,302



CM 2


CRN 110-15-6
CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864261-16-5 CAPLUS
CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-3-methyl-6-[(2-pyridinylmethyl)thio]-1H-3-benzazepine (1:1) (CA INDEX NAME)

CM 1


CRN 864261-15-4
CMF C17 H19 Cl N2 S



CM 2

CRN 110-15-6
CMF C4 H6 O4


10/598,302



RN 864261-17-6 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[2,2,2-trifluoro-1-(2-pyridinyl)ethyl]thio]-, hydrochloride (1:?), (+)- (CA INDEX NAME)

Rotation (+).




●x HCl

RN 864261-18-7 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[2,2,2-trifluoro-1-(2-pyridinyl)ethyl]thio]-, hydrochloride (1:?), (-)- (CA INDEX NAME)

Rotation (-).




●x HCl

RN 864261-19-8 CAPLUS

10/598,302

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[[1-(2-pyridinyl)propyl]thio]-, hydrochloride (1:?), (-)- (CA INDEX NAME)


Rotation (-).



●x HCl

RN 864261-20-1 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-6-[[1-(4-fluorophenyl)ethyl]thio]-2,3,4,5-tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 864261-21-2 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-6-[[1-(3-fluorophenyl)ethyl]thio]-2,3,4,5-tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)


10/598,302



● HCl

RN 864261-22-3 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[(1-methyl-2-phenylethyl)thio]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 864261-24-5 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-6-[[1-(4-fluorophenyl)ethyl]thio]-2,3,4,5-tetrahydro-1H-3-benzazepine (1:1) (CA INDEX NAME)


CM 1

CRN 864261-23-4

CMF C18 H19 Cl F N S

Rotation (+).

10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4

$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 864261-26-7 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-6-[[1-(4-fluorophenyl)ethyl]thio]-2,3,4,5-tetrahydro-1H-3-benzazepine (1:1) (CA INDEX NAME)

CM 1

CRN 864261-25-6

CMF C18 H19 Cl F N S

Rotation (-).



10/598,302

CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864261-28-9 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-6-[[1-(3-fluorophenyl)ethyl]thio]-2,3,4,5-tetrahydro-1H-3-benzazepine (1:1) (CA INDEX NAME)

CM 1

CRN 864261-27-8

CMF C18 H19 Cl F N S

Rotation (+).



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864261-30-3 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-6-[[1-(3-fluorophenyl)ethyl]thio]-2,3,4,5-tetrahydro-1H-3-benzazepine (1:1) (CA INDEX NAME)


CM 1

CRN 864261-29-0

CMF C18 H19 Cl F N S

10/598,302

Rotation (-).



CM 2

CRN 110-15-6


CMF C4 H6 O4

$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 864261-31-4 CAPLUS

CN 1-Butanone, 1-[4-[(1S)-1-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]ethyl]phenyl]-3,3-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

10/598,302

RN 864261-32-5 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[(1S)-1-phenylethyl]thio]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 864261-33-6 CAPLUS

CN Ethanone, 1-[4-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 864261-34-7 CAPLUS


CN 1-Propanone, 1-[4-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

10/598,302



● HCl


RN 864261-35-8 CAPLUS
CN 1-Butanone, 1-[4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 864261-36-9 CAPLUS
CN 1-Propanone, 1-[4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]phenyl]-2-methyl-, hydrochloride (1:1) (CA INDEX NAME)

10/598,302




● HCl

RN 864261-37-0 CAPLUS
CN 1-Butanone, 1-[4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]phenyl]-3-methyl-, hydrochloride (1:1) (CA INDEX NAME)




● HCl


RN 864261-38-1 CAPLUS
CN Methanone, [4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]phenyl]-2-pyridinyl-, hydrochloride (1:1) (CA INDEX NAME)




RN 864261-39-2 CAPLUS
 CN Methanone, [4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]phenyl]-3-pyridinyl-, hydrochloride (1:?) (CA INDEX NAME)



RN 864261-40-5 CAPLUS
 CN Methanone, [4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]phenyl]-4-pyridinyl-, hydrochloride (1:?) (CA INDEX NAME)




RN 864261-41-6 CAPLUS
 CN 1-Butanone, 1-[6-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-3-pyridinyl]-3-methyl-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl

RN 864261-42-7 CAPLUS
 CN 1-Butanone, 1-[5-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-2-pyridinyl]-3-methyl-, hydrochloride (1:?) (CA INDEX NAME)


10/598,302



● x HCl

RN 864261-43-8 CAPLUS


CN Benzonitrile, 3-[4-[[4-(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]benzoyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 864261-44-9 CAPLUS

CN Benzonitrile, 4-[4-[[4-(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]benzoyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 864261-45-0 CAPLUS
 CN Benzenecarbothioamide, 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-N-(1,1-dimethylethyl)-, hydrochloride (1:1) (CA INDEX NAME)



RN 864261-47-2 CAPLUS
 CN Butanedioic acid, compd. with 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-N-[(4-fluorophenyl)methyl]benzenecarbothioamide (1:1) (CA INDEX NAME)


10/598,302

CM 1


CRN 864261-46-1

CMF C25 H24 Cl F N2 S2

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864261-49-4 CAPLUS

CN Butanedioic acid, compd. with 5-[[7-chloro-2,3,4,5-tetrahydro-1H-3-


10/598,302

benzazepin-6-yl)thio]methyl]-N-cyclohexyl-2-pyridinamine (1:1) (CA INDEX NAME)

CM 1

CRN 864261-48-3

CMF C22 H28 Cl N3 S



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864261-51-8 CAPLUS


CN Butanedioic acid, compd. with 5-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-N-(2,2,2-trifluoroethyl)-2-pyridinamine (1:1) (CA INDEX NAME)

CM 1

CRN 864261-50-7

CMF C18 H19 Cl F3 N3 S


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864261-53-0 CAPLUS


CN Butanedioic acid, compd. with 5-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-N-(cyclohexylmethyl)-2-pyridinamine (1:1)
(CA INDEX NAME)

CM 1

CRN 864261-52-9

CMF C23 H30 Cl N3 S


10/598,302



CM 2


CRN 110-15-6

CMF C4 H6 O4



RN 864261-54-1 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-6-[(2,2-difluoro-2-phenylethyl)thio]-2,3,4,5-tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 864261-55-2 CAPLUS

CN 1H-3-Benzazepine, 7-chloro-6-[[2,2-difluoro-2-(2-pyridinyl)ethyl]thio]-2,3,4,5-tetrahydro-, hydrochloride (1:?) (CA INDEX NAME)

10/598,302



●x HCl


RN 864261-57-4 CAPLUS

CN Butanedioic acid, compd. with 1-[3-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]propyl]-1,3-dihydro-2H-indol-2-one (1:1) (CA INDEX NAME)

CM 1

CRN 864261-56-3

CMF C21 H23 Cl N2 O S



CM 2

CRN 110-15-6

CMF C4 H6 O4


HO₂C-CH₂-CH₂-CO₂H

10/598,302

RN 864261-59-6 CAPLUS
CN Butanedioic acid, compd. with 1-[2-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]ethyl]-2-pyrrolidinone (1:1) (CA INDEX NAME)

CM 1

CRN 864261-58-5
CMF C16 H21 Cl N2 O S



CM 2

CRN 110-15-6
CMF C4 H6 O4


$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 864261-61-0 CAPLUS
CN Butanedioic acid, compd. with 1-[2-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]ethyl]-1,3-dihydro-3,3-dimethyl-2H-indol-2-one (1:1) (CA INDEX NAME)

CM 1

CRN 864261-60-9
CMF C22 H25 Cl N2 O S


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4




RN 864261-63-2 CAPLUS

CN Butanedioic acid, compd. with 1-[3-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]propyl]-1,3-dihydro-3,3-dimethyl-2H-indol-2-one (1:1)
(CA INDEX NAME)

CM 1

CRN 864261-62-1

CMF C23 H27 Cl N2 O S



10/598,302

CM 2

CRN 110-15-6

CMF C4 H6 O4

$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$


RN 864261-65-4 CAPLUS

CN Butanedioic acid, compd. with 1-[4-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]butyl]-3,4-dihydro-2(1H)-quinolinone (1:1) (CA INDEX NAME)

CM 1

CRN 864261-64-3

CMF C23 H27 Cl N2 O S



CM 2

CRN 110-15-6

CMF C4 H6 O4

$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 864261-67-6 CAPLUS


CN Butanedioic acid, compd. with 1-[3-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]propyl]-1,3-dihydro-3-methyl-2H-benzimidazol-2-one (1:1) (CA INDEX NAME)

CM 1

CRN 864261-66-5

CMF C21 H24 Cl N3 O S


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4




RN 864261-69-8 CAPLUS

CN Butanedioic acid, compd. with 1-[4-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]butyl]-1,3-dihydro-3-methyl-2H-benzimidazol-2-one (1:1) (CA INDEX NAME)

CM 1

CRN 864261-68-7

CMF C22 H26 Cl N3 O S



CM 2

10/598,302


CRN 110-15-6
CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864261-71-2 CAPLUS
CN Butanedioic acid, compd. with 1-[3-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]propyl]-3-methyl-2-imidazolidinone (1:1) (CA INDEX NAME)

CM 1

CRN 864261-70-1
CMF C17 H24 Cl N3 O S



CM 2

CRN 110-15-6
CMF C4 H6 O4


HO₂C-CH₂-CH₂-CO₂H

RN 864261-73-4 CAPLUS
CN Butanedioic acid, compd. with 1-[3-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]propyl]-3-(1,1-dimethylethyl)-2-imidazolidinone (1:1) (CA INDEX NAME)

CM 1

CRN 864261-72-3
CMF C20 H30 Cl N3 O S


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4




RN 864261-75-6 CAPLUS

CN Butanedioic acid, compd. with 1-[3-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]propyl]-3,4-dihydro-2(1H)-quinolinone (1:1) (CA INDEX NAME)

CM 1

CRN 864261-74-5

CMF C22 H25 Cl N2 O S



CM 2

10/598,302


CRN 110-15-6
CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864261-77-8 CAPLUS
CN Butanedioic acid, compd. with 1-[3-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]propyl]-1,3-dihydro-2H-benzimidazol-2-one (1:1) (CA INDEX NAME)

CM 1

CRN 864261-76-7
CMF C20 H22 Cl N3 O S




CM 2

CRN 110-15-6
CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 864261-78-9 CAPLUS
CN 2H-Indol-2-one, 5-[3-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]propyl]-1,3-dihydro-3,3-dimethyl- (CA INDEX NAME)



IT	864261-79-0P	864261-81-4P	864261-83-6P
	864261-85-8P	864261-87-0P	864261-89-2P
	864261-91-6P	864261-93-8P	864261-95-0P
	864261-97-2P	864261-99-4P	864262-01-1P
	864262-03-3P	864262-05-5P	864262-07-7P
	864262-09-9P	864262-11-3P	864262-13-5P
	864262-15-7P	864262-17-9P	864262-19-1P
	864262-21-5P	864262-23-7P	864262-25-9P
	864262-27-1P	864262-29-3P	864262-31-7P
	864262-33-9P	864262-35-1P	864262-37-3P
	864262-39-5P	864268-88-2P	864268-89-3P
	864268-90-6P	864268-91-7P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT_{2c} receptor agonists)

RN 864261-79-0 CAPLUS


CN Butanedioic acid, compd. with 5-[3-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]propyl]-1,3-dihydro-3,3-dimethyl-2H-indol-2-one (1:1)
(CA INDEX NAME)

CM 1

CRN 864261-78-9

CMF C23 H27 Cl N2 O S

10/598,302



CM 2


CRN 110-15-6
CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864261-81-4 CAPLUS
CN Butanedioic acid, compd. with 2-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]-N-phenylacetamide (1:1) (CA INDEX NAME)

CM 1

CRN 864261-80-3
CMF C18 H19 Cl N2 O S



CM 2

CRN 110-15-6
CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864261-83-6 CAPLUS


10/598,302

CN Butanedioic acid, compd. with 4-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]-N-methylbutanamide (1:1) (CA INDEX NAME)

CM 1

CRN 864261-82-5

CMF C15 H21 Cl N2 O S



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H


RN 864261-85-8 CAPLUS

CN Butanedioic acid, compd. with 2-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]-2-methylpropanenitrile (1:1) (CA INDEX NAME)

CM 1

CRN 864261-84-7

CMF C14 H17 Cl N2 S



CM 2

CRN 110-15-6

CMF C4 H6 O4

10/598,302

HO₂C—CH₂—CH₂—CO₂H


RN 864261-87-0 CAPLUS

CN Butanedioic acid, compd. with 1-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]cyclopropanecarbonitrile (1:1) (CA INDEX NAME)

CM 1

CRN 864261-86-9

CMF C14 H15 Cl N2 S



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 864261-89-2 CAPLUS


CN Butanedioic acid, compd. with 4-[[[(7-chloro-9-fluoro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-N-(1,1-dimethylethyl)benzamide (1:1) (CA INDEX NAME)

CM 1

CRN 864261-88-1

CMF C22 H26 Cl F N2 O S


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864261-91-6 CAPLUS


CN Butanedioic acid, compd. with 1-[4-[[[(7-chloro-9-fluoro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]phenyl]-3,3-dimethyl-1-butanone (1:1)
(CA INDEX NAME)

CM 1

CRN 864261-90-5

CMF C23 H27 Cl F N O S


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864261-93-8 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[4-[(2,2-dimethylpropyl)sulfonyl]phenyl]methyl]-2,3,4,5-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 864261-92-7

CMF C22 H29 Cl N2 O2 S

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 864261-95-0 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-[[4-[(3,3,3-trifluoro-1-methylpropyl)sulfonyl]phenyl]methyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 864261-94-9

CMF C21 H24 Cl F3 N2 O2 S

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 864261-97-2 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[4-[[[(1,1-dimethylethyl)sulfonyl]methyl]phenyl]methyl]-2,3,4,5-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 864261-96-1

CMF C22 H29 C1 N2 O2 S


10/598,302



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.




RN 864261-99-4 CAPLUS
CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[4-[2-[(1,1-dimethylethyl)sulfonyl]ethyl]phenyl]methyl]-2,3,4,5-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 864261-98-3
CMF C23 H31 Cl N2 O2 S


10/598,302



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.




RN 864262-01-1 CAPLUS
CN 3-Pentanone, 1-[4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]phenyl]-4,4-dimethyl-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 864262-00-0
CMF C24 H31 Cl N2 O


10/598,302



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.




RN 864262-03-3 CAPLUS
CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[4-[[[(1,1-dimethylethyl)thio]methyl]phenyl]methyl]-2,3,4,5-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 864262-02-2
CMF C22 H29 Cl N2 S

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 864262-05-5 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[4-[2-[(1,1-dimethylethyl)thio]ethyl]phenyl]methyl]-2,3,4,5-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 864262-04-4

CMF C23 H31 Cl N2 S

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 864262-07-7 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[[6-(cycloheptylthio)-3-pyridinyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864262-06-6

CMF C23 H30 Cl N3 S


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864262-09-9 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-[[4-[(3,3,3-trifluoropropyl)sulfonyl]phenyl]methyl]-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864262-08-8

CMF C20 H22 Cl F3 N2 O2 S


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864262-11-3 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[5-(2-cyclohexylethyl)-2-pyridinyl]methyl]-2,3,4,5-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 864262-10-2

CMF C24 H32 Cl N3

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 864262-13-5 CAPLUS


CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[6-(2-cyclohexylethyl)-3-pyridinyl]methyl]-2,3,4,5-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 864262-12-4

CMF C24 H32 Cl N3

10/598,302




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 864262-15-7 CAPLUS


CN Butanedioic acid, compd. with 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-2-fluoro-N-(2,2,2-trifluoroethyl)benzamide (1:1) (CA INDEX NAME)

CM 1

CRN 864262-14-6

CMF C20 H20 Cl F4 N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864262-17-9 CAPLUS


CN Butanedioic acid, compd. with 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-2-fluoro-N-(1-methylpropyl)benzamide (1:1)
(CA INDEX NAME)

CM 1

CRN 864262-16-8

CMF C22 H27 Cl F N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864262-19-1 CAPLUS


CN Butanedioic acid, compd. with 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-cyclooctyl-2-fluorobenzamide (1:1) (CA INDEX NAME)

CM 1

CRN 864262-18-0

CMF C26 H33 Cl F N3 O

10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4

$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 864262-21-5 CAPLUS


CN Butanedioic acid, compd. with 4-[[[7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl]amino]methyl]-2-fluoro-N-(1-propylbutyl)benzamide (1:1)
(CA INDEX NAME)

CM 1

CRN 864262-20-4

CMF C25 H33 Cl F N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864262-23-7 CAPLUS


CN Butanedioic acid, compd. with 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-(1-ethylpropyl)-2-fluorobenzamide (1:1)
(CA INDEX NAME)

CM 1

CRN 864262-22-6

CMF C23 H29 Cl F N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864262-25-9 CAPLUS


CN Butanedioic acid, compd. with 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-(1,3-dimethylbutyl)-2-fluorobenzamide (1:1) (CA INDEX NAME)

CM 1

CRN 864262-24-8

CMF C24 H31 Cl F N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864262-27-1 CAPLUS


CN Butanedioic acid, compd. with 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-(1,2-dimethylpropyl)-2-fluorobenzamide (1:1) (CA INDEX NAME)

CM 1

CRN 864262-26-0

CMF C23 H29 Cl F N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864262-29-3 CAPLUS


CN Butanedioic acid, compd. with 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-ethyl-2-fluorobenzamide (1:1) (CA INDEX NAME)

CM 1

CRN 864262-28-2

CMF C20 H23 Cl F N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864262-31-7 CAPLUS


CN Butanedioic acid, compd. with 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-cyclooctylbenzamide (1:1) (CA INDEX NAME)

CM 1

CRN 864262-30-6

CMF C26 H34 Cl N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864262-33-9 CAPLUS


CN Butanedioic acid, compd. with 4-[[[7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl]amino]methyl]-N-(1-propylbutyl)benzamide (1:1) (CA INDEX NAME)

CM 1

CRN 864262-32-8

CMF C25 H34 Cl N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864262-35-1 CAPLUS


CN Butanedioic acid, compd. with 4-[[7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl]amino]methyl]-N-(1-ethylpropyl)benzamide (1:1) (CA INDEX NAME)

CM 1

CRN 864262-34-0

CMF C23 H30 Cl N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864262-37-3 CAPLUS


CN Butanedioic acid, compd. with 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl) amino]methyl]-N-(1,3-dimethylbutyl)benzamide (1:1) (CA INDEX NAME)

CM 1

CRN 864262-36-2

CMF C24 H32 Cl N3 O


10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 864262-39-5 CAPLUS


CN Butanedioic acid, compd. with 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-(1,2-dimethylpropyl)benzamide (1:1) (CA INDEX NAME)

CM 1

CRN 864262-38-4

CMF C23 H30 Cl N3 O


10/598,302



CM 2


CRN 110-15-6

CMF C4 H6 O4



RN 864268-88-2 CAPLUS


CN 1H-3-Benzazepin-6-amine, N-[(2-fluorophenyl)methyl]-2,3,4,5-tetrahydro-
(CA INDEX NAME)




RN 864268-89-3 CAPLUS

CN Benzamide, 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 864268-90-6 CAPLUS
 CN 1H-3-Benzazepin-6-amine, 7,9-dichloro-N-[(3,4-difluorophenyl)methyl]-
 2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 864268-91-7 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-chloro-6-[[[4-[(1,1-dimethylethyl)amino]carbonyl]-3-
 fluorophenyl]methyl]thio]-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester
 (CA INDEX NAME)



IT	864268-03-1P	1132979-89-5P	1133052-93-3P
	1133056-28-6P	1133062-71-1P	1133065-07-2P
	1133326-42-7P	1133329-82-4P	1133333-70-6P
	1133340-46-1P	1133342-42-3P	1133343-50-6P
	1133351-69-5P	1133379-84-6P	1133381-05-1P
	1133385-82-6P	1133395-05-7P	1133395-97-7P
	1133396-89-0P		


RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP
 (Preparation); RACT (Reactant or reagent)

(preparation of 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as
 5-HT_{2c} receptor agonists)

10/598,302


RN 864268-03-1 CAPLUS

CN Benzoic acid, 4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]-, methyl ester (CA INDEX NAME)




RN 1132979-89-5 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[(1-phenylcyclopropyl)amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 1133052-93-3 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[1-(4-pyridinyl)ethyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 1133056-28-6 CAPLUS


CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[5-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 1133062-71-1 CAPLUS

CN Ethanone, 2,2,2-trifluoro-1-[7-fluoro-6-[[[4-(2,2,2-trifluoroethoxy)phenyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]- (CA INDEX NAME)


10/598,302



RN 1133065-07-2 CAPLUS
CN Carbamothioic acid, N,N-dimethyl-,
O-[7-bromo-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-
yl] ester (CA INDEX NAME)




RN 1133326-42-7 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-1,2,4,5-tetrahydro-6-[[[4-
[[(methylsulfonyl)oxy]methyl]phenyl]methyl]thio]-, 1,1-dimethylethyl ester
(CA INDEX NAME)



RN 1133329-82-4 CAPLUS


CN 3H-3-Benzazepine-3-carboxylic acid,
6-[[[4-(bromomethyl)phenyl]methyl]thio]-7-chloro-1,2,4,5-tetrahydro-,
1,1-dimethylethyl ester (CA INDEX NAME)




RN 1133333-70-6 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-6-[[[5-[2-(4-fluorophenyl)ethynyl]-2-pyridinyl]methyl]thio]-
1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)


10/598,302




RN 1133340-46-1 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-1,2,4,5-tetrahydro-6-[[[4-(trifluoromethoxy)phenyl]methyl]thio]-,
1,1-dimethylethyl ester (CA INDEX NAME)




RN 1133342-42-3 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-6-[[[3,4-dichlorophenyl]methyl]thio]-1,2,4,5-tetrahydro-,
1,1-dimethylethyl ester (CA INDEX NAME)




RN 1133343-50-6 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 6-[[[4-(acetyloxy)phenyl]methyl]thio]-7-chloro-1,2,4,5-tetrahydro-,
 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1133351-69-5 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-chloro-6-[[[3-fluoro-4-(methoxycarbonyl)phenyl]methyl]thio]-1,2,4,5-
 tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1133379-84-6 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-chloro-1,2,4,5-tetrahydro-6-[(2-methoxy-2-oxoethyl)thio]-,
 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1133381-05-1 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-chloro-6-[[4-(dimethylamino)-4-oxobutyl]thio]-1,2,4,5-tetrahydro-,
 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1133385-82-6 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,

7-chloro-1,2,4,5-tetrahydro-6-[(4-hydroxybutyl)thio]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1133395-05-7 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
6-[[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]thio]-1,2,4,5-
tetrahydro-7-(trifluoromethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1133395-97-7 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
1,2,4,5-tetrahydro-6-[(2-hydroxyethyl)thio]-7-(trifluoromethyl)-,
1,1-dimethylethyl ester (CA INDEX NAME)



RN 1133396-89-0 CAPLUS

CN Benzoic acid, 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-2-fluoro-, methyl ester (CA INDEX NAME)



IT	1132971-72-2P	1132975-31-5P	1132985-48-8P
	1133012-74-4P	1133013-99-6P	1133017-14-7P
	1133027-41-4P	1133034-41-9P	1133039-55-0P
	1133050-64-2P	1133062-76-6P	1133069-57-4P
	1133072-91-9P	1133075-06-5P	1133085-78-5P
	1133088-63-7P	1133105-62-0P	1133107-67-1P
	1133136-86-3P	1133138-70-1P	1133142-35-4P
	1133147-65-5P	1133151-56-0P	1133153-29-3P
	1133154-28-5P		

RL: PRPH (Prophetic); SPN (Synthetic preparation); PREP (Preparation)
 (preparation of 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as
 5-HT_{2c} receptor agonists)

RN 1132971-72-2 CAPLUS


CN Butanedioic acid, compd. with 7-chloro-N-[1-(4-chlorophenyl)ethyl]-2,3,4,5-
 tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864255-37-8

CMF C18 H20 Cl2 N2

10/598,302



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H


RN 1132975-31-5 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-N-(2,3-dihydro-1H-inden-2-yl)-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864255-56-1

CMF C19 H21 Cl N2



CM 2

CRN 110-15-6

CMF C4 H6 O4

10/598,302

HO₂C—CH₂—CH₂—CO₂H


RN 1132985-48-8 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-N-[(2,3-dihydro-5-benzofuranyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1

CRN 864255-69-6

CMF C19 H21 Cl N2 O



CM 2

CRN 110-15-6


CMF C4 H6 O4

HO₂C—CH₂—CH₂—CO₂H

RN 1133012-74-4 CAPLUS


CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[(6-quinolinylmethyl)amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)

10/598,302




RN 1133013-99-6 CAPLUS

CN Ethanone, 1-[6-[(6-benzofuranylmethyl)amino]-7-chloro-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 1133017-14-7 CAPLUS


CN Ethanone, 1-[6-[(6-benzothiazolylmethyl)amino]-7-chloro-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 1133027-41-4 CAPLUS


CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[(8-quinolinylmethyl)amino]-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)

10/598,302



RN 1133034-41-9 CAPLUS


CN Ethanone, 1-[7-chloro-6-[(2-cyclohexyl-6-benzothiazolyl)methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 1133039-55-0 CAPLUS


CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[(1-methyl-1H-indol-4-yl)methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)

10/598,302



RN 1133050-64-2 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[(2-pyridinylmethyl)amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 1133062-76-6 CAPLUS

CN Butanedioic acid, compd. with 7-ethyl-N-[(1S)-1-(4-fluorophenyl)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)


CM 1

CRN 864256-73-5

CMF C20 H25 F N2

Absolute stereochemistry.


10/598,302



CM 2


CRN 110-15-6

CMF C4 H6 O4



RN 1133069-57-4 CAPLUS


CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-6-[(4-fluorophenyl)methoxy]-1,2,4,5-tetrahydro-,
1,1-dimethylethyl ester (CA INDEX NAME)



RN 1133072-91-9 CAPLUS


CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-6-[(4-cyanophenyl)methoxy]-1,2,4,5-tetrahydro-, 1,1-dimethylethyl
ester (CA INDEX NAME)

10/598,302




RN 1133075-06-5 CAPLUS

CN Ethanone, 1-[7-chloro-9-fluoro-6-[(4-fluorophenyl)methoxy]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 1133085-78-5 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 7-chloro-1,2,4,5-tetrahydro-6-(2-pyridinylmethoxy)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1133088-63-7 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[3-(2-pyridinyl)propoxy]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 1133105-62-0 CAPLUS


CN Benzamide, N-[2-[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]oxy]ethyl]- (CA INDEX NAME)



RN 1133107-67-1 CAPLUS


CN Urea, N-[2-[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]oxy]ethyl]-N'-phenyl- (CA INDEX NAME)

10/598,302




RN 1133136-86-3 CAPLUS

CN Benzamide, N-[2-[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]ethyl]- (CA INDEX NAME)



RN 1133138-70-1 CAPLUS


CN 3-Pyridinecarboxamide, N-[2-[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]ethyl]- (CA INDEX NAME)



RN 1133142-35-4 CAPLUS


10/598,302

CN Ethanone, 1-[7-chloro-6-[[[4-(ethylsulfonyl)phenyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 1133147-65-5 CAPLUS

CN Benzamide, 4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]-N-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 1133151-56-0 CAPLUS

CN Benzamide, 4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]-N-cyclohexyl-2-fluoro- (CA INDEX NAME)




RN 1133153-29-3 CAPLUS

CN Benzamide, 4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 1133154-28-5 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-1,2,4,5-tetrahydro-6-[[[4-[(3,3,3-trifluoro-1-methylpropyl)amino]carbonyl]phenyl]methyl]amino]-, 1,1-dimethylethyl ester
(CA INDEX NAME)




IT	864254-00-2	864268-21-3	864268-25-7
	864268-28-0	864268-32-6	864268-35-9
	864268-37-1	864268-41-7	864268-42-8
	864268-47-3	864268-49-5	864268-51-9
	864268-52-0	864268-53-1	864268-54-2
	864268-55-3	864268-56-4	864268-57-5
	864268-58-6	864268-59-7	864268-83-7
	864268-85-9	864268-86-0	864268-87-1
	864351-45-1	1133062-12-0	1140511-13-2

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2c receptor agonists)

RN 864254-00-2 CAPLUS


CN Benzamide, 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)amino]methyl]-N-(2,2,2-trifluoro-1-methylethyl)- (CA INDEX NAME)



10/598,302


RN 864268-21-3 CAPLUS

CN Benamide, 4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]-N-(3,3,3-trifluoro-1-methylpropyl)- (CA INDEX NAME)



RN 864268-25-7 CAPLUS

CN Benzenecarbothioamide, 4-[[[7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl]amino]methyl]-N-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 864268-28-0 CAPLUS


CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[methyl(1-phenylethyl)amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro-, (-)- (CA INDEX NAME)

Rotation (-).


10/598,302




RN 864268-32-6 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid,
6-[[1,1-dimethyl-2-phenylethyl]thio]-7-chloro-1,2,4,5-tetrahydro-,
1,1-dimethylethyl ester (CA INDEX NAME)




RN 864268-35-9 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-6-[[6-chloro-3-pyridazinyl]methyl]thio]-1,2,4,5-tetrahydro-,
1,1-dimethylethyl ester (CA INDEX NAME)




RN 864268-37-1 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 6-[[4-bromo-2-thienyl)methyl]thio]-7-chloro-1,2,4,5-tetrahydro-,
 1,1-dimethylethyl ester (CA INDEX NAME)



RN 864268-41-7 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 6-[[4-bromo-3-fluorophenyl)methyl]thio]-7-chloro-1,2,4,5-tetrahydro-,
 1,1-dimethylethyl ester (CA INDEX NAME)



RN 864268-42-8 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 6-[[[(3-bromo-4-chlorophenyl)methyl]thio]-7-chloro-1,2,4,5-tetrahydro-,
 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864268-47-3 CAPLUS
 CN Butanedioic acid, compd. with 2-[1-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]ethyl]benzonitrile (1:1) (CA INDEX NAME)

CM 1

CRN 864268-46-2
 CMF C19 H19 Cl N2 S

10/598,302




CM 2

CRN 110-15-6
CMF C4 H6 O4


$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 864268-49-5 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-1,2,4,5-tetrahydro-6-[(2-methoxy-2-oxo-1-phenylethyl)thio]-,
1,1-dimethylethyl ester (CA INDEX NAME)




RN 864268-51-9 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-1,2,4,5-tetrahydro-6-[[[(2S)-tetrahydro-5-oxo-2-
furanyl]methyl]thio]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.




RN 864268-52-0 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-chloro-1,2,4,5-tetrahydro-6-[(4-methoxy-4-oxobutyl)thio]-,
 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864268-53-1 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-chloro-1,2,4,5-tetrahydro-6-[[[3-(hydroxymethyl)phenyl]methyl]thio]-,
 1,1-dimethylethyl ester (CA INDEX NAME)



RN 864268-54-2 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-chloro-1,2,4,5-tetrahydro-6-[[[2-(hydroxymethyl)phenyl]methyl]thio]-,
 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864268-55-3 CAPLUS
 CN Butanoic acid, 4-[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]-,
 methyl ester (CA INDEX NAME)




RN 864268-56-4 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,

7-chloro-1,2,4,5-tetrahydro-6-[(2-hydroxy-1-phenylethyl)thio]-,
1,1-dimethylethyl ester (CA INDEX NAME)




RN 864268-57-5 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
7-bromo-6-[[dimethylamino)carbonyl]thio]-1,2,4,5-tetrahydro-,
1,1-dimethylethyl ester (CA INDEX NAME)




RN 864268-58-6 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
7-bromo-6-[(4-ethoxy-4-oxobutyl)thio]-1,2,4,5-tetrahydro-,
1,1-dimethylethyl ester (CA INDEX NAME)




RN 864268-59-7 CAPLUS


CN Carbamothioic acid, dimethyl-, S-[7-bromo-2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1H-3-benzazepin-6-yl] ester (9CI) (CA INDEX NAME)



RN 864268-83-7 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-chloro-6-[[1-(3-fluorophenyl)ethyl]thio]-1,2,4,5-tetrahydro-,
 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864268-85-9 CAPLUS
 CN Benzamide, 4-[[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-N-(1,1-dimethylethyl)- (CA INDEX NAME)




10/598,302

RN 864268-86-0 CAPLUS
CN Benzamide, 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl)thio]methyl]-N-[(4-fluorophenyl)methyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 864268-87-1 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid,
6-[[(4-carboxyphenyl)methyl]amino]-7-chloro-1,2,4,5-tetrahydro-,
3-(1,1-dimethylethyl) ester compd. with pentane (1:1) (CA INDEX NAME)

CM 1

CRN 864262-93-1
CMF C23 H27 Cl N2 O4


10/598,302



CM 2


CRN 109-66-0

CMF C5 H12




RN 864351-45-1 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[(3-fluorophenyl)methyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 1133062-12-0 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[[(3,4-difluorophenyl)methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 1140511-13-2 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-(phenylmethyl)-
(CA INDEX NAME)

IT	488838-92-2P	488838-93-3P	488838-94-4P
	847199-06-8P	847199-07-9P	847199-08-0P
	864257-10-3P	864262-40-8P	864262-41-9P
	864262-42-0P	864262-43-1P	864262-44-2P
	864262-45-3P	864262-46-4P	864262-51-1P
	864262-52-2P	864262-53-3P	864262-54-4P
	864262-57-7P	864262-58-8P	864262-59-9P
	864262-60-2P	864262-61-3P	864262-62-4P
	864262-63-5P	864262-64-6P	864262-65-7P
	864262-66-8P	864262-67-9P	864262-68-0P
	864262-69-1P	864262-70-4P	864262-71-5P
	864262-72-6P	864262-73-7P	864262-74-8P
	864262-75-9P	864262-76-0P	864262-77-1P
	864262-78-2P	864262-79-3P	864262-80-6P
	864262-81-7P	864262-82-8P	864262-83-9P
	864262-84-0P	864262-85-1P	864262-86-2P
	864262-87-3P	864262-88-4P	864262-89-5P
	864262-90-8P	864262-91-9P	864262-92-0P
	864262-93-1P	864264-11-9P	864264-12-0P
	864264-13-1P	864264-14-2P	864264-15-3P
	864264-16-4P	864264-17-5P	864264-18-6P
	864264-19-7P	864264-20-0P	864264-21-1P
	864264-22-2P	864264-23-3P	864264-24-4P
	864264-26-6P	864264-28-8P	864264-30-2P
	864264-32-4P	864264-35-7P	864264-37-9P

864264-38-0P	864264-39-1P	864264-40-4P
864264-41-5P	864264-42-6P	864264-43-7P
864264-44-8P	864264-45-9P	864264-46-0P
864264-47-1P	864264-48-2P	864264-49-3P
864264-50-6P	864264-51-7P	864264-52-8P
864264-53-9P	864264-54-0P	864264-55-1P
864264-56-2P	864264-57-3P	864264-58-4P
864264-59-5P	864264-60-8P	864264-61-9P
864264-62-0P	864264-64-2P	864264-65-3P
864264-66-4P	864264-67-5P	864264-68-6P
864264-69-7P	864264-70-0P	864264-71-1P
864264-72-2P	864264-73-3P	864264-74-4P
864264-75-5P	864264-76-6P	864264-77-7P
864264-78-8P	864264-79-9P	864264-80-2P
864264-81-3P	864264-82-4P	864264-83-5P
864264-84-6P	864264-85-7P	864264-86-8P
864264-87-9P	864264-88-0P	864264-89-1P
864264-90-4P	864264-91-5P	864264-92-6P
864264-93-7P	864264-94-8P	864264-95-9P
864265-19-0P	864265-20-3P	864265-21-4P
864265-22-5P	864265-23-6P	864265-24-7P
864265-25-8P	864265-26-9P	864265-27-0P
864265-28-1P	864265-29-2P	864265-30-5P
864265-31-6P	864265-32-7P	864265-33-8P
864265-34-9P	864265-35-0P	864265-36-1P
864265-37-2P	864265-38-3P	864265-39-4P
864265-40-7P	864265-41-8P	864265-42-9P
864265-43-0P	864265-44-1P	864265-45-2P
864265-46-3P	864265-47-4P	864265-48-5P
864265-49-6P	864265-50-9P	864265-51-0P
864265-52-1P	864265-53-2P	864265-54-3P
864265-55-4P	864265-56-5P	864265-57-6P
864265-58-7P	864265-59-8P	864265-60-1P
864265-61-2P	864265-62-3P	864265-63-4P
864265-64-5P	864265-65-6P	864265-66-7P
864265-68-9P	864265-69-0P	864265-71-4P
864265-73-6P	864265-74-7P	864266-44-4P
864266-45-5P	864267-04-9P	864267-05-0P
864267-06-1P	864267-07-2P	864267-08-3P
864267-09-4P	864267-10-7P	864267-11-8P
864267-12-9P	864267-13-0P	864267-14-1P
864267-15-2P	864267-16-3P	864267-17-4P
864267-18-5P	864267-19-6P	864267-20-9P
864267-21-0P	864267-22-1P	864267-23-2P
864267-24-3P	864267-25-4P	864267-26-5P
864267-27-6P	864267-28-7P	864267-29-8P
864267-30-1P	864267-31-2P	864267-32-3P
864267-33-4P	864267-34-5P	864267-35-6P
864267-36-7P	864267-37-8P	864267-38-9P
864267-64-1P	864267-65-2P	864267-66-3P
864267-67-4P	864267-68-5P	864267-69-6P
864267-70-9P	864267-71-0P	864267-72-1P
864267-73-2P	864267-74-3P	864267-75-4P
864267-76-5P		


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as

5-HT_{2c} receptor agonists)


RN 488838-92-2 CAPLUS

CN Ethanone, 2,2,2-trifluoro-1-(1,2,4,5-tetrahydro-6-methoxy-3H-3-benzazepin-3-yl)- (CA INDEX NAME)




RN 488838-93-3 CAPLUS

CN Ethanone, 2,2,2-trifluoro-1-(1,2,4,5-tetrahydro-6-hydroxy-3H-3-benzazepin-3-yl)- (CA INDEX NAME)




RN 488838-94-4 CAPLUS

CN Methanesulfonic acid, 1,1,1-trifluoro-, 2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl ester (CA INDEX NAME)




RN 847199-06-8 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-6-methoxy-, hydrochloride (1:1) (CA INDEX NAME)




● HCl


RN 847199-07-9 CAPLUS
CN Ethanone, 1-(7-chloro-1,2,4,5-tetrahydro-6-hydroxy-3H-3-benzazepin-3-yl)-
2,2,2-trifluoro- (CA INDEX NAME)




RN 847199-08-0 CAPLUS
CN Methanesulfonic acid, 1,1,1-trifluoro-,
7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl
ester (CA INDEX NAME)




RN 864257-10-3 CAPLUS
CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[(2-pyridinylmethyl)thio]-
(CA INDEX NAME)




RN 864262-40-8 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 1,2,4,5-tetrahydro-6-[(trifluoromethyl)sulfonyl]oxy-, 1,1-dimethylethyl
 ester (CA INDEX NAME)



RN 864262-41-9 CAPLUS
 CN Ethanone, 2,2,2-trifluoro-1-(7-fluoro-1,2,4,5-tetrahydro-6-hydroxy-3H-3-
 benzazepin-3-yl)- (CA INDEX NAME)




RN 864262-42-0 CAPLUS
 CN Methanesulfonic acid, 1,1,1-trifluoro-,
 7-fluoro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl
 ester (CA INDEX NAME)




RN 864262-43-1 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-1,2,4,5-tetrahydro-6-hydroxy-, 1,1-dimethylethyl ester (CA INDEX
NAME)




RN 864262-44-2 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
1,2,4,5-tetrahydro-6-(3-phenyl-1-propyn-1-yl)-, 1,1-dimethylethyl ester
(CA INDEX NAME)




RN 864262-45-3 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
6-(3,3-dimethyl-1-butyn-1-yl)-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester
(CA INDEX NAME)




RN 864262-46-4 CAPLUS

CN Ethanone, 1-[6-(3,3-dimethyl-1-butyn-1-yl)-7-fluoro-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 864262-51-1 CAPLUS

CN Ethanone, 2,2,2-trifluoro-1-(6-fluoro-1,2,4,5-tetrahydro-9-methoxy-3H-3-benzazepin-3-yl)- (CA INDEX NAME)




RN 864262-52-2 CAPLUS

CN Ethanone, 2,2,2-trifluoro-1-(6-fluoro-1,2,4,5-tetrahydro-9-hydroxy-3H-3-benzazepin-3-yl)- (CA INDEX NAME)




RN 864262-53-3 CAPLUS


CN Ethanone, 1-(7-chloro-9-fluoro-1,2,4,5-tetrahydro-6-hydroxy-3H-3-benzazepin-3-yl)-2,2,2-trifluoro- (CA INDEX NAME)




RN 864262-54-4 CAPLUS
 CN Methanesulfonic acid, 1,1,1-trifluoro-,
 7-chloro-9-fluoro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-
 benzazepin-6-yl ester (CA INDEX NAME)



RN 864262-57-7 CAPLUS
 CN Carbamic acid, [2-[[7-chloro-2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1H-3-
 benzazepin-6-yl]oxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX
 NAME)




RN 864262-58-8 CAPLUS
 CN Ethanone, 1-[6-(2-aminoethoxy)-7-chloro-1,2,4,5-tetrahydro-3H-3-benzazepin-
 3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 864262-59-9 CAPLUS

CN Ethanone, 1-[6-(3-aminopropoxy)-7-chloro-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 864262-60-2 CAPLUS


CN Ethanone, 1-[6-(4-aminobutoxy)-7-chloro-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 864262-61-3 CAPLUS


CN Ethanone, 1-[7-chloro-6-[2-(4-fluorophenyl)-2-oxoethoxy]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)

10/598,302




RN 864262-62-4 CAPLUS

CN Benzenesulfonamide, 4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]oxy]methyl]-N-methyl- (CA INDEX NAME)




RN 864262-63-5 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-(2-thiazolylmethoxy)-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 864262-64-6 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-(5-thiazolylmethoxy)-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 864262-65-7 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[3-(methylthio)propoxy]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 864262-66-8 CAPLUS

CN Benzamide, N-[2-[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]oxy]ethyl]-2-fluoro- (CA INDEX NAME)




RN 864262-67-9 CAPLUS

CN 2-Pyridinecarboxamide, N-[2-[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]oxy]ethyl]- (CA INDEX NAME)




RN 864262-68-0 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 7-chloro-1,2,4,5-tetrahydro-6-(4-methoxy-4-oxobutoxy)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864262-69-1 CAPLUS

CN Ethanone, 1-(7-bromo-1,2,4,5-tetrahydro-6-hydroxy-3H-3-benzazepin-3-yl)-2,2,2-trifluoro- (CA INDEX NAME)




RN 864262-70-4 CAPLUS

CN 1H-3-Benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro-6-hydroxy-3-(2,2,2-trifluoroacetyl)- (CA INDEX NAME)




RN 864262-71-5 CAPLUS

CN Methanesulfonic acid, 1,1,1-trifluoro-, 7-cyano-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl ester (CA INDEX NAME)




RN 864262-72-6 CAPLUS

CN Ethanone, 2,2,2-trifluoro-1-(1,2,4,5-tetrahydro-6-hydroxy-7-iodo-3H-3-benzazepin-3-yl)- (CA INDEX NAME)




RN 864262-73-7 CAPLUS

CN Methanesulfonic acid, 1,1,1-trifluoro-, 2,3,4,5-tetrahydro-7-iodo-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl ester (CA INDEX NAME)




RN 864262-74-8 CAPLUS

CN Methanesulfonic acid, 1,1,1-trifluoro-, 2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-7-(trifluoromethyl)-1H-3-benzazepin-6-yl ester (CA INDEX NAME)




RN 864262-75-9 CAPLUS


CN Ethanone, 1-(6-bromo-1,2,4,5-tetrahydro-9-hydroxy-3H-3-benzazepin-3-yl)-2,2,2-trifluoro- (CA INDEX NAME)




RN 864262-76-0 CAPLUS
 CN Ethanone, 1-[6-(acetyloxy)-9-bromo-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 864262-77-1 CAPLUS
 CN Ethanone, 1-(7-acetyl-9-bromo-1,2,4,5-tetrahydro-6-hydroxy-3H-3-benzazepin-3-yl)-2,2,2-trifluoro- (CA INDEX NAME)




RN 864262-78-2 CAPLUS
 CN Ethanone, 1-(7-acetyl-1,2,4,5-tetrahydro-6-hydroxy-3H-3-benzazepin-3-yl)-2,2,2-trifluoro- (CA INDEX NAME)




RN 864262-79-3 CAPLUS
 CN Ethanone, 1-(7-ethyl-1,2,4,5-tetrahydro-6-hydroxy-3H-3-benzazepin-3-yl)-2,2,2-trifluoro- (CA INDEX NAME)

2,2,2-trifluoro- (CA INDEX NAME)




RN 864262-80-6 CAPLUS

CN Methanesulfonic acid, 1,1,1-trifluoro-,
7-ethyl-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl
ester (CA INDEX NAME)




RN 864262-81-7 CAPLUS

CN Ethanone, 2,2,2-trifluoro-1-[1,2,4,5-tetrahydro-6-(2-propen-1-yloxy)-3H-3-
benzazepin-3-yl]- (CA INDEX NAME)




RN 864262-82-8 CAPLUS

CN Ethanone, 2,2,2-trifluoro-1-[1,2,4,5-tetrahydro-6-hydroxy-7-(2-propen-1-
yl)-3H-3-benzazepin-3-yl]- (CA INDEX NAME)




RN 864262-83-9 CAPLUS

CN Ethanone, 2,2,2-trifluoro-1-(1,2,4,5-tetrahydro-6-hydroxy-7-propyl-3H-3-benzazepin-3-yl)- (CA INDEX NAME)




RN 864262-84-0 CAPLUS

CN Methanesulfonic acid, 1,1,1-trifluoro-, 2,3,4,5-tetrahydro-7-propyl-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl ester (CA INDEX NAME)



RN 864262-85-1 CAPLUS


CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[4-methoxyphenyl)methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



10/598,302


RN 864262-86-2 CAPLUS

CN Ethanone, 1-(6-amino-7-chloro-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-2,2,2-trifluoro- (CA INDEX NAME)




RN 864262-87-3 CAPLUS

CN Carbamic acid, [2-[[7-chloro-2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 864262-88-4 CAPLUS


CN Ethanone, 1-[6-[(2-aminoethyl)amino]-7-chloro-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 864262-89-5 CAPLUS


CN Ethanone, 1-[6-[(3-aminopropyl)amino]-7-chloro-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)

10/598,302




RN 864262-90-8 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[4-(4-hydroxyphenyl)methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 864262-91-9 CAPLUS


CN Ethanone, 1-[7-chloro-6-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



10/598,302


RN 864262-92-0 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[(3-chloro-4-hydroxyphenyl)methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 864262-93-1 CAPLUS


CN 3H-3-Benzazepine-3-carboxylic acid, 6-[[(4-carboxyphenyl)methyl]amino]-7-chloro-1,2,4,5-tetrahydro-, 3-(1,1-dimethylethyl) ester (CA INDEX NAME)



RN 864264-11-9 CAPLUS


CN Urea, N-[3-[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]propyl]-N'-phenyl- (CA INDEX NAME)

10/598,302




RN 864264-12-0 CAPLUS

CN Ethanone, 2,2,2-trifluoro-1-[1,2,4,5-tetrahydro-6-[(2-phenoxyethyl)amino]-3H-3-benzazepin-3-yl]- (CA INDEX NAME)



RN 864264-13-1 CAPLUS


CN Ethanone, 1-[7-chloro-6-[(2-ethoxyethyl)amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 864264-14-2 CAPLUS


CN Ethanone, 2,2,2-trifluoro-1-[6-[[[(2-fluorophenyl)methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]- (CA INDEX NAME)

10/598,302




RN 864264-15-3 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[2-fluorophenyl)methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 864264-16-4 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[[4-(1,1-dimethylethyl)phenyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 864264-17-5 CAPLUS


CN Benzonitrile, 4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]- (CA INDEX NAME)



RN 864264-18-6 CAPLUS


CN Ethanone, 1-[6-[[[1,1'-biphenyl]-3-ylmethyl]amino]-7-chloro-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)

10/598,302




RN 864264-19-7 CAPLUS

CN Ethanone, 1-[7-chloro-6-[(4-chlorophenyl)methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 864264-20-0 CAPLUS

CN Ethanone, 1-[7-chloro-6-[(2-fluoro-4-phenoxyphenyl)methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 864264-21-1 CAPLUS
 CN Benzonitrile, 3-[[4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]phenoxy]methyl]- (CA INDEX NAME)


PAGE 1-A






RN 864264-22-2 CAPLUS

CN 2-Butanone, 1-[2-chloro-4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]phenoxy]-3,3-dimethyl-
(CA INDEX NAME)



RN 864264-23-3 CAPLUS


CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[4-(1-phenylethoxy)phenyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro-
(CA INDEX NAME)



10/598,302


RN 864264-24-4 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[[4-(3,3-dimethylbutoxy)phenyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 864264-26-6 CAPLUS


CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[3-(1-pyrrolidinyl)phenyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 864264-28-8 CAPLUS


CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[4-(2,2,3,3-tetrafluoropropoxy)phenyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)

10/598,302




RN 864264-30-2 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[4-(2,2,2-trifluoro-1-methylethoxy)phenyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 864264-32-4 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[4-(2-methyl-1,3-dioxolan-2-yl)phenyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 864264-35-7 CAPLUS

CN Ethanone, 1-[6-[[[(4-acetylphenyl)methyl]amino]-7-chloro-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 864264-37-9 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[4-[1-(hydroxyimino)ethyl]phenyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 864264-38-0 CAPLUS

CN Ethanone, 1-[6-[[[4-benzoylphenyl]methyl]amino]-7-chloro-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 864264-39-1 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[4-[(hydroxyimino)phenylmethyl]phenyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 864264-40-4 CAPLUS


CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[4-(4-pyridinyl)phenyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 864264-41-5 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[4-(1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)


10/598,302



RN 864264-42-6 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-1,2,4,5-tetrahydro-6-[[[4-
[(methylamino)carbonyl]phenyl]methyl]amino]-, 1,1-dimethylethyl ester (CA
INDEX NAME)




RN 864264-43-7 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-1,2,4,5-tetrahydro-6-[[[4-[[[2,2,2-trifluoro-1-
methylethyl]amino]carbonyl]phenyl]methyl]amino]-, 1,1-dimethylethyl ester
(CA INDEX NAME)




RN 864264-44-8 CAPLUS

CN Benzamide, 4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]-N-[2-(2-thienyl)ethyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 864264-45-9 CAPLUS
 CN Benzamide, 4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 864264-46-0 CAPLUS
 CN Ethanone, 1-[7-chloro-6-[[[(1S)-1-(4-fluorophenyl)ethyl]amino]-1,2,4,5-

10/598,302


tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 864264-47-1 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[1-(3-fluorophenyl)ethyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 864264-48-2 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[1-(3-fluorophenyl)ethyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro-, (-)- (CA INDEX NAME)


Rotation (-).

10/598,302



RN 864264-49-3 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[1-(2-fluorophenyl)ethyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 864264-50-6 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[1-(2-fluorophenyl)ethyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)

Absolute stereochemistry.


10/598,302



RN 864264-51-7 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[1-(3-chloro-4-fluorophenyl)ethyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro-, (-)- (CA INDEX NAME)


Rotation (-).



RN 864264-52-8 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[1-(4-chlorophenyl)ethyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)


10/598,302



RN 864264-53-9 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[1-(4-chlorophenyl)ethyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro-, (-)- (CA INDEX NAME)

Rotation (-).




RN 864264-54-0 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[1-(4-chlorophenyl)ethyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro-, (+)- (CA INDEX NAME)

Rotation (+).


10/598,302



RN 864264-55-1 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[1-(2,5-difluorophenyl)ethyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro-, (+)- (CA INDEX NAME)

Rotation (+).




RN 864264-56-2 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[1-(2,5-difluorophenyl)ethyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro-, (-)- (CA INDEX NAME)

Rotation (-).


10/598,302



RN 864264-57-3 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[1-(3,5-difluoro-4-methoxyphenyl)ethyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro-, (-)- (CA INDEX NAME)

Rotation (-).




RN 864264-58-4 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[1-(3,5-difluoro-4-methoxyphenyl)ethyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro-, (+)- (CA INDEX NAME)

Rotation (+).


10/598,302



RN 864264-59-5 CAPLUS

CN Ethanone, 1-[7-chloro-6-[(2,3-dihydro-1H-inden-1-yl)amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro-, (+)- (CA INDEX NAME)

Rotation (+).




RN 864264-60-8 CAPLUS

CN Ethanone, 1-[7-chloro-6-[(5-fluoro-2,3-dihydro-1H-inden-1-yl)amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro-, (+)- (CA INDEX NAME)


Rotation (+).

10/598,302




RN 864264-61-9 CAPLUS

CN Ethanone, 1-[7-chloro-6-[(2,3-dihydro-1H-inden-2-yl)amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 864264-62-0 CAPLUS


CN 3H-3-Benzazepine-3-carboxylic acid, 7-chloro-1,2,4,5-tetrahydro-6-[(phenylmethyl)amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 864264-64-2 CAPLUS


CN Ethanone, 1-[7-chloro-6-[[2,3-dihydro-5-benzofuranyl)methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)

10/598,302



RN 864264-65-3 CAPLUS


CN Ethanone, 1-[7-chloro-6-[[2-(2,3-dihydrobenzofuran-4-yl)methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 864264-66-4 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[1-(2-thienyl)ethyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)


10/598,302



RN 864264-67-5 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[1-(2-thienyl)ethyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro-, (+)- (CA INDEX NAME)


Rotation (+).



RN 864264-68-6 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[1-(5-methyl-2-thienyl)ethyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)


10/598,302



RN 864264-69-7 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[1-(5-phenyl-2-thienyl)ethyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro-, (+)- (CA INDEX NAME)


Rotation (+).



RN 864264-70-0 CAPLUS


CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[1-(5-phenyl-2-thienyl)ethyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro-, (-)- (CA INDEX NAME)

Rotation (-).



RN 864264-71-1 CAPLUS


CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[1-(3-thienyl)ethyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 864264-72-2 CAPLUS


CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-(3-pyridinylamino)-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)

10/598,302




RN 864264-73-3 CAPLUS

CN Ethanone, 1-[7,9-dichloro-6-[[(3,4-difluorophenyl)methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 864264-74-4 CAPLUS


CN Ethanone, 1-[7-chloro-9-fluoro-6-[[(3-fluorophenyl)methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 864264-75-5 CAPLUS

CN 1H-3-Benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro-6-
[(phenylmethyl)amino]-3-(2,2,2-trifluoroacetyl)- (CA INDEX NAME)

RN 864264-76-6 CAPLUS


CN Ethanone, 2,2,2-trifluoro-1-[6-[[(3-fluorophenyl)methyl]amino]-1,2,4,5-
tetrahydro-7-(trifluoromethyl)-3H-3-benzazepin-3-yl]- (CA INDEX NAME)

RN 864264-77-7 CAPLUS

CN Ethanone, 2,2,2-trifluoro-1-[6-[[(1S)-1-(4-fluorophenyl)ethyl]amino]-
1,2,4,5-tetrahydro-7-(trifluoromethyl)-3H-3-benzazepin-3-yl]- (CA INDEX
NAME)

10/598,302


Absolute stereochemistry.



RN 864264-78-8 CAPLUS


CN Ethanone, 1-[7-ethyl-6-[[(1S)-1-(4-fluorophenyl)ethyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 864264-79-9 CAPLUS


CN Ethanone, 2,2,2-trifluoro-1-[1,2,4,5-tetrahydro-7-propyl-6-[(2-thienylmethyl)amino]-3H-3-benzazepin-3-yl]- (CA INDEX NAME)




RN 864264-80-2 CAPLUS
 CN Carbamothioic acid, dimethyl-, O-[7-chloro-2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1H-3-benzazepin-6-yl] ester (9CI) (CA INDEX NAME)



RN 864264-81-3 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid, 7-chloro-6-[[(dimethylamino) carbonyl] thio]-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864264-82-4 CAPLUS
 CN Ethanone, 1-(7,9-dichloro-1,2,4,5-tetrahydro-6-hydroxy-3H-3-benzazepin-3-yl)-2,2,2-trifluoro- (CA INDEX NAME)




RN 864264-83-5 CAPLUS

CN Carbamothioic acid, dimethyl-, O-[7,9-dichloro-2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1H-3-benzazepin-6-yl] ester (9CI) (CA INDEX NAME)




RN 864264-84-6 CAPLUS

CN Carbamothioic acid, dimethyl-, S-[7-chloro-2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1H-3-benzazepin-6-yl] ester (9CI) (CA INDEX NAME)




RN 864264-85-7 CAPLUS


CN Carbamothioic acid, dimethyl-, S-[7,9-dichloro-2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1H-3-benzazepin-6-yl] ester (9CI) (CA INDEX NAME)




RN 864264-86-8 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7,9-dichloro-6-[[(dimethylamino) carbonyl]thio]-1,2,4,5-tetrahydro-,
 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864264-87-9 CAPLUS
 CN Ethanone, 1-(7-bromo-1,2,4,5-tetrahydro-6-methoxy-3H-3-benzazepin-3-yl)-
 2,2,2-trifluoro- (CA INDEX NAME)




RN 864264-88-0 CAPLUS
 CN Ethanone, 2,2,2-trifluoro-1-(1,2,4,5-tetrahydro-6-methoxy-7-methyl-3H-3-benzazepin-3-yl)- (CA INDEX NAME)




RN 864264-89-1 CAPLUS
 CN Ethanone, 2,2,2-trifluoro-1-(1,2,4,5-tetrahydro-6-hydroxy-7-methyl-3H-3-benzazepin-3-yl)- (CA INDEX NAME)



RN 864264-90-4 CAPLUS
 CN Carbamothioic acid, dimethyl-, O-[2,3,4,5-tetrahydro-7-methyl-3-(trifluoroacetyl)-1H-3-benzazepin-6-yl] ester (9CI) (CA INDEX NAME)




RN 864264-91-5 CAPLUS
 CN Carbamothioic acid, dimethyl-, S-[2,3,4,5-tetrahydro-7-methyl-3-(trifluoroacetyl)-1H-3-benzazepin-6-yl] ester (9CI) (CA INDEX NAME)




RN 864264-92-6 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
6-[[(dimethylamino)carbonyl]thio]-1,2,4,5-tetrahydro-7-methyl-,
1,1-dimethylethyl ester (CA INDEX NAME)




RN 864264-93-7 CAPLUS

CN Carbamothioic acid, dimethyl-, O-[7-cyano-2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1H-3-benzazepin-6-yl] ester (9CI) (CA INDEX NAME)




RN 864264-94-8 CAPLUS

CN Carbamothioic acid, dimethyl-, S-[7-cyano-2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1H-3-benzazepin-6-yl] ester (9CI) (CA INDEX NAME)




RN 864264-95-9 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
7-cyano-6-[[(dimethylamino)carbonyl]thio]-1,2,4,5-tetrahydro-,
1,1-dimethylethyl ester (CA INDEX NAME)




RN 864265-19-0 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 6-[[4-(4-carboxyphenyl)methyl]thio]-7-chloro-1,2,4,5-tetrahydro-,
 3-(1,1-dimethylethyl) ester (CA INDEX NAME)




RN 864265-20-3 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-chloro-1,2,4,5-tetrahydro-6-[[[4-(hydroxymethyl)phenyl]methyl]thio]-,
 1,1-dimethylethyl ester (CA INDEX NAME)


10/598,302




RN 864265-21-4 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-1,2,4,5-tetrahydro-6-[[[4-
[(methylsulfonyl)methyl]phenyl]methyl]thio]-, 1,1-dimethylethyl ester (CA
INDEX NAME)




RN 864265-22-5 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid,
6-[(carboxyphenylmethyl)thio]-7-chloro-1,2,4,5-tetrahydro-,
3-(1,1-dimethylethyl) ester (CA INDEX NAME)




RN 864265-23-6 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-chloro-1,2,4,5-tetrahydro-6-[[5-(methoxycarbonyl)-2-
 pyridinyl]methyl]thio]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 864265-24-7 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 6-[[5-(methoxycarbonyl)-2-pyridinyl]methyl]thio]-7-chloro-1,2,4,5-tetrahydro-,
 3-(1,1-dimethylethyl) ester (CA INDEX NAME)




RN 864265-25-8 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-chloro-6-[[[6-(2,2-dimethylpropoxy)-3-pyridazinyl]methyl]thio]-1,2,4,5-
 tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864265-26-9 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-chloro-1,2,4,5-tetrahydro-6-[(2-thienylmethyl)thio]-, 1,1-dimethylethyl
 ester (CA INDEX NAME)

10/598,302




RN 864265-27-0 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-6-[[4-(2-thienyl)methyl]thio]-1,2,4,5-tetrahydro-,
1,1-dimethylethyl ester (CA INDEX NAME)




RN 864265-28-1 CAPLUS


CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-6-[[2-(4-fluorophenyl)methyl]thio]-1,2,4,5-tetrahydro-,
1,1-dimethylethyl ester (CA INDEX NAME)




RN 864265-29-2 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-chloro-6-[(5-fluoro-2-pyridinyl)methyl]thio]-1,2,4,5-tetrahydro-,
 1,1-dimethylethyl ester (CA INDEX NAME)



RN 864265-30-5 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-chloro-1,2,4,5-tetrahydro-6-[[5-(3-methylbutyl)-2-
 pyridinyl]methyl]thio]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864265-31-6 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-chloro-6-[[[5-(2,2-dimethylpropyl)-2-pyridinyl]methyl]thio]-1,2,4,5-
 tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864265-32-7 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-chloro-6-[[[5-(2,2-dimethylpropyl)-2-pyridinyl]methyl]thio]-1,2,4,5-tetrahydro-,
 1,1-dimethylethyl ester (CA INDEX NAME)

10/598,302




RN 864265-33-8 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-1,2,4,5-tetrahydro-6-[[[5-(1-piperidinyl)-2-
pyridinyl]methyl]thio]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864265-34-9 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-6-[[[5-[(1Z)-2-(4-fluorophenyl)ethenyl]-2-pyridinyl]methyl]thio]-
1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)

Double bond geometry as shown.




RN 864265-35-0 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-chloro-6-[[[5-[[[2-fluoro-4-(trifluoromethyl)phenyl]methyl]amino]carbonyl]-2-pyridinyl]methyl]thio]-
 1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 864265-36-1 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-chloro-6-[[4-(3,3-dimethyl-2-oxobutoxy)phenyl]methyl]thio]-1,2,4,5-
 tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864265-37-2 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-6-[[[3-fluoro-4-(3-methylbutyl)phenyl]methyl]thio]-1,2,4,5-
tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864265-38-3 CAPLUS


CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-6-[[[2,5'-difluoro-2'-methoxy[1,1'-biphenyl]-4-yl]methyl]thio]-
1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 864265-39-4 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-chloro-6-[[[3-fluoro-4-(1-piperidinyl)phenyl]methyl]thio]-1,2,4,5-
 tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864265-40-7 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-chloro-6-[[[4-(cyclohexylmethoxy)phenyl]methyl]thio]-1,2,4,5-tetrahydro-
 , 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864265-41-8 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-1,2,4,5-tetrahydro-6-[[[4-[[3,3,3-trifluoro-2-methyl-2-(trifluoromethyl)propyl]sulfinyl]phenyl]methyl]thio]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864265-42-9 CAPLUS


CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-6-[[1-(2-cyanophenyl)ethyl]thio]-1,2,4,5-tetrahydro-,
1,1-dimethylethyl ester (CA INDEX NAME)




RN 864265-43-0 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 6-[[4-(4-cyanophenyl)methyl]thio]-7-chloro-1,2,4,5-tetrahydro-,
 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864265-44-1 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-chloro-6-[[[4-[3-(dimethylamino)-1-oxo-2-propen-1-yl]phenyl]methyl]thio]-
 1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 864265-45-2 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 6-[[[4-(1-butyl-1H-pyrazol-5-yl)phenyl]methyl]thio]-7-chloro-1,2,4,5-
 tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864265-46-3 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 6-[[[4-(1-butyl-1H-pyrazol-3-yl)phenyl]methyl]thio]-7-chloro-1,2,4,5-
 tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 864265-47-4 CAPLUS


CN 3H-3-Benzazepine-3-carboxylic acid,
6-[[[4-carboxy-3-fluorophenyl]methyl]thio]-7-chloro-1,2,4,5-tetrahydro-,
3-(1,1-dimethylethyl) ester (CA INDEX NAME)



RN 864265-48-5 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-6-[[[4-(chlorocarbonyl)-3-fluorophenyl]methyl]thio]-1,2,4,5-
tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)


10/598,302



RN 864265-49-6 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-6-[[[3-fluoro-4-[[[(1S)-1-
methylpropyl]amino]carbonyl]phenyl]methyl]thio]-1,2,4,5-tetrahydro-,
1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.




RN 864265-50-9 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-1,2,4,5-tetrahydro-6-mercapto-, 1,1-dimethylethyl ester (CA
INDEX NAME)


10/598,302



RN 864265-51-0 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-1,2,4,5-tetrahydro-6-[[[4-(phenylmethoxy)phenyl]methyl]thio]-,
1,1-dimethylethyl ester (CA INDEX NAME)




RN 864265-52-1 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-6-[[[2-fluoro-4-phenoxyphenyl]methyl]thio]-1,2,4,5-tetrahydro-,
1,1-dimethylethyl ester (CA INDEX NAME)




RN 864265-53-2 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-6-[[2-(4-fluorophenyl)-2-oxoethyl]thio]-1,2,4,5-tetrahydro-,
1,1-dimethylethyl ester (CA INDEX NAME)




RN 864265-54-3 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-1,2,4,5-tetrahydro-6-[(2-hydroxyethyl)thio]-, 1,1-dimethylethyl
ester (CA INDEX NAME)




RN 864265-55-4 CAPLUS


CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-6-[(1-cyanopropyl)thio]-1,2,4,5-tetrahydro-, 1,1-dimethylethyl
ester (CA INDEX NAME)



RN 864265-56-5 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-chloro-6-[(1-cyano-1-methylethyl)thio]-1,2,4,5-tetrahydro-,
 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864265-57-6 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-chloro-6-[[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]thio]-
 1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864265-58-7 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,


6-[(3-aminopropyl)thio]-7-chloro-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864265-59-8 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 6-[(2-aminoethyl)thio]-7-chloro-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864265-60-1 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-chloro-1,2,4,5-tetrahydro-6-[[[4-(methoxymethyl)phenyl]methyl]thio]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864265-61-2 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 6-[[[4-(fluorophenyl)methyl]thio]-1,2,4,5-tetrahydro-7-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864265-62-3 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-methyl-6-[[1-(4-fluorophenyl)ethyl]thio]-1,2,4,5-tetrahydro-,
 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864265-63-4 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-cyano-6-[[1-(4-fluorophenyl)ethyl]thio]-1,2,4,5-tetrahydro-,
 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864265-64-5 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 6-[[[(dimethylamino)carbonyl]thio]-1,2,4,5-tetrahydro-7-(trifluoromethyl)-,
 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864265-65-6 CAPLUS
 CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[2-(trimethylsilyl)ethynyl]-3H-
 3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 864265-66-7 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-chloro-6-ethynyl-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX
 NAME)




RN 864265-68-9 CAPLUS
 CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[2-(2-pyridinyl)ethynyl]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 864265-69-0 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid, 7-chloro-1,2,4,5-tetrahydro-6-[2-(2-thiazolyl)ethynyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864265-71-4 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid, 7-chloro-1,2,4,5-tetrahydro-6-[2-(3-pyridazinyl)ethynyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864265-73-6 CAPLUS

CN Ethanone, 1-[7-chloro-6-[2-(3-fluorophenyl)ethynyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 864265-74-7 CAPLUS

CN 2-Imidazolidinone, 1-[3-[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]-2-propyn-1-yl]-3-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 864266-44-4 CAPLUS


CN Benzoic acid, 4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]-2-fluoro-, methyl ester (CA INDEX NAME)



RN 864266-45-5 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 6-[[[4-carboxy-3-fluorophenyl)methyl]amino]-7-chloro-1,2,4,5-tetrahydro-,
 3-(1,1-dimethylethyl) ester (CA INDEX NAME)




RN 864267-04-9 CAPLUS
 CN Ethanone, 1-[7-chloro-6-[[[2,4-difluorophenyl)methyl]amino]-1,2,4,5-
 tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 864267-05-0 CAPLUS

CN Ethanone, 1-[7-chloro-6-[(2,2-difluoro-2-phenylethyl)amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 864267-06-1 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[(3-phenylbenzo[b]thien-6-yl)methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 864267-07-2 CAPLUS

CN 1-Butanone, 1-[4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]phenyl]-3,3-dimethyl- (CA INDEX NAME)




RN 864267-08-3 CAPLUS

CN 1-Butanone, 1-[4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]-2-fluorophenyl]-3,3-dimethyl- (CA INDEX NAME)




RN 864267-09-4 CAPLUS

CN 1-Butanone, 1-[4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]-3-fluorophenyl]-3,3-dimethyl- (CA INDEX NAME)




RN 864267-10-7 CAPLUS

CN 1-Butanone, 1-[2-chloro-4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]phenyl]-3,3-dimethyl-
(CA INDEX NAME)




RN 864267-11-8 CAPLUS

CN 1-Butanone, 1-[3-chloro-4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]phenyl]-3,3-dimethyl-
(CA INDEX NAME)




RN 864267-12-9 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[[4-[2-(3,3-dimethylbutyl)-1,3-dioxolan-2-yl]phenyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 864267-13-0 CAPLUS

CN 1-Pentanone, 1-[4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]phenyl]-4,4-dimethyl- (CA INDEX NAME)



RN 864267-14-1 CAPLUS


CN Ethanone, 1-[7-chloro-6-[[[4-(cyclohexylcarbonyl)phenyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 864267-15-2 CAPLUS

CN Benzamide, 4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]-N-cycloheptyl-2-fluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 864267-16-3 CAPLUS

CN Benzamide, 4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]-N-cycloheptyl-3-fluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 864267-17-4 CAPLUS

CN Benzamide, 4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]-N-cycloheptyl-2-methyl- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 864267-18-5 CAPLUS


CN Benzamide, 4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]-2-fluoro-N-[(1R)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)

Absolute stereochemistry.


10/598,302



RN 864267-19-6 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-6-[[[3-fluoro-4-[(1-
methylethyl)amino]carbonyl]phenyl]methyl]amino]-1,2,4,5-tetrahydro-,
1,1-dimethylethyl ester (CA INDEX NAME)




RN 864267-20-9 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-6-[[[3-fluoro-4-[(propylamino)carbonyl]phenyl]methyl]amino]-
1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 864267-21-0 CAPLUS


CN Ethanone, 1-[7-chloro-6-[[[6-(cyclohexylamino)-3-pyridinyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 864267-22-1 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[4-(2,2,3,3,3-pentafluoro-1-methylpropoxy)phenyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)


10/598,302



RN 864267-23-2 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[4-(2,2,3,3,3-pentafluoro-1-methylpropoxy)phenyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro-, (-)- (CA INDEX NAME)


Rotation (-).



RN 864267-24-3 CAPLUS


CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[4-(2,2,3,3,3-pentafluoro-1-methylpropoxy)phenyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro-, (+)- (CA INDEX NAME)

Rotation (+).




RN 864267-25-4 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[5-(2,2,3,3,3-pentafluoro-1-methylpropoxy)-2-pyridinyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 864267-26-5 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[4-[(1-methylcyclohexyl)methoxy]phenyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 864267-27-6 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[[4-(cyclohexyloxy)phenyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 864267-28-7 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[[4-[(3,3-dimethylcyclohexyl)oxy]phenyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-


10/598,302

benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 864267-29-8 CAPLUS


CN Ethanone, 1-[7-chloro-6-[[[6-(cyclohexylthio)-3-pyridinyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 864267-30-1 CAPLUS


CN Ethanone, 1-[7-chloro-6-[[[6-[(1,1-dimethylethyl)thio]-3-

pyridinyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 864267-31-2 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[[4-[(2,2-dimethylpropoxy)methyl]phenyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 864267-32-3 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[[4-(cyclohexylthio)phenyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 864267-33-4 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[3-chloro-4-ethoxyphenyl)methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 864267-34-5 CAPLUS


CN Ethanone, 1-[7-chloro-6-[[[4-(cycloheptyloxy)phenyl)methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 864267-35-6 CAPLUS
 CN Ethanone, 1-[7-chloro-6-[[[4-(cyclohexylmethyl)phenyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 864267-36-7 CAPLUS
 CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[4-(2-methylbutyl)phenyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 864267-37-8 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[[4-(3,3-dimethylbutyl)phenyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 864267-38-9 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[[6-(3,3-dimethylbutyl)-3-pyridinyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 864267-64-1 CAPLUS

CN Carbamothioic acid, dimethyl-, O-[7-chloro-9-fluoro-2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1H-3-benzazepin-6-yl] ester (9CI) (CA INDEX NAME)




RN 864267-65-2 CAPLUS

CN Carbamothioic acid, dimethyl-, S-[7-chloro-9-fluoro-2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1H-3-benzazepin-6-yl] ester (9CI) (CA INDEX NAME)




RN 864267-66-3 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 7-chloro-6-[[(dimethylamino)carbonyl]thio]-9-fluoro-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864267-67-4 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-chloro-1,2,4,5-tetrahydro-6-[(1,3,4-thiadiazol-2-ylmethyl)thio]-,
 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864267-68-5 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-chloro-6-[[2-chloro-5-thiazolyl)methyl]thio]-1,2,4,5-tetrahydro-,
 1,1-dimethylethyl ester (CA INDEX NAME)

10/598,302




RN 864267-69-6 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-1,2,4,5-tetrahydro-6-[[1-(2-thiazolyl)ethyl]thio]-,
1,1-dimethylethyl ester (CA INDEX NAME)




RN 864267-70-9 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-6-[[1-(4-fluorophenyl)ethyl]thio]-1,2,4,5-tetrahydro-,
1,1-dimethylethyl ester (CA INDEX NAME)

10/598,302




RN 864267-71-0 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-6-[[1-(1S)-1-[4-(3,3-dimethyl-1-oxobutyl)phenyl]ethyl]thio]-1,2,4,5-
tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.




RN 864267-72-1 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-1,2,4,5-tetrahydro-6-[[[4-(3-
pyridinylcarbonyl)phenyl]methyl]thio]-, 1,1-dimethylethyl ester (CA INDEX
NAME)



RN 864267-73-2 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-chloro-6-[[[4-(3-cyanobenzoyl)phenyl]methyl]thio]-1,2,4,5-tetrahydro-,
 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864267-74-3 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-chloro-6-[[[4-(6-chloro-3-pyridinyl)methyl]thio]-1,2,4,5-tetrahydro-,
 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864267-75-4 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-6-[[[6-(cyclohexylamino)-3-pyridinyl]methyl]thio]-1,2,4,5-
tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 864267-76-5 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-6-[[[6-[(cyclohexylmethyl)amino]-3-pyridinyl]methyl]thio]-1,2,4,5-
tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)




IT	864267-77-6P	864267-78-7P	864267-79-8P
	864267-80-1P	864267-81-2P	864267-82-3P
	864267-83-4P	864267-84-5P	864267-85-6P
	864267-86-7P	864267-87-8P	864268-02-0P
	864268-30-4P	864268-31-5P	1132783-04-0P
	1132783-07-3P	1132783-12-0P	1132784-48-5P
	1132786-85-6P	1132787-06-4P	1132789-32-2P
	1132790-16-9P	1132792-65-4P	1132793-64-6P
	1132795-29-9P	1132795-55-1P	1132795-80-2P
	1132799-26-8P	1132800-82-8P	1132801-40-1P
	1132803-91-8P	1132805-24-3P	1132809-57-4P
	1132810-47-9P	1132810-76-4P	1132811-08-5P
	1132816-99-9P	1132817-15-2P	1132817-37-8P
	1132819-32-9P	1132819-36-3P	1132820-68-8P
	1132821-09-0P	1132830-19-3P	1132832-01-9P
	1132832-63-3P	1132832-85-9P	1132832-87-1P
	1132832-88-2P	1132832-89-3P	1132833-25-0P
	1132833-36-3P	1132833-38-5P	1132835-07-4P
	1132835-60-9P	1132837-95-6P	1132840-24-4P
	1132841-82-7P	1132842-07-9P	1132842-46-6P
	1132842-47-7P	1132842-48-8P	1132842-49-9P
	1132842-50-2P	1132842-51-3P	1132842-54-6P
	1132904-89-2P	1132907-30-2P	1132908-16-7P
	1132914-90-9P	1132916-48-3P	1132918-62-7P
	1132924-76-5P	1132951-46-2P	1132959-77-3P
	1132986-82-3P	1132992-74-5P	1132994-33-2P
	1132999-94-0P	1133005-02-3P	1133008-70-4P
	1133012-70-0P	1133332-72-5P	1133396-64-1P
	1133422-81-7P	1133425-69-0P	

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT_{2c} receptor agonists)


RN 864267-77-6 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-6-[(2,2-difluoro-2-phenylethyl)thio]-1,2,4,5-tetrahydro-,
1,1-dimethylethyl ester (CA INDEX NAME)



RN 864267-78-7 CAPLUS


CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-6-[[3-(2,3-dihydro-2-oxo-1H-indol-1-yl)propyl]thio]-1,2,4,5-
tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 864267-79-8 CAPLUS


CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-6-[[3-(2,3-dihydro-3,3-dimethyl-2-oxo-1H-indol-1-yl)propyl]thio]-
1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)

10/598,302




RN 864267-80-1 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-6-[[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]thio]-
1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864267-81-2 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-6-[[3-(2,3-dihydro-3,3-dimethyl-2-oxo-1H-indol-5-yl)propyl]thio]-
1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864267-82-3 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-1,2,4,5-tetrahydro-6-[[2-oxo-2-(phenylamino)ethyl]thio]-,
1,1-dimethylethyl ester (CA INDEX NAME)




RN 864267-83-4 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
6-[(3-carboxypropyl)thio]-7-chloro-1,2,4,5-tetrahydro-,
3-(1,1-dimethylethyl) ester (CA INDEX NAME)




RN 864267-84-5 CAPLUS


CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-1,2,4,5-tetrahydro-6-[[4-(methylamino)-4-oxobutyl]thio]-,
1,1-dimethylethyl ester (CA INDEX NAME)



RN 864267-85-6 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-chloro-6-[(1-cyanoethyl)thio]-1,2,4,5-tetrahydro-, 1,1-dimethylethyl
 ester (CA INDEX NAME)




RN 864267-86-7 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-chloro-6-[(cyanomethyl)thio]-1,2,4,5-tetrahydro-, 1,1-dimethylethyl
 ester (CA INDEX NAME)




RN 864267-87-8 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-chloro-6-[(1-cyanocyclopropyl)thio]-1,2,4,5-tetrahydro-,
 1,1-dimethylethyl ester (CA INDEX NAME)

10/598,302



RN 864268-02-0 CAPLUS


CN Ethanone, 1-[7-chloro-6-[[[4-[(2,2-dimethylpropyl)sulfonyl]phenyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 864268-30-4 CAPLUS


CN 3H-3-Benzazepine-3-carboxylic acid, 7-chloro-1,2,4,5-tetrahydro-6-[(5-thiazolylmethylene)amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)

10/598,302




RN 864268-31-5 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-1,2,4,5-tetrahydro-6-[(5-thiazolylmethyl)amino]-,
1,1-dimethylethyl ester (CA INDEX NAME)



RN 1132783-04-0 CAPLUS


CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[(2-phenylethyl)amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 1132783-07-3 CAPLUS


CN Ethanone, 1-[7-chloro-6-[[2-(3-fluorophenyl)ethyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)

10/598,302




RN 1132783-12-0 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[(2-thiazolylmethyl)amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 1132784-48-5 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[(2-methyl-4-thiazolyl)methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 1132786-85-6 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[2-(2-pyridinyl)ethyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 1132787-06-4 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[2-(2-thienyl)ethyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 1132789-32-2 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[(2-propoxyethyl)amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 1132790-16-9 CAPLUS


CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[2-(1-methylethoxy)ethyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 1132792-65-4 CAPLUS


CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[2-(phenylmethoxy)ethyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)

10/598,302




RN 1132793-64-6 CAPLUS
CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[(1R)-1-methyl-2-(phenylmethoxy)ethyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 1132795-29-9 CAPLUS
CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[(1R)-1-methyl-2-phenoxyethyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 1132795-55-1 CAPLUS
CN Ethanone, 1-[7-chloro-6-[[(1R)-2-[(4-fluorophenyl)methoxy]-1-methylethyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)


10/598,302

Absolute stereochemistry.




RN 1132795-80-2 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[3-chlorophenyl)methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 1132799-26-8 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[3-chloro-4-fluorophenyl)methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 1132800-82-8 CAPLUS
 CN Ethanone, 1-[7-chloro-6-[[2-chloro-4-fluorophenyl)methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 1132801-40-1 CAPLUS
 CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[3-methoxyphenyl)methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)

10/598,302



RN 1132803-91-8 CAPLUS


CN Ethanone, 1-[7-chloro-6-[[2-fluoro-4-methylphenyl)methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 1132805-24-3 CAPLUS


CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[3-(trifluoromethoxy)phenyl)methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)

10/598,302




RN 1132809-57-4 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[4-(phenylmethoxy)phenyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro-
(CA INDEX NAME)




RN 1132810-47-9 CAPLUS

CN 2-Butanone, 1-[4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]phenoxy]-3,3-dimethyl- (CA INDEX NAME)



RN 1132810-76-4 CAPLUS


CN Ethanone, 1-[7-chloro-6-[[[4-(2,2-dimethylpropoxy)phenyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 1132811-08-5 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[[4-(2-cyclohexylethoxy)phenyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1132816-99-9 CAPLUS
 CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[4-(1H-pyrazol-1-yl)phenyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)

10/598,302



RN 1132817-15-2 CAPLUS


CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[4-(3-pyridinyloxy)phenyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro-
(CA INDEX NAME)



RN 1132817-37-8 CAPLUS


CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[4-[(phenylmethyl)thio]phenyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro-
(CA INDEX NAME)

10/598,302



RN 1132819-32-9 CAPLUS


CN Ethanone, 1-[7-chloro-6-[[[4-(2-fluorophenoxy)phenyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 1132819-36-3 CAPLUS


CN Ethanone, 1-[7-chloro-6-[[[4-(3-fluorophenoxy)phenyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)

10/598,302




RN 1132820-68-8 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[[4-(4-fluorophenoxy)phenyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 1132821-09-0 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[[4-(3-chlorophenoxy)phenyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 1132830-19-3 CAPLUS
 CN Ethanone, 1-[7-chloro-6-[[[4-(3,5-difluorophenoxy)phenyl]methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 1132832-01-9 CAPLUS
 CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[4-(4-methylphenoxy)phenyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)

10/598,302




RN 1132832-63-3 CAPLUS
CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[4-(3-methylphenoxy)phenyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro-
(CA INDEX NAME)



RN 1132832-85-9 CAPLUS


10/598,302

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[4-(2-methylphenoxy)phenyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro-
(CA INDEX NAME)



RN 1132832-87-1 CAPLUS


CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[4-[3-(1-methylethyl)phenoxy]phenyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro-
(CA INDEX NAME)



10/598,302


RN 1132832-88-2 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[4-[2-(1-methylethyl)phenoxy]phenyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 1132832-89-3 CAPLUS


CN Benzonitrile, 2-[4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]phenoxy]- (CA INDEX NAME)



10/598,302

RN 1132833-25-0 CAPLUS


CN Benzonitrile, 3-[4-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]phenoxy]- (CA INDEX NAME)



RN 1132833-36-3 CAPLUS


CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[4-[2-(trifluoromethyl)phenoxy]phenyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)

10/598,302



RN 1132833-38-5 CAPLUS


CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[4-[3-(trifluoromethyl)phenoxy]phenyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 1132835-07-4 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[[4-(1-piperidinylcarbonyl)phenyl]methyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)

10/598,302



RN 1132835-60-9 CAPLUS
CN 2-Pyridinecarboxamide, 5-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]-N-cyclohexyl- (CA INDEX NAME)




RN 1132837-95-6 CAPLUS

10/598,302


CN Ethanone, 1-[7-chloro-6-[[(1R)-1-(4-fluorophenyl)ethyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 1132840-24-4 CAPLUS


CN Benzonitrile, 4-[1-[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]ethyl]- (CA INDEX NAME)



RN 1132841-82-7 CAPLUS


CN Ethanone, 1-[7-chloro-6-[[1-(2,3-difluorophenyl)ethyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)

10/598,302



RN 1132842-07-9 CAPLUS


CN Ethanone, 1-[7-chloro-6-[[1-(2,4-difluorophenyl)ethyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 1132842-46-6 CAPLUS


CN Ethanone, 1-[6-[[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]amino]-7-chloro-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)

10/598,302



RN 1132842-47-7 CAPLUS


CN Benzonitrile, 3-[1-[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]ethyl]- (CA INDEX NAME)



RN 1132842-48-8 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[(1R)-1-phenylethyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)


Absolute stereochemistry.



10/598,302


RN 1132842-49-9 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[1-[4-(trifluoromethyl)phenyl]ethyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro-
(CA INDEX NAME)




RN 1132842-50-2 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[1-[3-(trifluoromethyl)phenyl]ethyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro-
(CA INDEX NAME)




RN 1132842-51-3 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[1-(3,4-difluorophenyl)ethyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 1132842-54-6 CAPLUS
 CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[1-(3,4,5-trifluorophenyl)ethyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 1132904-89-2 CAPLUS
 CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[1-(3-methoxyphenyl)ethyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)

10/598,302



RN 1132907-30-2 CAPLUS


CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[1-(4-methoxyphenyl)ethyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 1132908-16-7 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[1-(4-phenoxyphenyl)ethyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)


10/598,302



RN 1132918-62-7 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[(1R)-1-(4-methylphenyl)ethyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)


Absolute stereochemistry.




RN 1132924-76-5 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[[(1S)-1-(4-methylphenyl)ethyl]amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 1132951-46-2 CAPLUS
 CN Ethanone, 1-[7-chloro-6-[[1-(3-chloro-4-fluorophenyl)ethyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 1132959-77-3 CAPLUS
 CN Ethanone, 1-[7-chloro-6-[[1-(3,5-difluorophenyl)ethyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 1132986-82-3 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[(2,3-dihydro-3-methyl-5-benzofuranyl)methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 1132992-74-5 CAPLUS


CN Ethanone, 1-[7-chloro-6-[[(2,3-dihydro-3-methyl-6-benzofuranyl)methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 1132994-33-2 CAPLUS


10/598,302

CN Ethanone, 1-[7-chloro-6-[[(2,3-dihydro-3,3-dimethyl-6-benzofuranyl)methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 1132999-94-0 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[(2,3-dihydro-3,3-dimethyl-5-benzofuranyl)methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 1133005-02-3 CAPLUS

CN 3(2H)-Benzofuranone, 5-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]-2,2-dimethyl- (CA INDEX NAME)




RN 1133008-70-4 CAPLUS

CN 3(2H)-Benzofuranone, 6-[[[7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]amino]methyl]-2,2-dimethyl- (CA INDEX NAME)




RN 1133012-70-0 CAPLUS

CN Ethanone, 1-[7-chloro-6-[[[(3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-6-yl)methyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




10/598,302

RN 1133332-72-5 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-1,2,4,5-tetrahydro-6-[[1-(3-pyridazinyl)ethyl]thio]-,
1,1-dimethylethyl ester (CA INDEX NAME)



RN 1133396-64-1 CAPLUS
CN Ethanone, 1-[7-chloro-6-[2-(2-fluorophenyl)ethynyl]-1,2,4,5-tetrahydro-3H-
3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 1133422-81-7 CAPLUS
CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[4-(cyclohexylmethyl)phenyl]methyl]-
2,3,4,5-tetrahydro-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 864260-90-2
CMF C24 H31 Cl N2


10/598,302



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 1133425-69-0 CAPLUS


CN 3H-3-Benzazepine-3-carboxylic acid,
7-chloro-1,2,4,5-tetrahydro-6-[[1-(2-thiazolyl)ethyl]thio]-,
1,1-dimethylethyl ester, (-)- (CA INDEX NAME)

Rotation (-).

10/598,302



IT 864351-62-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as
5-HT_{2c} receptor agonists)
RN 864351-62-2 CAPLUS
CN Benzamide, 4-[[(7-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-6-
yl)amino]methyl]-N-(1,1-dimethylethyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 13 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:490294 CAPLUS

DOCUMENT NUMBER: 143:43785

TITLE: Preparation of
7-phenylsulfonyl-tetrahydro-3-benzazepine derivatives
as antipsychotic agentsINVENTOR(S): Forbes, Ian Thomson; Gentile, Gabriella; Gribble,
Andrew Derrick; Lightfoot, Andrew P.; Payne, Andrew
H.; Walker, Graham

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 30 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2005051397	A1	20050609	WO 2004-EP13417	20041125
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: GB 2003-27737 A 20031128

OTHER SOURCE(S): CASREACT 143:43785; MARPAT 143:43785


GI




AB Title compds. I [R1 = alkyl, trifluoromethoxy or halo; R2 = H, alkyl or halo; or when R1 and R2 are positioned at the 3- and 4-positions, R1 and R2 together with the carbon atoms to which they are attached may form a 1,4-dioxane ring], and their pharmaceutically acceptable salts and

solvates thereof, are prepared and disclosed as potential antipsychotic agents. Thus, e.g., II was prepared by substitution of 1-(4-bromophenyl)-1-(3-fluoro-4-methylphenyl)methane (preparation given) with 8-methoxy-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulfonyl fluoride (preparation given) followed by acid catalyzed demethylation. I were evaluated for binding to dopamine D2 and D3 receptors and demonstrated pKi values ranging for 7.6-8.4 for D2 and 7.3-8.2 for D3. I were also evaluated for binding to 5-HT6 receptor (pKi 8.5-9.0) as well as 5HT2A and 5-HT2C receptors (pKi 8.0-8.8 and 8.9-9.5 resp.).

IT 1020087-89-1P 1020087-99-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of phenylsulfonyltetrahydrobenzazepine derivs. as antipsychotic agents)
 RN 1020087-89-1 CAPLUS
 CN 1H-3-Benzazepine-6-sulfonic acid, 2,3,4,5-tetrahydro-7-methoxy-3-methyl- (CA INDEX NAME)



RN 1020087-99-3 CAPLUS
 CN 1H-3-Benzazepine-6-sulfonyl chloride, 2,3,4,5-tetrahydro-7-methoxy-3-methyl- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 14 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:474617 CAPLUS

DOCUMENT NUMBER: 143:26492

TITLE: Preparation of benzofuran derivatives as adrenaline α_2c receptor antagonists

INVENTOR(S): Iida, Kyoichiro; Hagiwara, Koji; Kashima, Shu; Nonaka, Hiromi; Uchida, Shinichi; Kurokawa, Masako; Shiozaki, Shizuo; Shimada, Junichi

PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 184 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
JP 2005139106	A	20050602	JP 2003-375822	20031105
PRIORITY APPLN. INFO.:			JP 2003-375822	20031105
OTHER SOURCE(S):	MARPAT	143:26492		

GI




AB The title compds. I [R1 = H, (un)substituted alkyl; R2 = (un)substituted aryl, etc.; R3, R4 = H, (un)substituted alkyl, etc.; or NR3R4 = (un)substituted heterocyclyl] are prepared. Thus, 4-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-ylmethyl)-2-(2-furyl)-7-methoxybenzofuran 1 fumaric acid salt was prepared in a multistep process starting from 6-bromo-3-methoxysalicylaldehyde. In an in vitro assay for adrenaline α_2c receptor binding inhibition, compds. of this invention at 10^{-7} mol/L showed 60% to 97% inhibition of binding.

IT 852606-10-1P 852606-28-1P 852608-41-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzofuran derivs. as adrenaline α_2c receptor antagonists)


RN 852606-10-1 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-6,8-dimethoxy-3-[(7-methoxy-2-phenyl-4-benzofuranyl)methyl]- (CA INDEX NAME)




RN 852606-28-1 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-6,8-dimethoxy-3-[(7-methoxy-2-phenyl-5-benzofuranyl)methyl]- (CA INDEX NAME)



RN 852608-41-4 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-6,8-dimethoxy-3-[(7-methoxy-2-phenyl-5-benzofuranyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

IT 852609-29-1

RL: RCT (Reactant); RACT (Reactant or reagent)


(preparation of benzofuran derivs. as adrenaline α_2c receptor

10/598,302

antagonists)

RN 852609-29-1 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-6,8-dimethoxy- (CA INDEX NAME)



L27 ANSWER 15 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:182632 CAPLUS

DOCUMENT NUMBER: 142:280073

TITLE: Preparation of
 6-(2,2,2-trifluoroethylamino)-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine as a 5-HT_{2c} receptor agonist

INVENTOR(S): Galka, Christopher Stanley; Rodriguez, Michael John

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 39 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005019180	A1	20050303	WO 2004-US22299	20040730
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004267027	A1	20050303	AU 2004-267027	20040730
CA 2532020	A1	20050303	CA 2004-2532020	20040730
EP 1656352	A1	20060517	EP 2004-756905	20040730
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1832926	A	20060913	CN 2004-80022870	20040730
BR 2004013342	A	20061010	BR 2004-13342	20040730
JP 2007502272	T	20070208	JP 2006-523190	20040730
IN 2006KN00179	A	20070309	IN 2006-KN179	20060123
US 20060264418	A1	20061123	US 2006-568136	20060209
MX 2006001647	A	20060428	MX 2006-1647	20060210
PRIORITY APPLN. INFO.:			US 2003-494208P	P 20030811
			WO 2004-US22299	W 20040730

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 142:280073

GI



AB The present invention provides 7-chloro-6-(2,2,2-trifluoroethylamino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine of formula (I) or a pharmaceutically acceptable salt thereof, and its use as a selective 5-HT_{2c} agonist for the treatment of 5-HT_{2c} associated disorders including obesity, obsessive/compulsive disorder, anxiety, and depression. Thus, 7-chloro-3-(2,2,2-trifluoroacetyl)-6-(trifluoromethylsulfonyloxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (6.68 g, 15.7 mmol) was aminated by 2,2,2-trifluoroethylamine (7.0 mL, 88.0 mmol) in the presence of Pd(OAc)₂ (334 mg, 1.48 mmol), rac-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (rac-BINAP) (1.0 g, 1.60 mmol), and Cs₂CO₃ (7.08 g, 21.7 mmol) in a high pressure flask in toluene at 100° for 21 h to give 7-chloro-3-(2,2,2-trifluoroacetyl)-6-(2,2,2-trifluoroethylamino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (II) (4.07 g, 69 % yield). II (3.97 g, 10.59 mmol) was stirred with a mixture of 5 N NaOH (6 mL) and ethanol (20 mL) at 23° for 30 min to give, after workup, 2.84 g I as a free base.


IT 488838-92-2P, 6-Methoxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine 488838-93-3P, 6-Hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine 847199-06-8P, 6-Methoxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine hydrochloride 847199-07-9P, 7-Chloro-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine 847199-08-0P, 7-Chloro-3-(2,2,2-trifluoroacetyl)-6-(trifluoromethylsulfonyloxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine 847199-09-1P, 7-Chloro-3-(2,2,2-trifluoroacetyl)-6-(2,2,2-trifluoroethylamino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of

6-(2,2,2-trifluoroethylamino)-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine as 5-HT_{2c} receptor agonist)

RN 488838-92-2 CAPLUS


CN Ethanone, 2,2,2-trifluoro-1-(1,2,4,5-tetrahydro-6-methoxy-3H-3-benzazepin-3-yl)- (CA INDEX NAME)



10/598,302


RN 488838-93-3 CAPLUS

CN Ethanone, 2,2,2-trifluoro-1-(1,2,4,5-tetrahydro-6-hydroxy-3H-3-benzazepin-3-yl)- (CA INDEX NAME)



RN 847199-06-8 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-6-methoxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 847199-07-9 CAPLUS

CN Ethanone, 1-(7-chloro-1,2,4,5-tetrahydro-6-hydroxy-3H-3-benzazepin-3-yl)-2,2,2-trifluoro- (CA INDEX NAME)




RN 847199-08-0 CAPLUS

CN Methanesulfonic acid, 1,1,1-trifluoro-, 7-chloro-2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl ester (CA INDEX NAME)



RN 847199-09-1 CAPLUS

CN Ethanone, 1-[7-chloro-1,2,4,5-tetrahydro-6-[(2,2,2-trifluoroethyl)amino]-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)




IT 847199-03-5P, 7-Chloro-6-(2,2,2-trifluoroethylamino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine 847199-10-4P, 7-Chloro-6-(2,2,2-trifluoroethylamino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine succinate 847199-11-5P, 7-Chloro-6-(2,2,2-trifluoroethylamino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine mesylate

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 6-(2,2,2-trifluoroethylamino)-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine as 5-HT_{2c} receptor agonist)

RN 847199-03-5 CAPLUS

CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 847199-10-4 CAPLUS

CN Butanedioic acid, compd. with 7-chloro-2,3,4,5-tetrahydro-N-(2,2,2-trifluoroethyl)-1H-3-benzazepin-6-amine (1:1) (CA INDEX NAME)

CM 1


10/598,302

CRN 847199-03-5
CMF C12 H14 Cl F3 N2



CM 2


CRN 110-15-6
CMF C4 H6 O4



RN 847199-11-5 CAPLUS
CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-N-(2,2,2-trifluoroethyl)-, methanesulfonate (1:1) (CA INDEX NAME)


CM 1

CRN 847199-03-5
CMF C12 H14 Cl F3 N2



CM 2

CRN 75-75-2
CMF C H4 O3 S



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

10/598,302

REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 16 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:31564 CAPLUS

DOCUMENT NUMBER: 142:316682

TITLE: Dopamine D1/D5 Receptor Antagonists with Improved Pharmacokinetics: Design, Synthesis, and Biological Evaluation of Phenol Bioisosteric Analogues of Benzazepine D1/D5 Antagonists

AUTHOR(S): Wu, Wen-Lian; Burnett, Duane A.; Spring, Richard; Greenlee, William J.; Smith, Michelle; Favreau, Leonard; Fawzi, Ahmad; Zhang, Hongtao; Lachowicz, Jean E.

CORPORATE SOURCE: Schering-Plough Research Institute, Kenilworth, NJ, 07033, USA

SOURCE: Journal of Medicinal Chemistry (2005), 48(3), 680-693
CODEN: JMCMAR; ISSN: 0022-2623




PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 142:316682

GI



AB Nonracemic fused benzazepines and naphthazepines such as I (R = H, Me) are prepared as selective dopamine D1 and D5 receptor antagonists with improved bioavailability over related high affinity dopamine D1 and D5 receptor antagonists by replacement of the phenol moiety in II (X = CH₂CH₂) with a variety of fused hydrogen-bond donating moieties. Benzazepines in which the hydrogen bond donor is pointed approx. parallel to an axis through the benzazepine nitrogen and the benzo ring are more effective as selective dopamine D1 and D5 receptor antagonists than benzazepines in which the hydrogen bond donor is pointed away from the axis. Attempts to replace the phenol group in a benzazepine II (X = H₂) with a bioisostere lead to decreased binding to the desired dopamine receptors; an indazolobenzazepine III is an active dopamine D1 and D5 receptor antagonist. I (R = H, Me) show improved pharmacokinetic behavior over II (X = CH₂CH₂) in rats; III shows similar pharmacokinetic behavior in rats

to II (X = H₂).

IT 668476-49-1P 668476-50-4P 668476-51-5P

668476-52-6P 668476-53-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of nonracemic benzazepines and naphthazepines containing bioisosteric replacements for a phenol moiety and their activity as selective dopamine D₁/D₅ receptor antagonists and the pharmacokinetic behavior of selected benzazepines)

RN 668476-49-1 CAPLUS

CN 1H-3-Benzazepin-7-ol, 8-chloro-2,3,4,5-tetrahydro-3-methyl-6-nitro-5-phenyl-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 668476-50-4 CAPLUS

CN Acetamide, 2-[[(5R)-8-chloro-2,3,4,5-tetrahydro-3-methyl-6-nitro-5-phenyl-1H-3-benzazepin-7-yl]oxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 668476-51-5 CAPLUS

CN Acetamide, N-[(5R)-8-chloro-2,3,4,5-tetrahydro-3-methyl-6-nitro-5-phenyl-1H-3-benzazepin-7-yl]-2-hydroxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 668476-52-6 CAPLUS

CN 1H-3-Benzazepin-7-amine, 8-chloro-2,3,4,5-tetrahydro-3-methyl-6-nitro-5-phenyl-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 668476-53-7 CAPLUS

CN 1H-3-Benzazepine-6,7-diamine, 8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 27

THERE ARE 27 CAPLUS RECORDS THAT CITE THIS RECORD (29 CITINGS)

REFERENCE COUNT: 60

THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 17 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:370903 CAPLUS

DOCUMENT NUMBER: 140:375087

TITLE: Preparation of bicyclic benzamides as histamine H3
receptor ligands useful in the treatment of
neurological diseases

INVENTOR(S): Best, Desmond John; Orlek, Barry Sidney

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 51 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037788	A1	20040506	WO 2003-EP11650	20031020
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003278119	A1	20040513	AU 2003-278119	20031020
EP 1554243	A1	20050720	EP 2003-769430	20031020
EP 1554243	B1	20061122		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006505623	T	20060216	JP 2005-501524	20031020
AT 346044	T	20061215	AT 2003-769430	20031020
ES 2276125	T3	20070616	ES 2003-769430	20031020
US 20070105838	A1	20070510	US 2005-532373	20050421
US 7446103	B2	20081104		
US 20090042862	A1	20090212	US 2008-239874	20080929
PRIORITY APPLN. INFO.:			GB 2002-24557	A 20021022
			GB 2003-6328	A 20030319
			WO 2003-EP11650	W 20031020
			US 2005-532373	A3 20050421

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 140:375087

GI



AB The title compds. [I; R1, R2 = halo, OH, CN, etc.; a, b = 0-2 (a and b cannot both = 0); R3 = halo, alkyl, alkoxy, CN, NH2, CF3; m, n = 0-2; p = 0-3 (when p = > 1 then two R1 may instead be linked to form a heterocyclyl); R4 = (CH2)_qNR₁₁R₁₂, II (wherein q = 2-4; R₁₁, R₁₂ = alkyl; or NR₁₁R₁₂ = (un)substituted heterocyclyl; R13 = H, alkyl, cycloalkyl, alkylaryl, heterocyclyl; R14 = halo, alkyl, haloalkyl, OH, dialkylamino, alkoxy; f, k = 0-2; g = 0-2 and h = 0-3 (g and h cannot both be 0)], useful in the treatment of neurol. and psychiatric disorders, were prepared. Thus, reacting 4-[3-(piperidin-1-yl)propoxy]benzoic acid hydrochloride (preparation given) with indoline afforded III which exhibited pK_b ≥ 8.5 in the histamine H₃ functional antagonist assay. The pharmaceutical composition comprising the compound I is claimed.


IT 685564-84-5P 685564-85-6P 685564-86-7P
685564-88-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of bicyclic benzamides as histamine H₃ receptor ligands useful in the treatment of neurol. diseases)

RN 685564-84-5 CAPLUS


CN Methanone, [4-[3-(1-piperidinyl)propoxy]phenyl](1,2,4,5-tetrahydro-6,7-dimethoxy-1-phenyl-3H-3-benzazepin-3-yl)- (CA INDEX NAME)



RN 685564-85-6 CAPLUS


CN Methanone, [4-[3-(1-piperidinyl)propoxy]phenyl](1,2,4,5-tetrahydro-8,9-

dimethoxy-1-phenyl-3H-3-benzazepin-3-yl)- (CA INDEX NAME)




RN 685564-86-7 CAPLUS

CN Methanone, [4-[3-(1-piperidinyl)propoxy]phenyl](1,2,4,5-tetrahydro-7,9-dimethoxy-1-phenyl-3H-3-benzazepin-3-yl)- (CA INDEX NAME)



RN 685564-88-9 CAPLUS

CN Methanone, [4-[3-(1-piperidinyl)propoxy]phenyl][1,2,4,5-tetrahydro-6,9-dimethoxy-1-(4-methoxyphenyl)-3H-3-benzazepin-3-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 18 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:203836 CAPLUS

DOCUMENT NUMBER: 140:235618

TITLE: Preparation of benzazepine derivatives as selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders

INVENTOR(S): Wu, Wen-Lian; Burnett, Duane A.; Greenlee, William J.; Sasikumar, Thavalakulam K.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 54 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004020442	A1	20040311	WO 2003-US26878	20030827
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2495879	A1	20040311	CA 2003-2495879	20030827
AU 2003262926	A1	20040319	AU 2003-262926	20030827
US 20040058906	A1	20040325	US 2003-649495	20030827
US 7211574	B2	20070501		
EP 1537115	A1	20050608	EP 2003-791865	20030827
EP 1537115	B1	20080528		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1688584	A	20051026	CN 2003-824385	20030827
JP 2006501244	T	20060112	JP 2004-531584	20030827
AT 396996	T	20080615	AT 2003-791865	20030827
ES 2308016	T3	20081201	ES 2003-791865	20030827
MX 2005002249	A	20050608	MX 2005-2249	20050225
PRIORITY APPLN. INFO.:			US 2002-406856P	P 20020829
			WO 2003-US26878	W 20030827

OTHER SOURCE(S): MARPAT 140:235618

GI



AB The title compds. I and II [R1 = H, alkyl, allyl, cycloalkyl, cycloalkyl(alkyl); R2 = H, halo, alkyl, alkylthio, alkylsulfonyl, OH, alkoxy, CF3, CF3O, aryl, CHO, NO2, substituted amines, CN, etc.; G = H, halo, alkyl, alkylthio, NO2, CN, OH, alkoxy, alkylsulfinyl, alkylsulfonyl, CF3, or CF3O; X = CH, C(alkyl), CCF3, or N; Y = CH, C(alkyl) or N; Z = NH, N(alkyl), S, or O; V = CH2; n = 0-2, when n = 0, the carbons to which (V)n is shown connected are not linked to each other but are linked to hydrogen] were prepared as selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders. For example, treatment of (6aS,13bR)-12,13-diamino-11-chloro-6,6a,7,8,9,13b-hexahydro-7-methyl-5H-benzo[d]naphth[2,1-b]azepine (preparation given) with thiocarbonyldiimidazole gave compound III. The latter is a novel antagonist for D1 receptor with Ki = 40 nM.

IT 668476-49-1P 668476-50-4P 668476-51-5P
668476-52-6P 668476-53-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of benzazepine derivs. as selective D1/D5 receptor antagonists for treatment of obesity and CNS disorders)

RN 668476-49-1 CAPLUS

CN 1H-3-Benzazepin-7-ol, 8-chloro-2,3,4,5-tetrahydro-3-methyl-6-nitro-5-phenyl-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.


10/598,302



RN 668476-50-4 CAPLUS

CN Acetamide, 2-[[1H-3-benzazepin-7-yl]oxy]-8-chloro-6-nitro-5-phenyl-1H-3-benzazepine- (CA INDEX NAME)


Absolute stereochemistry.



RN 668476-51-5 CAPLUS

CN Acetamide, N-[[1H-3-benzazepin-7-yl]-2-hydroxy]-8-chloro-6-nitro-5-phenyl-1H-3-benzazepine- (CA INDEX NAME)


Absolute stereochemistry.



RN 668476-52-6 CAPLUS

CN 1H-3-Benzazepine-7-amine, 8-chloro-2,3,4,5-tetrahydro-3-methyl-6-nitro-5-phenyl-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 668476-53-7 CAPLUS

CN 1H-3-Benzazepine-6,7-diamine, 8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-, (5R)- (CA INDEX NAME)

10/598,302

phenyl-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 19 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:434553 CAPLUS

DOCUMENT NUMBER: 139:6775

TITLE: Preparation of tetrahydrobenzazepines as 5-HT receptor ligands

INVENTOR(S): Fu, Jian-Min

PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA

SOURCE: PCT Int. Appl., 66 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003045940	A2	20030605	WO 2002-US37715	20021126
WO 2003045940	A3	20030912		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2468010	A1	20030605	CA 2002-2468010	20021126
AU 2002346507	A1	20030610	AU 2002-346507	20021126
US 20030149024	A1	20030807	US 2002-305408	20021126
US 6861420	B2	20050301		
EP 1451176	A2	20040901	EP 2002-784572	20021126
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005535560	T	20051124	JP 2003-547390	20021126
BR 2002014529	A	20060530	BR 2002-14529	20021126
MX 2004005151	A	20040811	MX 2004-5151	20040528
PRIORITY APPLN. INFO.:			US 2001-334012P	P 20011128
			WO 2002-US37715	W 20021126

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 139:6775

GI



AB Tetrahydrobenzazepines I [X = O, S, (un)substituted NH; R1 =

(un)substituted heterocyclic; R2 = H, alkyl, aralkyl; R3-R6 = H, OH, NO2, halo, CN, N3, amidine, guanidine, thioguanidine, cyanoguanidine, alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, aryl, (un)substituted heteroaryl, S(O)NH2, SO2NH2, NH2, SH, S(O)H, SO2H, CONH2, CSNH2, NHS(O)H, NHSO2H] were prepared for use as 5-HT receptor ligands as diagnostic tools and for treating diseases of the central nervous system (no data). Thus, I [X = O, R1 = 6-(2-methyl-3-pyridinyloxy)pyridin-3-yl, R2-R6 = H] was obtained by treating the amine with ClCO2Ph, followed by


IT 488838-89-7P

RL: BYP (Byproduct); PREP (Preparation)

(preparation of tetrahydrobenzazepines as 5-HT receptor ligands)

RN 488838-89-7 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-6-nitro-, methyl ester (CA INDEX NAME)



OS.CITING REF COUNT:	4	THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT:	1	THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 20 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:58090 CAPLUS

DOCUMENT NUMBER: 138:122638

TITLE: Preparation of hexahydroazepino[4,5-g]indoles and indolines as 5-HT receptor ligands

INVENTOR(S): Fu, Jian-Min; Morris, Jeanette Kay; Romero, Arthur Glenn

PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA

SOURCE: PCT Int. Appl., 50 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003006466	A1	20030123	WO 2002-US19804	20020710
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2452610	A1	20030123	CA 2002-2452610	20020710
AU 2002345783	A1	20030129	AU 2002-345783	20020710
EP 1406902	A1	20040414	EP 2002-744532	20020710
EP 1406902	B1	20051019		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005522408	T	20050728	JP 2003-512236	20020710
BR 2002011140	A	20051025	BR 2002-11140	20020710
AT 307133	T	20051115	AT 2002-744532	20020710
ES 2250667	T3	20060416	ES 2002-744532	20020710
US 20030060458	A1	20030327	US 2002-192918	20020711
US 7022694	B2	20060404		
MX 2004000358	A	20040504	MX 2004-358	20040113
PRIORITY APPLN. INFO.:			US 2001-305305P	P 20010713
			WO 2002-US19804	W 20020710

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 138:122638

GI




AB The title compds. [I; R1, R2 = H, halo, alkyl, etc.; or R1 and R2 together form 3-8 membered (un)saturated chain comprising one or more carbon atoms and optionally comprising one or two O, S, SO, SO2 or NR10 in the chain; R3 = H, alkyl, cycloalkyl, etc.; R4 = H, alkyl, cycloalkyl, etc.; R5, R6 = H, halo, alkyl, etc.; R10 = H, alkyl, cycloalkyl, etc.], useful as 5-HT ligands for treating anxiety, obesity, depression, or a stress-related disease, were prepared. Thus, reducing Me 6,7,9,10-tetrahydroazepino[4,5-g]indole-8(1H)-carboxylate (preparation given) with LiAlH4 in THF afforded 98% II.

IT 488838-88-6P, tert-Butyl
 6-nitro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate
 488838-89-7P, Methyl 6-nitro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 488838-90-0P,
 6-Nitro-2,3,4,5-tetrahydro-1H-3-benzazepine 488838-91-1P
 488838-92-2P, 6-Methoxy-3-(trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepine 488838-93-3P,
 3-(Trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-6-ol
 488838-94-4P, 3-(2,2,2-Trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-6-yl trifluoromethanesulfonate 488838-95-5P,
 3-(Trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine
 488838-96-6P 488838-97-7P,
 6-Nitro-3-(trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepine
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of hexahydroazepino[4,5-g]indoles and indolines as 5-HT receptor ligands)

RN 488838-88-6 CAPLUS


CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-6-nitro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 488838-89-7 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-6-nitro-, methyl ester (CA INDEX NAME)

10/598,302




RN 488838-90-0 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-6-nitro- (CA INDEX NAME)



RN 488838-91-1 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-6-nitro-, (2Z)-2-butenedioate (1:1)
(CA INDEX NAME)

CM 1


CRN 488838-90-0
CMF C10 H12 N2 O2



CM 2


CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




RN 488838-92-2 CAPLUS
CN Ethanone, 2,2,2-trifluoro-1-(1,2,4,5-tetrahydro-6-methoxy-3H-3-benzazepin-

3-yl)- (CA INDEX NAME)




RN 488838-93-3 CAPLUS

CN Ethanone, 2,2,2-trifluoro-1-(1,2,4,5-tetrahydro-6-hydroxy-3H-3-benzazepin-3-yl)- (CA INDEX NAME)




RN 488838-94-4 CAPLUS

CN Methanesulfonic acid, 1,1,1-trifluoro-, 2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl ester (CA INDEX NAME)



RN 488838-95-5 CAPLUS


CN Ethanone, 1-(6-amino-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-2,2,2-trifluoro- (CA INDEX NAME)



10/598,302


RN 488838-96-6 CAPLUS

CN Ethanone, 1-[6-[(diphenylmethylene)amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 488838-97-7 CAPLUS

CN Ethanone, 2,2,2-trifluoro-1-(1,2,4,5-tetrahydro-6-nitro-3H-3-benzazepin-3-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 21 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2002:736233 CAPLUS

DOCUMENT NUMBER: 137:247615

TITLE: Preparation of benzazepine derivatives as 5-HT_{2C} receptor agonists

INVENTOR(S): Maeno, Kyoichi; Shimada, Itsuro; Kondoh, Yutaka; Kaku, Hidetaka; Sugasawa, Keizo; Wanibuchi, Fumikazu

PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 49 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002074746	A1	20020926	WO 2002-JP2306	20020312
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002236304	A1	20021003	AU 2002-236304	20020312
PRIORITY APPLN. INFO.:			JP 2001-76413	A 20010316
			WO 2002-JP2306	W 20020312

OTHER SOURCE(S): MARPAT 137:247615

GI




AB The title compds. I [R₁ - R₃ = H, (un)substituted alkyl, etc.] are prepared In an in vitro test for binding to the 5-HT_{2C} receptor, compds. of this invention showed the K_i values of 2.4 nM to 16 nM. Formulations are given.

IT 461435-81-4P 461435-86-9P 461436-01-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of benzazepine derivs. as 5-HT_{2C} receptor agonists)


RN 461435-81-4 CAPLUS

CN Ethanone, 1-[6-(2,2-diethoxyethoxy)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]- (CA INDEX NAME)


10/598,302



RN 461435-86-9 CAPLUS
CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-3-methyl-6-nitro- (CA INDEX NAME)



RN 461436-01-1 CAPLUS
CN 1H-3-Benzazepin-6-amine, 7-chloro-2,3,4,5-tetrahydro-3-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
REFERENCE COUNT: 73 THERE ARE 73 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 22 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2002:332201 CAPLUS

DOCUMENT NUMBER: 136:355169

TITLE: Preparation of substituted ureas as modulators of the CCR5 receptor

INVENTOR(S): Bondinell, William E.; Neeb, Michael J.

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 51 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002034760	A2	20020502	WO 2001-US51175	20011023
WO 2002034760	A3	20030123		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002035277	A	20020506	AU 2002-35277	20011023
EP 1343796	A2	20030917	EP 2001-985647	20011023
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:			US 2000-242427P	P 20001023
			WO 2001-US51175	W 20011023

OTHER SOURCE(S): MARPAT 136:355169

GI



II

AB The title compds. Q'CONER'' [I; a basic N atom in moiety E may be optionally quaternized with alkyl or is optionally present as N-oxide; R'' = H, alkyl; or R'' together with the nitrogen to which it is attached may form a heterocyclic ring with an aryl ring of E; Q' = (un)substituted isoindolyl, benzoisoindolyl, benzazepinyl, etc.; E = (un)substituted Ph, spiro[benzofuran-5-yl-3,4'-piperidine], etc.] which are modulators, agonists or antagonists, of the CCR5 receptor, were prepared Thus, treating

3-(2-diisopropylaminoethoxy)-4-methoxyaniline with triphosgene in CH₂Cl₂ followed by addition of Et₃N and 5,6-dichloro-2,3-dihydro-1H-isoindole afforded the urea II. The compds. I showed IC₅₀ values in the range of 0.0001-100 μ M against CCR5 receptor binding. In addition, this invention relates to the treatment and prevention of disease states mediated by CCR5, including, but not limited to, asthma and atopic disorders (for example atopic dermatitis and allergies), rheumatoid arthritis, sarcoidosis, or idiopathic pulmonary fibrosis and other fibrotic diseases, atherosclerosis, psoriasis, autoimmune diseases such as multiple sclerosis, treating and/or preventing rejection of transplanted organs, and inflammatory bowel disease, all in mammals, by the use of compds. I which are CCR5 receptor antagonists. Furthermore, since CD8⁺ T cells have been implicated in COPD, CCR5 may play a role in their recruitment and therefore antagonists to CCR5 could provide potential therapeutic in the treatment of COPD. Also since CCR5 is a co-receptor for the entry of HIV into cells, selective receptor modulators maybe useful in the treatment of HIV infection.


IT 420123-30-4P 420123-48-4P 420123-51-9P
420123-54-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted ureas as modulators of the CCR5 receptor)


RN 420123-30-4 CAPLUS

CN 3H-3-Benzazepine-3-carboxamide, N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-1,2,4,5-tetrahydro-6-phenoxy- (CA INDEX NAME)




RN 420123-48-4 CAPLUS

CN 3H-3-Benzazepine-3-carboxamide, 1,2,4,5-tetrahydro-6-hydroxy-N-[4-methoxy-3-[1-(1-methylethyl)-4-piperidinyl]phenyl]-9-(methylsulfonyl)- (CA INDEX NAME)




RN 420123-51-9 CAPLUS

CN 3H-3-Benzazepine-3-carboxamide, 1,2,4,5-tetrahydro-N-[4-methoxy-3-[1-(1-methylethyl)-4-piperidinyl]phenyl]-6-phenoxy- (CA INDEX NAME)



RN 420123-54-2 CAPLUS

CN 3H-3-Benzazepine-3-carboxamide, 1,2,4,5-tetrahydro-6-hydroxy-N-[4-methoxy-3-[1-(1-methylethyl)-4-piperidinyl]phenyl]- (CA INDEX NAME)




IT 143620-35-3 420123-65-5 420123-70-2

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of substituted ureas as modulators of the CCR5 receptor)


RN 143620-35-3 CAPLUS

CN 1H-3-Benzazepin-6-ol, 2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 420123-65-5 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-6-phenoxy- (CA INDEX NAME)



RN 420123-70-2 CAPLUS

CN 1H-3-Benzazepin-6-ol, 2,3,4,5-tetrahydro-9-(methanesulfonyl)- (CA INDEX NAME)

10/598,302



OS.CITING REF COUNT:	4	THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
REFERENCE COUNT:	2	THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 23 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2001:664087 CAPLUS

DOCUMENT NUMBER: 135:357806

TITLE: Intramolecular Electrophilic Aromatic Substitution
Reactions of 2-Amidoacroleins : A New Method for the
Preparation of Tetrahydroisoquinolines,
Tetrahydro-3-benzazepines, and
Hexahydro-3-benzazocines

AUTHOR(S): Fuchs, James R.; Funk, Raymond L.

CORPORATE SOURCE: Department of Chemistry, Pennsylvania State
University, University Park, PA, 16802, USA

SOURCE: Organic Letters (2001), 3(21), 3349-3351

CODEN: ORLEF7; ISSN: 1523-7060

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 135:357806


AB A variety of heterocyclic ring systems can be prepared by subjecting
N-aryl-substituted 5-amido-1,3-dioxins to Lewis acids. The reactions
proceed via catalyzed retrocycloaddns. to afford 2-amidoacroleins and
concomitant regioselective electrophilic aromatic substitution reactions.
The transformation is also successful using dioxins with amides that are
within the incipient ring to afford the analogous lactams.

IT 372516-27-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(intramol. electrophilic aromatic substitution reactions of
amidoacroleins)

RN 372516-27-3 CAPLUS

CN 1H-3-Benzazepine-2-carboxaldehyde,
2,3,4,5-tetrahydro-9-methoxy-3-[(trifluoromethyl)sulfonyl]- (CA INDEX
NAME)



OS.CITING REF COUNT: 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS
RECORD (18 CITINGS)

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 24 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2001:98457 CAPLUS

DOCUMENT NUMBER: 134:147611

TITLE: Preparation of tetrahydrobenzo[d]azepines as
metabotropic glutamate receptor 1 antagonists

INVENTOR(S): Adam, Geo; Binggeli, Alfred; Maerki, Hans-Peter;
Mutel, Vincent; Wilhelm, Maurice; Wostl, Wolfgang

PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.

SOURCE: Eur. Pat. Appl., 85 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1074549	A2	20010207	EP 2000-116091	20000727
EP 1074549	A3	20020731		
EP 1074549	B1	20031119		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AT 254614	T	20031215	AT 2000-116091	20000727
ES 2209728	T3	20040701	ES 2000-116091	20000727
CA 2314798	A1	20010206	CA 2000-2314798	20000801
US 6218385	B1	20010417	US 2000-630702	20000801
NZ 506096	A	20020828	NZ 2000-506096	20000801
ZA 2000003927	A	20010206	ZA 2000-3927	20000802
AU 2000048979	A	20010208	AU 2000-48979	20000802
AU 774485	B2	20040701		
HR 2000000520	A2	20010630	HR 2000-520	20000802
SG 93251	A1	20021217	SG 2000-4344	20000802
IN 2000MA00616	A	20050304	IN 2000-MA616	20000802
NO 2000003966	A	20010207	NO 2000-3966	20000804
CN 1283623	A	20010214	CN 2000-122523	20000804
CN 1146455	C	20040421		
TR 2000002298	A2	20010321	TR 2000-2298	20000804
JP 2001089472	A	20010403	JP 2000-236848	20000804
JP 3260350	B2	20020225		
MX 2000007661	A	20020312	MX 2000-7661	20000804
HU 2000003112	A2	20021128	HU 2000-3112	20000804
HU 2000003112	A3	20030728		
RU 2240317	C2	20041120	RU 2000-120522	20000804
BR 2000003375	A	20010313	BR 2000-3375	20000807
			EP 1999-115557	A 19990806

PRIORITY APPLN. INFO.:

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 134:147611

GI



AB The title compds. (I) [wherein R1 = H, alkyl, O, halo, OR, cycloalkoxy, (un)substituted cycloalkylalkoxy, cyanoalkoxy, (fluoro)alkoxy, aminoalkoxy, alkenyloxy, phenylalkoxy, heterocyclylalkoxy, sulfonyloxyalkoxy, SR, carboxyalkylthio, NR2, hydroxyalkylamino, or heterocyclylalkylamino; n = 1-6; R = independently H, alkyl, or alkenyl; R2 = NO2 or CN; R3 = H, alkyl, O, S, SR, alkylsulfonyl, cycloalkyl, CONR2, NR2, alkyl, OR, or (un)substituted piperazino, carbamoylalkyl, alkoxyalkyl, fluoroalkyl, trifluoroacetoxyalkyl, carboxyalkyl, phenylthioalkyl, heterocyclylalkoxy, acylamino, alkylamino, phenoxyalkylamino, heterocyclylalkylamino, fluoroalkoxy, etc.; R4 = H, alkyl, alkenyl, NO2, OR, NR2, or (un)substituted fluoroalkoxy, fluoroalkyl, phenylalkyl, alkoxyalkanol, aminoalkyl, carboxyalkyl, alkylsulfonyloxyalkyl, fluoroalkenyl, heterocyclylalkyl, heterocyclylalkylamino, alkoxy-carbonylamino, alkoxy-carbonylhydrazino, aminofluoroalkenylamino; or R4 and R1 or R3 and R4 form an addnl. ring; R5 and R6 = independently H, alkyl, alkoxy, NH2, HO2, SO2NH2, or halo; or R5 and R6 = OCH2O; R7 and R8 = independently H, alkyl, alkoxy, NH2, NO2, or halo; R9 and R10 = independently H or alkyl; R11 and R12 = independently H, alkyl, OH, alkoxy, alkoxy-carbonyloxy, or alkanoyloxy; R13 and R14 = independently H, T, or alkyl; R15 and R16 = independently H, T, alkyl, OH, alkoxy, alkoxy-carbonyloxy, or alkanoyloxy; or R15 and R16 = O; X = N or C; Y = N, NH, or CH] were prepared. For example, addition of Et 2-cyano-3,3-bis(methylthio)acrylate to 2,3,4,5-tetrahydro-1H-benzo[d]azepine•HCl using TEA and K2CO3 in EtOH gave 2-cyano-3-methylsulfanyl-3-(1,2,4,5-tetrahydrobenzo[d]azepin-3-yl)acrylic acid Et ester (64%). The benzazepinylacrylate ester was treated with NH2C(NH)NH2•HNO3 and 1,8-diazabicyclo[5.4.0]undec-7-ene in DMF to give II (R = H). Ethylation of II (R = H) with EtI in DMF in the presence of K2CO3 afforded the preferred metabotropic glutamate receptor 1 (mGluR1) antagonist II (R = Et), which gave an IC50 values of

0.009 μM and 0.003 μM , resp. in functional and binding assays for the characterization of mGluR1 antagonist properties. I are useful in the prevention or control of acute and/or chronic neurol. disorders and as radiolabeled mGluR1 receptor antagonists in binding assays (no data).


IT 324554-92-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tetrahydrobenzo[d]azepine mGluR1 antagonists by addition of chloroheterocycles or halobenzenes to tetrahydrobenzo[d]azepines or by cycloaddn. of guanidines to 3-methylthio-3-(tetrahydrobenzo[d]azepin-3-yl)acrylates)

RN 324554-92-9 CAPLUS

CN 4(3H)-Pyrimidinone, 2-methyl-5-nitro-6-(1,2,4,5-tetrahydro-6-methoxy-3H-3-benzazepin-3-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 25 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2000:260270 CAPLUS

DOCUMENT NUMBER: 132:293680

TITLE: Preparation of tetrahydrobenzazepine derivatives as modulators of dopamine D3 receptors (antipsychotic agents)

INVENTOR(S): Hadley, Michael Stewart; Johnson, Christopher Norbert; MacDonald, Gregor James; Stemp, Geoffrey; Vong, Antonio Kuok Keong

PATENT ASSIGNEE(S): Smithkline Beecham P.L.C., UK

SOURCE: PCT Int. Appl., 102 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000021951	A1	20000420	WO 1999-EP7763	19991006
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2346689	A1	20000420	CA 1999-2346689	19991006
EP 1119563	A1	20010801	EP 1999-953833	19991006
EP 1119563	B1	20060201		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
TR 2001001025	T2	20010921	TR 2001-1025	19991006
BR 9914370	A	20011127	BR 1999-14370	19991006
HU 2001004280	A2	20020328	HU 2001-4280	19991006
HU 2001004280	A3	20020729		
JP 2002527433	T	20020827	JP 2000-575857	19991006
AU 761018	B2	20030529	AU 2000-10381	19991006
NZ 511018	A	20030926	NZ 1999-511018	19991006
AT 316969	T	20060215	AT 1999-953833	19991006
ES 2255311	T3	20060616	ES 1999-953833	19991006
IN 2001MN00358	A	20050304	IN 2001-MN358	20010403
ZA 2001002758	A	20020604	ZA 2001-2758	20010404
NO 2001001745	A	20010606	NO 2001-1745	20010406
MX 2001003645	A	20020311	MX 2001-3645	20010409
BG 105467	A	20011130	BG 2001-105467	20010424
US 6605607	B1	20030812	US 2001-806902	20010716
PRIORITY APPLN. INFO.:			GB 1998-21976	A 19981008
			GB 1998-24340	A 19981106
			GB 1999-10711	A 19990507
			GB 1999-18032	A 19990730
			WO 1999-EP7763	W 19991006

OTHER SOURCE(S): MARPAT 132:293680

GI




AB The title compds. I [R1 represents a hydrogen or halogen atom, hydroxy,, etc.; R2 represents a hydrogen atom or a C1-4alkyl group; m is 1 or 2; A represents Ar, etc.; (Ar represents an optionally substituted Ph ring or an optionally substituted 5- or 6-membered aromatic heterocyclic ring; or an optionally substituted bicyclic ring system)] are prepared In binding expts. on cloned dopamine receptors, compds. of this invention had pKi values in the range 7 - 9. Formulations are given.

IT 264262-56-8P 264262-57-9P 264262-58-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of tetrahydrobenzazepine derivs. as modulators of dopamine D3 receptors (antipsychotic agents))

RN 264262-56-8 CAPLUS

CN 2-Propenamide, 3-(4-fluorophenyl)-N-[trans-4-[2-(1,2,4,5-tetrahydro-6-methoxy-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 264262-57-9 CAPLUS

CN 4-Quinolinecarboxamide, N-[trans-4-[2-(1,2,4,5-tetrahydro-6-methoxy-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 264262-58-0 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide,
N-[trans-4-[2-(1,2,4,5-tetrahydro-6-methoxy-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



IT 264264-23-5P 264264-26-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of tetrahydrobenzazepine derivs. as modulators of dopamine D3 receptors (antipsychotic agents))

RN 264264-23-5 CAPLUS

CN Carbamic acid, [trans-4-[2-(1,2,4,5-tetrahydro-6-methoxy-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/598,302



RN 264264-26-8 CAPLUS

CN Cyclohexanamine, 4-[2-(1,2,4,5-tetrahydro-6-methoxy-3H-3-benzazepin-3-yl)ethyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 26 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1999:297406 CAPLUS

DOCUMENT NUMBER: 130:325093

TITLE: Preparation of substituted isoquinolines as anticonvulsants

INVENTOR(S): Thompson, Mervyn; Harling, John David; Edwards, Peter David

PATENT ASSIGNEE(S): Smithkline Beecham Plc, UK

SOURCE: PCT Int. Appl., 72 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9921836	A1	19990506	WO 1998-GB3165	19981022
W: CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2307030	A1	19990506	CA 1998-2307030	19981022
EP 1025087	A1	20000809	EP 1998-949134	19981022
R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
JP 2001521026	T	20011106	JP 2000-517948	19981022
US 20010025045	A1	20010927	US 2001-840550	20010422
PRIORITY APPLN. INFO.:				
			GB 1997-22537	A 19971024
			GB 1997-26663	A 19971217
			WO 1998-GB3165	W 19981022
			US 2000-530027	A1 20000607

OTHER SOURCE(S): MARPAT 130:325093

GI



AB The title compds. [I; n, p = 1-4 and n + p = 2-5; R1 = H, cycloalkyl, etc.; R2 = H, halo, CN, etc.; R3 = H, halo, NO2, etc.; R2R3 = (un)substituted (un)saturated carbocyclic ring; R4 = H, alkyl, alkenyl, etc.], useful as anticonvulsants, were prepared Thus, conversion of 2-ethoxy-4-isopropyl-5-cyanobenzoic acid into the acid chloride followed by coupling with 5-amino-2-methyl-1,2,3,4-tetrahydroisoquinoline afforded 60% II.HCl which showed a 336% increase in seizure threshold for rat MEST. Compds. I are useful in the prophylaxis and treatment of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid hemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alc. and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischemia, Alzheimer's disease and other degenerative diseases such as Huntington's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurol. deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia and narcolepsy), tics (e.g. Gilles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neuron disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction and amyotrophic lateral sclerosis (ALS).


IT 78495-53-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of substituted isoquinolines as anticonvulsants)

RN 78495-53-1 CAPLUS

CN 1H-3-Benzazepin-6-amine, 9-chloro-2,3,4,5-tetrahydro-3-methyl- (CA INDEX NAME)



IT 201150-81-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of substituted isoquinolines as anticonvulsants)

RN 201150-81-4 CAPLUS

CN 1H-3-Benzazepin-6-amine, 2,3,4,5-tetrahydro-3-methyl- (CA INDEX NAME)

10/598,302



OS.CITING REF COUNT:	8	THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)
REFERENCE COUNT:	6	THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 27 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1998:626161 CAPLUS

DOCUMENT NUMBER: 129:326413

ORIGINAL REFERENCE NO.: 129:66431a,66434a

TITLE: Functional differentiation of multiple dopamine D1-like receptors by NNC 01-0012

AUTHOR(S): Sugamori, Kim S.; Hamadanizadeh, Soheila A.; Scheideler, Mark A.; Hohlweg, Rolf; Vernier, Philippe; Niznik, Hyman B.

CORPORATE SOURCE: Department of Pharmacology, University of Toronto, Toronto, ON, Can.

SOURCE: Journal of Neurochemistry (1998), 71(4), 1685-1693
CODEN: JONRA9; ISSN: 0022-3042

PUBLISHER: Lippincott-Raven Publishers

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Although members of the multiple vertebrate/mammalian dopamine D1 receptor gene family can be selectively classified on the basis of their mol./phylogenetic, structural, and tissue distribution profiles, no subtype-specific discriminating agents have yet been identified that can functionally differentiate these receptors. To define distinct pharmacol./functional attributes of multiple D1-like receptors, we analyzed the ligand binding profiles, affinity, and functional activity of 12 novel NNC compds. at mammalian/vertebrate D1/D1A and D5/D1B, as well as vertebrate D1C/D1D, dopamine receptors transiently expressed in COS-7 cells. Of all the compds. tested, only NNC 01-0012 displayed preferential selectivity for vertebrate D1C receptors, inhibiting [3H]SCH-23390 binding with an estimated affinity (.apprx.0.6 nM) 20-fold higher than either mammalian/vertebrate D1/D1A or D5/D1B receptors or the D1D receptor. Functionally, NNC 01-0012 is a potent antagonist at D1C receptors, inhibiting to basal levels dopamine (10 μ M)-stimulated adenylyl cyclase activity. In contrast, NNC 01-0012 (10 μ M) exhibits weak antagonist activity at D1A receptors, inhibiting only 60% of maximal cAMP production by dopamine, while acting as a partial agonist at vertebrate D1B and D1D receptors, stimulating adenylyl cyclase activity by .apprx.33% relative to the full agonist dopamine (10 μ M), an effect that was blocked by the selective D1 receptor antagonist NNC 22-0010. These data clearly suggest that the benzazepine NNC 01-0012, despite lacking the N-Me residue in the R3 position, is a selective and potent D1C receptor antagonist. Moreover, the differential signal transduction properties exhibited by NNC 01-0012 at these receptor subtypes provide further evidence, at least in vertebrates, for the classification of the D1C receptor as a distinct D1 receptor subtype.

IT 215226-68-9, NNC 01-0787


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(dopamine D1-like receptor subtype functional differentiation by NNC 01-0012)

RN 215226-68-9 CAPLUS

CN 1H-3-Benzazepin-7-ol, 5-(2,3-dihydro-7-benzofuranyl)-2,3,4,5-tetrahydro-3-methyl-6-nitro- (CA INDEX NAME)

10/598,302



OS.CITING REF COUNT:	13	THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)
REFERENCE COUNT:	35	THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 28 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN



ACCESSION NUMBER: 1998:28749 CAPLUS
 DOCUMENT NUMBER: 128:102013
 ORIGINAL REFERENCE NO.: 128:19989a
 TITLE: Preparation of
 N-(1,2,3,4-tetrahydroisoquinolinyl)benzamides as
 anticonvulsants
 INVENTOR(S): Harling, John David; Orlek, Barry Sidney; Thompson,
 Mervyn
 PATENT ASSIGNEE(S): Smithkline Beecham PLC, UK
 SOURCE: PCT Int. Appl., 74 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9748683	A1	19971224	WO 1997-EP3131	19970613
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2258238	A1	19971224	CA 1997-2258238	19970613
AU 9732595	A	19980107	AU 1997-32595	19970613
AU 729124	B2	20010125		
ZA 9705262	A	19981214	ZA 1997-5262	19970613
EP 906283	A1	19990407	EP 1997-928214	19970613
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI				
CN 1222145	A	19990707	CN 1997-195515	19970613
BR 9709906	A	19990810	BR 1997-9906	19970613
HU 9902166	A2	19991028	HU 1999-2166	19970613
HU 9902166	A3	20010129		
JP 2001508402	T	20010626	JP 1998-502244	19970613
IN 1997DE01612	A	20050311	IN 1997-DE1612	19970616
NO 9805891	A	19981216	NO 1998-5891	19981216
KR 2000016715	A	20000325	KR 1998-710322	19981216
US 6110934	A	20000829	US 1998-202524	19981216
PRIORITY APPLN. INFO.:			GB 1996-12608	A 19960617
			GB 1996-15352	A 19960722
			GB 1997-11013	A 19970528
			WO 1997-EP3131	W 19970613

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 128:102013

GI




AB The title compds. [I; n, p = 1-4; n + p = 2-5; R1 = C1-6 alkyl-O-; R2 = H, halo, CN, etc.; R3 = H, halo, NO2, etc.; R4 = H, C1-6 alkyl, C1-6 alkenyl, etc.], useful as anticonvulsants, were prepared Thus, reaction of 4-amino-5-chloro-2-methoxybenzoic acid with 5-amino-2-methyl-1,2,3,4-tetrahydroisoquinoline in the presence of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 1-hydroxybenzotriazole in DMF afforded II.HCl which showed pKi > 7 against binding to the novel receptor obtainable from rat forebrain tissue.

IT 201149-68-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(1,2,3,4-tetrahydroisoquinolinyl)benzamides as anticonvulsants)


RN 201149-68-0 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-2-methoxy-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-6-yl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

IT 78495-53-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of N-(1,2,3,4-tetrahydroisoquinolinyl)benzamides as
 anticonvulsants)
 RN 78495-53-1 CAPLUS
 CN 1H-3-Benzazepin-6-amine, 9-chloro-2,3,4,5-tetrahydro-3-methyl- (CA INDEX
 NAME)



IT 201150-81-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of N-(1,2,3,4-tetrahydroisoquinolinyl)benzamides as
 anticonvulsants)
 RN 201150-81-4 CAPLUS
 CN 1H-3-Benzazepin-6-amine, 2,3,4,5-tetrahydro-3-methyl- (CA INDEX NAME)



10/598,302

OS.CITING REF COUNT:	12	THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS)
REFERENCE COUNT:	2	THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 29 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN


ACCESSION NUMBER: 1997:549378 CAPLUS
 DOCUMENT NUMBER: 127:190758
 ORIGINAL REFERENCE NO.: 127:36997a,37000a
 TITLE: Herbicidal 1,2,4,6-thiatriazines
 INVENTOR(S): Zondler, Helmut; Stoller, Andre
 PATENT ASSIGNEE(S): Novartis A.-G., Switz.
 SOURCE: PCT Int. Appl., 353 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9725318	A1	19970717	WO 1996-EP5770	19961220
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9713038	A	19970801	AU 1997-13038	19961220
EP 876358	A1	19981111	EP 1996-944614	19961220
R: CH, DE, FR, GB				
JP 2000500775	T	20000125	JP 1997-524799	19961220
ZA 9700043	A	19970707	ZA 1997-43	19970103
US 6362134	B1	20020326	US 1998-101096	19980701
PRIORITY APPLN. INFO.:			CH 1996-38	A 19960105
			WO 1996-EP5770	W 19961220

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 127:190758

GI



AB Title compds. I [R¹ = (un)substituted alk(en/yn)oxy, non-aromatic heterocyclyloxy, amino, N-heterocyclyl, etc.; R² = halo, alk(en/yn)oxy, cyano, NO₂, alkylthio, heterocyclyl, aryl, aryloxy, amino; R³ = halo, OH, alk(en/yn)oxy, cyano, NO₂, alkylthio, heterocyclyl, aryl, aryloxy, etc.; with certain exclusions] are useful as herbicides or their intermediates. A large number of specific compds. are listed, with characterizing data for over 480 compds. For instance, etherification of

3-amino-5-chloro-1-(piperidin-1-yl)-1,2,4,6-thiatriazine with pentafluorophenol in the presence of NaOH and aqueous Me₃N gave title compound II. In a preemergence test at 2000 g/ha, II showed good to very good herbicidal activity against Avena, Setaria, Sinapis, and Stellaria.


IT 1230980-66-1 1230981-42-6 1230986-78-3

RL: PRPH (Prophetic)

(Herbicidal 1,2,4,6-thiatriazines)


RN 1230980-66-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1230981-42-6 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



RN 1230986-78-3 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




REFERENCE COUNT:

8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 30 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1996:432465 CAPLUS
 DOCUMENT NUMBER: 125:195465
 ORIGINAL REFERENCE NO.: 125:36607a,36610a
 TITLE: Synthesis of a carbon-14 ring-labeled benzothiophene
 via degradation and recyclization of an unlabeled
 benzothiophene
 AUTHOR(S): Landvatter, Scott W.
 CORPORATE SOURCE: SmithKline Beecham, Synthetic Chem. Dep., Radiochem.
 Section, King of Prussia, PA, 19406, USA
 SOURCE: Heterocycles (1996), 43(6), 1189-1199
 CODEN: HTCYAM; ISSN: 0385-5414
 PUBLISHER: Japan Institute of Heterocyclic Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB Synthesis of 7-chloro-2-ethyl-3,4,5,6-tetrahydro-4-methyl-[2-¹⁴C]-thieno[4,3,2-ef][3]benzazepine (I) has been accomplished via degradation, alkylation and recyclization of an unlabeled benzothiophene. Ozonolysis of the benzothiophene II gave the benzazepinone disulfide III which was reduced with tributylphosphine to the thiol. Direct treatment of the thiol with Et bromo-[2-¹⁴C]acetate and sodium ethoxide gave the recyclized benzothiophene IV. The ester side chain of IV was reduced with LAH to give ¹⁴C-labeled form of the original starting material. Transformation to I was readily accomplished by a manganese dioxide oxidn, Wittig reaction, catalytic reduction sequence.

IT 173092-68-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of carbon-14 labeled benzothiophene derivative)


RN 173092-68-7 CAPLUS

CN 1H-3-Benzazepin-1-one, 9,9'-dithiobis[6-chloro-2,3,4,5-tetrahydro-3-methyl-(9CI) (CA INDEX NAME)

10/598,302



IT 180906-15-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of carbon-14 labeled benzothiophene derivative)
RN 180906-15-4 CAPLUS
CN Acetic-2-14C acid, 2-[(9-chloro-2,3,4,5-tetrahydro-3-methyl-5-oxo-1H-3-benzazepin-6-yl)thio]-, ethyl ester (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)

L27 ANSWER 31 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1995:911414 CAPLUS

DOCUMENT NUMBER: 124:117002

ORIGINAL REFERENCE NO.: 124:21793a,21796a

TITLE: Synthesis of a carbon-14 labeled benzothiophene via degradation and recyclization of an unlabeled benzothiophene

AUTHOR(S): Landvatter, Scott W.; Beecham, SmithKline

CORPORATE SOURCE: Radiochemistry Section, Synthetic Chemistry Department, King of Prussia, PA, 19406, USA


SOURCE: Synthesis and Applications of Isotopically Labelled Compounds 1994, Proceedings of the International Symposium, 5th, Strasbourg, June 20-24, 1994 (1995), Meeting Date 1994, 683-8. Editor(s): Allen, John; Voges, Rolf. Wiley: Chichester, UK.

CODEN: 61UMAF

DOCUMENT TYPE: Conference

LANGUAGE: English

GI



AB Synthesis of 7-chloro-2-ethyl-[2-¹⁴C]-3,4,5,6-tetrahydro-4-methylthieno[4,3,2-ef][3]benzazepine (I, R = Et) (II) has been accomplished via degradation and recyclization of an unlabeled benzothiophene (I, R = CH₂OH) (III). Transformation of III to II was readily accomplished by a manganese dioxide oxidation, Wittig reaction, and catalytic reduction sequence.

IT 173092-68-7P 173092-69-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis of a carbon-14 labeled benzothiophene via degradation and recyclization of an unlabeled benzothiophene)


RN 173092-68-7 CAPLUS

CN 1H-3-Benzazepin-1-one, 9,9'-dithiobis[6-chloro-2,3,4,5-tetrahydro-3-methyl-(9CI) (CA INDEX NAME)

10/598,302



RN 173092-69-8 CAPLUS
CN 1H-3-Benzazepin-1-one, 6-chloro-2,3,4,5-tetrahydro-9-mercapto-3-methyl-
(CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L27 ANSWER 32 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1995:295758 CAPLUS

DOCUMENT NUMBER: 122:71680

ORIGINAL REFERENCE NO.: 122:13407a,13410a

TITLE: Role of renal dopamine D1 receptors in natriuresis induced by calcium channel blockers

AUTHOR(S): Eisner, Gilbert M.; Yamaguchi, Ikuyo; Felder, Robin A.; Asico, Laureano D.; Jose, Pedro A.

CORPORATE SOURCE: Dep. Med. Physiol. Biophys., Georgetown Univ. Med. Cent., Washington, DC, 20007, USA

SOURCE: American Journal of Physiology (1994), 267(6, Pt. 2), F965-F970

CODEN: AJPHAP; ISSN: 0002-9513

PUBLISHER: American Physiological Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The direct tubular natriuretic effect of calcium channel blockers (CCBs) may be due to an interaction between CCBs and a renal tubular dopamine receptor. The authors therefore studied the effects of two chemical unrelated CCBs, diltiazem and isradipine, infused into the right renal artery of 5% saline-loaded anesthetized rats alone or in the presence of a D1 antagonist, SKF-83742. Isradipine ($0.03 \mu\text{g.kg}^{-1}\text{min}^{-1}$) or diltiazem (20 but not $10 \mu\text{g.kg}^{-1}\text{min}^{-1}$) alone produced an increase in urine flow and an approx. doubling of absolute and fractional sodium excretion, which was not seen in the left kidney or in the control animals (anal. of variance, Scheffe's test). SKF-83742 alone given systemically or into the right renal artery did not affect these parameters but did block the actions of diltiazem or isradipine. There was no change in mean arterial pressure, renal blood flow, or glomerular filtration rate in any of the expts. In addnl. studies, the authors found that a combined infusion of dopamine ($0.1 \mu\text{g.kg}^{-1}\text{min}^{-1}$) and diltiazem ($10 \mu\text{g.kg}^{-1}\text{min}^{-1}$) (doses that by themselves did not alter renal function) produced a twofold or greater increase in urine flow and absolute and fractional sodium excretion; glomerular filtration rate was not significantly changed. Intrarenal arterial CCBs, without a change in renal hemodynamics, produce a natriuresis that is blocked by a D1 antagonist. Concomitant administration of diltiazem and dopamine (each in subeffective doses when used alone) produces a synergistic effect. CCBs may exert their natriuretic effect by interacting with the renal D1 receptor/signal transduction pathway.


IT 73943-42-7, SKF-83742

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(role of renal dopamine D1 receptors in natriuresis induced by calcium channel blockers)

RN 73943-42-7 CAPLUS

CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-3-methyl-6-(phenylthio)- (CA INDEX NAME)



10/598,302

OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD
(7 CITINGS)

L27 ANSWER 33 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN


ACCESSION NUMBER: 1994:680564 CAPLUS
 DOCUMENT NUMBER: 121:280564
 ORIGINAL REFERENCE NO.: 121:51219a,51222a
 TITLE: Tricyclic benzazepines, their use as CNS agents, and preparation
 INVENTOR(S): Hohlweg, Rolf; Nielsen, Erik Bardrum
 PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
 SOURCE: PCT Int. Appl., 32 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9420472	A1	19940915	WO 1994-DK69	19940218
W: AU, BG, BY, CA, CN, CZ, FI, HU, JP, KP, KR, KZ, LV, NO, NZ, PL, RO, RU, SK, UA, UZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2157668	A1	19940915	CA 1994-2157668	19940218
CA 2157668	C	20060530		
AU 9461386	A	19940926	AU 1994-61386	19940218
AU 682494	B2	19971009		
EP 688320	A1	19951227	EP 1994-908289	19940218
EP 688320	B1	19990506		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CN 1121710	A	19960501	CN 1994-191882	19940218
CN 1045957	C	19991027		
JP 08507498	T	19960813	JP 1994-519470	19940218
JP 3779319	B2	20060524		
AT 179700	T	19990515	AT 1994-908289	19940218
ES 2133542	T3	19990916	ES 1994-908289	19940218
IL 108730	A	19990817	IL 1994-108730	19940222
US 5512562	A	19960430	US 1994-202401	19940224
ZA 9401377	A	19950828	ZA 1994-1377	19940228
FI 9504229	A	19950908	FI 1995-4229	19950908
FI 111944	B1	20031015		
NO 9503543	A	19950908	NO 1995-3543	19950908
PRIORITY APPLN. INFO.:			DK 1993-267	A 19930310
			WO 1994-DK69	W 19940218

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 121:280564

GI




AB Tricyclic benzazepines of formula I [A = atoms to form a cyclopentene, cyclohexene, furan, dihydrofuran, pyran, dihydropyran, thiophene, oxazole, pyrrole, pyrroline, tetrahydropyridine, or dioxole ring; R1 = H or alkyl; R2, R3 = H, alkoxy, halo, nitro, cyano or OH; or R2R3 = atoms to form a furan, dihydrofuran, cyclopentene or dioxole ring; R4 = H, alkoxy, nitro, cyano, OH, or halo], and pharmaceutically acceptable salts thereof, are useful in the treatment of CNS disorders, e.g., psychosis (especially), pain, depression, sleep disturbances, dyskinesia, Parkinson's disease, and stroke. For example, 7-(carboxymethyl)benzofuran underwent conversion to the N-methylamide (85%), followed by reduction of this to 2-(benzofuran-7-yl)ethyl-N-methylamine (46%), N-alkylation of this with 7-(epoxyethyl)benzofuran (97%), and finally cyclization in CF₃CO₂H in the presence of H₂SO₄ (27%), to give title compound II, isolated as the HCl salt. In an assay for antipsychotic activity by binding to dopamine D1 receptor in rat striatum homogenate (method of Andersen, et. al, 1985), II had IC₅₀ of 12 nM. Seven addnl. synthetic examples are given.

IT 159737-53-8P 159737-54-9P 159737-55-0P
159737-56-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of tricyclic benzazepines as CNS agents)

RN 159737-53-8 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-6-nitro-1-phenyl- (CA INDEX NAME)




RN 159737-54-9 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-3-methyl-6-nitro-1-phenyl- (CA INDEX NAME)


10/598,302



RN 159737-55-0 CAPLUS
CN 1H-3-Benzazepin-7-ol, 2,3,4,5-tetrahydro-3-methyl-6-nitro-1-phenyl- (CA INDEX NAME)



RN 159737-56-1 CAPLUS
CN 1H-3-Benzazepin-7-ol, 6-amino-2,3,4,5-tetrahydro-3-methyl-1-phenyl- (CA INDEX NAME)




OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 34 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1993:495363 CAPLUS
 DOCUMENT NUMBER: 119:95363
 ORIGINAL REFERENCE NO.: 119:17193a,17196a
 TITLE: Preparation and formulation of aralkoxy-3-benzazepines and analogs as adrenergic antagonists
 INVENTOR(S): Demarinis, Robert Michael; Pfeiffer, Francis Richard
 PATENT ASSIGNEE(S): SmithKline Beecham Corp., USA
 SOURCE: PCT Int. Appl., 34 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9304686	A1	19930318	WO 1992-US7694	19920911
W: AU, CA, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
AU 9226547	A	19930405	AU 1992-26547	19920911
EP 603314	A1	19940629	EP 1992-920317	19920911
R: BE, CH, DE, FR, GB, IT, LI, NL				
JP 06510545	T	19941124	JP 1992-505509	19920911
PRIORITY APPLN. INFO.:			GB 1991-19467	A 19910912
			WO 1992-US7694	A 19920911
OTHER SOURCE(S):		MARPAT 119:95363		
GI				



AB Title compds. [I; R = alkyl, alkenyl; R5 = ABR6; A = bond, O2C(CH2)1-4, OCH2CH:CH, CO2(CH2)1-4, alkylene, etc.; B = bond, O, S; R6 = (substituted) Ph; X = H, halo, alkyl, alkoxycarbonyl, etc.; n = 1-3] were prepared as adrenergic antagonists (no data). Thus, benzazepine II (R6 = H) was condensed with 4-(MeO)C6H4CH2Cl to give II [R6 = CH2C6H4(OMe)-4].


IT 148596-06-9P 148596-07-0P 148596-08-1P
 148596-09-2P 148596-10-5P 148596-11-6P
 148596-12-7P 148596-13-8P 148612-61-7P
 148612-62-8P 148612-63-9P 148612-64-0P
 148612-65-1P 148612-66-2P 148612-67-3P
 148612-68-4P 148612-69-5P 148612-70-8P
 148612-71-9P 148612-72-0P 148612-73-1P
 148612-74-2P 148612-75-3P 149299-26-3P
 149299-27-4P 149299-28-5P 149299-29-6P
 149299-30-9P 149299-32-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as adrenergic antagonist)

10/598,302

RN 148596-06-9 CAPLUS


CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-phenoxy-,
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 148596-07-0 CAPLUS

CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(2-phenylethoxy)-
, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 148596-08-1 CAPLUS


CN 1H-3-Benzazepine, 6-chloro-9-[2-(3,4-dimethoxyphenyl)ethoxy]-2,3,4,5-
tetrahydro-3-methyl-, hydrochloride (1:1) (CA INDEX NAME)

10/598,302



RN 148596-09-2 CAPLUS


CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[(3-phenyl-2-propen-1-yl)oxy]-, hydrochloride (1:1) (CA INDEX NAME)



RN 148596-10-5 CAPLUS

CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(2-phenoxyethoxy)-, hydrochloride (1:1) (CA INDEX NAME)


10/598,302



● HCl

RN 148596-11-6 CAPLUS

CN 1H-3-Benzazepine, 6-chloro-9-[2-(2,6-dimethoxyphenoxy)ethoxy]-2,3,4,5-tetrahydro-3-methyl-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 148596-12-7 CAPLUS


CN Benzenamine, 4-[4-[(9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-6-yl)oxy]butyl]-, hydrochloride (1:2) (CA INDEX NAME)

10/598,302



● 2 HCl


RN 148596-13-8 CAPLUS
CN Benzenamine, 4-[4-[(9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-6-yl)oxy]butyl]-2-iodo-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 148612-61-7 CAPLUS
CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-phenoxy- (CA INDEX NAME)

10/598,302




RN 148612-62-8 CAPLUS

CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-9-[(4-methoxyphenyl)methoxy]-3-methyl- (CA INDEX NAME)



RN 148612-63-9 CAPLUS

CN 1H-3-Benzazepine, 6-chloro-9-[(2,6-dimethoxyphenyl)methoxy]-2,3,4,5-tetrahydro-3-methyl- (CA INDEX NAME)




RN 148612-64-0 CAPLUS

CN 1H-3-Benzazepine, 6-chloro-9-[(4-chlorophenyl)methoxy]-2,3,4,5-tetrahydro-


10/598,302

3-methyl- (CA INDEX NAME)



RN 148612-65-1 CAPLUS


CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-9-[2-(2-methoxyphenyl)ethoxy]-3-methyl- (CA INDEX NAME)



RN 148612-66-2 CAPLUS


CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-9-[2-(3-methoxyphenyl)ethoxy]-3-methyl- (CA INDEX NAME)

10/598,302



RN 148612-67-3 CAPLUS


CN 1H-3-Benzazepine, 6-chloro-9-[2-(3,4-dimethoxyphenyl)ethoxy]-2,3,4,5-tetrahydro-3-methyl- (CA INDEX NAME)



RN 148612-68-4 CAPLUS


CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[(3-phenyl-2-propen-1-yl)oxy]- (CA INDEX NAME)

10/598,302




RN 148612-69-5 CAPLUS

CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(2-phenoxyethoxy)-
(CA INDEX NAME)



RN 148612-70-8 CAPLUS


CN 1H-3-Benzazepine, 6-chloro-9-[2-(2,6-dimethoxyphenoxy)ethoxy]-2,3,4,5-tetrahydro-3-methyl- (CA INDEX NAME)



RN 148612-71-9 CAPLUS


CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[4-(4-nitrophenyl)butoxy]- (CA INDEX NAME)

10/598,302



RN 148612-72-0 CAPLUS


CN Benzenamine, 4-[4-[(9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-6-yl)oxy]butyl]- (CA INDEX NAME)



RN 148612-73-1 CAPLUS


CN Benzenamine, 4-[4-[(9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-6-yl)oxy]butyl]-2-iodo- (CA INDEX NAME)

10/598,302



RN 148612-74-2 CAPLUS


CN Benzenebutanoic acid, 4-amino-, 9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-6-yl ester (CA INDEX NAME)



RN 148612-75-3 CAPLUS

CN Benzenebutanoic acid, 4-amino-, 9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-6-yl ester (CA INDEX NAME)

10/598,302




RN 149299-26-3 CAPLUS

CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-9-[(4-methoxyphenyl)methoxy]-3-methyl-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 148612-62-8

CMF C19 H22 Cl N O2




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.

10/598,302




RN 149299-27-4 CAPLUS

CN 1H-3-Benzazepine, 6-chloro-9-[(2,6-dimethoxyphenyl)methoxy]-2,3,4,5-tetrahydro-3-methyl-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 148612-63-9

CMF C20 H24 Cl N O3




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



RN 149299-28-5 CAPLUS


CN 1H-3-Benzazepine, 6-chloro-9-[(4-chlorophenyl)methoxy]-2,3,4,5-tetrahydro-3-methyl-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 148612-64-0

CMF C18 H19 Cl2 N O

10/598,302




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



RN 149299-29-6 CAPLUS


CN 1H-3-Benzazepine, 6-chloro-9-[2-(2-methoxyphenyl)ethoxy]-2,3,4,5-tetrahydro-3-methyl-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 148612-65-1

CMF C20 H24 Cl N O2

10/598,302




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



RN 149299-30-9 CAPLUS


CN 1H-3-Benzazepine, 6-chloro-9-[2-(3-methoxyphenyl)ethoxy]-2,3,4,5-tetrahydro-3-methyl-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 148612-66-2

CMF C20 H24 Cl N O2

10/598,302




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



RN 149299-32-1 CAPLUS


CN 1H-3-Benzazepine, 6-chloro-9-[(2,3-dihydro-1,4-benzodioxin-2-yl)methoxy]-2,3,4,5-tetrahydro-3-methyl-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 149299-31-0

CMF C20 H22 Cl N O3

10/598,302




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




IT 78495-53-1 90047-50-0

RL: RCT (Reactant); RACT (Reactant or reagent)

(reaction of, in preparation of adrenergic antagonist)

RN 78495-53-1 CAPLUS


CN 1H-3-Benzazepin-6-amine, 9-chloro-2,3,4,5-tetrahydro-3-methyl- (CA INDEX NAME)



RN 90047-50-0 CAPLUS

CN 1H-3-Benzazepin-6-ol, 9-chloro-2,3,4,5-tetrahydro-3-methyl- (CA INDEX NAME)

10/598,302



OS.CITING REF COUNT:	3	THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT:	4	THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 35 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN


ACCESSION NUMBER: 1993:495362 CAPLUS
 DOCUMENT NUMBER: 119:95362
 ORIGINAL REFERENCE NO.: 119:17193a,17196a
 TITLE: Preparation of (heteroalkoxy)benzazepines
 INVENTOR(S): Demarinis, Robert Michael; Pfeiffer, Francis Richard
 PATENT ASSIGNEE(S): SmithKline Beckman Corp., USA
 SOURCE: PCT Int. Appl., 37 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9303015	A1	19930218	WO 1992-US6538	19920805
W: AU, CA, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
AU 9224330	A	19930302	AU 1992-24330	19920805
JP 06511239	T	19941215	JP 1992-503834	19920805
EP 630372	A1	19941228	EP 1992-917522	19920805
R: BE, CH, DE, FR, GB, IT, LI, NL				
US 5639748	A	19970617	US 1994-193075	19940204
PRIORITY APPLN. INFO.:			GB 1991-16824	A 19910805
			WO 1992-US6538	A 19920805

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 119:95362

GI



AB Title compds. I (X = H, halo, F3C, C1-6 alkyl, NC, O2N, F3CS, R1CO, R1S (wherein R1 = C1-6 alkyl, Ph, (CH2)0-6), R2O2C, (R2)2NCO (wherein R2 = H, C1-6 alkyl, Ph(CH2)0-6), R4R3N, R3O (wherein R3 = H, C1-6 alkyl, CHO, R1CO, R1O2S, R4 = H, C1-6 alkyl); R = H, C1-6 alkyl, C3-5 alkenyl; A = OCO(CH2)1-4 OCH2CH:CH, CO2(CH2)1-4, (CH2)0-6, (CH2)nZ(CH2)m wherein Z = O, S, n = 0-4, m = 1-5, m + n = ≤5; Het = (substituted) thienyl, furanyl, pyrazolyl, imidazolyl, etc.) or a salt thereof, useful as α -adrenoceptor antagonists in treatment of congestive heart failure, peripheral vascular disease and benign prostatic cancer (no data), are prepared Reduction of 9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-benzazepine-6-carbonitrile (preparation given) with LiAlH4 in THF (reflux 3 h) gave the 6-methanamine derivative which was treated with 2,5-dimethoxytetrahydrofuran to give I (X = 6-Cl, R = Me, A = 9-CH2, Het = 1H-pyrrol-1-yl) and converted to the HCl salt. Addnl. I were prepared Pharmaceutical formulations comprising I, are given.


IT 147829-68-3P 147829-69-4P 147829-70-7P
 147829-71-8P 147829-72-9P 147847-24-3P

147847-25-4P 147847-26-5P 147847-27-6P
 147847-28-7P 147847-29-8P 147847-30-1P
 147847-31-2P 147847-32-3P 147847-33-4P
 147847-34-5P 148528-07-8P 148528-08-9P
 148528-09-0P 148528-10-3P 148528-11-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as α -adrenergic antagonist)

RN 147829-68-3 CAPLUS

CN 1H-3-Benzazepine, 6-chloro-9-[(4-chloro-1H-pyrazol-1-yl)methoxy]-2,3,4,5-tetrahydro-3-methyl-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 147829-69-4 CAPLUS


CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[2-(1H-pyrazol-1-yl)ethoxy]-, hydrochloride (1:1) (CA INDEX NAME)

10/598,302



● HCl


RN 147829-70-7 CAPLUS
CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(1H-1,2,4-triazol-1-ylmethoxy)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 147829-71-8 CAPLUS
CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(4-pyridinylmethoxy)-, hydrochloride (1:2) (CA INDEX NAME)


10/598,302



● 2 HCl

RN 147829-72-9 CAPLUS

CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[2-(1H-1,2,4-triazol-1-yl)ethoxy]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 147847-24-3 CAPLUS


CN 1H-3-Benzazepine, 6-chloro-9-[(4-chloro-1H-pyrazol-1-yl)methoxy]-2,3,4,5-tetrahydro-3-methyl- (CA INDEX NAME)

10/598,302



RN 147847-25-4 CAPLUS


CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(1H-pyrazol-1-ylmethoxy)- (CA INDEX NAME)



RN 147847-26-5 CAPLUS


CN 1H-3-Benzazepine, 6-chloro-9-(2-furanylmethoxy)-2,3,4,5-tetrahydro-3-methyl- (CA INDEX NAME)

10/598,302



RN 147847-27-6 CAPLUS


CN 1H-3-Benzazepine, 6-chloro-9-(3-furanylmethoxy)-2,3,4,5-tetrahydro-3-methyl- (CA INDEX NAME)



RN 147847-28-7 CAPLUS


CN 1H-3-Benzazepine, 6-chloro-9-[[3-(2-furanyl)-2-propen-1-yl]oxy]-2,3,4,5-tetrahydro-3-methyl- (CA INDEX NAME)

10/598,302



RN 147847-29-8 CAPLUS


CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(2-thienylmethoxy)- (CA INDEX NAME)



RN 147847-30-1 CAPLUS


CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(3-thienylmethoxy)- (CA INDEX NAME)

10/598,302



RN 147847-31-2 CAPLUS


CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[2-(1H-pyrazol-1-yl)ethoxy]- (CA INDEX NAME)



RN 147847-32-3 CAPLUS


CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(1H-1,2,4-triazol-1-ylmethoxy)- (CA INDEX NAME)

10/598,302



RN 147847-33-4 CAPLUS


CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(4-pyridinylmethoxy)- (CA INDEX NAME)



RN 147847-34-5 CAPLUS

CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[2-(1H-1,2,4-triazol-1-yl)ethoxy]- (CA INDEX NAME)

10/598,302




RN 148528-07-8 CAPLUS

CN 1H-3-Benzazepine, 6-chloro-9-(2-furanylmethoxy)-2,3,4,5-tetrahydro-3-methyl-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 147847-26-5

CMF C16 H18 Cl N O2




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.


10/598,302



RN 148528-08-9 CAPLUS
CN 1H-3-Benzazepine, 6-chloro-9-(3-furanylmethoxy)-2,3,4,5-tetrahydro-3-methyl-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1


CRN 147847-27-6
CMF C16 H18 Cl N O2



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




RN 148528-09-0 CAPLUS
CN 1H-3-Benzazepine, 6-chloro-9-[[3-(2-furanyl)-2-propen-1-yl]oxy]-2,3,4,5-tetrahydro-3-methyl-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 147847-28-7
CMF C18 H20 Cl N O2

10/598,302




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



RN 148528-10-3 CAPLUS


CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(2-thienylmethoxy)-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 147847-29-8

CMF C16 H18 Cl N O S

10/598,302




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 148528-11-4 CAPLUS

CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(3-thienylmethoxy)-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 147847-30-1

CMF C16 H18 Cl N O S




10/598,302

CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




IT 78495-53-1 90047-50-0

RL: RCT (Reactant); RACT (Reactant or reagent)

(reaction of, in preparation of α -adrenergic antagonists)


RN 78495-53-1 CAPLUS

CN 1H-3-Benzazepin-6-amine, 9-chloro-2,3,4,5-tetrahydro-3-methyl- (CA INDEX NAME)



RN 90047-50-0 CAPLUS

CN 1H-3-Benzazepin-6-ol, 9-chloro-2,3,4,5-tetrahydro-3-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 6

THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

REFERENCE COUNT: 4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 36 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1993:240951 CAPLUS
 DOCUMENT NUMBER: 118:240951
 ORIGINAL REFERENCE NO.: 118:41609a,41612a
 TITLE: Combinations of selective α -adrenergic agonists
 and antagonists useful in lowering intraocular
 pressure
 INVENTOR(S): Burke, James A.
 PATENT ASSIGNEE(S): Allergan, Inc., USA
 SOURCE: U.S., 9 pp. Cont.-in-part of U.S. 5,021,410.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5180721	A	19930119	US 1991-709915	19910530
US 5021410	A	19910604	US 1989-354969	19890522
CA 2014036	A1	19901122	CA 1990-2014036	19900406
JP 03020219	A	19910129	JP 1990-133720	19900522
WO 9221349	A1	19921210	WO 1992-US4398	19920526
W: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD				
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, MC, ML, MR, NL, SE, SN, TD, TG				
AU 9221764	A	19930108	AU 1992-21764	19920526
US 5281591	A	19940125	US 1992-967888	19921028
PRIORITY APPLN. INFO.:			US 1989-354969	A2 19890522
			US 1991-709915	A 19910530
			WO 1992-US4398	A 19920526

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 118:240951

AB Ophthalmic pharmaceuticals containing α 2-adrenergic agonists and
 α 3-adrenergic antagonists are useful in lowering intraocular
 pressure. Combination of 0.03% clonidine and 1%
 9-(3-methyl-2-butenyloxy)-6-chloro-3-methyl-2,3,4,5-tetrahydro-1-H-3-
 benzazepine decreased the intraocular pressure by 4.1mmHg after 0.5h.
 IT 110857-23-3D, mixture with α 2-adrenergic agonists
 134862-72-9 134862-73-0 134862-74-1
 134862-77-4 147390-53-2 147663-21-6
 RL: BIOL (Biological study)
 (ophthalmic pharmaceutical containing, for lowering intraocular pressure)
 RN 110857-23-3 CAPLUS
 CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(1-propen-1-
 yloxy)- (CA INDEX NAME)

10/598,302




RN 134862-72-9 CAPLUS

CN 1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro-, mixt. with
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[(3-methyl-2-butenyl)oxy]-1H-3-
benzazepine (9CI) (CA INDEX NAME)

CM 1

CRN 110857-22-2


CMF C16 H22 Cl N O



CM 2

CRN 4205-90-7

CMF C9 H9 Cl2 N3



RN 134862-73-0 CAPLUS


CN 1,4-Benzenediamine, 2,6-dichloro-N1-(4,5-dihydro-1H-imidazol-2-yl)-, mixt.
with 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[(3-methyl-2-butenyl)oxy]-1H-3-
benzazepine (9CI) (CA INDEX NAME)

CM 1

CRN 110857-22-2

CMF C16 H22 Cl N O


10/598,302



CM 2

CRN 66711-21-5

CMF C9 H10 Cl2 N4




RN 134862-74-1 CAPLUS

CN 1,2-Benzenediol, 4-[(4,5-dihydro-1H-imidazol-2-yl)amino]-, mixt. with 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[(3-methyl-2-butenyl)oxy]-1H-3-benzazepine (9CI) (CA INDEX NAME)

CM 1

CRN 110857-22-2

CMF C16 H22 Cl N O




CM 2

CRN 57101-49-2

CMF C9 H11 N3 O2


10/598,302



RN 134862-77-4 CAPLUS
CN 4H-Thiazolo[4,5-d]azepin-2-amine, 5,6,7,8-tetrahydro-6-(2-propenyl)-, mixt. with 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[(3-methyl-2-butenyl)oxy]-1H-3-benzazepine (9CI) (CA INDEX NAME)


CM 1

CRN 110857-22-2
CMF C16 H22 Cl N O



CM 2

CRN 101626-70-4
CMF C10 H15 N3 S




RN 147390-53-2 CAPLUS
CN 6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-, mixt. with 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[(3-methyl-2-butenyl)oxy]-1H-3-benzazepine (9CI) (CA INDEX NAME)

CM 1

CRN 110857-22-2
CMF C16 H22 Cl N O


10/598,302



CM 2

CRN 59803-98-4

CMF C11 H10 Br N5




RN 147663-21-6 CAPLUS

CN 4H-Oxazolo[4,5-d]azepin-2-amine, 6-ethyl-5,6,7,8-tetrahydro-, hydrochloride, compd. with 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[(3-methyl-2-buten-1-yl)oxy]-1H-3-benzazepine (1:1:1) (CA INDEX NAME)

CM 1

CRN 147663-20-5

CMF C9 H15 N3 O . Cl H




● HCl

CM 2

CRN 110857-22-2

CMF C16 H22 Cl N O

10/598,302



OS.CITING REF COUNT: 13

THERE ARE 13 CAPLUS RECORDS THAT CITE THIS
RECORD (18 CITINGS)


REFERENCE COUNT: 20

THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 37 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1993:233902 CAPLUS
 DOCUMENT NUMBER: 118:233902
 ORIGINAL REFERENCE NO.: 118:40507a,40510a
 TITLE: Preparation of 2,3,4,5-tetrahydro-1H-benzazepines as drugs
 INVENTOR(S): Ward, John Gerard; Young, Rodney Christopher; Kaumann, Alberto Julio
 PATENT ASSIGNEE(S): Smithkline Beecham PLC, UK
 SOURCE: PCT Int. Appl., 26 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9300094	A2	19930107	WO 1992-GB1083	19920617
WO 9300094	A3	19930304		
W: AU, CA, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
CA 2110575	A1	19930107	CA 1992-2110575	19920617
AU 9219279	A	19930125	AU 1992-19279	19920617
EP 589973	A1	19940406	EP 1992-912293	19920617
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
JP 06508352	T	19940922	JP 1992-511087	19920617
ZA 9204524	A	19931220	ZA 1992-4524	19920619
PRIORITY APPLN. INFO.:			GB 1991-13377	A 19910621
			GB 1991-13379	A 19910621
			WO 1992-GB1083	A 19920617
OTHER SOURCE(S):			MARPAT 118:233902	
GI				




AB Title compds. I [R = H, C1-3 alkyl, C3-5 alkenyl; R1 = O2N, cyano, halo, COR3, R4SON, R6R5NSOn wherein R3 = H, C1-4 alkyl, R5O, R6R5N; R4 = (halo) C1-3 alkyl; R5, R6 = H, C1-6 alkyl, C3-6 cycloalkyl, n = 1, 2; R2 = H, HO, C1-4 alkoxy] or a salt thereof, useful as 5-HT2 and 5-HT1-like receptor agonists in treatment and prophylaxis of portal hypertension and migraine, are prepared 3-Acetyl-7-methoxy-8-(methylthio)-2,3,4,5-tetrahydro-1H-benzazepine in MeOH was treated with TiCl3 followed by H2O2 to give 3-acetyl-7-methoxy-8-(methylsulfinyl)-2,3,4,5-tetrahydro-1H-benzazepine which was hydrolyzed with 40% aqueous NaOH to give I (R = H, R1 = 7-MeSO, R2 = MeO) converted to the monooxalate salt (II). In an 5-HT1-like receptor screen, the ED50 of II was 20 mM. Pharmaceutical formulations comprising I are given.
 IT 147119-58-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and reaction of, in preparation of drugs)

RN 147119-58-2 CAPLUS

CN Ethanone, 1-(1,2,4,5-tetrahydro-7-methoxy-6-nitro-3H-3-benzazepin-3-yl)-
(CA INDEX NAME)




IT 147098-43-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as drug)

RN 147098-43-9 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-6-nitro-, hydrochloride
(1:1) (CA INDEX NAME)



● HCl

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(7 CITINGS)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 38 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1993:175795 CAPLUS
 DOCUMENT NUMBER: 118:175795
 ORIGINAL REFERENCE NO.: 118:30007a,30010a
 TITLE: Pharmaceutical compositions containing combination of
 alpha2 adrenergic agonists with alpha3 antagonists for
 lowering intraocular pressure
 INVENTOR(S): Burke, James A.
 PATENT ASSIGNEE(S): Allergan, Inc., USA
 SOURCE: PCT Int. Appl., 35 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9221349	A1	19921210	WO 1992-US4398	19920526
W: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD				
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, MC, ML, MR, NL, SE, SN, TD, TG				
US 5180721	A	19930119	US 1991-709915	19910530
AU 9221764	A	19930108	AU 1992-21764	19920526
PRIORITY APPLN. INFO.:			US 1991-709915	A 19910530
			US 1989-354969	A2 19890522
			WO 1992-US4398	A 19920526

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 118:175795

AB The title compns. (Markush structures are given) are useful in lowering intraocular pressure. An ophthalmic solution contained 5-bromo-6-(2-imidazole-2-ylamino)quinoxaline (I) 0.1, 9-(3-methyl-2-butenyloxy)-6-chloro-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (II) 0.3%. The hypotensive effect of I was potentiated by coadministration with II in lowering intraocular pressure of monkeys.

IT 110857-23-3D, mixts. with alpha2 adrenergic agonists

134862-72-9 134862-73-0 134862-74-1


134862-76-3 134862-77-4 134862-78-5

RL: BIOL (Biological study)

(synergistic ophthalmic composition containing, for lowering intraocular pressure)

RN 110857-23-3 CAPLUS

CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(1-propen-1-yloxy)- (CA INDEX NAME)




10/598,302

RN 134862-72-9 CAPLUS
CN 1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro-, mixt. with
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[(3-methyl-2-butenyl)oxy]-1H-3-
benzazepine (9CI) (CA INDEX NAME)


CM 1

CRN 110857-22-2
CMF C16 H22 Cl N O



CM 2


CRN 4205-90-7
CMF C9 H9 Cl2 N3



RN 134862-73-0 CAPLUS
CN 1,4-Benzenediamine, 2,6-dichloro-N1-(4,5-dihydro-1H-imidazol-2-yl)-, mixt.
with 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[(3-methyl-2-butenyl)oxy]-1H-3-
benzazepine (9CI) (CA INDEX NAME)

CM 1

CRN 110857-22-2
CMF C16 H22 Cl N O




10/598,302

CM 2

CRN 66711-21-5

CMF C9 H10 Cl2 N4




RN 134862-74-1 CAPLUS

CN 1,2-Benzenediol, 4-[(4,5-dihydro-1H-imidazol-2-yl)amino]-, mixt. with 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[(3-methyl-2-butenyl)oxy]-1H-3-benzazepine (9CI) (CA INDEX NAME)

CM 1

CRN 110857-22-2


CMF C16 H22 Cl N O



CM 2

CRN 57101-49-2

CMF C9 H11 N3 O2



RN 134862-76-3 CAPLUS


CN 6-Quinoxalinamine, 5-bromo-N-2-imidazolidinyl-, mixt. with 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[(3-methyl-2-butenyl)oxy]-1H-3-benzazepine (9CI) (CA INDEX NAME)

10/598,302

CM 1

CRN 134862-75-2


CMF C11 H12 Br N5



CM 2

CRN 110857-22-2

CMF C16 H22 Cl N O




RN 134862-77-4 CAPLUS

CN 4H-Thiazolo[4,5-d]azepin-2-amine, 5,6,7,8-tetrahydro-6-(2-propenyl)-, mixt. with 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[(3-methyl-2-butenyl)oxy]-1H-3-benzazepine (9CI) (CA INDEX NAME)

CM 1

CRN 110857-22-2

CMF C16 H22 Cl N O




CM 2

CRN 101626-70-4

CMF C10 H15 N3 S

10/598,302




RN 134862-78-5 CAPLUS

CN 4H-Oxazolo[4,5-d]azepin-2-amine, 6-ethyl-5,6,7,8-tetrahydro-, dihydrochloride, mixt. with 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[(3-methyl-2-butenyl)oxy]-1H-3-benzazepine (9CI) (CA INDEX NAME)

CM 1

CRN 110857-22-2


CMF C16 H22 Cl N O



CM 2

CRN 36067-72-8

CMF C9 H15 N3 O . 2 Cl H



● 2 HCl

OS.CITING REF COUNT: 6


THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

REFERENCE COUNT: 1


THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 39 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1992:612295 CAPLUS
 DOCUMENT NUMBER: 117:212295
 ORIGINAL REFERENCE NO.: 117:36663a,36666a
 TITLE: 6-Hydroxy-3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepine
 and analogs: new centrally acting 5-HT1a receptor
 agonists
 AUTHOR(S): Wikstroem, Haakan; Andersson, Bengt; Elebring, Thomas;
 Lagerkvist, Soeren; Hallnemo, Gerd; Pettersson,
 Ingrid; Jovall, Per Aake; Svensson, Kjell; Ekman,
 Agneta; Carlsson, Arvid
 CORPORATE SOURCE: Dep. Pharmacol., Univ. Goeteborg, Goeteborg, S-400 33,
 Swed.
 SOURCE: Journal of Medicinal Chemistry (1992), 35(22), 3984-90
 CODEN: JMCMAR; ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 117:212295
 GI




AB The ring-closed phenylethylamine analog
 6-hydroxy-3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepine (I) is a 5-HT1a
 receptor agonist of moderate potency, according to both in vivo biochem.
 data and in vitro binding data. The active compds. of this series also
 induce the 5-HT behavioral syndrome. Mol. modeling studies were performed
 with mol. mechanics calcns., and a tentative explanation for the
 relatively low potency of these serotonergic benzazepines is provided.
 IT 143620-35-3, 2,3,4,5-Tetrahydro-1H-benzazepine-6-ol
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (alkylation of)
 RN 143620-35-3 CAPLUS
 CN 1H-3-Benzazepin-6-ol, 2,3,4,5-tetrahydro- (CA INDEX NAME)




IT 143620-24-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and bromination and activity of, as 5-HT1a- and D2-receptor
 agonist)
 RN 143620-24-0 CAPLUS
 CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-6-methoxy-3-propyl-, hydrochloride

(1:1) (CA INDEX NAME)




● HCl

IT 143620-27-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and demethylation of)
 RN 143620-27-3 CAPLUS
 CN 1H-3-Benzazepine, 3-butyl-2,3,4,5-tetrahydro-6-methoxy- (CA INDEX NAME)



IT 143620-26-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and reduction of)
 RN 143620-26-2 CAPLUS
 CN 1-Propanone, 1-(1,2,4,5-tetrahydro-6-methoxy-3H-3-benzazepin-3-yl)- (CA
 INDEX NAME)



IT	143620-23-9P	143620-25-1P	143620-28-4P
	143620-30-8P	143620-31-9P	143620-32-0P
	143620-33-1P	143620-36-4P	143620-37-5P
	143620-38-6P	143620-39-7P	143620-40-0P
	143620-41-1P	143620-42-2P	143620-43-3P
	143620-44-4P	143631-82-7P	


RL: SPN (Synthetic preparation); PREP (Preparation)

10/598,302

(preparation of, as 5-HT1a- and D2-receptor agonist)

RN 143620-23-9 CAPLUS


CN 1H-3-Benzazepin-6-ol, 2,3,4,5-tetrahydro-3-propyl-, hydrobromide (1:1)
(CA INDEX NAME)



● HBr

RN 143620-25-1 CAPLUS


CN 1H-3-Benzazepine, 6-bromo-2,3,4,5-tetrahydro-9-methoxy-3-propyl-,
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 143620-28-4 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-6-methoxy-,
hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 143620-30-8 CAPLUS

10/598,302


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-6-methoxy-3-methyl-, hydrochloride
(1:1) (CA INDEX NAME)



● HCl

RN 143620-31-9 CAPLUS


CN 1H-3-Benzazepine, 3-ethyl-2,3,4,5-tetrahydro-6-methoxy-, hydrochloride
(1:1) (CA INDEX NAME)



● HCl

RN 143620-32-0 CAPLUS

CN 1H-3-Benzazepin-6-ol, 2,3,4,5-tetrahydro-3-methyl-, hydrobromide (1:1)
(CA INDEX NAME)




● HBr

RN 143620-33-1 CAPLUS


CN 1H-3-Benzazepin-6-ol, 3-ethyl-2,3,4,5-tetrahydro-, hydrobromide (1:1) (CA
INDEX NAME)

10/598,302




● HBr


RN 143620-36-4 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-6-methoxy-3-methyl- (CA INDEX NAME)



RN 143620-37-5 CAPLUS
CN 1H-3-Benzazepine, 3-ethyl-2,3,4,5-tetrahydro-6-methoxy- (CA INDEX NAME)




RN 143620-38-6 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-6-methoxy-3-propyl- (CA INDEX NAME)




RN 143620-39-7 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-6-methoxy- (CA INDEX NAME)

10/598,302




RN 143620-40-0 CAPLUS

CN 1H-3-Benzazepine, 6-bromo-2,3,4,5-tetrahydro-9-methoxy-3-propyl- (CA INDEX NAME)




RN 143620-41-1 CAPLUS

CN 1H-3-Benzazepin-6-ol, 2,3,4,5-tetrahydro-3-methyl- (CA INDEX NAME)



RN 143620-42-2 CAPLUS


CN 1H-3-Benzazepin-6-ol, 3-ethyl-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 143620-43-3 CAPLUS


CN 1H-3-Benzazepin-6-ol, 2,3,4,5-tetrahydro-3-propyl- (CA INDEX NAME)

10/598,302




RN 143620-44-4 CAPLUS

CN 1H-3-Benzazepin-6-ol, 3-butyl-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 143631-82-7 CAPLUS

CN 1H-3-Benzazepin-6-ol, 3-butyl-2,3,4,5-tetrahydro-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

L27 ANSWER 40 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1991:530974 CAPLUS

DOCUMENT NUMBER: 115:130974

ORIGINAL REFERENCE NO.: 115:22341a,22344a

TITLE: α 2-Adrenergic receptor purification

AUTHOR(S): Regan, John W.; Matsui, Hiroaki

CORPORATE SOURCE: Coll. Pharm., Univ. Arizona, Tucson, AZ, 85721, USA

SOURCE: Recept. Biochem. (1990), 141-61. Editor(s): Hulme, E.

C. IRL: Oxford, UK.

CODEN: 57CGA6

DOCUMENT TYPE: Conference

LANGUAGE: English

AB Two affinity adsorbents have been developed for the purification of α 2-adrenergic receptors. Both adsorbents take advantage of α 2-selective antagonists that are covalently coupled to agarose and thereby immobilized. One employs SKF 101253, a benzazepine derivative, and the other uses yohimbinic acid, a congener of the α 2-adrenergic antagonist yohimbine.


IT 86120-57-2, SKF 101253

RL: ANST (Analytical study)

(in α 2-adrenergic receptor purification by affinity chromatog.)

RN 86120-57-2 CAPLUS

CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(2-propen-1-yloxy)- (CA INDEX NAME)



L27 ANSWER 41 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1991:457176 CAPLUS
 DOCUMENT NUMBER: 115:57176
 ORIGINAL REFERENCE NO.: 115:9760h,9761a
 TITLE: Pharmaceutical ophthalmic compositions containing
 α -adrenergic agonists and antagonists for
 lowering intraocular pressure
 INVENTOR(S): Burke, James A.
 PATENT ASSIGNEE(S): Allergan, Inc., USA
 SOURCE: Eur. Pat. Appl., 18 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
EP 399791	A1	19901128	EP 1990-305559	19900522
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 5021410	A	19910604	US 1989-354969	19890522
CA 2014036	A1	19901122	CA 1990-2014036	19900406
JP 03020219	A	19910129	JP 1990-133720	19900522
			US 1989-354969	A 19890522

PRIORITY APPLN. INFO.:

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 115:57176

AB An ophthalmic composition contains α 3-adrenoceptor antagonist and
 α 2-adrenoceptor agonist for reducing intraocular pressure. A solution
 containing 1% 9-(3-methyl-2-butenoxy)-6-chloro-3-methyl-2,3,4,5-tetrahydro-1H-
 3-benzazepine was instilled into the lower conjunctival sac of the
 rabbits' eyes, followed by 0.03% solution of clonidine; a significant reduction
 in intraocular pressure was observed

IT 110857-23-3D, mixture with α 2 adrenergic agonists

134862-72-9 134862-73-0 134862-74-1


134862-76-3 134862-77-4 134862-78-5

RL: BIOL (Biological study)

(ophthalmic pharmaceutical containing, for lowering intraocular pressure)

RN 110857-23-3 CAPLUS

CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(1-propen-1-
 yloxy)- (CA INDEX NAME)



RN 134862-72-9 CAPLUS


CN 1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro-, mixt. with
 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[(3-methyl-2-butenyl)oxy]-1H-3-
 benzazepine (9CI) (CA INDEX NAME)

10/598,302

CM 1

CRN 110857-22-2


CMF C16 H22 Cl N O



CM 2

CRN 4205-90-7

CMF C9 H9 Cl2 N3




RN 134862-73-0 CAPLUS

CN 1,4-Benzenediamine, 2,6-dichloro-N1-(4,5-dihydro-1H-imidazol-2-yl)-, mixt. with 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[(3-methyl-2-butenyl)oxy]-1H-3-benzazepine (9CI) (CA INDEX NAME)

CM 1

CRN 110857-22-2

CMF C16 H22 Cl N O




CM 2

CRN 66711-21-5

CMF C9 H10 Cl2 N4

10/598,302




RN 134862-74-1 CAPLUS

CN 1,2-Benzenediol, 4-[(4,5-dihydro-1H-imidazol-2-yl)amino]-, mixt. with
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[(3-methyl-2-butenyl)oxy]-1H-3-
benzazepine (9CI) (CA INDEX NAME)

CM 1

CRN 110857-22-2


CMF C16 H22 Cl N O



CM 2

CRN 57101-49-2

CMF C9 H11 N3 O2



RN 134862-76-3 CAPLUS


CN 6-Quinoxalinamine, 5-bromo-N-2-imidazolidinyl-, mixt. with
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[(3-methyl-2-butenyl)oxy]-1H-3-
benzazepine (9CI) (CA INDEX NAME)

CM 1

CRN 134862-75-2

CMF C11 H12 Br N5


10/598,302



CM 2

CRN 110857-22-2

CMF C16 H22 Cl N O




RN 134862-77-4 CAPLUS

CN 4H-Thiazolo[4,5-d]azepin-2-amine, 5,6,7,8-tetrahydro-6-(2-propenyl)-, mixt. with 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[(3-methyl-2-butenyl)oxy]-1H-3-benzazepine (9CI) (CA INDEX NAME)

CM 1

CRN 110857-22-2

CMF C16 H22 Cl N O




CM 2

CRN 101626-70-4

CMF C10 H15 N3 S

10/598,302




RN 134862-78-5 CAPLUS

CN 4H-Oxazolo[4,5-d]azepin-2-amine, 6-ethyl-5,6,7,8-tetrahydro-, dihydrochloride, mixt. with 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[(3-methyl-2-butenyl)oxy]-1H-3-benzazepine (9CI) (CA INDEX NAME)

CM 1

CRN 110857-22-2


CMF C16 H22 Cl N O



CM 2

CRN 36067-72-8

CMF C9 H15 N3 O . 2 Cl H



● 2 HCl

OS.CITING REF COUNT: 7

THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD
(9 CITINGS)

L27 ANSWER 42 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1991:81550 CAPLUS

DOCUMENT NUMBER: 114:81550

ORIGINAL REFERENCE NO.: 114:13913a,13916a

TITLE: Specific bradycardic agents. 1. Chemistry, pharmacology, and structure-activity relationships of substituted benzazepinones, a new class of compounds exerting antiischemic properties [Erratum to document cited in CA112(21):198106m]

AUTHOR(S): Reiffen, Manfred; Eberlein, Wolfgang; Mueller, Peter; Psiorz, Manfred; Noll, Klaus; Heider, Joachim; Lillie, Christian; Kobinger, Walter; Luger, Peter

CORPORATE SOURCE: Dep. Chem. Res., Dr. Karl Thomae G.m.b.H., Biberach, D-7950/1, Germany

SOURCE: Journal of Medicinal Chemistry (1990), 33(12), 3229
CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English


AB Errors in the contribution line have been corrected The errors were not reflected in the abstract or the index entries.

IT 85176-93-8P 85176-96-1P 96255-02-6P
96255-04-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and bradycardic activity of (Erratum))

RN 85176-93-8 CAPLUS

CN 2H-3-Benzazepin-2-one, 3-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-1,3,4,5-tetrahydro-6,9-dimethoxy-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 85176-96-1 CAPLUS


CN 2H-3-Benzazepin-2-one, 3-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-1,3,4,5-tetrahydro-8,9-dimethoxy-, hydrochloride (1:1) (CA INDEX NAME)

10/598,302




● HCl

RN 96255-02-6 CAPLUS
CN 2H-3-Benzazepin-2-one, 3-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-1,3,4,5-tetrahydro-6,9-dimethoxy-
(CA INDEX NAME)



RN 96255-04-8 CAPLUS
CN 2H-3-Benzazepin-2-one, 3-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-1,3,4,5-tetrahydro-8,9-dimethoxy-
(CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L27 ANSWER 43 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1990:545733 CAPLUS

DOCUMENT NUMBER: 113:145733

ORIGINAL REFERENCE NO.: 113:24589a,24592a

TITLE: Dopamine receptor agonists: selectivity and dopamine D1 receptor efficacy

AUTHOR(S): Andersen, Peter H.; Jansen, Jens Aas

CORPORATE SOURCE: Dep. Biochem. Pharmacol., Novo Nordisk A/S, Bagsvaerd, DK-2880, Den.

SOURCE: European Journal of Pharmacology, Molecular Pharmacology Section (1990), 188(6), 335-47
CODEN: EJPPET; ISSN: 0922-4106

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Dopamine receptor selectivity was investigated for a number of dopamine receptor agonists. In vitro, the benzazepine derivs., e.g., SKF 38393 and SKF 75670 as well as the isoquinoline derivs., SKF 89626 and SKF 89615, were D1 receptor-selective. All other compds. like apomorphine, CY 208-243, 6,7-ADTN, and 3-PPP were either D2-selective or did not discriminate between subtypes. In general, the same receptor profile seen in vitro was observed in vivo. The exceptions to this pattern were: compds. which did not cross the blood-brain barrier, like 6,7-ADTN and SKF 89626, and compds. which appeared nonselective in vitro but demonstrated D2 selectivity in vivo like apomorphine, CI 201-678, and CY 208-243. A number of compds. were characterized in detail with respect to a GTP-induced affinity shift in inhibition of [3H]SCH 23390 binding, and potency and efficacy in stimulating adenylate cyclase from rat striatum. Inhibition of specific [3H]SCH 23390 binding by these agonists in the absence of GTP occurred with Hill slopes < 1 and could best be explained by a 2-site model with high (KH)- and low-affinity (KL) components. Inhibition of [3H]SCH 23390 binding in the presence of 15 μ M GTP occurred with Hill slopes of 1. The KI values obtained in the presence of 15 μ M GTP were similar to the KL values, the low-affinity component observed in the absence of GTP. The capability of the agonists to stimulate adenylate cyclase was analyzed in relation to dopamine (efficacy = 100%). The efficacy of the benzazepine derivs. varied from 24 (SKF 75670) to 100% (SKF 83189), dependent on the substituents on the benzazepine core. The isoquinolines, SKF 89626 and SKF 89615 had full efficacy, whereas most other agonists tested appeared to have only partial efficacy. The present paper presents data on dopamine receptor selectivity and efficacy in stimulating adenylate cyclase for a number of dopaminergic agonists. These data may create a basis for selection of agonists in future characterizations of dopaminergic-mediated events.

IT 129548-93-2 129548-94-3

RL: BIOL (Biological study)


(dopaminergic receptor subtype selectivity of)

RN 129548-93-2 CAPLUS

CN 1H-3-Benzazepine-7,8-diol, 6-amino-1-(3,4-dihydroxyphenyl)-2,3,4,5-tetrahydro-3-methyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/598,302



RN 129548-94-3 CAPLUS

CN 1H-3-Benzazepine-7,8-diol, 6-amino-1-(3,4-dihydroxyphenyl)-2,3,4,5-tetrahydro-3-methyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 103 THERE ARE 103 CAPLUS RECORDS THAT CITE THIS RECORD (103 CITINGS)

L27 ANSWER 44 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1990:198106 CAPLUS

DOCUMENT NUMBER: 112:198106

ORIGINAL REFERENCE NO.: 112:33485a,33488a

TITLE: Specific bradycardic agents. 1. Chemistry, pharmacology, and structure-activity relationships of substituted benzazepinones, a new class of compounds exerting antiischemic properties

AUTHOR(S): Reiffen, Manfred; Eberlein, Wolfgang; Mueller, Peter; Psiorz, Manfred; Noll, Klaus; Heider, Joachim; Lillie, Christian; Kobinger, Walter; Luger, Peter

CORPORATE SOURCE: Dep. Chem. Res., Dr. Karl Thomae G.m.b.H., Biberach, D-7950/1, Germany

SOURCE: Journal of Medicinal Chemistry (1990), 33(5), 1496-504
CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English


OTHER SOURCE(S): CASREACT 112:198106

AB Structural modification of the calcium-antagonist verapamil by replacement of the lipophilic α -isopropyl- α -cyano moiety by various heterocyclic ring systems led to a new class of cardiovascular compds. characterized by a specific bradycardic activity. These agents reduce heart rate without binding to classical Ca channels or β -adrenoceptors, interacting instead specifically with structures at the sinoatrial node. Therefore they are also termed sinus node inhibitors. The prototype falipamil was further optimized mainly by manipulation of the phthalimidine moiety. This resulted in a 2nd generation of specific bradycardic agents with increased potency and selectivity and prolonged duration of action represented by the benzazepinone derivative UL-FS 49. Structure-activity relationships within this novel class of compds. revealed a marked dependence of activity on the substitution pattern of the aromatic rings, the nature of the central N atom, and the length of the connecting alkyl chains. The crucial role of the benzazepinone ring for bradycardic activity is best explained by its special impact on the overall mol. conformation.

IT 85176-93-8P 85176-96-1P 96255-02-6P
96255-04-8PRL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and bradycardic activity of)


RN 85176-93-8 CAPLUS

CN 2H-3-Benzazepin-2-one, 3-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-1,3,4,5-tetrahydro-6,9-dimethoxy-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 85176-96-1 CAPLUS
 CN 2H-3-Benzazepin-2-one, 3-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-1,3,4,5-tetrahydro-8,9-dimethoxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 96255-02-6 CAPLUS
 CN 2H-3-Benzazepin-2-one, 3-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-1,3,4,5-tetrahydro-6,9-dimethoxy- (CA INDEX NAME)



RN 96255-04-8 CAPLUS
 CN 2H-3-Benzazepin-2-one, 3-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-1,3,4,5-tetrahydro-8,9-dimethoxy-

10/598,302

(CA INDEX NAME)



OS.CITING REF COUNT: 25 THERE ARE 25 CAPLUS RECORDS THAT CITE THIS
RECORD (26 CITINGS)

L27 ANSWER 45 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1990:152253 CAPLUS

DOCUMENT NUMBER: 112:152253

ORIGINAL REFERENCE NO.: 112:25563a,25566a

TITLE: No evidence for differences between pre- and postjunctional α_2 -adrenoceptors in the periphery

AUTHOR(S): Connaughton, Sonia; Docherty, J. R.

CORPORATE SOURCE: Dep. Clin. Pharmacol., R. Coll. Surg. Ireland, Dublin, Ire.

SOURCE: British Journal of Pharmacology (1990), 99(1), 97-102
CODEN: BJPCBM; ISSN: 0007-1188

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Prejunctional α_2 -adrenoceptors in rat and guinea pig vas deferens and rat and guinea pig atria were compared with postjunctional α_2 -adrenoceptors in human saphenous vein and human platelets employing the antagonists yohimbine and SKF 104078 and other α_2 -adrenoceptor antagonists. Yohimbine was approx. 10 times more potent prejunctionally than SKF 104078 at antagonizing the inhibition by the α_2 -adrenoceptor agonist xylazine of stimulation-evoked contractions in rat and guinea pig vas deferens, and at increasing stimulation-evoked release of 3H in rat and guinea pig atria pre-incubated with [3H]noradrenaline. Yohimbine was approx. 10 times more potent postjunctionally than SKF 104078 at antagonizing contractions to noradrenaline in human saphenous vein and at displacing [3H]yohimbine binding in human platelet membranes. For the antagonists yohimbine, SKF 104078, prazosin, phentolamine, CH 38083 and urapidil, there was a correlation between prejunctional potency in rat vas deferens atrium and postjunctional potency in human platelet, although the correlation was improved by the omission of prazosin. There is no evidence for differences between functional pre- and postjunctional α_2 -adrenoceptors in the periphery, although these functional receptors may differ from the ligand binding site in the human platelet.

IT 126104-24-3

RL: BIOL (Biological study)

(pre- and postjunctional adrenoceptors of periphery response to)


RN 126104-24-3 CAPLUS

CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[(3-methyl-2-buten-1-yl)oxy]-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 110857-22-2

CMF C16 H22 Cl N O




10/598,302

CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



OS.CITING REF COUNT: 9

THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD
(9 CITINGS)

L27 ANSWER 46 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1990:138896 CAPLUS

DOCUMENT NUMBER: 112:138896

ORIGINAL REFERENCE NO.: 112:23479a, 23482a

TITLE: Enantiospecific synthesis of
 (+)-(R)-1-phenyl-3-methyl-1,2,4,5-
 tetrahydrobenz[d]azepine from
 (+)-(S)-N-methyl-1-phenylethanolamine (halostachine)
 via arenechromium tricarbonyl methodology

AUTHOR(S): Coote, Steven J.; Davies, Stephen G.; Middlemiss,
 David; Naylor, Alan

CORPORATE SOURCE: Dyson Perrins Lab., Oxford, OX1 3QY, UK

SOURCE: Tetrahedron Letters (1989), 30(27), 3581-4



CODEN: TELEAY; ISSN: 0040-4039

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 112:138896

GI



AB Stereospecific cyclization of (R)-N-(3,4-dimethoxyphenethyl)halostachine
 chromium tricarbonyl (I) proceeds with retention of configuration, to
 afford, after decomplexation, (+)-(R)-1-phenyl-3-methyl-1,2,4,5-
 tetrahydrobenz[d]azepine (II).


IT 125890-31-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and decomplexation of)

RN 125890-31-5 CAPLUS

CN Chromium, tricarbonyl[2,3,4,5-tetrahydro-6,7-dimethoxy-3-methyl-1-(η6-
 phenyl)-1H-3-benzazepine]-, stereoisomer (9CI) (CA INDEX NAME)

10/598,302



OS.CITING REF COUNT: 17 THERE ARE 17 CAPLUS RECORDS THAT CITE THIS
RECORD (17 CITINGS)

L27 ANSWER 47 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN


ACCESSION NUMBER: 1989:553661 CAPLUS
 DOCUMENT NUMBER: 111:153661
 ORIGINAL REFERENCE NO.: 111:25621a,25624a
 TITLE: Preparation of sulfinyl- and sulfonyl-substituted
 2,3,4,5-tetrahydro-1H-3-benzazepines for use in
 treating gastrointestinal motility disorders and
 emesis
 INVENTOR(S): Bondinell, William E.; Ormsbee, Herbert S., III
 PATENT ASSIGNEE(S): SmithKline Beckman Corp., USA
 SOURCE: U.S., 9 pp. Cont.-in-part of U.S. Ser. No. 13,103,
 abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4824839	A	19890425	US 1988-167663	19880314
US 4659706	A	19870421	US 1985-811789	19851220
WO 8807858	A1	19881020	WO 1988-US1169	19880404
W: AU, JP				
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
AU 8817006	A	19881104	AU 1988-17006	19880404
PRIORITY APPLN. INFO.:			US 1985-811789	A2 19851220
			US 1987-13103	A2 19870210
			US 1987-36403	A2 19870409
			US 1988-167663	A 19880314
			WO 1988-US1169	A 19880404

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 111:153661

GI



AB The title compds. (I; R = H, C1-6 alkyl, C3-5 alkenyl; R1 = SOR3, SO2R3, SO2NR4R5; R2 = H, halo, CF3, C1-6 alkyl, R6O; R3 = C1-6 alkyl, CF3; R4, R5 = H, C1-6 alkyl; R6 = C2-6 alkyl) were prepared 3-MeOC6H4CH2CONHCH2CH(OMe)2 (preparation given) was stirred 16 h in concentrated HCl to give 2,3-dihydro-8-methoxy-2-oxo-1H-3-benzazepine which was converted in 3 steps to benzazepine II (R = Ac, R1 = OMe, R2 = H). The latter was stirred 16 h with ClSO3H and the product treated with Na2SO3 and NaHCO3 in H2O followed by 45 min reflux with MeI to give II (R = Ac, R1 = OMe, R2 = MeSO2) which gave, after 16 h reflux with 48% HBr, II.HBr (R = H, R1 = OH, R2 = MeSO2). The latter doubled the rate of gastric emptying in rats at 0.5 mg/kg i.v.


IT 108963-01-5P 123018-24-6P 123018-33-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)

10/598,302

(preparation of, for gastrointestinal motility disorders and as antiemesis agent)


RN 108963-01-5 CAPLUS

CN Ethanone, 1-[8-bromo-1,2,4,5-tetrahydro-7-methoxy-6-(methylsulfonyl)-3H-3-benzazepin-3-yl]- (CA INDEX NAME)



RN 123018-24-6 CAPLUS

CN 1H-3-Benzazepine-6-sulfonamide, 2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 123018-33-7 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-6-methoxy-, (2Z)-2-butenedioate (1:1)
(CA INDEX NAME)

CM 1

CRN 90047-53-3

CMF C11 H15 N O




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.

10/598,302



OS.CITING REF COUNT:	1	THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT:	2	THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 48 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1989:400545 CAPLUS

DOCUMENT NUMBER: 111:545

ORIGINAL REFERENCE NO.: 111:99a,102a

TITLE: Dopamine D1 and D2 receptor selectivities of agonists and antagonists

AUTHOR(S): Seeman, Philip; Ulpian, Carla

CORPORATE SOURCE: Dep. Pharmacol., Univ. Toronto, Toronto, ON, M5S 1A8, Can.

SOURCE: Advances in Experimental Medicine and Biology (1988), 235(Cent. D1 Dopamine Recept.), 55-63

CODEN: AEMBAP; ISSN: 0065-2598

DOCUMENT TYPE: Journal

LANGUAGE: English


AB The selectivities of various dopamine agonists and antagonists for dopamine D1 and D2 receptors were obtained by comparing their relative dissociation consts. for inhibiting the binding of [³H]SCH 23390 at D1 receptors (calf caudate nucleus) and at D2 receptors (pig anterior pituitary tissue). The most selective agonists were SKF 38393 (for D1) and L 647339 (for D2) whereas the most selective antagonists were SCH 23390 (for D1) and raclopride or eticlopride (for D2).

IT 67942-40-9, SKF 81466 121034-67-1, SKF 81427

RL: BIOL (Biological study)
(dopamine receptor subtype selectivity of)


RN 67942-40-9 CAPLUS

CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-6-(methylthio)-1-phenyl- (CA INDEX NAME)



RN 121034-67-1 CAPLUS

CN 1H-3-Benzazepine-7,8-diol, 6-ethoxy-2,3,4,5-tetrahydro-1-phenyl- (CA INDEX NAME)




OS.CITING REF COUNT: 20 THERE ARE 20 CAPLUS RECORDS THAT CITE THIS RECORD (20 CITINGS)

L27 ANSWER 49 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1989:95030 CAPLUS
 DOCUMENT NUMBER: 110:95030
 ORIGINAL REFERENCE NO.: 110:15707a,15710a
 TITLE: Preparation and formulation of 3-benzazepines for use
 in treating gastrointestinal motility disorders
 INVENTOR(S): Bondinell, William Edward; Ormsbee, Herbert Stowell,
 III
 PATENT ASSIGNEE(S): SmithKline Beckman Corp., USA
 SOURCE: Eur. Pat. Appl., 13 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 285287	A2	19881005	EP 1988-302319	19880317
EP 285287	A3	19900816		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 63255226	A	19881021	JP 1988-67059	19880318
PRIORITY APPLN. INFO.:			US 1987-29289	A 19870323
OTHER SOURCE(S):	MARPAT	110:95030		

GI



AB Title compds. (I; R1 = H, C1-6 alkyl, C3-5 alkenyl; R2 = H, halo, F3C, C1-6 alkyl, R4O; R3 = halo, F3C, C1-6 alkyl, HO, C1-6 alkoxy, C1-6 alkylthio, F3CS, O2N, (un)substituted PhSO_n, etc.; R4 = H, C1-6 alkyl, C1-6 alkanoyl; n = 0-2) or a pharmaceutically acceptable addition salt thereof, were prepared I (R1 = Me; R2 = 7-Br; R3 = 8-MeO) (preparation given)

in


Et₂O was added to BuLi in Et₂O, stirred at -75° for 45 min, treated with Ph₂S₂ to give the phenylthio-HCl derivative which was converted to I.HCl (R1 = Me; R2 = 7-PhS; R3 = 8-HO). In test on gastrointestinal motility in dogs I (R1 = Me; R2 = 7-PhS; R3 = 8-HO) had an ED₅₀ of 14 µg/kg, i.v., to increase lower esophageal sphincter pressure. A capsule formulation contained I.fumarate (R1 = Me, R2 = 7-PhS, R3 = H) 10, lactose 75, and Mg stearate 2 mg.

IT 119018-68-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and methylation of)

RN 119018-68-7 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-6-(phenylthio)- (CA INDEX NAME)




IT 119018-69-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and O-deprotection of)
 RN 119018-69-8 CAPLUS
 CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-3-methyl-6-(phenylthio)-,
 hydrochloride (1:1) (CA INDEX NAME)




● HCl

IT 73943-16-5P 119018-70-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, for treatment of gastrointestinal disorder)
 RN 73943-16-5 CAPLUS
 CN 1H-3-Benzazepin-7-ol, 2,3,4,5-tetrahydro-3-methyl-6-(phenylthio)- (CA
 INDEX NAME)



RN 119018-70-1 CAPLUS
 CN 1H-3-Benzazepin-7-ol, 2,3,4,5-tetrahydro-3-methyl-6-(phenylthio)-,
 hydrochloride (1:1) (CA INDEX NAME)

10/598,302



● HCl

OS.CITING REF COUNT:

4

THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(5 CITINGS)

L27 ANSWER 50 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1989:8025 CAPLUS

DOCUMENT NUMBER: 110:8025

ORIGINAL REFERENCE NO.: 110:1467a,1470a

TITLE: Oxidative ring expansion of isoquinoline enamides.
Facile formation of 3-benzazepines

AUTHOR(S): Lenz, George R.

CORPORATE SOURCE: Health Care Res. Dev., BOC Group Tech. Cent., Murray Hill, NJ, 07974, USA



SOURCE: Journal of Organic Chemistry (1988), 53(24), 5791-3
CODEN: JOCEAH; ISSN: 0022-3263

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 110:8025

GI




AB Treating isoquinoline enamides I [R1 = 6,7-(MeO)2, 5,6-(MeO)2, H, 6-MeO, R2 = EtO, Me, 2,3-(MeO)2C6H3; R3 = H, Me) with Pb(OAc)4 in HDA2 gave benzazepinones II in 43-92% yield.


IT 117734-28-8P 117734-32-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 117734-28-8 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
1,2,4,5-tetrahydro-7,8,9-trimethoxy-2-oxo-, ethyl ester (CA INDEX NAME)


RN 117734-32-4 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
1,2,4,5-tetrahydro-6,7-dimethoxy-2-oxo-, ethyl ester (CA INDEX NAME)

10/598,302

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L27 ANSWER 51 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1989:1418 CAPLUS
 DOCUMENT NUMBER: 110:1418
 ORIGINAL REFERENCE NO.: 110:263a,266a
 TITLE: Evidence for heterogeneity between pre- and postjunctional α -2 adrenoceptors using 9-substituted 3-benzazepines
 AUTHOR(S): Daly, Robert N.; Sulpizio, Anthony C.; Levitt, Blanche; DeMarinis, Robert M.; Regan, John W.; Ruffolo, Robert R., Jr.; Hieble, J. Paul
 CORPORATE SOURCE: Dep. Pharmacol., Smith Kline and French Lab., Philadelphia, PA, USA
 SOURCE: Journal of Pharmacology and Experimental Therapeutics (1988), 247(1), 122-8
 CODEN: JPETAB; ISSN: 0022-3565
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB A series of α -adrenoceptor antagonists, including both reference compds. and the novel benzazepine antagonists, SKF 86466 (I, R = H) and 2 of its derivs., SKF 101253 and SKF 104078, I (R = OCH₂CH:CH₂ and OCH₂CH:CM₂, resp.), were tested in vitro for affinity at central and peripheral α -adrenoceptor subtypes. Peripheral α 1-adrenoceptor antagonist potency of these agents, as assessed by the receptor dissociation constant (K_a) against norepinephrine-induced contraction in the rabbit aorta, correlated with the K_i value for inhibition of [3H]prazosin binding to central α 1-adrenoceptors in rat brain homogenates. Central α 2-adrenoceptor affinity, measured as the K_i for inhibition of [3H]rauwolscine binding to rat brain homogenates, correlated well with antagonist activity at peripheral postjunctional α 2-adrenoceptors as reflected by the KB against B-HT 920-induced contraction in canine saphenous vein. The 9-substituted benzazepines, SKF 101253 and SKF 104078, produce preferential blockade of postjunctional vs. prejunctional α 2-adrenoceptors in peripheral models. The high affinity of SKF 104078 for postjunctional α 2-adrenoceptors in the canine saphenous vein was confirmed by its ability to inhibit [3H]rauwolscine binding to postjunctional α 2-adrenoceptors in this tissue. The observation that the K_i values for these antagonists against [3H]rauwolscine binding correlate with their KB values at the postjunctional α 2-adrenoceptors, rather than those at the prejunctional neuroinhibitory α 2-adrenoceptor, suggests a pharmacol. similarity between the postjunctional vascular α 2-adrenoceptors and the central [3H]rauwolscine binding site. SKF 104078, the most selective postjunctional vis-a-vis prejunctional α 2-adrenoceptor antagonist in the series, inhibited the binding of [3H]yohimbine to human platelet

membranes with a K_i nearly identical to that observed in rat brain, suggesting that the platelet α_2 -adrenoceptor is also similar to that in the rat brain and canine saphenous vein. Thus, selective postjunctional α_2 -adrenoceptor antagonists may represent novel and useful pharmacol. tools with which to subclassify α -adrenoceptors.


IT 86120-57-2

RL: BIOL (Biological study)

(central and peripheral α_2 -adrenergic receptors differential responses to)

RN 86120-57-2 CAPLUS

CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(2-propen-1-yloxy)- (CA INDEX NAME)



OS.CITING REF COUNT: 3

THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)

L27 ANSWER 52 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1988:131604 CAPLUS

DOCUMENT NUMBER: 108:131604

ORIGINAL REFERENCE NO.: 108:21587a,21590a

TITLE: Preparation of 1-phenyl-3-benzazepine derivatives for treatment of gastroenteric disorders

PATENT ASSIGNEE(S): SmithKline Beckman Corp., USA

SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62158256	A	19870714	JP 1986-305159	19861220
US 4707483	A	19871117	US 1985-811790	19851220
EP 230755	A1	19870805	EP 1986-309847	19861217
EP 230755	B1	19900516		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 52776	T	19900615	AT 1986-309847	19861217
ZA 8609500	A	19870930	ZA 1986-9500	19861218
DK 8606197	A	19870621	DK 1986-6197	19861219
AU 8666780	A	19870625	AU 1986-66780	19861219
AU 586724	B2	19890720		
CA 1263385	A1	19891128	CA 1986-525852	19861219
PRIORITY APPLN. INFO.:			US 1985-811790	A 19851220
			EP 1986-309847	A 19861217


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 108:131604; MARPAT 108:131604

GI



I



II

AB The title compds. I (R1 = H, C1-6 alkyl, C3-5 alkenyl; R2 = H, OH, C1-6 alkoxy, halo, CF3, C1-6 alkyl, SOnR5 where R5 = C1-6 alkyl, Ph, SOnCF3, SO2NR6R7 where R6, R7 = H, C1-6 alkyl; R3 = H, C1-6 alkyl, C1-6 alkanoyl; R4 = SO2NR6R7, SOnR8 where R8 = R2C6H4, CF3; n = 0, 1, 2), useful for treating motility disorders of stomach and intestines, are prepared Treatment of II (R3 = Me, R4 = Br) with BuLi in hexane and Et2O, followed by addition of PhSSPh gave II (R4 = PhS) which was demethylated in the presence of MeSO3H and methionine to afford II (R3 = H, R4 = PhS) (III). III showed increase of gastroenteric motility ED20 of 20 µg/kg i.v. in dogs. A gelatine capsule was formulated containing III.HCl 15, lactose 85,

and Mg stearate 3 mg.


IT 113520-88-0P 113520-89-1P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, as therapeutics for gastroenteric disorders)


RN 113520-88-0 CAPLUS

CN 1H-3-Benzazepine, 1-(4-chlorophenyl)-2,3,4,5-tetrahydro-8-methoxy-6-
[(trifluoromethyl)thio]- (CA INDEX NAME)



RN 113520-89-1 CAPLUS

CN 1H-3-Benzazepin-7-ol, 5-(4-chlorophenyl)-2,3,4,5-tetrahydro-9-
[(trifluoromethyl)thio]- (CA INDEX NAME)



OS.CITING REF COUNT: 3


THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)

L27 ANSWER 53 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1987:598115 CAPLUS
 DOCUMENT NUMBER: 107:198115
 ORIGINAL REFERENCE NO.: 107:31782h,31783a
 TITLE: Preparation and formulation of
 6-halo-9-alkenyloxy-3-alkyl-2,3,4,5-tetrahydro-1H-3-
 benzazepines and their use as selective
 alpha-adrenergic receptor antagonists
 INVENTOR(S): Demarinis, Robert M.; Pfeiffer, Francis R.
 PATENT ASSIGNEE(S): SmithKline Beckman Corp., USA
 SOURCE: U.S., 7 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4683229	A	19870728	US 1986-840621	19860317
EP 238281	A1	19870923	EP 1987-302214	19870316
EP 238281	B1	19900516		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AU 8770046	A	19870924	AU 1987-70046	19870316
JP 62226963	A	19871005	JP 1987-60878	19870316
ZA 8701893	A	19871125	ZA 1987-1893	19870316
AT 52777	T	19900615	AT 1987-302214	19870316
DK 8701369	A	19870918	DK 1987-1369	19870317
PRIORITY APPLN. INFO.:			US 1986-840621	A 19860317
			EP 1987-302214	A 19870316


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 107:198115
 GI




AB Title compds. I (R = C1-5 alkyl; X = Br, Cl, F; Y = Me₂C:CHCH₂, MeCH:CH, Me₂C:CH, etc.) and salts, were prepared I (R = Me, X = Cl, Y = H) was treated with KH in DMF and the mixture was added to Me₂C:CHCH₂Br in DMF to give I (R = Me, X = Cl, Y = Me₂C:CHCH₂) (II). In dog saphenous vein test system for measuring α ₃-receptor activity, II at 150 nM concentration had a KB (receptor dissociation constant) of 37 and no α ₂ effect. A hard gelatin capsule contained II 50, Mg stearate 5, and lactose 75 mg.
 IT 90047-50-0
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (addition reaction of, to bromomethylbutene)

10/598,302


RN 90047-50-0 CAPLUS
CN 1H-3-Benzazepin-6-ol, 9-chloro-2,3,4,5-tetrahydro-3-methyl- (CA INDEX NAME)



IT 86120-57-2
RL: PROC (Process)
(formulation of, as α 3-adrenoreceptor antagonist)
RN 86120-57-2 CAPLUS
CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(2-propen-1-yloxy)- (CA INDEX NAME)



IT 110857-23-3P 110857-24-4P 110941-56-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as α 3-adrenoreceptor antagonist)
RN 110857-23-3 CAPLUS
CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(1-propen-1-yloxy)- (CA INDEX NAME)




RN 110857-24-4 CAPLUS
CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(1-propenyloxy)-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

10/598,302


CRN 110857-23-3
CMF C14 H18 Cl N O



CM 2

CRN 110-16-7
CMF C4 H4 O4


Double bond geometry as shown.



RN 110941-56-5 CAPLUS
CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[(3-methyl-2-butenyl)oxy]-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 110857-22-2
CMF C16 H22 Cl N O




CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.

10/598,302



OS.CITING REF COUNT:	5	THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
REFERENCE COUNT:	5	THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 54 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1987:470814 CAPLUS
 DOCUMENT NUMBER: 107:70814
 ORIGINAL REFERENCE NO.: 107:11541a,11544a
 TITLE: Use of α 2-adrenergic receptor antagonists for
 the production of pharmaceutical compositions for
 treating colonic spasm, irritable bowel syndrome and
 constipation and process for preparing such
 pharmaceutical compositions
 INVENTOR(S): Pendelton, Robert G.
 PATENT ASSIGNEE(S): Merck and Co., Inc. , USA
 SOURCE: Eur. Pat. Appl., 36 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 216247	A2	19870401	EP 1986-112490	19860909
EP 216247	A3	19891115		
R: CH, DE, FR, GB, IT, LI, NL				
US 4673680	A	19870616	US 1985-777472	19850918
JP 62067031	A	19870326	JP 1986-218265	19860918
			US 1985-777472	A 19850918

PRIORITY APPLN. INFO.:

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 107:70814

GI For diagram(s), see printed CA Issue.

AB An α 2-adrenergic receptor antagonist [I; Ar = aromatic heterocycle,
 R1,R2-benzo[b]furo, R2-benzo[b]thieno, pyridino, etc.; R1, R2 = H, halo,
 etc.; R3 = H, (un)substituted C1-6 alkyl, etc.; X = C:O, C:S, SO2; R4 =
 OR8, N(R8)2, CO2R8, etc.; R8 = H, (un)substituted C1-6 alkyl; R5 =
 (un)substituted C1-6 alkyl, etc.; n = 0-3; or R3, R4 or R3, R5 or R4, R5
 complete a 5- or 6-membered heterocycle], a salt thereof, or a mixture of
 these compds. is used to prepare a pharmaceutical composition for treating
 colonic spasm, irritable bowel syndrome, and constipation. The compds.
 are prepared by acylation of I (XR4 = H).
 (2SR,12BRS)-N-(1,3,4,6,7,12b-hexahydro-2H-benzo[b]furo[2,3-a]quinolizin-2-
 yl)-N-methyl-2-hydroxyethanesulfonamide (II) was prepared in 7 steps from
 3-cyanomethylbenzo[b]furan. For a pharmaceutical formulation, the HCl
 salt of II 6 mg was blended with starch 87 and Mg stearate 7 mg and the
 mixture was used to fill hard capsules (100 mg/capsule). The (2R,12bS) form
 of II was also used to study the effect on colonic muscle activity in
 anesthetized cats. A dose of 300 μ g/kg given i.v. caused a reduction in
 circular muscle contractility.

IT 86120-57-2


RL: BIOL (Biological study)

(as α 2-adrenergic receptor antagonist for treatment of colonic
 spasm and irritable bowel syndrome and constipation)

RN 86120-57-2 CAPLUS

CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(2-propen-1-
 yloxy)- (CA INDEX NAME)

10/598,302



OS.CITING REF COUNT: 7

THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD
(9 CITINGS)

L27 ANSWER 55 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN


ACCESSION NUMBER: 1987:439651 CAPLUS
 DOCUMENT NUMBER: 107:39651
 ORIGINAL REFERENCE NO.: 107:6627a,6630a
 TITLE: Preparation and formulation of sulfinyl and sulfonyl substituted 3-benzazepines for treatment of gastrointestinal motility disorders
 INVENTOR(S): Bondinell, William E.; Ormsbee, Herbert S., III
 PATENT ASSIGNEE(S): SmithKline Beckman Corp., USA
 SOURCE: U.S., 7 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4659706	A	19870421	US 1985-811789	19851220
DK 8606106	A	19870621	DK 1986-6106	19861217
EP 229510	A1	19870722	EP 1986-309846	19861217
EP 229510	B1	19900606		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 53385	T	19900615	AT 1986-309846	19861217
ZA 8609501	A	19870826	ZA 1986-9501	19861218
FI 8605220	A	19870621	FI 1986-5220	19861219
NO 8605203	A	19870622	NO 1986-5203	19861219
AU 8666779	A	19870625	AU 1986-66779	19861219
AU 589240	B2	19891005		
CN 86108627	A	19870722	CN 1986-108627	19861219
HU 43826	A2	19871228	HU 1986-5351	19861219
CA 1263384	A1	19891128	CA 1986-525851	19861219
JP 62158255	A	19870714	JP 1986-305158	19861220
US 4824839	A	19890425	US 1988-167663	19880314
PRIORITY APPLN. INFO.:			US 1985-811789	A 19851220
			EP 1986-309846	A 19861217
			US 1987-13103	A2 19870210
			US 1987-36403	A2 19870409

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 107:39651; MARPAT 107:39651

GI



AB Title compds. I (R = H, alkyl, C3-5 alkenyl; R1 = SOR3, SO2R3, SO2NR4R5, R3 = F3C, alkyl; R4, R5 = H, alkyl; R2 = H, alkanoyl) and their salts, were prepared 8-Hydroxy-7-(methylsulfonyl)-2,3,4,5-tetrahydro-1H-3-

10/598,302


benzazepine-HBr (II) was prepared in 11 steps from 3-MeOC₆H₄CH₂CO₂H. In tests for the effect on gastrointestinal motility II had an ED₂₀ of 27 µg/kg, i.v., on a test for increase in resting pressure of the lower esophageal sphincter in dogs, and at 0.5 mg/kg, i.v., doubled the rate of gastric emptying compared to control in rats. A hard gelatin capsule was formulated with II 10, lactone 75, and Mg stearate 2 mg.

IT 108963-01-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and conversion of)

RN 108963-01-5 CAPLUS

CN Ethanone, 1-[8-bromo-1,2,4,5-tetrahydro-7-methoxy-6-(methylsulfonyl)-3H-3-benzazepin-3-yl]- (CA INDEX NAME)



IT 108963-04-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 108963-04-8 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-6-methoxy-, (2Z)-2-butenedioate (9CI)
(CA INDEX NAME)

CM 1

CRN 90047-53-3

CMF C11 H15 N O




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.

10/598,302




IT 108963-02-6P 108963-03-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, for treatment of gastric motility disorders)
RN 108963-02-6 CAPLUS
CN 1H-3-Benzazepin-7-ol, 2,3,4,5-tetrahydro-6-(methylsulfonyl)-, hydrobromide
(1:1) (CA INDEX NAME)



● HBr

RN 108963-03-7 CAPLUS
CN 1H-3-Benzazepin-6-ol, 2,3,4,5-tetrahydro-3-methyl-8-(methylsulfonyl)-,
hydrobromide (1:1) (CA INDEX NAME)



● HBr

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(13 CITINGS)
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 56 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1986:511412 CAPLUS

DOCUMENT NUMBER: 105:111412

ORIGINAL REFERENCE NO.: 105:17971a,17974a

TITLE: Photoaffinity labelling of platelet
 α 2-adrenoceptorsAUTHOR(S): DeMarinis, R. M.; Regan, J. W.; Caron, M. G.;
Lefkowitz, R. J.CORPORATE SOURCE: Smith Kline and French Lab., Philadelphia, PA, 19101,
USASOURCE: Pharmacol. Adrenoceptors, [Proc. Satell. Symp.] (1985)
, Meeting Date 1984, 297-8. Editor(s): Szabadi,
Elmer; Bradshaw, Christopher M.; Nahorski, S. R.
Macmillan: Basingstoke, UK.
CODEN: 55CBAB

DOCUMENT TYPE: Conference


LANGUAGE: English

AB Photolysis of the platelet α 2-adrenergic receptor in the presence of
1 μ M SKF 102229 (3-methyl-6-chloro-9-azido-1H-2,3,4,5-tetrahydro-3-
benzazepine) decreased the receptor number by 69% relative to controls.
Preincubation with phentolamine or p-aminoclonidine protected against the
SKF 102229-induced receptor photolysis. The SKF 102229-dependent
photoinactivation of the α 2-adrenergic receptor was concentration dependent
at 10-1000 nM. The results indicate there is a true receptor-ligand
interaction between SKF 102229 and the α 2-adrenergic receptor.

IT 99795-09-2


RL: ANST (Analytical study)
(α 2-adrenergic receptor photoaffinity labeling with, in blood
platelet)

RN 99795-09-2 CAPLUS


CN 1H-3-Benzazepine, 6-chloro-9-azido-2,3,4,5-tetrahydro-3-methyl- (CA INDEX
NAME)

L27 ANSWER 57 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1986:491844 CAPLUS
 DOCUMENT NUMBER: 105:91844
 ORIGINAL REFERENCE NO.: 105:14733a,14736a
 TITLE: Photoaffinity labeling of human platelet and rabbit kidney α 2-adrenoceptors with [3H]SKF 102229
 AUTHOR(S): Regan, John W.; Raymond, John R.; Lefkowitz, Robert J.; DeMarinis, Robert M.
 CORPORATE SOURCE: Med. Cent., Duke Univ., Durham, NC, 27710, USA
 SOURCE: Biochemical and Biophysical Research Communications (1986), 137(2), 606-13
 CODEN: BBRCA9; ISSN: 0006-291X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB A newly developed α 2-adrenergic photoaffinity ligand, SKF 102229 (I) [99795-09-2], was labeled with tritium to a specific activity of .apprx.80 Ci/mmol. Using membranes prepared from human platelets and from rabbit kidney, α 2-adrenoceptors were covalently labeled following photolysis in the presence of [3H]SKF 102229 [103846-99-7]. The apparent mol. weight of α 2-adrenoceptors from both of these tissues was 64,000. The yield of covalent insertion of [3H]SKF 102229 into the α 2-adrenoceptor was very good. Thus, following photolysis, \leq 90% of the α 2-adrenoceptors could be irreversibly labeled with [3H]SKF 102229.
 IT 103847-00-3
 RL: BIOL (Biological study)
 (azide formation from)
 RN 103847-00-3 CAPLUS
 CN 1H-3-Benzazepin-6-amine, 9-chloro-2,3,4,5-tetrahydro-3-(methyl-t3)- (9CI)
 (CA INDEX NAME)




IT 78495-53-1
 RL: BIOL (Biological study)

10/598,302

(demethylation and methylation with tritiated Me of)

RN 78495-53-1 CAPLUS

CN 1H-3-Benzazepin-6-amine, 9-chloro-2,3,4,5-tetrahydro-3-methyl- (CA INDEX NAME)




IT 103846-99-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, for α 2-adrenergic receptor labeling in humans and laboratory animals)

RN 103846-99-7 CAPLUS

CN 1H-3-Benzazepine, 6-azido-9-chloro-2,3,4,5-tetrahydro-3-(methyl-t3)- (9CI)
(CA INDEX NAME)




IT 99795-09-2

RL: BIOL (Biological study)
(α 2-adrenergic receptors photoaffinity labeling with, of humans and laboratory animals)

RN 99795-09-2 CAPLUS

CN 1H-3-Benzazepine, 6-azido-9-chloro-2,3,4,5-tetrahydro-3-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L27 ANSWER 58 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN


ACCESSION NUMBER: 1986:403064 CAPLUS
 DOCUMENT NUMBER: 105:3064
 ORIGINAL REFERENCE NO.: 105:595a,598a
 TITLE: Azidobenzazepines as photoaffinity probes for α 2-adrenoreceptor sites
 INVENTOR(S): Demarinis, Robert Michael
 PATENT ASSIGNEE(S): SmithKline Beckman Corp., USA
 SOURCE: Eur. Pat. Appl., 11 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 176222	A1	19860402	EP 1985-305903	19850820
EP 176222	B1	19890802		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
US 4652642	A	19870324	US 1984-643341	19840823
AT 45147	T	19890815	AT 1985-305903	19850820
JP 61057560	A	19860324	JP 1985-184989	19850821
CA 1260465	A1	19890926	CA 1985-489154	19850821
PRIORITY APPLN. INFO.:			US 1984-643341	A 19840823
			EP 1985-305903	A 19850820

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 105:3064

GI



AB Azidobenzazepines I (X = halo; R = C1-6 alkyl) are prepared from their 9-amino congeners and used as photoaffinity probes for α 2-adrenoceptor sites in biol. samples (no data). Thus, 6-chloro-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine was nitrated to form 6-chloro-3-methyl-9-nitro-2,3,4,5-tetrahydro-1H-benzazepine, which was reduced to give 9-amino-6-chloro-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (II). II was subjected to diazotization and treated with sodium azide to produce 9-azido-6-chloro-3-methyl-2,3,4,5-tetrahydro-1H-benzazepine.


IT 78495-53-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and diazotization and reaction of, with sodium azide)


RN 78495-53-1 CAPLUS

CN 1H-3-Benzazepin-6-amine, 9-chloro-2,3,4,5-tetrahydro-3-methyl- (CA INDEX NAME)


10/598,302



IT 78495-50-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and reduction of)
RN 78495-50-8 CAPLUS
CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-nitro- (CA INDEX
NAME)




IT 99795-09-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as photoaffinity probe for adrenoreceptor)
RN 99795-09-2 CAPLUS
CN 1H-3-Benzazepine, 6-azido-9-chloro-2,3,4,5-tetrahydro-3-methyl- (CA INDEX
NAME)




IT 102774-84-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as photoaffinity probes for adrenoreceptor)
RN 102774-84-5 CAPLUS
CN 1H-3-Benzazepine, 6-azido-9-chloro-2,3,4,5-tetrahydro-3-methyl-, sulfate
(1:1) (CA INDEX NAME)
CM 1

10/598,302

CRN 99795-09-2
CMF C11 H13 Cl N4



CM 2
CRN 7664-93-9
CMF H2 O4 S



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L27 ANSWER 59 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1986:215042 CAPLUS

DOCUMENT NUMBER: 104:215042

ORIGINAL REFERENCE NO.: 104:33943a,33946a

TITLE: Electrochemical and spectral investigations of
oxidative pathways of
6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1H-3-
benzazepine-7,8-diol (fenoldopam)AUTHOR(S): Cheng, Hung Yuan; Davis, Louisa Lam; Webb, R. Lee;
Carr, Steven; Roberts, Gerald D.; Staiger, David B.;
Zuber, Gary E.CORPORATE SOURCE: Dep. Anal., Phys. Struct. Chem., Smith Kline and
French Lab., Philadelphia, PA, 19101, USASOURCE: Journal of the Electrochemical Society (1986), 133(3),
515-21

CODEN: JESOAN; ISSN: 0013-4651

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Fenoldopam, a selective D-1 dopamine receptor agonist currently under development for treatment of hypertension and congestive heart failure, undergoes 2-electron, 2-proton oxidation in acidic to neutral pH aqueous buffer to form the corresponding o-quinone (I). The fate of I in aqueous solution depends on pH, with a half-life of a few seconds at pH 7.4 to a few days in 0.1M HCl. Certain physiol. important nucleophiles and reducing agents also react rapidly with I. For example, I is reduced immediately by ascorbic acid to fenoldopam. In the presence of glutathione (GSH), both the 6 and 9 positions of I can be attacked by the sulfhydryl nucleophile to form 6-Cl-9-SG and 6,9-di-SG adducts. Spectral studies show that substitutions at the 6 and 9 positions induce a systematic change in the IR region. Addnl., CD spectra indicate that the configuration of the chiral center for the R- or S-enantiomer is preserved in these reactions. Oxidation of the 8-O-sulfate of I, an important metabolite of fenoldopam in mammals, is at a much more pos. potential. However, the unstable oxidation product is rapidly hydrolyzed to form I. The biol. implications, as well as synthetic and anal. utilities, of these findings are discussed.


IT 102430-73-9P

RL: PREP (Preparation)
(preparation of)

RN 102430-73-9 CAPLUS


CN Glycine, N-[S-[9-fluoro-2,3,4,5-tetrahydro-7,8-dihydroxy-5-(4-
hydroxyphenyl)-1H-3-benzazepin-6-yl]-N-L-γ-glutamyl-L-cysteinyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 102430-71-7P 102430-72-8P
 RL: PREP (Preparation)
 (preparation of, electrochem.)
 RN 102430-71-7 CAPLUS
 CN Glycine, 2,2'-[2,3,4,5-tetrahydro-7,8-dihydroxy-1-(4-hydroxyphenyl)-1H-3-benzazepine-6,9-diyl]bis[L- γ -glutamyl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 102430-72-8 CAPLUS
 CN Glycine, N-[S-[9-chloro-2,3,4,5-tetrahydro-7,8-dihydroxy-5-(4-hydroxyphenyl)-1H-3-benzazepin-6-yl]-N-L- γ -glutamyl-L-cysteinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L27 ANSWER 60 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1986:48228 CAPLUS

DOCUMENT NUMBER: 104:48228

ORIGINAL REFERENCE NO.: 104:7733a,7736a

TITLE: Arylazide photoaffinity probe for α 2-adrenoceptors

AUTHOR(S): Regan, John W.; DeMarinis, Robert M.; Lefkowitz, Robert J.

CORPORATE SOURCE: Med. Cent., Duke Univ., Durham, NC, 27710, USA

SOURCE: Biochemical Pharmacology (1985), 34(20), 3667-72
CODEN: BCPA6; ISSN: 0006-2952

DOCUMENT TYPE: Journal

LANGUAGE: English

AB An arylazide photoaffinity probe for α 2-adrenoceptors was developed and characterized. The compound, 3-methyl-6-chloro-9-azido-1H-2,3,4,5-tetrahydro-3-benzazepine (SKF 102229), had a K_i for the human platelet α 2-adrenoceptor of .apprx.40 nM. Upon exposure to UV light, SKF 102229 irreversibly blocked the binding of [3H]yohimbine to both membrane-bound and solubilized, partially purified, receptors. The extent of α 2-adrenoceptor blockade was dependent upon both the length of exposure to UV light and the concentration of SKE 102229. Typically, a 60% decrease in α 2-adrenoceptor number is obtained following 8 min of photolysis in the presence of 100 nM SKF 102229. The pharmacol. characteristics of the irreversible blockade produced by SKF 102229 were those of an α 2-adrenoceptor. Thus, photodependent, irreversible blockade of α 2-adrenoceptors by SKF 102229 was prevented by the concomitant presence of phentolamine or p-aminoclonidine but not by prazosin. Given its specificity and efficient blockage of the ligand binding site, SKF 102229 should prove useful for studies of the structure and function of α 2-adrenoceptors.


IT 99795-09-2

RL: ANST (Analytical study)

(as photoaffinity probe, of α 2-adrenergic receptors, of human blood platelets)

RN 99795-09-2 CAPLUS

CN 1H-3-Benzazepine, 6-azido-9-chloro-2,3,4,5-tetrahydro-3-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)

L27 ANSWER 61 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1985:400382 CAPLUS

DOCUMENT NUMBER: 103:382

ORIGINAL REFERENCE NO.: 103:75a,78a

TITLE: Effects of SK&F 82526 and SK&F 83742 on the renal vascular dopamine receptor

AUTHOR(S): Schmidt, M.; Imbs, J. L.; Giesen-Crouse, E. M.; Schwartz, J.

CORPORATE SOURCE: Inst. Pharmacol. Med. Exp., Fac. Med., Strasbourg, F 67000, Fr.


SOURCE: Journal de Pharmacologie (1985), 16(1), 15-22

CODEN: JNPHAG; ISSN: 0021-793X

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB The renal vascular effects of benzazepine derivs. were studied on the isolated perfused rat kidney in the presence of phenoxybenzamine and totalol after contraction of the vascular bed with prostaglandin F_{2α}. SKF 82526 (I) [87900-90-1] was a very potent dopaminomimetic drug (ED₅₀ = 7.6 + 10⁻⁹ M) on the renal vascular dopamine receptor. It displayed partial agonist activity (similar to SK&F 38393) and was devoid of α-adrenomimetic effects. SKF 83742 (II) [73943-42-7] was a potent dopaminolytic drug. It antagonized dopamine-induced relaxation of the renal vascular bed in a competitive way, with an apparent pA₂ of 7.47.


IT 73943-42-7

RL: BIOL (Biological study)

(kidney circulation response to, as dopaminergic antagonist)

RN 73943-42-7 CAPLUS

CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-3-methyl-6-(phenylthio)- (CA INDEX NAME)



L27 ANSWER 62 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN


ACCESSION NUMBER: 1985:203882 CAPLUS
 DOCUMENT NUMBER: 102:203882
 ORIGINAL REFERENCE NO.: 102:31953a,31956a
 TITLE: Benzazepine derivatives, and their use
 INVENTOR(S): Reiffen, Manfred; Heider, Joachim; Hauer, Norbert;
 Austel, Volkhard; Eberlein, Wolfgang; Kobinger,
 Walter; Lillie, Christian; Noll, Klaus; Pieper,
 Helmut; et al.
 PATENT ASSIGNEE(S): Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.
 SOURCE: U.S., 38 pp. Cont.-in-part of U.S. Ser. No. 523,630,
 abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4490369	A	19841225	US 1983-547940	19831102
DE 3119874	A1	19821209	DE 1981-3119874	19810519
DE 3242599	A1	19840524	DE 1982-3242599	19821118
PRIORITY APPLN. INFO.:			DE 1981-3119874	A 19810519
			US 1982-377599	A2 19820512
			DE 1982-3242599	A 19821118
			US 1983-523630	A2 19830815

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 102:203882

GI



I

AB About 145 examples of the title compds. I [A = CH₂CH₂, CH:CH, NHCO, CH₂CO, CR₇:N (R₇ = alkyl); A₁ = CH₂, CO, CS, COCO, N:CH, CH(OH)CO, CH(OH)CH₂, C(:NOH)CO, CH(NHR₈)CO (R₈ = H, substituted alkyl), CH₂; E, G = (un)substituted alkylene; R₁ = H, halo, CF₃, NH₂, OH, alkyl, alkoxy; R₂ = H, halo, OH, alkyl, alkoxy; R₁R₂ = alkylenedioxy; R₃ = H, halo, OH, -CN, NO₂, CF₃, alkyl, alkoxy; R₄ = H, alkyl, OH alkoxy, NH₂, alkylamino, substituted amino; R₃R₄ = alkylenedioxy; R₅ = H, Cl, Br, -CN, OH, alkyl, alkoxy; R₆ = H, alkyl, phenylalkyl, alkanoyl, alkoxy carbonyl, alkenyl], useful as bradycardiacs, were prepared Thus, 3,4-dimethoxyphenylacetic acid was treated with thionyl chloride, then with aminoacetaldehyde di-Me acetal, and cyclized in the presence of HCl and HOAc to give 7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one. The last was treated with 1-bromo-3-chloropropane, then hydrogenated to give 1-[7,8-dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepin-2-on-3-yl]-3-[N-methyl-


N-(2-(3,4-dimethoxyphenyl)ethyl)amino]propane dihydrochloride (II). At 1.0 mg/kg i.v., II gave a 55% reduction in heart rate in anesthetized cats with a half life of 120 min.

IT 85176-93-8P 85176-96-1P 96255-02-6P
96255-04-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and bradycardiac activity of)

RN 85176-93-8 CAPLUS


CN 2H-3-Benzazepin-2-one, 3-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-1,3,4,5-tetrahydro-6,9-dimethoxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 85176-96-1 CAPLUS

CN 2H-3-Benzazepin-2-one, 3-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-1,3,4,5-tetrahydro-8,9-dimethoxy-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 96255-02-6 CAPLUS


CN 2H-3-Benzazepin-2-one, 3-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-1,3,4,5-tetrahydro-6,9-dimethoxy- (CA INDEX NAME)

10/598,302



RN 96255-04-8 CAPLUS

CN 2H-3-Benzazepin-2-one, 3-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-1,3,4,5-tetrahydro-8,9-dimethoxy-(CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 63 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1985:143735 CAPLUS

DOCUMENT NUMBER: 102:143735

ORIGINAL REFERENCE NO.: 102:22455a,22458a

TITLE: Interactions of dopamine agonists with brain D1 receptors labeled by tritium-antagonists. Evidence for the presence of high and low affinity agonist-binding states

AUTHOR(S): Leff, Stuart E.; Hamblin, Mark W.; Creese, Ian

CORPORATE SOURCE: Sch. Med., Univ. California, La Jolla, CA, 92093, USA

SOURCE: Molecular Pharmacology (1985), 27(2), 171-83

CODEN: MOPMA3; ISSN: 0026-895X

DOCUMENT TYPE: Journal

LANGUAGE: English


AB The interactions of dopaminergic agonists and antagonists with [3H]antagonist-labeled D1 dopamine receptors of rat striatum were characterized. [3H]flupentixol labeled selectively D1 dopamine receptors when its binding to D2 dopamine receptors was blocked by the inclusion of D2 selective concns. of unlabeled spiroperidol or domperidone. Antagonist/[3H]antagonist competition curves are of uniformly steep slope ($nH = 1.0$), suggesting the presence of a single D1 dopamine receptor. Agonist/[3H]antagonist competition curves are extremely shallow ($nH \leq 0.5$) for agonists of high relative efficacy, suggesting the presence of heterogeneous populations of agonist-binding states of the D1 dopamine receptor. Computer-modeling techniques were used to estimate affinities and relative site densities for these heterogeneous binding states. The anal. indicates that the ratio of agonist affinities for low- and high-affinity agonist-binding states is correlated with agonist relative efficacies in activating adenylate cyclase [9012-42-4] in membrane homogenates. Under the assay conditions employed, the addition of saturating concns. of guanine nucleotides reduced, but did not abolish, the relative d. of high-affinity agonist-binding sites. These binding data can, at least in part, be explained by postulating 2 states of D1 dopamine receptor, inducible by agonists but not by antagonists and modulated by guanine nucleotides.

IT 73943-42-7

RL: PROC (Process)

(dopaminergic D1 receptor binding of, in brain striatum)

RN 73943-42-7 CAPLUS

CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-3-methyl-6-(phenylthio)-
(CA INDEX NAME)

OS.CITING REF COUNT: 8

THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD
(8 CITINGS)

L27 ANSWER 64 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN


ACCESSION NUMBER: 1984:438371 CAPLUS
 DOCUMENT NUMBER: 101:38371
 ORIGINAL REFERENCE NO.: 101:5997a,6000a
 TITLE: Tetrahydrobenzazepines
 PATENT ASSIGNEE(S): Smithkline Beckman Corp., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 59042371	A	19840308	JP 1983-137453	19830726
US 4469634	A	19840904	US 1982-403229	19820729
CA 1193254	A1	19850910	CA 1983-431459	19830629
AU 8316494	A	19840202	AU 1983-16494	19830701
AU 558321	B2	19870129		
ZA 8304888	A	19840328	ZA 1983-4888	19830705
DK 8303393	A	19840130	DK 1983-3393	19830725
EP 103961	A1	19840328	EP 1983-304407	19830729
EP 103961	B1	19860402		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AT 18906	T	19860415	AT 1983-304407	19830729
PRIORITY APPLN. INFO.:				
			US 1982-403229	A 19820729
			EP 1983-304407	A 19830729

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 101:38371; MARPAT 101:38371

GI



AB Title compds. I (R = H, alkyl; R1, R2, R3 = allyloxy, allylthio, halo, H),
 useful as antihypertensives (data on α -2 adrenergic antagonists
 activity given), were prepared Thus, stirring I (R = Ac, R1-R3 = H) with
 NaSMe and CH₂:CHCH₂Br in hexamethylenetriamide gave, after treatment with
 HCl/EtOH, I HCl (R-R2 = H, R3 = 7-allylthio).


IT 90047-47-5P 90047-51-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and α -2 adrenergic receptor antagonist activity of)

RN 90047-47-5 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-methyl-6-(2-propen-1-yloxy)-,
 hydrochloride (1:1) (CA INDEX NAME)

10/598,302




● HCl

RN 90047-51-1 CAPLUS
CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(2-propen-1-yloxy)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

IT 90931-77-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 90931-77-4 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-methyl-6-(2-propen-1-ylthio)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(4 CITINGS)

L27 ANSWER 65 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1984:416804 CAPLUS

DOCUMENT NUMBER: 101:16804

ORIGINAL REFERENCE NO.: 101:2563a,2566a

TITLE: Development of an affinity ligand for purification of α 2-adrenoceptors from human platelet membranes

AUTHOR(S): DeMarinis, R. M.; Krog, A. J.; Shah, D. H.; Lafferty, J.; Holden, K. G.; Hieble, J. P.; Matthews, W. D.; Regan, J. W.; Lefkowitz, R. J.; Caron, M. G.


CORPORATE SOURCE: Dep. Med. Chem., Smith Kline and French Lab., Philadelphia, PA, USA

SOURCE: Journal of Medicinal Chemistry (1984), 27(7), 918-21
CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

GI




AB The tetrahydro-1H-3-benzazepines I (R = H or Me; R1 = H, Cl, or allyloxy; R2 = H or allyloxy; R3 = H, NO2, or allyloxy, HCl) were prepared and evaluated as affinity ligand for the isolation and purification of the α 2-adrenoceptor from human platelet membranes.
9-(Allyloxy)-6-chloro-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (I; R = Me, R1 = Cl, R2 = H, R3 = allyloxy) [90047-51-1] an α 2-adrenoceptor antagonist showed the greatest affinity.
Structure-activity relations are discussed.

IT 90047-46-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and acylation of)


RN 90047-46-4 CAPLUS

CN 1H-3-Benzazepin-6-ol, 2,3,4,5-tetrahydro-, hydrobromide (1:1) (CA INDEX NAME)




● HBr


IT 90047-50-0P 90047-55-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and allylation of)
 RN 90047-50-0 CAPLUS
 CN 1H-3-Benzazepin-6-ol, 9-chloro-2,3,4,5-tetrahydro-3-methyl- (CA INDEX
 NAME)



RN 90047-55-5 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-6-hydroxy-, ethyl
 ester (CA INDEX NAME)




IT 78495-53-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and diazotization and displacement of)
 RN 78495-53-1 CAPLUS
 CN 1H-3-Benzazepin-6-amine, 9-chloro-2,3,4,5-tetrahydro-3-methyl- (CA INDEX
 NAME)



IT 90047-54-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and hydrolysis of)
 RN 90047-54-4 CAPLUS

10/598,302


CN 3H-3-Benzazepine-3-carboxylic acid,
6-[(ethoxycarbonyl)oxy]-1,2,4,5-tetrahydro-, ethyl ester (CA INDEX NAME)



IT 78495-50-8P 90047-56-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and reduction of)


RN 78495-50-8 CAPLUS

CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-nitro- (CA INDEX NAME)



RN 90047-56-6 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
1,2,4,5-tetrahydro-6-(2-propen-1-yloxy)-, ethyl ester (CA INDEX NAME)




IT 90047-47-5P 90047-51-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and α 2-adrenergic receptor binding of)

RN 90047-47-5 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-methyl-6-(2-propen-1-yloxy)-,
hydrochloride (1:1) (CA INDEX NAME)

10/598,302




● HCl

RN 90047-51-1 CAPLUS
CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(2-propen-1-yloxy)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

IT 86120-57-2 90047-57-7
RL: PROC (Process)
(α 2-adrenergic receptor binding of)
RN 86120-57-2 CAPLUS
CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(2-propen-1-yloxy)- (CA INDEX NAME)



RN 90047-57-7 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-methyl-6-(2-propen-1-yloxy)- (CA INDEX NAME)

10/598,302



OS.CITING REF COUNT: 4

THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(4 CITINGS)

L27 ANSWER 66 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1983:422340 CAPLUS

DOCUMENT NUMBER: 99:22340

ORIGINAL REFERENCE NO.: 99:3609a,3612a

TITLE: Benzazepines and their application as pharmaceutical preparations

INVENTOR(S): Reiffen, Manfred; Heider, Joachim; Huel, Norbert; Austel, Volkhard; Eberlein, Wolfgang; Kobinger, Walter; Lillie, Christian; Noll, Klaus; Pieper, Helmut; et al.

PATENT ASSIGNEE(S): Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.

SOURCE: Eur. Pat. Appl., 134 pp.

CODEN: EPXXDW



DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 65229	A1	19821124	EP 1982-103931	19820506
EP 65229	B1	19850807		
R: AT, BE, CH, DE, FR, IT, LU, NL, SE				
HU 27405	A2	19831028	HU 1982-1581	19810518
HU 186584	B	19850828		
DE 3119874	A1	19821209	DE 1981-3119874	19810519
AT 14725	T	19850815	AT 1982-103931	19820506
CS 251760	B2	19870813	CS 1982-3456	19820512
SU 1160935	A3	19850607	SU 1982-3435639	19820513
DK 8202223	A	19821120	DK 1982-2223	19820517
DK 156720	B	19890925		
DK 156720	C	19900219		
DD 202872	A5	19831005	DD 1982-239912	19820517
PL 136914	B1	19860430	PL 1982-236474	19820517
FI 77856	B	19890131	FI 1982-1724	19820517
FI 77856	C	19890510		
NO 8201645	A	19821122	NO 1982-1645	19820518
NO 159166	B	19880829		
NO 159166	C	19881207		
AU 8283794	A	19821125	AU 1982-83794	19820518
AU 551509	B2	19860501		
JP 57193462	A	19821127	JP 1982-83915	19820518
JP 01036829	B	19890802		
GB 2099425	A	19821208	GB 1982-14503	19820518
GB 2099425	B	19850206		
ZA 8203413	A	19840125	ZA 1982-3413	19820518
CA 1185239	A1	19850409	CA 1982-403172	19820518
IL 65814	A	19860228	IL 1982-65814	19820518
PRIORITY APPLN. INFO.:			DE 1981-3119874	A 19810519
			EP 1982-103931	A 19820506
OTHER SOURCE(S):	MARPAT 99:22340			
GI				



AB Benzazepines I [R1, R2 independently = OH, C1-3 alkyl or alkoxy, C7-9 phenylalkoxy, R1 ≠ R2 = H; R1R2 = C1-2 alkylenedioxy; R3, R4 independently = H, halo, OH, C1-4 alkyl or alkoxy, CF3, cyano, R2 ≠ R3 = NO2, R3R4 = C1-2 alkylenedioxy; R5 = H, OH, NH2, C1-3 alkyl-containing alkyl, alkoxy, (di)alkylamino, alkanoylamino, (bis)alkoxycarbonylamino, CF3 (un)substituted MeNH or EtNH; R6 = H, C1-3 alkyl-containing alkyl, phenylalkyl, alkanoyl, or alkoxycarbonyl, C3-5 alkenyl; X = CH2CH2, CH:CH, NHCO, CH2CO, CR7:N (NH, CH2, CR7 at 5, R7 = C1-3 alkyl), X1 = CH2, CO; X = COCO, X1 = CH2; Z = C1-3 alkyl (un) substituted, CH2CH2, propylene, or butylene, CH2CH(OH)CH2, 2- or 3-OH substituted butylene; Z1 = C1-3 alkyl (un)substituted CH2, CH2CH2] and their physiol. tolerable acid addition salts, useful in lowering the heart rate, were prepared Successively converting 3,4-(MeO)2C6H3CH2CO2H to 80.8% 3,4-(MeO)2C6H3CH2COCl, amidating with H2NCH2CH(OMe)2 in CH2Cl2 to 95% 3,4-(MeO)2C6H3CH2CONHCH2CH(OMe)2, cyclizing in 17 h at room temperature in HCl-AcOH to 75.4% 7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one, N-alkylating to 87.3% the 3-(3-chloropropyl) derivative with Cl(CH2)3Br and KOCMe3 in Me2SO, and aminolyzing with 3,4-(MeO)2C6H3CH2CH2NHMe in aqueous AcOH at 100° in 3 h gave 70.3% II. At 1.0 mg/kg i.v. in the narcotized cat, II lowered the heart rate 45%.


IT 85176-93-8 85176-96-1

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation as heart rate lowering agent)

RN 85176-93-8 CAPLUS

CN 2H-3-Benzazepin-2-one, 3-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-1,3,4,5-tetrahydro-6,9-dimethoxy-, hydrochloride (1:1) (CA INDEX NAME)


10/598,302



● HCl

RN 85176-96-1 CAPLUS

CN 2H-3-Benzazepin-2-one, 3-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-1,3,4,5-tetrahydro-8,9-dimethoxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

OS.CITING REF COUNT: 5

THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
(6 CITINGS)

L27 ANSWER 67 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1983:47066 CAPLUS

DOCUMENT NUMBER: 98:47066

ORIGINAL REFERENCE NO.: 98:7123a,7126a

TITLE: Affinity chromatography of human platelet
 α 2-adrenergic receptorsAUTHOR(S): Regan, John W.; Barden, Nicholas; Lefkowitz, Robert
J.; Caron, Marc G.; DeMarinis, Robert M.; Krog, Arnold
J.; Holden, Kenneth G.; Matthews, William D.; Hieble,
J. Paul

CORPORATE SOURCE: Med. Cent., Duke Univ., Durham, NC, 27710, USA

SOURCE: Proceedings of the National Academy of Sciences of the
United States of America (1982), '79(23), '7223-7
CODEN: PNASA6; ISSN: 0027-8424

DOCUMENT TYPE: Journal

LANGUAGE: English

AB SKF 101253 is coupled to Sepharose CL-4B by using a bifunctional reagent (1,4-butanediol diglycidyl ether) which also provides a hydrophilic spacer moiety between the ligand and the gel matrix. Membranes from human platelets, containing α 2-adrenergic receptors, can be specifically labeled with [3H]yohimbine and can be solubilized with digitonin without loss of their α 2-adrenergic binding characteristics. Chromatog. of solubilized human platelet membrane preps. on the SKF 101253-Sepharose CL-4B [84137-29-1] affinity gel results in the adsorption of 70-80% of the initial [3H]yohimbine binding activity. Adsorption to the affinity gel is blocked by both α -adrenergic antagonists (phentolamine \geq yohimbine $>$ prazosin) and by α -adrenergic agonists [p-aminoclonidine $>$ (-)-epinephrine $>$ (+)-epinephrine]. Similarly, elution of specific [3H]yohimbine binding activity from the affinity gel is effected with the aforementioned agonists and antagonists in the same order of potency. Other drugs that do not interact appreciably with α -adrenergic receptors, such as (-)-isoproterenol, (-)-alprenolol, atropine, and carbachol, are ineffective for both the blockade of adsorption and the elution of specific [3H]yohimbine binding activity from the affinity gel. In addition to the specificity of the interaction, chromatog. of solubilized human platelet membrane preps. on the SKF 101253-Sepharose CL-4B affinity gel results in a 40-50% overall yield and an .apprx.200-fold increase in the specific binding activity for [3H]yohimbine. The SKF 101253-Sepharose CL-4B affinity adsorbent should provide a powerful tool for the purification of the adenylate cyclase-inhibitory α 2-adrenergic receptor of human platelets.

IT 84137-29-1

RL: BIOL (Biological study)
(as adsorbent, for adrenergic receptors)

RN 84137-29-1 CAPLUS


CN Sepharose CL 4B, 3-[4-[3-[[3-[(9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-6-yl)oxy]propyl]thio]-2-hydroxypropoxy]butoxy]-2-hydroxypropyl ether (9CI) (CA INDEX NAME)

CM 1

CRN 237065-98-4

CMF C24 H40 Cl N O6 S

PAGE 1-A



PAGE 1-B

— OH

CM 2

CRN 61970-08-9



CMF Unspecified

CCI PMS, MAN


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L27 ANSWER 68 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1982:527476 CAPLUS
 DOCUMENT NUMBER: 97:127476
 ORIGINAL REFERENCE NO.: 97:21157a,21160a
 TITLE: New synthesis of some arylthio-substituted
 2,3,4,5-tetrahydro-1H-3-benzazepines
 AUTHOR(S): Ku, Thomas W.; McCarthy, Mary E.; Bondinell, William
 E.; Dandridge, Penelope A.; Girard, Gerald R.; Kaiser,
 Carl
 CORPORATE SOURCE: Smith Kline and French Lab., Philadelphia, PA, 19101,
 USA
 SOURCE: Journal of Organic Chemistry (1982), 47(20), 3862-5
 CODEN: JOCEAH; ISSN: 0022-3263
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB Neuroleptic agent (no data) I was prepared by a multistep synthesis
 involving II (R = Me, R1 = PhS) as key intermediate. The PhS group was
 introduced by phenylsulfenylation of II (R = CO2Et, R1 = H) with PhSCl in
 the presence of ZnCl2 or of II (R = Me, R1 = Br) with Ph2S2.
 IT 73942-96-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and chlorination or S-oxidation of)
 RN 73942-96-8 CAPLUS
 CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7,8-dimethoxy-3-methyl-6-(phenylthio)-
 (CA INDEX NAME)




IT 82614-92-4P 82614-93-5P 82614-94-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and demethylation of)
 RN 82614-92-4 CAPLUS
 CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-7,8-dimethoxy-3-methyl-9-
 (phenylthio)- (CA INDEX NAME)

10/598,302




RN 82614-93-5 CAPLUS

CN 1H-3-Benzazepine, 6-chloro-9-[(4-chlorophenyl)thio]-2,3,4,5-tetrahydro-7,8-dimethoxy-3-methyl- (CA INDEX NAME)



RN 82614-94-6 CAPLUS

CN 1H-3-Benzazepine, 6-chloro-9-[(2,4-dichlorophenyl)thio]-2,3,4,5-tetrahydro-7,8-dimethoxy-3-methyl- (CA INDEX NAME)




IT 73943-27-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and hydride reduction of)

RN 73943-27-8 CAPLUS


CN 3H-3-Benzazepine-3-carboxylic acid,
1,2,4,5-tetrahydro-7,8-dimethoxy-6-(phenylthio)-, ethyl ester (CA INDEX
NAME)

IT 73943-28-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation and reaction with thionyl chloride)


RN 73943-28-9 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7,8-dimethoxy-3-methyl-6-
(phenylsulfinyl)- (CA INDEX NAME)

IT 73943-05-2P 82614-95-7P 82614-96-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 73943-05-2 CAPLUS

CN 1H-3-Benzazepine-7,8-diol, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-
(phenylthio)- (CA INDEX NAME)

RN 82614-95-7 CAPLUS


CN 1H-3-Benzazepine-7,8-diol, 6-chloro-9-[(4-chlorophenyl)thio]-2,3,4,5-
tetrahydro-3-methyl- (CA INDEX NAME)

10/598,302



RN 82614-96-8 CAPLUS

CN 1H-3-Benzazepine-7,8-diol, 6-chloro-9-[(2,4-dichlorophenyl)thio]-2,3,4,5-tetrahydro-3-methyl- (CA INDEX NAME)



OS.CITING REF COUNT:

1

THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L27 ANSWER 69 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1982:520406 CAPLUS

DOCUMENT NUMBER: 97:120406

ORIGINAL REFERENCE NO.: 97:19849a,19852a

TITLE: Interactions of novel dopaminergic ligands with D-1 and D-2 dopamine receptors

AUTHOR(S): Sibley, David R.; Leff, Stuart E.; Creese, Ian

CORPORATE SOURCE: Sch. Med., Univ. California, La Jolla, CA, 92093, USA


SOURCE: Life Sciences (1982), 31(7), 637-45

CODEN: LIFSAK; ISSN: 0024-3205

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB The interactions of 3 novel dopaminergic ligands, SKF38393 (I) [67287-49-4], SKF82526 (II) [67227-56-9], and SKF83742 (III) [73943-42-7], with D-1 and D-2 dopamine (DA) receptors were investigated using radioligand binding techniques and computer modeling procedures. Using the bovine anterior pituitary D-2 DA receptor system, SKF38393 and SKF82526 behaved as agonists demonstrating biphasic agonist/3H-antagonist competition curves. For both drugs, the high-affinity phase comprised 30% of the total displacement curve. Such findings are atypical, as previously tested classical dopamine agonists demonstrated high- and low-affinity displacement phases in equal proportions. In contrast, SKF83742 behaved as an antagonist exhibiting homogeneous monophasic competition curves. Similar results were obtained in the rat striatal membrane D-2 DA receptor system. Both SKF38393 and SKF82526 also demonstrated shallow biphasic displacement curves on rat striatal D-1 receptors labeled with [3H]flupentixol, whereas SKF83742/3H-flupentixol curves were uniphasic. Of all the ligands, only SKF38393 clearly demonstrated higher affinity for [3H]flupentixol labeled D-1 receptors.

IT 73943-42-7


RL: PROC (Process)

(dopaminergic receptor binding of)

RN 73943-42-7 CAPLUS

CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-3-methyl-6-(phenylthio)- (CA INDEX NAME)

10/598,302




OS.CITING REF COUNT:

9

THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD
(9 CITINGS)

L27 ANSWER 70 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1982:180876 CAPLUS
 DOCUMENT NUMBER: 96:180876
 ORIGINAL REFERENCE NO.: 96:29795a,29798a
 TITLE: Spasmolytic agents. I. Amino alcohol esters having a phenethylamine-like moiety
 AUTHOR(S): Kanao, Munefumi; Hashizume, Takeshi; Ichikawa, Yoshifumi; Irie, Kiyoshi; Satoh, Yoshinari; Isoda, Sumiro
 CORPORATE SOURCE: Res. Inst., Daiichi Seiyaku Co., Ltd., Tokyo, 132, Japan
 SOURCE: Chemical & Pharmaceutical Bulletin (1982), 30(1), 180-8
 CODEN: CPBTAL; ISSN: 0009-2363
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB A series of semi-rigid analogs of phenethylamine was prepared as fixed transoid and cisoid analogs of mebeverine, and tested for spasmolytic activity in vitro. The fixed transoid analogs were more potent than the corresponding cisoid analogs. In this series, tetrahydro-2-naphthylamine derivative I, which is presumed to take the transoid conformation, had the most potent activity, and tetrahydroisoquinoline derivs., which are presumed to take typical cisoid conformations, were less active. These results suggested that the phenethylamine moiety of mebeverine takes the transoid conformation for the manifestation of the spasmolytic activity.

IT 81593-58-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 81593-58-0 CAPLUS

CN 1H-3-Benzazepin-1-one, 2,3,4,5-tetrahydro-9-methoxy-3-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD

L27 ANSWER 71 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1981:480765 CAPLUS

DOCUMENT NUMBER: 95:80765

ORIGINAL REFERENCE NO.: 95:13658h,13659a

TITLE: 6-Lower alkyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines

INVENTOR(S): Brush, Charles K.; Weinstock, Joseph

PATENT ASSIGNEE(S): Smithkline Corp., USA

SOURCE: U.S., 10 pp. Cont.-in.-part of U.S. Ser. No. 903,325, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
US 4265889	A	19810505	US 1978-972296	19781222
US 4165372	A	19790821	US 1977-852404	19771117
JP 54081290	A	19790628	JP 1978-139291	19781110
FR 2422641	A1	19791109	FR 1978-32074	19781114
FR 2422641	B1	19830107		
EP 2327	A1	19790613	EP 1978-300633	19781116
EP 2327	B1	19820804		
R: BE, CH, DE, FR, GB, LU, NL, SE				
EP 26505	A1	19810408	EP 1980-200781	19781116
EP 26505	B1	19820915		
R: BE, CH, DE, FR, GB, LU, NL, SE				
GB 2008586	A	19790606	GB 1978-45131	19781117
FR 2415104	A1	19790817	FR 1979-4521	19790222
US 4342686	A	19820803	US 1980-206428	19801113
PRIORITY APPLN. INFO.:			US 1977-852404	A2 19771117
			US 1978-903325	A2 19780505
			US 1978-972296	A3 19781222

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 95:80765; MARPAT 95:80765

GI




AB Benzazepines I (R = C1-6 alkyl; R1 = H, alkyl, alkenyl; R2, R3 = H, alkanoyl; R4 = H, CF₃, halo, Me, MeO, HO, alkanoyloxy, MeS) and their salts were prepared and possessed central dopaminergic-antiparkinsonism and cardiovascular dopaminergic activities. Thus, cyclocondensation of the phenethylamine II in F3CCO₂H containing H₂SO₄ gave the benzazepine III (R₅ = Br, R₆ = H) which was lithiated and treated with HCONMePh to give III (R₅ = CHO, R₆ = H). III (R₅ = R₆ = CHO) underwent consecutive addition reaction with EtLi, chlorination, and reduction to give III (R₅ = Pr, R₆ = CHO). Hydrolysis of the latter and subsequent demethylation gave I (R = Pr, R1-R4 = H) (IV). IV possessed cardiovascular dopaminergic activity in the anesthetized dog with an ED₁₅ of 0.57 µg/kg.

IT 78495-76-8

RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction. of, with methyllithium)

RN 78495-76-8 CAPLUS

CN Acetic acid, 2-[[2,3,4,5-tetrahydro-7,8-dimethoxy-1-phenyl-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-6-yl]oxy]- (CA INDEX NAME)



OS.CITING REF COUNT: 1

THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L27 ANSWER 72 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN


ACCESSION NUMBER: 1981:480764 CAPLUS
 DOCUMENT NUMBER: 95:80764
 ORIGINAL REFERENCE NO.: 95:13655a,13658a
 TITLE: 6-Phenylthio- and
 6-cyclohexylthio-2,3,4,5-tetrahydro-1H-3-benzazepines
 INVENTOR(S): Holden, Kenneth G.; Kaiser, Carl
 PATENT ASSIGNEE(S): Smithkline Corp., USA
 SOURCE: U.S., 12 pp. Cont.-in-part of U.S. Ser. No. 922,613,
 abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4265890	A	19810505	US 1979-39713	19790517
ZA 7902785	A	19800827	ZA 1979-2785	19790605
IL 57532	A	19820831	IL 1979-57532	19790611
JP 55011584	A	19800126	JP 1979-82527	19790628
JP 01053271	B	19891113		
DK 7902783	A	19800108	DK 1979-2783	19790702
DK 156001	B	19890612		
DK 156001	C	19891106		
CS 213381	B2	19820409	CS 1979-4635	19790702
AU 7948613	A	19800207	AU 1979-48613	19790703
AU 525789	B2	19821202		
CA 1115271	A1	19811229	CA 1979-331022	19790703
EP 80012	A1	19830601	EP 1982-105188	19790704
EP 80012	B1	19860409		
R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
AT 19069	T	19860415	AT 1982-105188	19790704
FI 7902125	A	19800108	FI 1979-2125	19790705
FI 67215	B	19841031		
FI 67215	C	19850211		
HU 21669	A2	19820128	HU 1979-SI1705	19790705
HU 179315	B	19820928		
NO 7902267	A	19800108	NO 1979-2267	19790706
NO 152213	B	19850513		
NO 152213	C	19850828		
DD 147355	A5	19810401	DD 1979-214179	19790706
SU 1029827	A3	19830715	SU 1979-2783746	19790706
PRIORITY APPLN. INFO.:				
			US 1978-922613	A2 19780707
			EP 1982-105188	A 19790704


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 95:80764


GI




- AB Benzazepines I (R = Me, allyl, dimethylallyl, PhCH₂CH₂, cyclopropylmethyl, HOCH₂CH₂; R₁ = Ph, F₃CC₆H₄, ClC₆H₄, MeOC₆H₄, MeC₆H₄, FC₆H₄, O₂NC₆H₄, cyclohexyl; R₂ = H, MeO, alkanoyloxy; R₃ = H, Cl, Br, F₃C, F, Me) and their salts were prepared and possessed dopamine receptor blocking, antipsychotic, and antiemetic activities. Thus, cyclocondensation of H₂NCH₂CH(OMe)₂ and 3,4-(MeO)₂C₆H₃CH₂CO₂H gave the oxobenzazepine II, which underwent successive hydrogenation, diborane reduction, and demethylation to give dihydroxybenzazepine III. Treatment of III with dichlorodicyanobenzoquinone gave the corresponding benzazepinedione which condensed with PhSH to give I (R = R₃ = H, R₁ = PhS, R₂ = HO). I (R = Me, R₁ = Ph, R₂ = HO, R₃ = H) possessed antipsychotic activity in the dopamine receptor blocking test in rats with an ED₅₀ of 0.5 mg/kg.
- IT 73973-80-5 78495-55-3
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (antipsychotic activity of)
- RN 73973-80-5 CAPLUS
- CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-3-methyl-6-[[4-(trifluoromethyl)phenyl]thio]- (CA INDEX NAME)




- RN 78495-55-3 CAPLUS
- CN 1H-3-Benzazepine-7,8-diol, 6-[(2-furanylmethyl)thio]-2,3,4,5-tetrahydro-3-methyl- (CA INDEX NAME)



IT 78495-66-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (formylation of)
 RN 78495-66-6 CAPLUS
 CN 1H-3-Benzazepine, 6-bromo-2,3,4,5-tetrahydro-7,8-dimethoxy-3-methyl-9-(phenylthio)- (CA INDEX NAME)




IT 78495-53-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and acetylation of)
 RN 78495-53-1 CAPLUS
 CN 1H-3-Benzazepin-6-amine, 9-chloro-2,3,4,5-tetrahydro-3-methyl- (CA INDEX NAME)



IT 73943-42-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and antipsychotic activity and substitution reactions of)
 RN 73943-42-7 CAPLUS

10/598,302

CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-3-methyl-6-(phenylthio)-
(CA INDEX NAME)




IT 73942-93-5P 73943-05-2P 73943-06-3P
73943-25-6P 73943-30-3P 73943-32-5P
73943-33-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antipsychotic activity of)


RN 73942-93-5 CAPLUS

CN 1H-3-Benzazepine-7,8-diol, 6-(cyclohexylthio)-2,3,4,5-tetrahydro-3-methyl-
(CA INDEX NAME)




RN 73943-05-2 CAPLUS

CN 1H-3-Benzazepine-7,8-diol, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(phenylthio)-
(CA INDEX NAME)




RN 73943-06-3 CAPLUS


CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-3-methyl-6-(2-thienylthio)-
(CA INDEX NAME)




RN 73943-25-6 CAPLUS
 CN 1H-3-Benzazepine-7,8-diol, 6-bromo-2,3,4,5-tetrahydro-3-methyl-9-(phenylthio)- (CA INDEX NAME)



RN 73943-30-3 CAPLUS
 CN 1H-3-Benzazepin-7-ol, 2,3,4,5-tetrahydro-8-methoxy-3-methyl-9-(phenylthio)- (CA INDEX NAME)




RN 73943-32-5 CAPLUS
 CN 1H-3-Benzazepine-7,8-diol, 6-[(4-fluorophenyl)thio]-2,3,4,5-tetrahydro-3-methyl- (CA INDEX NAME)



RN 73943-33-6 CAPLUS

CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-3-methyl-6-[(4-methylphenyl)thio]- (CA INDEX NAME)




IT 73943-28-9P 78495-68-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and chlorination of)

RN 73943-28-9 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7,8-dimethoxy-3-methyl-6-(phenylsulfinyl)- (CA INDEX NAME)




RN 78495-68-8 CAPLUS

CN 1H-3-Benzazepine-6-methanol, 2,3,4,5-tetrahydro-7,8-dimethoxy-3-methyl-9-


(phenylthio)- (CA INDEX NAME)



IT 73943-19-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and deamination of)
 RN 73943-19-8 CAPLUS
 CN 1H-3-Benzazepin-6-amine, 9-chloro-2,3,4,5-tetrahydro-3-methyl-7-nitro-
 (CA INDEX NAME)




IT 73943-29-0P 78495-58-6P 78495-70-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and demethylation of)
 RN 73943-29-0 CAPLUS
 CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-7,8-dimethoxy-3-methyl-9-
 (phenylthio)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 78495-58-6 CAPLUS
 CN 3H-3-Benzazepine-3-ethanol, 1,2,4,5-tetrahydro-7,8-dimethoxy-6-

(phenylthio)- (CA INDEX NAME)



RN 78495-70-2 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7,8-dimethoxy-3,6-dimethyl-9-(phenylthio)- (CA INDEX NAME)




IT 73943-13-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and diazotization-chlorination of)

RN 73943-13-2 CAPLUS

CN 1H-3-Benzazepin-6-amine, 2,3,4,5-tetrahydro-3-methyl-9-(phenylthio)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

IT 78495-57-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydroxyethylation of)

RN 78495-57-5 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7,8-dimethoxy-6-(phenylthio)- (CA INDEX NAME)




IT 73943-15-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and hydroxylation of)

RN 73943-15-4 CAPLUS

CN 1H-3-Benzazepin-7-amine, 2,3,4,5-tetrahydro-3-methyl-6-(phenylthio)- (CA
INDEX NAME)




IT 73943-18-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and nitration of)

RN 73943-18-7 CAPLUS

CN Acetamide, N-(9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-6-yl)-
(CA INDEX NAME)




IT 73942-96-8P 74427-00-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and oxidation of)


RN 73942-96-8 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7,8-dimethoxy-3-methyl-6-(phenylthio)-
(CA INDEX NAME)

10/598,302



RN 74427-00-2 CAPLUS
CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-3-methyl-6-(phenylthio)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

IT 73943-12-1P 73943-27-8P 73943-35-8P
78495-50-8P 78495-60-0P 78495-67-7P
78495-69-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)

RN 73943-12-1 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-methyl-6-nitro-9-(phenylthio)- (CA INDEX NAME)




RN 73943-27-8 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7,8-dimethoxy-6-(phenylthio)-, ethyl ester (CA INDEX NAME)

10/598,302




RN 73943-35-8 CAPLUS

CN 1H-3-Benzazepine, 6-[(4-fluorophenyl)thio]-2,3,4,5-tetrahydro-3-methyl-9-nitro- (CA INDEX NAME)




RN 78495-50-8 CAPLUS

CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-nitro- (CA INDEX NAME)




RN 78495-60-0 CAPLUS


CN Methanone, cyclopropyl[1,2,4,5-tetrahydro-7,8-dimethoxy-6-(phenylthio)-3H-3-benzazepin-3-yl]- (CA INDEX NAME)



RN 78495-67-7 CAPLUS

CN 1H-3-Benzazepine-6-carboxaldehyde,
2,3,4,5-tetrahydro-7,8-dimethoxy-3-methyl-9-(phenylthio)- (CA INDEX NAME)

RN 78495-69-9 CAPLUS


CN 1H-3-Benzazepine, 6-(chloromethyl)-2,3,4,5-tetrahydro-7,8-dimethoxy-3-
methyl-9-(phenylthio)- (CA INDEX NAME)

IT 73943-36-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and reduction-chlorination of)

RN 73943-36-9 CAPLUS

CN 1H-3-Benzazepin-6-amine, 9-[(4-fluorophenyl)thio]-2,3,4,5-tetrahydro-3-
methyl-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

IT 78495-50-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and substitution reactions of, with thiophenols)

RN 78495-50-8 CAPLUS

CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-nitro- (CA INDEX NAME)




IT	73942-89-9P	73942-92-4P	73942-95-7P
	73942-97-9P	73942-99-1P	73943-03-0P
	73943-08-5P	73943-14-3P	73943-17-6P
	73943-21-2P	73943-25-6P	73943-31-4P
	73943-37-0P	73943-39-2P	73954-35-5P
	73954-36-6P	73954-37-7P	73954-39-9P
	73954-40-2P	78495-46-2P	78495-49-5P
	78495-51-9P	78495-52-0P	78495-55-3P
	78495-56-4P	78495-59-7P	78495-61-1P
	78495-62-2P	78495-71-3P	78495-72-4P
	78495-73-5P		

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 73942-89-9 CAPLUS


CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-6-(phenylthio)-, hydrobromide (1:1) (CA INDEX NAME)

10/598,302



● HBr

RN 73942-92-4 CAPLUS
CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-3-methyl-6-(phenylthio)-, hydrobromide (1:1) (CA INDEX NAME)




● HBr

RN 73942-95-7 CAPLUS
CN 1H-3-Benzazepine-7,8-diol, 6-[(4-chlorophenyl)thio]-2,3,4,5-tetrahydro-3-methyl-, (2E)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 73942-94-6
CMF C17 H18 Cl N O2 S




10/598,302

CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 73942-97-9 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7,8-dimethoxy-3-methyl-6-(phenylthio)-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 73942-96-8

CMF C19 H23 N O2 S




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 73942-99-1 CAPLUS


CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-3-methyl-6-(phenylthio)-, diacetate (ester), (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 73942-98-0

CMF C21 H23 N O4 S

10/598,302




CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.



RN 73943-03-0 CAPLUS


CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-6-(phenylthio)-3-(2-propen-1-yl)-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 73943-08-5 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-methyl-6-(phenylthio)- (CA INDEX NAME)



RN 73943-14-3 CAPLUS

CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(phenylthio)-, hydrochloride (1:1) (CA INDEX NAME)

10/598,302




● HCl

RN 73943-17-6 CAPLUS
CN 1H-3-Benzazepin-7-ol, 2,3,4,5-tetrahydro-3-methyl-6-(phenylthio)-, sulfate
(salt) (9CI) (CA INDEX NAME)


CM 1

CRN 73943-16-5
CMF C17 H19 N O S




CM 2

CRN 7664-93-9
CMF H2 O4 S




RN 73943-21-2 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-methyl-8-nitro-6-(phenylthio)- (CA
INDEX NAME)




RN 73943-25-6 CAPLUS

CN 1H-3-Benzazepine-7,8-diol, 6-bromo-2,3,4,5-tetrahydro-3-methyl-9-(phenylthio)- (CA INDEX NAME)



RN 73943-31-4 CAPLUS

CN 1H-3-Benzazepine-7-ol, 2,3,4,5-tetrahydro-8-methoxy-3-methyl-9-(phenylthio)-, 7-acetate, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 73943-37-0 CAPLUS


CN 1H-3-Benzazepine, 6-chloro-9-[(4-fluorophenyl)thio]-2,3,4,5-tetrahydro-3-methyl-, hydrochloride (1:1) (CA INDEX NAME)

10/598,302




● HCl

RN 73943-39-2 CAPLUS
CN 1H-3-Benzazepine, 6-bromo-2,3,4,5-tetrahydro-7,8-dimethoxy-3-methyl-9-(phenylthio)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 73954-35-5 CAPLUS
CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-3-methyl-6-[[3-(trifluoromethyl)phenyl]thio]- (CA INDEX NAME)



10/598,302

RN 73954-36-6 CAPLUS


CN 1H-3-Benzazepine-7,8-diol, 6-(cyclohexylthio)-2,3,4,5-tetrahydro-3-methyl-, 7,8-diacetate, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 73954-37-7 CAPLUS


CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-3-methyl-6-(3-thienylthio)- (CA INDEX NAME)



RN 73954-39-9 CAPLUS


CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-3-methyl-6-[(4-nitrophenyl)thio]- (CA INDEX NAME)

10/598,302



RN 73954-40-2 CAPLUS

CN 1H-3-Benzazepine-7,8-diol, 6-[(4-fluorophenyl)thio]-2,3,4,5-tetrahydro-3-methyl-, 7,8-diacetate (CA INDEX NAME)



RN 78495-46-2 CAPLUS


CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-3-methyl-6-[[4-(trifluoromethyl)phenyl]thio]-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 73973-80-5

CMF C18 H18 F3 N O2 S


10/598,302



CM 2

CRN 110-17-8
CMF C4 H4 O4


Double bond geometry as shown.



RN 78495-49-5 CAPLUS
CN Sulfamic acid, N-cyclohexyl-, compd. with
2,3,4,5-tetrahydro-3-methyl-6-(phenylthio)-1H-3-benzazepine (1:1) (CA
INDEX NAME)

CM 1


CRN 73943-08-5
CMF C17 H19 N S



CM 2


CRN 100-88-9
CMF C6 H13 N O3 S

10/598,302




RN 78495-51-9 CAPLUS

CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(phenylthio)-
(CA INDEX NAME)




RN 78495-52-0 CAPLUS

CN 1H-3-Benzazepin-6-ol, 2,3,4,5-tetrahydro-3-methyl-9-(phenylthio)- (CA
INDEX NAME)



RN 78495-55-3 CAPLUS


CN 1H-3-Benzazepine-7,8-diol, 6-[(2-furanylmethyl)thio]-2,3,4,5-tetrahydro-3-
methyl- (CA INDEX NAME)



RN 78495-56-4 CAPLUS

10/598,302


CN 1H-3-Benzazepine-7,8-diol, 6-(2-furanylthio)-2,3,4,5-tetrahydro-3-methyl-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 78495-59-7 CAPLUS


CN 3H-3-Benzazepine-7,8-diol, 1,2,4,5-tetrahydro-3-(2-hydroxyethyl)-6-(phenylthio)-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 78495-61-1 CAPLUS


CN 1H-3-Benzazepine, 3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-7,8-dimethoxy-6-(phenylthio)- (CA INDEX NAME)



RN 78495-62-2 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7,8-dimethoxy-3-(2-phenylethyl)-6-(phenylthio)- (CA INDEX NAME)

10/598,302




RN 78495-71-3 CAPLUS

CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-3,6-dimethyl-9-(phenylthio)-
(CA INDEX NAME)




RN 78495-72-4 CAPLUS

CN 1H-3-Benzazepin-7-ol, 6-chloro-2,3,4,5-tetrahydro-8-methoxy-3-methyl-9-(phenylthio)- (CA INDEX NAME)



RN 78495-73-5 CAPLUS

CN 1H-3-Benzazepin-7-ol, 6-chloro-2,3,4,5-tetrahydro-8-methoxy-3-methyl-9-(phenylthio)-, 7-acetate (CA INDEX NAME)



OS.CITING REF COUNT:

4


THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(4 CITINGS)

L27 ANSWER 73 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN


ACCESSION NUMBER: 1981:424855 CAPLUS
 DOCUMENT NUMBER: 95:24855
 ORIGINAL REFERENCE NO.: 95:4331a, 4334a
 TITLE: 6-Halo-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines
 INVENTOR(S): Weinstock, Joseph
 PATENT ASSIGNEE(S): Smithkline Corp., USA
 SOURCE: U.S., 9 pp. Cont.-in-part of U.S. 4,160,765.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 8
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4255422	A	19810310	US 1978-893238	19780404
US 4160765	A	19790710	US 1976-742965	19761117
ZA 7705910	A	19780530	ZA 1977-5910	19771004
US 4352754	A	19821005	US 1980-158833	19800612
US 4359464	A	19821116	US 1981-289949	19810804
PRIORITY APPLN. INFO.:			US 1976-742965	A2 19761117
			ZA 1977-5910	A 19771004
			US 1978-893238	A3 19780404
			US 1980-158833	A3 19800612

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
GI




AB The cyclization of N-(2-hydroxy-2-phenylethyl)phenethylamines gave benzazepines I (R = H; R1 = halo, CF3; R2 and R3 are H, alkanoyl; R4 = H, CF3, halo, Me, OMe), which exhibited renal vasodilator and antiparkinsonian properties. A mixture of 2,3,4-Cl(MeO)2C6H2NHCH2CH(OH)Ph, CF3CO2H, and concentrated H2SO4 was refluxed, and the product was demethylated to give I (R = R2 = R3 = R4 = H, R1 = Cl).HBr.
 IT 77969-24-5
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (antiparkinsonian activity of)
 RN 77969-24-5 CAPLUS
 CN 1H-3-Benzazepine-6,7,8-triol, 2,3,4,5-tetrahydro-1-phenyl-, hydrobromide (1:1) (CA INDEX NAME)



● HBr


IT 71636-34-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and antiparkinsonian activity of)
 RN 71636-34-5 CAPLUS
 CN 1H-3-Benzazepine-6,7-diol, 9-chloro-2,3,4,5-tetrahydro-5-phenyl-,
 hydrobromide (1:1) (CA INDEX NAME)



● HBr

IT 62717-83-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and demethylation of)
 RN 62717-83-3 CAPLUS
 CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-8,9-dimethoxy-1-phenyl-,
 hydrochloride (1:1) (CA INDEX NAME)

10/598,302



● HCl

L27 ANSWER 74 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN


ACCESSION NUMBER: 1981:47157 CAPLUS
 DOCUMENT NUMBER: 94:47157
 ORIGINAL REFERENCE NO.: 94:7689a,7692a
 TITLE: Substituted 1,2,4,5-tetrahydro-3H,3 benzazepines
 INVENTOR(S): Shetty, Bola V.
 PATENT ASSIGNEE(S): Pennwalt Corp., USA
 SOURCE: U.S., 30 pp. Division of U.S. Ser. No. 747,151,
 abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4210749	A	19800701	US 1979-41574	19790521
US 4233217	A	19801111	US 1979-41575	19790521
PRIORITY APPLN. INFO.:			US 1968-711897	A1 19680311
			US 1972-241091	A2 19720404
			US 1974-523092	A1 19741112
			US 1976-747151	A3 19761203

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 94:47157

GI




AB Benzazepines I (R = H, alkyl, alkenyl, aralkenyl, cycloalkylalkyl, aralkyl, heterocyclic alkyl; R1 = H, alkyl, Ph, phenylalkyl; R2 = H, alkyl; R3 = H, alkoxy, alkyl, halo, NO2, HO), useful as analgesics and narcotic antagonists, were prepared. Thus, treatment of 3,4-(NCCH2)2C6H3OMe with HBr-AcOH followed by heating at 85° with NaOAc gave II, which was treated with BH3 to give I (R = R1 = R2 = H, R3 = MeO) (III). Refluxing III in 48% HBr gave I (R = R1 = R2 = H, R3 = HO).

IT 76209-79-5P 76209-80-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 76209-79-5 CAPLUS


CN 1H-3-Benzazepin-6-ol, 2,3,4,5-tetrahydro-2-methyl-3-(3-methyl-2-buten-1-yl)-, hydrochloride (1:1) (CA INDEX NAME)

10/598,302



● HCl


RN 76209-80-8 CAPLUS
CN 1H-3-Benzazepin-6-ol, 2,3,4,5-tetrahydro-2-methyl-3-(3-methyl-2-buten-1-yl)- (CA INDEX NAME)




OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
(5 CITINGS)

L27 ANSWER 75 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1981:30546 CAPLUS
 DOCUMENT NUMBER: 94:30546
 ORIGINAL REFERENCE NO.: 94:5035a,5038a
 TITLE: 6,9-Dimethoxy-2-oxo-2,3,4,5-tetrahydro-1H-3-benzazepine
 AUTHOR(S): Tatevosyan, G. T.; Durgaryan, A. K.
 CORPORATE SOURCE: USSR
 SOURCE: Sintezy Geterotsiklicheskikh Soedinenii (1979), 11, 66-7
 CODEN: SGSAAQ; ISSN: 0583-4325
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 GI



AB The title benzazepine was prepared in 49.9-57.1% yield by heating I (R = SO₂C₆H₄Me-4) (II) in an autoclave. II was obtained in 83.3-90.9% yield by treatment of I (R = H) with 4-MeC₆H₄SO₂Cl. I (R = H) was obtained in 74.4-93.0% yield from the resp. ketone.
 IT 50525-85-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 50525-85-4 CAPLUS
 CN 2H-3-Benzazepin-2-one, 1,3,4,5-tetrahydro-6,9-dimethoxy- (CA INDEX NAME)



L27 ANSWER 76 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1980:639189 CAPLUS

DOCUMENT NUMBER: 93:239189

ORIGINAL REFERENCE NO.: 93:38307a,38310a

TITLE: Benzolactams. II. Synthesis of tetrahydrobenz[d]indeno[1,2-b]azepines and their 12-oxo derivatives

AUTHOR(S): Orito, Kazuhiko; Kaga, Harumi; Itoh, Mitsuomi; De

CORPORATE SOURCE: Silva, S. Osmund; Manske, Richard H.; Rodrigo, Russel
Dep. Chem. Process Eng., Hokkaido Univ., Sapporo, 060,
Japan


SOURCE: Journal of Heterocyclic Chemistry (1980), 17(3), 417-23

CODEN: JHTCAD; ISSN: 0022-152X

DOCUMENT TYPE: Journal

LANGUAGE: English


GI



AB The benzindenoazepines I (R-R3 = MeO; R = R1 = MeO, R2R3 = methylenedioxy; RR1 = methylenedioxy, R2 = R3 = MeO; RR1 = R2R3 = methylenedioxy; X = H2, O) were prepared by two types of intramol. dehydrative cyclizations. N-Methyl-N-β-phenethylacetamides were cyanomethylated in the two-step process of chloromethylation and treatment of the resultant benzyl chlorides with NaCN. The condensation of the benzyl cyanides with the appropriate benzaldehydes, followed by reduction of the benzylidene function, gave α,β-diphenylpropionitriles II. Successive hydrolysis to the amino acids and the thermal cyclization converted I to the benzylbenzazepinones III, which were also prepared by benzylation of the corresponding benzazepinones. Heating of III with POCl3 gave I (X = H2). I (X = H2) underwent autoxidn. to the I (X = O) on exposure to O in the presence of Triton B.

10/598,302

IT 75428-30-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and reaction with benzyl bromides)
RN 75428-30-7 CAPLUS
CN 2H-3-Benzazepin-2-one, 1,3,4,5-tetrahydro-7,8,9-trimethoxy-3-methyl- (CA
INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(5 CITINGS)

L27 ANSWER 77 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1980:620611 CAPLUS

DOCUMENT NUMBER: 93:220611

ORIGINAL REFERENCE NO.: 93:35222h,35223a

TITLE: Alkylthio-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines having dopaminergic activity

INVENTOR(S): Holden, Kenneth G.

PATENT ASSIGNEE(S): Smithkline Corp., USA

SOURCE: U.S., 8 pp. Cont.-in-part of U.S. Ser. No. 760,500, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
US 4206210	A	19800603	US 1978-912131	19780602
ZA 7707444	A	19781025	ZA 1977-7444	19771214
GB 1597911	A	19810916	GB 1978-953	19780110
GB 1597912	A	19810916	GB 1978-20952	19780110
BE 862878	A1	19780713	BE 1978-184290	19780113
FR 2378017	A1	19780818	FR 1978-998	19780113
FR 2378017	B1	19810710		
DK 7800199	A	19780720	DK 1978-199	19780116
SE 7800455	A	19780720	SE 1978-455	19780116
SE 437265	B	19850218		
SE 437265	C	19850606		
AU 7832465	A	19790726	AU 1978-32465	19780116
AU 510459	B2	19800626		
CA 1090334	A1	19801125	CA 1978-294973	19780116
NL 7800637	A	19780721	NL 1978-637	19780118
JP 53090281	A	19780808	JP 1978-4769	19780118
JP 60040423	B	19850911		
HU 175836	B	19801028	HU 1978-SI1612	19780118
CH 642634	A5	19840430	CH 1978-525	19780118
FR 2384759	A1	19781020	FR 1978-16583	19780602
FR 2384759	B1	19800718		
AU 8057822	A	19800731	AU 1980-57822	19800424
AU 516608	B2	19810611		
CH 640228	A5	19831230	CH 1982-3573	19820609
PRIORITY APPLN. INFO.:			US 1977-760500	A2 19770119
			GB 1978-953	A 19780110
			CH 1978-525	A 19780118

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 93:220611

GI




AB The benzodiazepines I (R = H, alkylthio, alkylsulfinyl, alkylsulfonyl, F3CS, F3CSO, F3SO2; R1 = H, alkyl, C3-5 alkenyl; R2 = H, halo, F3C, MeO, HO; R3 = H, alkylthio) were prepared. Thus, I.HBr (R-R3 = H) was oxidized to the dione, which was treated with MeSH to give 11% I (R = MeS, R1-R3 = H) and 22% I (R-R2 = H, R3 = MeS). The dopaminergic ED15 of I (R = MeS, R1-R3 = H) was 372 mg/kg. I had antiparkinsonism activity.

IT 67942-28-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and dopaminergic activity of)

RN 67942-28-3 CAPLUS

CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-6-(methylthio)-1-phenyl-, hydrobromide (1:1) (CA INDEX NAME)




● HBr


IT 75510-71-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)

RN 75510-71-3 CAPLUS


CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7,8-dihydroxy-6-(methylsulfonyl)-1-phenyl-, phenylmethyl ester (CA INDEX NAME)



IT 75510-69-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and methylation of)
 RN 75510-69-9 CAPLUS
 CN Ethanone, 2,2,2-trifluoro-1-[1,2,4,5-tetrahydro-7,8-dihydroxy-6-(methylthio)-1-phenyl-3H-3-benzazepin-3-yl]- (CA INDEX NAME)



IT 67942-30-7P 67942-31-8P 69213-57-6P
 75510-62-2P 75510-63-3P 75510-68-8P
 75510-70-2P 75510-72-4P 75510-73-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 67942-30-7 CAPLUS
 CN 1H-3-Benzazepine-7,8-diol, 9-(butylthio)-2,3,4,5-tetrahydro-1-phenyl-, hydrobromide (1:1) (CA INDEX NAME)




● HBr

RN 67942-31-8 CAPLUS
 CN 1H-3-Benzazepine-7,8-diol, 6-(butylthio)-2,3,4,5-tetrahydro-1-phenyl-,

10/598,302


hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 69213-57-6 CAPLUS


CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-9-(methylthio)-1-phenyl-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 75510-62-2 CAPLUS

CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-6-[(1-methylethyl)thio]-, hydrobromide (1:1) (CA INDEX NAME)




● HBr

RN 75510-63-3 CAPLUS

CN 1H-3-Benzazepine-7,8-diol, 6-(ethylthio)-2,3,4,5-tetrahydro-, hydrobromide (1:1) (CA INDEX NAME)


10/598,302



● HBr


RN 75510-68-8 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7,8-dimethoxy-6-(methylthio)-1-phenyl-
(CA INDEX NAME)



RN 75510-70-2 CAPLUS

CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-6-(methylsulfonyl)-1-phenyl-
, hydrobromide (1:1) (CA INDEX NAME)




● HBr

RN 75510-72-4 CAPLUS


CN Ethanone, 2,2,2-trifluoro-1-[1,2,4,5-tetrahydro-7,8-dimethoxy-6-(methylthio)-1-phenyl-3H-3-benzazepin-3-yl]- (CA INDEX NAME)

10/598,302



RN 75510-73-5 CAPLUS

CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-6-(methylsulfinyl)-1-phenyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

OS.CITING REF COUNT: 3

THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)

L27 ANSWER 78 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1980:542668 CAPLUS

DOCUMENT NUMBER: 93:142668

ORIGINAL REFERENCE NO.: 93:22555a,22558a

TITLE: 6-(Phenylthio)-substituted
2,3,4,5-tetrahydro-1H-3-benzazepines, a novel class of
dopamine receptor antagonists and neuroleptics

AUTHOR(S): Kaiser, Carl; Ali, Fadia E.; Bondinell, William E.;
Brenner, Martin; Holden, Kenneth G.; Ku, Thomas W.;
Oh, Hye-Ja; Ross, Stephen T.; Yim, Nelson C. F.; et
al.

CORPORATE SOURCE: Smith Kline and French Lab., Philadelphia, PA, 19101,
USA

SOURCE: Journal of Medicinal Chemistry (1980), 23(9), 975-6


CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 93:142668

GI



AB Potent and selective dopamine [51-61-6] receptor antagonist and
neuroleptic activities were observed in 3 title compds. I (R = H or Cl, R1 =
H or Me. I are unique dopamine receptor antagonists because they
incorporate the structural features of the biogenic amine. The
neuroleptic potency of I (R = H, R1 = Me, ·HBr) [73942-92-4]
in rats and dopamine receptor antagonist activity were
enhanced by introduction of a 9-Cl substituent but decreased by
N-demethylation.

IT 73942-89-9P 73942-92-4P 73943-05-2P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and dopamine receptor antagonist and neuroleptic activity of)

RN 73942-89-9 CAPLUS


CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-6-(phenylthio)-,
hydrobromide (1:1) (CA INDEX NAME)

10/598,302




● HBr

RN 73942-92-4 CAPLUS
CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-3-methyl-6-(phenylthio)-,
hydrobromide (1:1) (CA INDEX NAME)




● HBr

RN 73943-05-2 CAPLUS
CN 1H-3-Benzazepine-7,8-diol, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(
phenylthio)- (CA INDEX NAME)




IT 73943-42-7P 74427-00-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 73943-42-7 CAPLUS
CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-3-methyl-6-(phenylthio)-
(CA INDEX NAME)

10/598,302



RN 74427-00-2 CAPLUS

CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-3-methyl-6-(phenylthio)-,
hydrochloride (1:1) (CA INDEX NAME)





● HCl

OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
(5 CITINGS)

L27 ANSWER 79 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1980:446454 CAPLUS
 DOCUMENT NUMBER: 93:46454
 ORIGINAL REFERENCE NO.: 93:7671a, 7674a
 TITLE: Substituted 1-thienyl- and
 furyl-2,3,4,5-tetrahydro-1H-3-benzazepine derivatives
 with cardiovascular activity
 PATENT ASSIGNEE(S): Smithkline Corp., USA
 SOURCE: Neth. Appl., 34 pp.
 CODEN: NAXXAN
 DOCUMENT TYPE: Patent
 LANGUAGE: Dutch
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
NL 7807819	A	19800123	NL 1978-7819	19780721
PRIORITY APPLN. INFO.: GI			NL 1978-7819	19780721



AB Benzazepines I (R = H, CH₂Ph, CH₂CH₂Ph, acyl, alkyl, alkenyl, CH₂CH₂OH; R₁ = H, halogen, CF₃, SMe, SCF₃, Me, OMe; R₂, R₃ = H, alkyl, alkanoyl; R₂R₃ = CH₂, CH₂CH₂; R₄ = optionally substituted thienyl, furyl) were prepared. Thus 2-formylthiophene was treated with trimethylsulfonium iodide to give 2-oxiranylthiophene which was treated with homoveratrylamine to give II. Cyclization of II with acid gave I (R = R₁ = H, R₂ = R₃ = Me, R₄ = 2-thienyl). Demethylation of the latter compound gave I (R-R₃ = H, R₄ = 2-thienyl), which at 30 mg/kg in dogs caused a 30% decrease in renal blood vessel resistance. I also have antihypertensive, anti-Parkinson, and diuretic activity.


IT 68277-64-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 68277-64-5 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-6-(methylthio)-1-(2-thienyl)-,
 hydrobromide (1:1) (CA INDEX NAME)

10/598,302




● HBr

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L27 ANSWER 80 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1980:426300 CAPLUS
 DOCUMENT NUMBER: 93:26300
 ORIGINAL REFERENCE NO.: 93:4413a,4416a
 TITLE: 2,3,4,5-Tetrahydro-1H-3-benzazepines and
 pharmaceutical compositions having dopamine receptor
 blocking activity
 INVENTOR(S): Holden, Kenneth George; Kaiser, Carl
 PATENT ASSIGNEE(S): Smithkline Corp., USA
 SOURCE: Eur. Pat. Appl., 44 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 7070	A1	19800123	EP 1979-102279	19790704
EP 7070	B1	19830119		
R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
ZA 7902785	A	19800827	ZA 1979-2785	19790605
IL 57532	A	19820831	IL 1979-57532	19790611
JP 55011584	A	19800126	JP 1979-82527	19790628
JP 01053271	B	19891113		
DK 7902783	A	19800108	DK 1979-2783	19790702
DK 156001	B	19890612		
DK 156001	C	19891106		
CS 213381	B2	19820409	CS 1979-4635	19790702
AU 7948613	A	19800207	AU 1979-48613	19790703
AU 525789	B2	19821202		
CA 1115271	A1	19811229	CA 1979-331022	19790703
AT 2267	T	19830215	AT 1979-102279	19790704
EP 80012	A1	19830601	EP 1982-105188	19790704
EP 80012	B1	19860409		
R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
AT 19069	T	19860415	AT 1982-105188	19790704
FI 7902125	A	19800108	FI 1979-2125	19790705
FI 67215	B	19841031		
FI 67215	C	19850211		
HU 21669	A2	19820128	HU 1979-SI1705	19790705
HU 179315	B	19820928		
NO 7902267	A	19800108	NO 1979-2267	19790706
NO 152213	B	19850513		
NO 152213	C	19850828		
DD 147355	A5	19810401	DD 1979-214179	19790706
SU 1029827	A3	19830715	SU 1979-2783746	19790706
PRIORITY APPLN. INFO.:				
			US 1978-922613	19780707
			EP 1979-102279	A 19790704
			EP 1982-105188	A 19790704
OTHER SOURCE(S): MARPAT 93:26300				
GI				




AB Tetrahydrobenzazepines I (R = Me, allyl, dimethylallyl, PhCH₂CH₂, cyclopropylmethyl, HOCH₂CH₂; R₁ = optionally Ph, cyclohexyl, thienyl, thienylmethyl, furyl, furylmethyl; R₂ = H, OMe, OH, alkanoyloxy; R₃ = H, Cl, Br, CF₃, F, Me) were prepared. Thus H₂NCH₂CH(OMe)₂ was treated with 3,4-(MeO)₂C₆H₃CH₂CO₂H and the resulting amide cyclized to 2,3-dihydro-7,8-dimethoxy-3-benzazepin-2(1H)-one which was reduced in 2 steps to 7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepine (II). II was reductively methylated with CH₂O to give 3-Me derivs. which was demethylated to the 7,8-diol and oxidized to 3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-dione. The dione was treated with PhSH-MeOH to give I (R = Me, R₁ = Ph, R₂ = OH, R₃ = H) which had a ED₅₀ of 0.5 mg/kg i.p. in the avoidance test in rats.

IT 73943-32-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and acetylation of)

RN 73943-32-5 CAPLUS

CN 1H-3-Benzazepine-7,8-diol, 6-[(4-fluorophenyl)thio]-2,3,4,5-tetrahydro-3-methyl- (CA INDEX NAME)




IT 73943-28-9P 73954-38-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and chlorination of)

RN 73943-28-9 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7,8-dimethoxy-3-methyl-6-(phenylsulfinyl)- (CA INDEX NAME)




RN 73954-38-8 CAPLUS

CN 1H-3-Benzazepine-6-diazonium, 2,3,4,5-tetrahydro-3-methyl-9-(phenylthio)-
(CA INDEX NAME)

IT 73943-29-0P 73943-39-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and demethylation of)


RN 73943-29-0 CAPLUS

CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-7,8-dimethoxy-3-methyl-9-
(phenylthio)-, hydrochloride (1:1) (CA INDEX NAME)

● HCl


RN 73943-39-2 CAPLUS

CN 1H-3-Benzazepine, 6-bromo-2,3,4,5-tetrahydro-7,8-dimethoxy-3-methyl-9-
(phenylthio)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

IT 73943-15-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and diazotization and hydrolysis of)
 RN 73943-15-4 CAPLUS
 CN 1H-3-Benzazepin-7-amine, 2,3,4,5-tetrahydro-3-methyl-6-(phenylthio)- (CA INDEX NAME)




IT 73943-13-2P 73943-19-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and diazotization of)
 RN 73943-13-2 CAPLUS
 CN 1H-3-Benzazepin-6-amine, 2,3,4,5-tetrahydro-3-methyl-9-(phenylthio)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 73943-19-8 CAPLUS
 CN 1H-3-Benzazepin-6-amine, 9-chloro-2,3,4,5-tetrahydro-3-methyl-7-nitro-

(CA INDEX NAME)




IT 73942-92-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and methylation of)

RN 73942-92-4 CAPLUS

CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-3-methyl-6-(phenylthio)-, hydrobromide (1:1) (CA INDEX NAME)




● HBr

IT 73943-18-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and nitration of)

RN 73943-18-7 CAPLUS

CN Acetamide, N-(9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-6-yl)- (CA INDEX NAME)




IT 73942-96-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and oxidation of)

RN 73942-96-8 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7,8-dimethoxy-3-methyl-6-(phenylthio)-
(CA INDEX NAME)

IT 73943-12-1P 73943-27-8P 73943-35-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation and reduction of)

RN 73943-12-1 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-methyl-6-nitro-9-(phenylthio)- (CA
INDEX NAME)

RN 73943-27-8 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
1,2,4,5-tetrahydro-7,8-dimethoxy-6-(phenylthio)-, ethyl ester (CA INDEX
NAME)

RN 73943-35-8 CAPLUS

CN 1H-3-Benzazepine, 6-[(4-fluorophenyl)thio]-2,3,4,5-tetrahydro-3-methyl-9-
nitro- (CA INDEX NAME)




IT 73943-05-2P 73943-06-3P 73943-08-5P
 73943-25-6P 73943-33-6P 73943-34-7P
 73943-42-7P 73954-39-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and tranquilizing activity of)


RN 73943-05-2 CAPLUS

CN 1H-3-Benzazepine-7,8-diol, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(phenylthio)- (CA INDEX NAME)




RN 73943-06-3 CAPLUS

CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-3-methyl-6-(2-thienylthio)- (CA INDEX NAME)




RN 73943-08-5 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-methyl-6-(phenylthio)- (CA INDEX NAME)




RN 73943-25-6 CAPLUS
 CN 1H-3-Benzazepine-7,8-diol, 6-bromo-2,3,4,5-tetrahydro-3-methyl-9-(phenylthio)- (CA INDEX NAME)




RN 73943-33-6 CAPLUS
 CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-3-methyl-6-[(4-methylphenyl)thio]- (CA INDEX NAME)




RN 73943-34-7 CAPLUS
 CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-3-methyl-6-[(2-thienylmethyl)thio]- (CA INDEX NAME)



RN 73943-42-7 CAPLUS

CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-3-methyl-6-(phenylthio)-
(CA INDEX NAME)

RN 73954-39-9 CAPLUS

CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-3-methyl-6-[(4-nitrophenyl)thio]-
(CA INDEX NAME)


IT	73942-89-9P	73942-95-7P	73942-97-9P
	73942-99-1P	73943-03-0P	73943-09-6P
	73943-14-3P	73943-17-6P	73943-21-2P
	73943-25-6P	73943-31-4P	73943-37-0P
	73954-35-5P	73954-36-6P	73954-37-7P
	73954-40-2P	73973-80-5P	

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 73942-89-9 CAPLUS

10/598,302

CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-6-(phenylthio)-,
hydrobromide (1:1) (CA INDEX NAME)



● HBr


RN 73942-95-7 CAPLUS

CN 1H-3-Benzazepine-7,8-diol, 6-[(4-chlorophenyl)thio]-2,3,4,5-tetrahydro-3-
methyl-, (2E)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 73942-94-6

CMF C17 H18 Cl N O2 S




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 73942-97-9 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7,8-dimethoxy-3-methyl-6-(phenylthio)-,
, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

10/598,302

CM 1

CRN 73942-96-8

CMF C19 H23 N O2 S




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 73942-99-1 CAPLUS

CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-3-methyl-6-(phenylthio)-, diacetate (ester), (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 73942-98-0

CMF C21 H23 N O4 S




CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.



10/598,302

RN 73943-03-0 CAPLUS
CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-6-(phenylthio)-3-(2-propen-1-yl)-, hydrobromide (1:1) (CA INDEX NAME)




● HBr

RN 73943-09-6 CAPLUS
CN Cyclohexanesulfonamide, compd. with
2,3,4,5-tetrahydro-3-methyl-6-(phenylthio)-1H-3-benzazepine (1:1) (CA INDEX NAME)


CM 1

CRN 73943-08-5
CMF C17 H19 N S




CM 2

CRN 2438-38-2
CMF C6 H13 N O2 S



RN 73943-14-3 CAPLUS
CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(phenylthio)-, hydrochloride (1:1) (CA INDEX NAME)

10/598,302




● HCl

RN 73943-17-6 CAPLUS
CN 1H-3-Benzazepin-7-ol, 2,3,4,5-tetrahydro-3-methyl-6-(phenylthio)-, sulfate
(salt) (9CI) (CA INDEX NAME)


CM 1

CRN 73943-16-5
CMF C17 H19 N O S




CM 2


CRN 7664-93-9
CMF H2 O4 S




RN 73943-21-2 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-methyl-8-nitro-6-(phenylthio)- (CA
INDEX NAME)



RN 73943-25-6 CAPLUS
 CN 1H-3-Benzazepine-7,8-diol, 6-bromo-2,3,4,5-tetrahydro-3-methyl-9-(phenylthio)- (CA INDEX NAME)




RN 73943-31-4 CAPLUS
 CN 1H-3-Benzazepine-7-ol, 2,3,4,5-tetrahydro-8-methoxy-3-methyl-9-(phenylthio)-, 7-acetate, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 73943-37-0 CAPLUS
 CN 1H-3-Benzazepine, 6-chloro-9-[(4-fluorophenyl)thio]-2,3,4,5-tetrahydro-3-methyl-, hydrochloride (1:1) (CA INDEX NAME)


10/598,302



● HCl

RN 73954-35-5 CAPLUS


CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-3-methyl-6-[[3-(trifluoromethyl)phenyl]thio]- (CA INDEX NAME)



RN 73954-36-6 CAPLUS


CN 1H-3-Benzazepine-7,8-diol, 6-(cyclohexylthio)-2,3,4,5-tetrahydro-3-methyl-, 7,8-diacetate, hydrobromide (1:1) (CA INDEX NAME)

10/598,302




● HBr

RN 73954-37-7 CAPLUS
CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-3-methyl-6-(3-thienylthio)-
(CA INDEX NAME)




RN 73954-40-2 CAPLUS
CN 1H-3-Benzazepine-7,8-diol, 6-[(4-fluorophenyl)thio]-2,3,4,5-tetrahydro-3-methyl-, 7,8-diacetate (CA INDEX NAME)




RN 73973-80-5 CAPLUS
CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-3-methyl-6-[[4-


(trifluoromethyl)phenyl]thio]- (CA INDEX NAME)



IT 73942-93-5P 73943-30-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation, acetylation, and tranquilizing activity of)
 RN 73942-93-5 CAPLUS
 CN 1H-3-Benzazepine-7,8-diol, 6-(cyclohexylthio)-2,3,4,5-tetrahydro-3-methyl-
 (CA INDEX NAME)




RN 73943-30-3 CAPLUS
 CN 1H-3-Benzazepin-7-ol, 2,3,4,5-tetrahydro-8-methoxy-3-methyl-9-(phenylthio)-
 (CA INDEX NAME)



IT 73943-36-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation, diazotization of, and chlorination of)
 RN 73943-36-9 CAPLUS

10/598,302

CN 1H-3-Benzazepin-6-amine, 9-[(4-fluorophenyl)thio]-2,3,4,5-tetrahydro-3-methyl-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

OS.CITING REF COUNT:

4

THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(4 CITINGS)

L27 ANSWER 81 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1979:593199 CAPLUS
 DOCUMENT NUMBER: 91:193199
 ORIGINAL REFERENCE NO.: 91:31115a,31118a
 TITLE: 6-Bromination of
 1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine compounds
 INVENTOR(S): Weinstock, Joseph
 PATENT ASSIGNEE(S): Smithkline Corp., USA
 SOURCE: U.S., 10 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 8
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4160765	A	19790710	US 1976-742965	19761117
ZA 7705910	A	19780530	ZA 1977-5910	19771004
GB 1595502	A	19810812	GB 1977-46184	19771107
GB 1595503	A	19810812	GB 1980-20951	19771107
CA 1092107	A1	19801223	CA 1977-290593	19771110
DK 7705004	A	19780518	DK 1977-5004	19771111
DK 156057	B	19890619		
DK 156057	C	19891113		
RO 72905	A1	19811104	RO 1977-92097	19771111
BE 860774	A1	19780516	BE 1977-182575	19771114
NO 7703901	A	19780519	NO 1977-3901	19771114
NO 147029	B	19821011		
NO 147029	C	19830119		
AU 7730626	A	19790524	AU 1977-30626	19771114
AU 509754	B2	19800522		
IL 53377	A	19820930	IL 1977-53377	19771114
FI 7703448	A	19780518	FI 1977-3448	19771115
FI 67374	B	19841130		
FI 67374	C	19850311		
NL 7712567	A	19780519	NL 1977-12567	19771115
NL 185563	B	19891218		
NL 185563	C	19900516		
FR 2371430	A1	19780616	FR 1977-34311	19771115
FR 2371430	B1	19800627		
AT 7708163	A	19801015	AT 1977-8163	19771115
AT 362379	B	19810511		
SE 7712944	A	19780518	SE 1977-12944	19771116
SE 436646	B	19850114		
SE 436646	C	19850425		
DE 2751258	A1	19780601	DE 1977-2751258	19771116
DE 2751258	C2	19900104		
JP 53063335	A	19780606	JP 1977-138410	19771116
JP 62025658	B	19870604		
DD 133563	A5	19790110	DD 1977-202113	19771116
PL 109672	B1	19800630	PL 1977-202177	19771116
HU 18950	A2	19801028	HU 1977-SI1605	19771116
HU 176709	B	19810428		
SU 976847	A3	19821123	SU 1977-2544154	19771116
CS 219333	B2	19830325	CS 1977-7593	19771117
US 4197297	A	19800408	US 1978-885823	19780313

US 4192872	A	19800311	US 1978-892063	19780331
US 4255422	A	19810310	US 1978-893238	19780404
IN 150172	A1	19820407	IN 1978-DE790	19781103
US 4321195	A	19820323	US 1979-41661	19790523
US 4251525	A	19810217	US 1979-42680	19790525
US 4352754	A	19821005	US 1980-158833	19800612
US 4359464	A	19821116	US 1981-289949	19810804
DK 8105086	A	19811117	DK 1981-5086	19811117
DK 156058	B	19890619		
DK 156058	C	19891113		
CH 635079	A5	19830315	CH 1982-210	19820114
JP 58113153	A	19830705	JP 1982-222834	19821218
JP 61025697	B	19860617		
FI 8304519	A	19831209	FI 1983-4519	19831209
FI 75800	B	19880429		
FI 75800	C	19880808		
JP 62155218	A	19870710	JP 1986-199885	19860825
JP 63066808	B	19881222		

PRIORITY APPLN. INFO.:

US 1976-742965	A	19761117
ZA 1977-5910	A	19771004
GB 1977-46184	A	19771107
DK 1977-5004	A	19771111
FI 1977-3448	A	19771115
CH 1977-14010	A	19771116
US 1978-885823	A3	19780313
US 1978-893238	A3	19780404
US 1980-158833	A3	19800612

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 91:193199


AB The treatment of a 7,8-dimethoxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine with Br₂ in HOAc at room temperature gave the resp. 6-bromo-7,8-dimethoxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide; some of the compds. prepared showed diuretic and antiparkinsonism activity (no data). Thus, Br₂ was added to 7,8-dimethoxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine in HOAc and the mixture was agitated 2 h to yield 6-bromo-7,8-dimethoxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide.

IT 62717-83-3P 71636-33-4P 71636-34-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 62717-83-3 CAPLUS

CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-8,9-dimethoxy-1-phenyl-, hydrochloride (1:1) (CA INDEX NAME)


10/598,302



● HCl


RN 71636-33-4 CAPLUS

CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-8,9-dimethoxy-1-phenyl- (CA INDEX NAME)



RN 71636-34-5 CAPLUS

CN 1H-3-Benzazepine-6,7-diol, 9-chloro-2,3,4,5-tetrahydro-5-phenyl-, hydrobromide (1:1) (CA INDEX NAME)



● HBr


OS.CITING REF COUNT: 6

THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD
(6 CITINGS)

L27 ANSWER 82 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN


ACCESSION NUMBER: 1979:121445 CAPLUS
 DOCUMENT NUMBER: 90:121445
 ORIGINAL REFERENCE NO.: 90:19223a,19226a
 TITLE: 2,3,4,5-Tetrahydro-1H-3-benzazepine-7,8-diones
 INVENTOR(S): Holden, Kenneth George
 PATENT ASSIGNEE(S): Smithkline Corp., USA
 SOURCE: U.S., 8 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4108989	A	19780822	US 1977-783574	19770401
US 4172890	A	19791030	US 1978-904823	19780511
PRIORITY APPLN. INFO.:			US 1977-783574	A3 19770401
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S):		MARPAT 90:121445		
GI				



AB Benzazepinediones I [R = H, halo; R1 = C1-C5 alkyl or alkanoyl, PhCH2, PhCH2CH2, CO2CH2Ph, HOCH2CH2; R2 = (un)substituted phenyl] or their salts having dopaminergic activity (no data) were prepared Thus, I.HBr (R = R1 = H, R2 = Ph) was prepared by oxidation of the 7,8-dihydroxy compound with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone in MeOH. Approx. 15 other I were similarly prepared The starting diols are prepared by known methods.
 IT 67942-28-3P 69213-57-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 67942-28-3 CAPLUS
 CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-6-(methylthio)-1-phenyl-, hydrobromide (1:1) (CA INDEX NAME)


10/598,302



● HBr

RN 69213-57-6 CAPLUS

CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-9-(methylthio)-1-phenyl-,
hydrobromide (1:1) (CA INDEX NAME)




● HBr

L27 ANSWER 83 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1978:597353 CAPLUS
 DOCUMENT NUMBER: 89:197353
 ORIGINAL REFERENCE NO.: 89:30671a,30674a
 TITLE: 1-Thienyl- and
 1-furyl-2,3,4,5-tetrahydro-1H-3-benzazepines
 INVENTOR(S): Holden, Kenneth George; Yim, Nelson Chia Fai
 PATENT ASSIGNEE(S): Smithkline Corp., USA
 SOURCE: Ger. Offen., 31 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2804285	A1	19780803	DE 1978-2804285	19780201
DE 2804285	C2	19880107		
US 4111957	A	19780905	US 1977-764672	19770202
GB 1599705	A	19811007	GB 1978-2628	19780123
FR 2379534	A1	19780901	FR 1978-2275	19780127
FR 2379534	B1	19811127		
JP 53095989	A	19780822	JP 1978-9812	19780130
JP 63041912	B	19880819		
US 4187314	A	19800205	US 1978-909073	19780524
IL 54975	A	19821231	IL 1978-54975	19780622
CH 636871	A5	19830630	CH 1978-7339	19780705
FR 2383929	A1	19781013	FR 1978-20342	19780707
FR 2383929	B1	19810731		
JP 62161764	A	19870717	JP 1986-288630	19861203
PRIORITY APPLN. INFO.:			US 1977-764672	A 19770202
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S): CASREACT 89:197353; MARPAT 89:197353				
GI				



AB The title compds. I (R = H, C1-5 alkyl or alkanoyl, C3-5 alkenyl, OH, PhCH₂, PhCH₂CH₂; R1 = H, halo, CF₃, Me, MeO, MeS, F₃CS; R2 = R3 = H, lower alkyl or alkanoyl; R2R3 = CH₂, CH₂CH₂; R4 = H, halo, CH₂CN, Me, CO₂Me; X = O, S) were prepared for use as pharmaceuticals. Thus, treating


homoveratrylamine with 2-epoxyethylthiophene, and then cyclizing in HCl-HOAc gave 96% I (R = R1 = R4 = H, R2 = R3 = Me, X = S, 2-thienyl). I are useful as renal vasodilators, diuretics, and anti-Parkinson's agents (animal tests described).

IT 68277-64-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and formylation of)

RN 68277-64-5 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-6-(methylthio)-1-(2-thienyl)-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)

L27 ANSWER 84 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1978:579872 CAPLUS

DOCUMENT NUMBER: 89:179872

ORIGINAL REFERENCE NO.: 89:27935a,27938a

TITLE: 1-Phenyl-2,3,4,5-tetrahydro-7,8-dihydroxy-1H-3-benzazepines

INVENTOR(S): Holden, Kenneth George

PATENT ASSIGNEE(S): Smithkline Corp., USA

SOURCE: Ger. Offen., 25 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent


LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2802086	A1	19780720	DE 1978-2802086	19780118
ZA 7707444	A	19781025	ZA 1977-7444	19771214
GB 1597911	A	19810916	GB 1978-953	19780110
GB 1597912	A	19810916	GB 1978-20952	19780110
BE 862878	A1	19780713	BE 1978-184290	19780113
FR 2378017	A1	19780818	FR 1978-998	19780113
FR 2378017	B1	19810710		
DK 7800199	A	19780720	DK 1978-199	19780116
SE 7800455	A	19780720	SE 1978-455	19780116
SE 437265	B	19850218		
SE 437265	C	19850606		
AU 7832465	A	19790726	AU 1978-32465	19780116
AU 510459	B2	19800626		
CA 1090334	A1	19801125	CA 1978-294973	19780116
NL 7800637	A	19780721	NL 1978-637	19780118
JP 53090281	A	19780808	JP 1978-4769	19780118
JP 60040423	B	19850911		
HU 175836	B	19801028	HU 1978-SI1612	19780118
CH 642634	A5	19840430	CH 1978-525	19780118
FR 2384759	A1	19781020	FR 1978-16583	19780602
FR 2384759	B1	19800718		
AU 8057822	A	19800731	AU 1980-57822	19800424
AU 516608	B2	19810611		
CH 640228	A5	19831230	CH 1982-3573	19820609
PRIORITY APPLN. INFO.:			US 1977-760500	A 19770119
			GB 1978-953	A 19780110
			CH 1978-525	A 19780118

GI




AB Phenylbenzazepines I (R, R3 = H, alkylthio, alkylsulfinyl, alkylsulfonyl, SCF3, SOCF3, SO2CF3; R1 = H, alkyl, C3-5 alkenyl, CH2CH2OH, CH2Ph, CH2CH2Ph, CO2CH2Ph, alkanoyl; R2 = H, halogen, CF3, Me, OMe, OH) and their ethers, esters, and salts were prepared. Thus, I (R-R3 = H) was oxidized to the dione and treated with MeSH to give I (R = SMe, R1-R3 = H; R-R2 = H, R3 = SMe) which had 8 and 3 times resp. the central dopaminergic activity of I (R-R3 = H).

IT 67942-40-9

RL: RCT (Reactant); RACT (Reactant or reagent)
(oxidation of)

RN 67942-40-9 CAPLUS

CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-6-(methylthio)-1-phenyl-
(CA INDEX NAME)




IT 67942-28-3P 67942-29-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and dopaminergic activity of)

RN 67942-28-3 CAPLUS


CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-6-(methylthio)-1-phenyl-,
hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 67942-29-4 CAPLUS

CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-9-(methylthio)-1-phenyl-
(CA INDEX NAME)




IT 67942-30-7P 67942-31-8P 67942-32-9P
67942-33-0P 67942-34-1P 67942-35-2P
67942-42-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 67942-30-7 CAPLUS

CN 1H-3-Benzazepine-7,8-diol, 9-(butylthio)-2,3,4,5-tetrahydro-1-phenyl-,
hydrobromide (1:1) (CA INDEX NAME)




● HBr

RN 67942-31-8 CAPLUS

CN 1H-3-Benzazepine-7,8-diol, 6-(butylthio)-2,3,4,5-tetrahydro-1-phenyl-,
hydrobromide (1:1) (CA INDEX NAME)


10/598,302



● HBr

RN 67942-32-9 CAPLUS


CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-9-[(1-methylethyl)thio]-1-phenyl-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 67942-33-0 CAPLUS

CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-6-[(1-methylethyl)thio]-1-phenyl-, hydrobromide (1:1) (CA INDEX NAME)




● HBr

RN 67942-34-1 CAPLUS

CN 1H-3-Benzazepine-7,8-diol, 9-(ethylthio)-2,3,4,5-tetrahydro-1-phenyl-, hydrobromide (1:1) (CA INDEX NAME)


10/598,302



● HBr

RN 67942-35-2 CAPLUS


CN 1H-3-Benzazepine-7,8-diol, 6-(ethylthio)-2,3,4,5-tetrahydro-1-phenyl-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 67942-42-1 CAPLUS

CN Benzeneacetic acid, 1,2,4,5-tetrahydro-7,8-dihydroxy-6-(methylsulfonyl)-1-phenyl-3H-3-benzazepin-3-yl ester (CA INDEX NAME)




L27 ANSWER 85 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1978:509151 CAPLUS
 DOCUMENT NUMBER: 89:109151
 ORIGINAL REFERENCE NO.: 89:16805a,16808a
 TITLE: Trisubstituted
 1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines and
 their salts
 INVENTOR(S): Weinstock, Joseph
 PATENT ASSIGNEE(S): Smithkline Corp., USA
 SOURCE: Ger. Offen., 61 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 8
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2751258	A1	19780601	DE 1977-2751258	19771116
DE 2751258	C2	19900104		
US 4160765	A	19790710	US 1976-742965	19761117
PRIORITY APPLN. INFO.:			US 1976-742965	A 19761117

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 GI




AB Benzazepines I (R = H, CH₂Ph, CH₂CH₂OH, lower alkyl, alkenyl, alkanoyl, propargyl, CH₂CH₂Ph, furoyl, thenoyl, furylmethyl, thienylmethyl, Bz, BzCH₂; R₁ = halogen, CF₃; R₂, R₃ = OH, C1-5 alkoxy, C2-5 alkanoyloxy, OCH₂O, OCH₂CH₂O; R₄ = H, 1-3 halogen, CF₃, Me, OMe, OH, OAc) were prepared. Thus isovanillin was chlorinated and methylated to give 2,3,4-Cl(MeO)₂C₆H₂CHO, which was treated with MeNO₂ to give 2,3,4-Cl(MeO)₂C₆H₂CH:CHNO₂. Reduction of the nitrostyrene gave 2,3,4-Cl(MeO)₂C₆H₂CH₂CH₂NH₂ which was treated with 4-methoxystyrene oxide to give I (R = H, R₁ = Cl, R₂ = 7-OMe, R₃ = 8-OMe, R₄ = p-OMe). Demethylation gave I (R = H, R₁ = Cl, R₂ = 7-OH, R₃ = 8-OH, R₄ = p-OH), which had a dopaminergic ED₅₀ of 0.3 µg/kg.

IT 62717-83-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 62717-83-3 CAPLUS

CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-8,9-dimethoxy-1-phenyl-,
 hydrochloride (1:1) (CA INDEX NAME)

10/598,302




● HCl

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L27 ANSWER 86 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN


ACCESSION NUMBER: 1978:89536 CAPLUS
 DOCUMENT NUMBER: 88:89536
 ORIGINAL REFERENCE NO.: 88:14031a,14034a
 TITLE: 1-Phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine derivatives
 INVENTOR(S): Ross, Stephen Torey; Weinstock, Joseph; Yim, Nelson Chi-Fai
 PATENT ASSIGNEE(S): Smithkline Corp., USA
 SOURCE: Ger. Offen., 22 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
DE 2722043	A1	19771208	DE 1977-2722043	19770516
GB 1574208	A	19800903	GB 1976-20666	19760519
JP 52144686	A	19771202	JP 1977-56967	19770516
FR 2351967	A1	19771216	FR 1977-15361	19770518
FR 2351967	B1	19800118		
PRIORITY APPLN. INFO.:			GB 1976-20666	A 19760519
GI				



AB Phenyltetrahydrobenzazepines I (R = H, F, Cl, Br, Me, CF₃, OMe, OH; R₁ = H, OH, OMe; R₂ = OH, OMe) were prepared for use as dopaminergic stimulants and in the treatment of Parkinsonism (no data). Thus, 3,4-(MeO)₂C₆H₃CH₂CH₂NH₂ was treated with styrene oxide and 3,4-(MeO)₂C₆H₃CH₂CH₂NHCH₂CHPhOH cyclized with HBr to give I (R = H, R₁ = 7-OH, R₂ = 8-OH).
 IT 62717-73-1P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 62717-73-1 CAPLUS
 CN 1H-3-Benzazepin-6-ol, 2,3,4,5-tetrahydro-5-phenyl-, hydrobromide (1:1) (CA INDEX NAME)

10/598,302




● HBr

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L27 ANSWER 87 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1977:189747 CAPLUS
 DOCUMENT NUMBER: 86:189747
 ORIGINAL REFERENCE NO.: 86:29753a,29756a
 TITLE: 1-Phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine
 derivative-containing drugs with peripheral dopamine
 receptor-stimulating, renal vessel-dilating, diuretic
 and Parkinson disease-palliating activity
 INVENTOR(S): Kaiser, Carl; Pendleton, Robert G.; Setler, Paulette
 E.
 PATENT ASSIGNEE(S): Smithkline Corp., USA
 SOURCE: Ger. Offen., 48 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2629887	A1	19770120	DE 1976-2629887	19760702
US 4011319	A	19770308	US 1975-592708	19750702
US 4052506	A	19771004	US 1975-602042	19750805
GB 1561305	A	19800220	GB 1976-25008	19760617
BE 843422	A1	19761227	BE 1976-168324	19760625
FR 2315934	A1	19770128	FR 1976-19601	19760628
FR 2315934	B1	19781117		
CA 1079639	A1	19800617	CA 1976-255817	19760628
IL 49931	A	19811231	IL 1976-49931	19760629
NL 7607184	A	19770104	NL 1976-7184	19760630
JP 52007981	A	19770121	JP 1976-79404	19760701
ZA 7603917	A	19770525	ZA 1976-3917	19760701
AU 507272	B2	19800207	AU 1976-15540	19760702
JP 57163314	A	19821007	JP 1982-35696	19820305
JP 60033409	B	19850802		
PRIORITY APPLN. INFO.:			US 1975-592708	A 19750702
			US 1975-602042	A 19750805
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
GI				



AB Benzazepines I (R = R1 = H, R2 = H, 3-Cl, 2-Cl, 4-Cl, 3-Me, 2-Me, 4-Me,
 3-CF3, 4-OH, 3-OH, 2-OH; R = CH2CH2OH, Bu, Me, Et, Pr, allyl, R1 = R2 = H;
 R = R2 = H, R1 = Me, Ac, COCMe3, COEt) and some related compds. were


prepared Thus, 3,4-(MeO)2C6H3CH2CH2NH2 was treated with styrene oxide and 3,4-(MeO)2C6H3CH2CH2NHCH2CHPhOH cyclized with HBr to give I (R-R2 = H). At 550 mg/kg i.v. in dogs I (R-R2 = H) gave a 22% increase in renal bloodflow and 47% decrease in the resistance of the renal vessels. It was diuretic at 12.5 mg/kg i.p. in rats and at 1.2 mg/kg i.p. in rats. It caused contralateral rotation in 6-hydroxydopamine brain-damaged rats.

IT 62717-84-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and demethylation of)

RN 62717-84-4 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-8,9-dimethoxy-1-phenyl-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

IT 62717-83-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)

RN 62717-83-3 CAPLUS

CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-8,9-dimethoxy-1-phenyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


IT 62717-73-1P 62717-85-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 62717-73-1 CAPLUS

CN 1H-3-Benzazepin-6-ol, 2,3,4,5-tetrahydro-5-phenyl-, hydrobromide (1:1) (CA INDEX NAME)


10/598,302



● HBr

RN 62717-85-5 CAPLUS

CN 1H-3-Benzazepine-6,7-diol, 2,3,4,5-tetrahydro-5-phenyl-, hydrobromide
(1:1) (CA INDEX NAME)



● HBr

OS.CITING REF COUNT: 5

THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
(6 CITINGS)

L27 ANSWER 88 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1977:55268 CAPLUS

DOCUMENT NUMBER: 86:55268

ORIGINAL REFERENCE NO.: 86:8805a,8808a

TITLE: Photocyclization of N-chloroacetyl-2-methoxy- and 2,4-dimethoxyphenethylamines to 4-azabicyclo[5.3.1]undec-9-ene-3,8-diones

AUTHOR(S): Okuno, Yohmei; Yonemitsu, Osamu

CORPORATE SOURCE: Fac. Pharm. Sci., Hokkaido Univ., Sapporo, Japan


SOURCE: Heterocycles (1976), 4(8), 1371-6

CODEN: HTCYAM; ISSN: 0385-5414

DOCUMENT TYPE: Journal

LANGUAGE: English

GI




AB Photocyclization of 2,4-(MeO)₂C₆H₃CH₂CH₂NHCOCH₂Cl gave 26% azabicycloundecane I (R = OMe) and a trace of the benzazepinone II. 2-MeOC₆H₄CH₂CH₂NHCOCH₂Cl gave 23% I (R = H) as the only product.

IT 61429-54-7P

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)

RN 61429-54-7 CAPLUS

CN 2H-3-Benzazepin-2-one, 1,3,4,5-tetrahydro-6,8-dimethoxy- (CA INDEX NAME)



L27 ANSWER 89 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1976:559032 CAPLUS

DOCUMENT NUMBER: 85:159032

ORIGINAL REFERENCE NO.: 85:25457a, 25460a

TITLE: Intra- and intermolecular photoreactions of
N-chloroacetyl derivatives of
dimethylaminophenethylamines and
dimethylaminobenzylamines in both acidic and basic
solutions

AUTHOR(S): Numao, Naganori; Yonemitsu, Osamu

CORPORATE SOURCE: Fac. Pharm. Sci., Hokkaido Univ., Sapporo, Japan


SOURCE: Heterocycles (1976), 4(6), 1095-100

CODEN: HTCYAM; ISSN: 0385-5414

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB Photocyclization of *m*-Me₂NC₆H₄CH₂CH₂NHCOCH₂Cl gave 40% I (R = NH₂, R₁ = H) and 32% I (R = H, R₁ = NH₂), whereas the *para* isomer gave 11.7% cage compound (II) and 13% metacyclophane (III; *n* = 2). The intramol. reaction was little affected by acid. Intermol. photocyclization of *p*-Me₂NC₆H₄CH₂NHCOCH₂Cl to give 8.8% III (*n* = 1) and 4.3% *p*-H₂NC₆H₄CH₂NHCOCH₂Cl was strongly depressed by acid. Both cyclizations involved the singlet excited state of the dimethylaniline moiety.


IT 59019-32-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 59019-32-8 CAPLUS

CN 2H-3-Benzazepin-2-one, 9-(dimethylamino)-1,3,4,5-tetrahydro- (CA INDEX
NAME)

10/598,302



OS.CITING REF COUNT:

1

THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L27 ANSWER 90 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1976:163840 CAPLUS

DOCUMENT NUMBER: 84:163840

ORIGINAL REFERENCE NO.: 84:26598h,26599a

TITLE: Mechanism of photocyclization of N-chloroacetamide derivatives having electron-rich aromatic ring

AUTHOR(S): Yonemitsu, Osamu; Okuno, Yohmei; Numao, Naganori; Hirao, Kenichi

CORPORATE SOURCE: Fac. Pharm. Sci., Hokkaido Univ., Sapporo, Japan

SOURCE: Hukusokan Kagaku Toronkai Koen Yoshishu, 8th (1975), 29-33. Pharm. Inst., Tohoku Univ.: Sendai, Japan. CODEN: 32KOAD

DOCUMENT TYPE: Conference

LANGUAGE: Japanese


AB Photocyclization of m-RC₆H₄CH₂CH₂NHCOCH₂Cl (R = NMe₂, OMe) was studied with respect to solvent effects, pH dependence, fluorescence quenching, and calcn. of odd electron d. In aqueous solvents, photoionization from the excited singlet state of an aromatic chromophore to the ClCH₂CO moiety via an exciplex led to the cleavage of the C-Cl bond and the resultant methylene radical coupled readily with the aromatic cation radical to form cyclized products. In organic solvents, intramol. energy transfer caused homolytic cleavage of the C-Cl bond and the resultant methylene radical, after escape from a solvent cage, abstracted a H from solvents to give reduction products.

IT 36688-74-1P 59019-32-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 36688-74-1 CAPLUS

CN 2H-3-Benzazepin-2-one, 1,3,4,5-tetrahydro-9-methoxy- (CA INDEX NAME)



RN 59019-32-8 CAPLUS

CN 2H-3-Benzazepin-2-one, 9-(dimethylamino)-1,3,4,5-tetrahydro- (CA INDEX NAME)



L27 ANSWER 91 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1976:59150 CAPLUS

DOCUMENT NUMBER: 84:59150

ORIGINAL REFERENCE NO.: 84:9719a,9722a

TITLE: Photocyclization of
N-chloroacetyl-2,5-dimethoxyphenethylamine. Synthesis
of pyrroloindolesAUTHOR(S): Okuno, Yohmei; Kawamori, Masatoshi; Hirao, Kenichi;
Yonemitsu, Osamu

CORPORATE SOURCE: Fac. Pharm. Sci., Hokkaido Univ., Sapporo, Japan

SOURCE: Chemical & Pharmaceutical Bulletin (1975), 23(11),
2584-90

CODEN: CPBTAL; ISSN: 0009-2363

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 84:59150

GI For diagram(s), see printed CA Issue.


AB Irradiation of dimethoxyphenethylamine I in aqueous solution gave azepin-2-ones
II(R = H, R1 = DH; R = OMe, R1 = H) and
1-azatricyclo[6,2,1,0⁴,1¹]undec-7-ene-2,6-diones III and IV, characterized
on the basis of their ir, uv, NMR, and mass spectra and by chemical
correlations. Presumably II(R = H, R1 = OH), III, and IV formed via
cations V - VII, resp.

IT 50525-85-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 50525-85-4 CAPLUS

CN 2H-3-Benzazepin-2-one, 1,3,4,5-tetrahydro-6,9-dimethoxy- (CA INDEX NAME)



L27 ANSWER 92 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1975:488649 CAPLUS
DOCUMENT NUMBER: 83:88649
ORIGINAL REFERENCE NO.: 83:13835a,13838a
TITLE: Cage effect for the photochemical formation of the
ten-membered lactam from
N-chloroacetyl-3-methoxyphenethylamine
AUTHOR(S): Okuno, Yohmei; Yonemitsu, Osamu
CORPORATE SOURCE: Fac. Pharm. Sci., Hokkaido Univ., Sapporo, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1975), 23(5),
1039-44
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English


AB Photocyclization of N-chloroacetyl-3-methoxyphenethylamine (I) in H₂O gave 7- and 9-methoxy-1,2,4,5-tetrahydro-3H-3-benzazepin-2-one (II and III), whereas in organic solvents the main products changed to N-acetyl-3-methoxyphenethylamine and 2-oxa-6-azabicyclo[7.3.1]trideca-1(13),9,11-trien-5-one (IV). Quantum yield for the formation of II and III is clearly dependent on the polarity of solvent indicating that the formation of II and III involves an ionic process. Inorganic solvents, viscous media favor the formation of IV. Viscosity dependence in some alcohols is probably an indication of a novel cage reaction operative in the formation of the lactam IV.

IT 36688-74-1P

RL: FORM (Formation, nonpreparative); PREP (Preparation)
(formation of, from photocyclization of
chloroacetylmethoxyphenethylamine in aqueous solution)

RN 36688-74-1 CAPLUS

CN 2H-3-Benzazepin-2-one, 1,3,4,5-tetrahydro-9-methoxy- (CA INDEX NAME)



L27 ANSWER 93 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1974:520432 CAPLUS

DOCUMENT NUMBER: 81:120432

ORIGINAL REFERENCE NO.: 81:19035a,19038a

TITLE: N-Substituted 6,9-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepines

AUTHOR(S): Durgaryan, A. K.; Chshmarityan, S. G.; Tatevosyan, G. T.

CORPORATE SOURCE: Inst. Tonkoi Org. Khim. im. Mndzhoyana, Yerevan, USSR

SOURCE: Armyanskii Khimicheskii Zhurnal (1974), 27(6), 510-15

CODEN: AYKZAN; ISSN: 0515-9628

DOCUMENT TYPE: Journal

LANGUAGE: Russian

GI For diagram(s), see printed CA Issue.


AB The tetralone I was converted (93%) to its oxime, which was converted to 83% the tosylate. Heating the tosylate in an autoclave 4 hr gave 79.5% the benzazepinone II (R = H), which was alkylated or acetylated to give 16.7-63.7% II (R = Me, PhCH₂, Me₂NCH₂CH₂, Ac). Reduction of II (R = H) gave 47.7% the benzazepine III. III (R = Me, Et, PhCH₂, CH₂CH₂NMe₂) were prepared (41.2-67.3%) similarly. III were potential tranquilizers (no data).

IT	50525-85-4P	53970-44-8P	53970-45-9P
	53970-46-0P	53970-47-1P	53970-48-2P
	53970-49-3P	53970-50-6P	53970-51-7P
	53970-52-8P	53970-53-9P	53970-54-0P
	53970-55-1P	53970-56-2P	53970-57-3P
	53970-58-4P		

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 50525-85-4 CAPLUS

CN 2H-3-Benzazepin-2-one, 1,3,4,5-tetrahydro-6,9-dimethoxy- (CA INDEX NAME)



RN 53970-44-8 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-6,9-dimethoxy- (CA INDEX NAME)



10/598,302


RN 53970-45-9 CAPLUS

CN 1H-3-Benzazepine, 3-ethyl-2,3,4,5-tetrahydro-6,9-dimethoxy- (CA INDEX NAME)




RN 53970-46-0 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-6,9-dimethoxy-3-(phenylmethyl)- (CA INDEX NAME)



RN 53970-47-1 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-6,9-dimethoxy-3-methyl- (CA INDEX NAME)




RN 53970-48-2 CAPLUS

CN 3H-3-Benzazepine-3-ethanamine, 1,2,4,5-tetrahydro-6,9-dimethoxy-N,N-dimethyl- (CA INDEX NAME)

10/598,302




RN 53970-49-3 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-6,9-dimethoxy-, hydrochloride (1:1)
(CA INDEX NAME)




● HCl

RN 53970-50-6 CAPLUS
CN 1H-3-Benzazepine, 3-ethyl-2,3,4,5-tetrahydro-6,9-dimethoxy-, hydrochloride
(1:1) (CA INDEX NAME)




● HCl

RN 53970-51-7 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-6,9-dimethoxy-3-(phenylmethyl)-,
hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 53970-52-8 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-6,9-dimethoxy-3-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 53970-53-9 CAPLUS
CN 3H-3-Benzazepine-3-ethanamine, 1,2,4,5-tetrahydro-6,9-dimethoxy-N,N-dimethyl-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 53970-54-0 CAPLUS
CN 2H-3-Benzazepin-2-one, 1,3,4,5-tetrahydro-6,9-dimethoxy-3-methyl- (CA INDEX NAME)

10/598,302




RN 53970-55-1 CAPLUS

CN 2H-3-Benzazepin-2-one, 1,3,4,5-tetrahydro-6,9-dimethoxy-3-(phenylmethyl)-
(CA INDEX NAME)




RN 53970-56-2 CAPLUS

CN 2H-3-Benzazepin-2-one, 3-[2-(dimethylamino)ethyl]-1,3,4,5-tetrahydro-6,9-
dimethoxy- (CA INDEX NAME)



RN 53970-57-3 CAPLUS


CN 2H-3-Benzazepin-2-one, 3-acetyl-1,3,4,5-tetrahydro-6,9-dimethoxy- (CA
INDEX NAME)



RN 53970-58-4 CAPLUS

10/598,302

CN 2H-3-Benzazepin-2-one, 3-[2-(dimethylamino)ethyl]-1,3,4,5-tetrahydro-6,9-dimethoxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L27 ANSWER 94 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1974:82731 CAPLUS
 DOCUMENT NUMBER: 80:82731
 ORIGINAL REFERENCE NO.: 80:13309a,13312a
 TITLE: 1,2,4,5-Tetrahydro-3H,3-benzazepines
 INVENTOR(S): Shetty, Bola V.
 PATENT ASSIGNEE(S): Pennwalt Corp.
 SOURCE: Fr. Demande, 73 pp.
 CODEN: FRXXBL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2171879	A1	19730928	FR 1972-4829	19720214
FR 2171879	B1	19750425		

PRIORITY APPLN. INFO.: FR 1972-4829 19720214


GI For diagram(s), see printed CA Issue.

AB Benzazepines I (R = CH₂CH:CM₂, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, allyl, 2-(4-phenylpiperazino)-ethyl, CH₂CM₂:CH₂, CH₂C.tplbond.CH, Me, Et, Pr, CH₂CH₂Ph, CHMeCH₂Ph, CH₂CH₂C₆H₄NH₂-p, CH₂CH₂C₆H₄NHAc-p, CH₂CH:CHPh, trans-2-phenylcyclopropylmethyl, CH₂CH₂OAc, CH₂CHMeOAc, CHMeCH₂C₆H₄NH₂-p) were prepared by substitution of I (R = H). I (R = H, R₁ = Me) was prepared by methylating 3,4-Me₂C₆H₃OH, oxidizing the 3,4-Me₂C₆H₃OMe, converting the 4-MeOC₆H₄(CO₂H)₂-1,2 to its anhydride, reducing to 4-MeOC₆H₄(CH₂OH)₂-1,2, and converting to 4-MeOC₆H₄(CH₂Br)₂-1,2 and 4-MeOC₆H₄(CH₂CN)₂-1,2, which was cyclized to 7-methoxy-1,2,4,5-tetrahydro-3H-3-benzazepine-2,4-dione and reduced with BH₃. Demethylation with HBr gave I (R = R₁ = H). I are analgesics and narcotic antagonists. Thus, I (R = CH₂CH₂C₆H₄NHAc-p, R₁ = Me) had an oral ED₅₀ in the writhing test of 32 mg/kg.

IT 36134-42-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 36134-42-6 CAPLUS

CN 1H-3-Benzazepin-1-one, 2,3,4,5-tetrahydro-9-methoxy-4-methyl-3-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)

L27 ANSWER 95 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1974:3336 CAPLUS

DOCUMENT NUMBER: 80:3336

ORIGINAL REFERENCE NO.: 80:579a,582a

TITLE: Photochemical formation of pyrroloindole skeleton from
N-chloroacetyl-2,5-dimethoxyphenethylamine

AUTHOR(S): Okuno, Yohmei; Kawamori, Masatoshi; Yonemitsu, Osamu

CORPORATE SOURCE: Fac. Pharm. Sci., Hokkaido Univ., Sapporo, Japan

SOURCE: Tetrahedron Letters (1973), (32), 3009-12

CODEN: TELEAY; ISSN: 0040-4039

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.

AB Irradiation of the title compound gave 8% tetrahydrobenzazepinone (I) and 12
and


3% pyrroloindoles (II and III, resp.).

IT 50525-85-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 50525-85-4 CAPLUS

CN 2H-3-Benzazepin-2-one, 1,3,4,5-tetrahydro-6,9-dimethoxy- (CA INDEX NAME)



L27 ANSWER 96 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1973:526338 CAPLUS
 DOCUMENT NUMBER: 79:126338
 ORIGINAL REFERENCE NO.: 79:20507a,20510a
 TITLE: 1,2,4,5-Tetrahydro-3H-3-benzazepines
 INVENTOR(S): Shetty, Bola V.
 PATENT ASSIGNEE(S): Pennwalt Corp.
 SOURCE: Ger. Offen., 82 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2207430	A1	19730823	DE 1972-2207430	19720214
DE 2207430	B2	19810723		
DE 2207430	C3	19820513		

PRIORITY APPLN. INFO.: DE 1972-2207430 19720214

GI For diagram(s), see printed CA Issue.


AB Benzazepines I (R = H, CH₂CH:Me₂, CH₂Me:CH₂, CH₂CH:CHPh, allyl, CH₂C.tplbond.CH, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, trans-2-phenylcyclopropylmethyl, Me, Et, Pr, CH₂CH₂Ph, CHMeCH₂Ph, CH₂CH₂C₆H₄NH₂-p, CHMeCH₂C₆H₄NH₂-p, CH₂CH₂C₆H₄NHAc-p, CH₂CH₂OAc, (CH₂)₃OAc, 4-phenylpiperazinylethyl; R₁ = H, Me) were prepared. Thus, 3,4-Me₂C₆H₃OH was methylated and oxidized to give 3,4-(HO₂C)C₆H₃OMe, whose anhydride was reduced to 3,4-(HOCH₂)C₆H₃OMe, brominated to 3,4-(BrCH₂)C₆H₃OMe, treated with NaCN to give 3,4-(NCCH₂)C₆H₃OMe, which was cyclized with HBr-HOAc to 7-methoxy-1,2,4,5-tetrahydro-3H-3-benzazepine-2,4-dione and reduced with B₂H₆ to I (R = H, R₁ = Me) from which the other I were derived. I demonstrated antihistaminic, analgesic, anticholinergic, and morphine antagonist activity.

IT 36134-42-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 36134-42-6 CAPLUS

CN 1H-3-Benzazepin-1-one, 2,3,4,5-tetrahydro-9-methoxy-4-methyl-3-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)

L27 ANSWER 97 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1973:404640 CAPLUS

DOCUMENT NUMBER: 79:4640

ORIGINAL REFERENCE NO.: 79:795a,798a

TITLE: Mechanism of photocyclization of
N-chloroacetyl-m-tyramine. Flash photolysis study

AUTHOR(S): Naruto, Shnji; Yonemitsu, Osamu

CORPORATE SOURCE: Fac. Pharm. Sci., Hokkaido Univ., Sapporo, Japan

SOURCE: Chemical & Pharmaceutical Bulletin (1973), 21(3),
629-33
CODEN: CPBTAL; ISSN: 0009-2363

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.


AB The flash photolysis of m-(RCONHCH₂CH₂)C₆H₄OH (I, R = ClCH₂) in non-degassed aqueous solution afforded a transient absorption spectrum which consisted of 2 groups with different intensities and lifetimes. The weak bands at 380, 386, and 412 nm (τ = 200-400 μ sec), which were also observed in the photolysis of I (R = Me), corresponded to the spectrum of the phenoxy radical. The strong bands at 322 and 330 nm decayed according to a 1st-order kinetics (τ = 530 μ sec in neutral solution, τ = 48 μ sec in alkaline solution) and were attributed to II, which is an intermediate of the photocyclization of I (R = ClCH₂) to III.

IT 34014-41-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, by photocyclization of chloroacetyltyramine)

RN 34014-41-0 CAPLUS

CN 2H-3-Benzazepin-2-one, 1,3,4,5-tetrahydro-9-hydroxy- (CA INDEX NAME)



L27 ANSWER 98 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1972:501364 CAPLUS

DOCUMENT NUMBER: 77:101364

ORIGINAL REFERENCE NO.: 77:16706h,16707a

TITLE: Exciplexes and cage complexes in the photolysis of

N-chloroacetylmescaline and other phenethylamines

AUTHOR(S): Yonemitsu, O.; Nakai, H.; Okuno, Y.; Naruto, S.;

Hemmi, K.; Witkop, B.

CORPORATE SOURCE: Fac. Pharm. Sci., Hokkaido Univ., Sapporo, Japan

SOURCE: Photochemistry and Photobiology (1972), 15(5), 509-13

CODEN: PHCBAP; ISSN: 0031-8655

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.


AB Solns. of N-chloroacetylmescaline (I), 3-methoxy- and 3,5-dimethoxyphenethylamines were irradiated with an Hg lamp under N₂; 2 equivs. of Ag₂CO₃ were present with the latter 2 compds. Gas-liquid chromatog. was used to analyze the reaction mixts., and determine the effects of O and several solvents. For I with decrease in dielectric constant of the solvent going from H₂O to C₆H₆ there was an increase in recovery of unchanged I (<10-79.8%). In addition there was a rel. decrease in yields of photoproducts II (R = H, Me, Et) and III (R = R₁ = R₂ = MeO, R₃ = H) and increased formation of IV (R = R₁ = MeO) and N-acetyl-I. SCF-MO calcns. explained the reactivity of the mescaline system especially at position 4. For the substituted phenethylamine N-chloroacetyl derivs., III (R = H), III (R₃ = H), IV, and V were the photoproducts. Yields of all 4 types of photoproduct decreased with decrease in dielectric constant, and IV and V were obtained only in organic solvents. Formation of V was strongly suppressed by O₂ in contrast to the other product IV. III (R = H) and III (R₃ = H) were more characteristic of hydroxylic solvents but small amts. were formed in benzene.

IT 23137-72-6P 36688-74-1P 36694-93-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 23137-72-6 CAPLUS


CN 2H-3-Benzazepin-2-one, 1,3,4,5-tetrahydro-7,8,9-trimethoxy- (CA INDEX NAME)



RN 36688-74-1 CAPLUS


CN 2H-3-Benzazepin-2-one, 1,3,4,5-tetrahydro-9-methoxy- (CA INDEX NAME)

10/598,302



RN 36694-93-6 CAPLUS

CN 2H-3-Benzazepin-2-one, 1,3,4,5-tetrahydro-7,9-dimethoxy- (CA INDEX NAME)



L27 ANSWER 99 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1972:487448 CAPLUS

DOCUMENT NUMBER: 77:87448

ORIGINAL REFERENCE NO.: 77:14421a,14424a

TITLE: Photocyclization of
N-chloroacetyl-3-methoxyphenethylamine and
N-chloroacetyl-3,5-dimethoxyphenethylamine
AUTHOR(S): Okuno, Yohmei; Hemmi, Keiji; Yonemitsu, Osamu
CORPORATE SOURCE: Fac. Pharm. Sci., Hokkaido Univ., Sapporo, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1972), 20(6),
1164-9

CODEN: CPBTAL; ISSN: 0009-2363

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.


AB On irradiation of N-chloroacetyl derivs. of 3-methoxyphenethylamine and
3,5-dimethoxyphenethylamine in 10% aqueous ethanol,
methoxy-1,2,4,5-tetrahydro-3H-3-benzazepin-2-ones were synthesized in good
yield, whereas in ethanol novel ten-membered lactams (I, R = H, MeO) were
main products. The photo-reaction of N-chloroacetylphenethylamine in the
presence or absence of veratrol gave the intermol. reaction product (II)
or the radical reaction products PhCH₂CH₂NHAc and (PhCH₂CH₂NHCOCH₂)₂,
which may support the proposed dualistic mechanism.

IT 36688-74-1P 36694-93-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 36688-74-1 CAPLUS

CN 2H-3-Benzazepin-2-one, 1,3,4,5-tetrahydro-9-methoxy- (CA INDEX NAME)



RN 36694-93-6 CAPLUS

CN 2H-3-Benzazepin-2-one, 1,3,4,5-tetrahydro-7,9-dimethoxy- (CA INDEX NAME)



L27 ANSWER 100 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1972:461780 CAPLUS

DOCUMENT NUMBER: 77:61780

ORIGINAL REFERENCE NO.: 77:10219a,10222a

TITLE: Novel synthesis of aromatic methoxy and methylenedioxy-substituted

2,3,4,5-tetrahydro-1H-3-benzazepines

AUTHOR(S): Pecherer, B.; Sunbury, R. C.; Brossi, A.

CORPORATE SOURCE: Chem. Res. Lab., Hoffmann-La Roche Inc., Nutley, NJ, USA

SOURCE: Journal of Heterocyclic Chemistry (1972), 9(3), 609-16

CODEN: JHTCAD; ISSN: 0022-152X

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 77:61780


AB A new synthesis of aromatic methoxy and methylenedioxy substituted 2,3,4,5-tetrahydro-1H-3-benzazepines is described. Suitably substituted phenethylamines and their α -methyl homologs in the form of their N-acetyl derivs. are chloromethylated, the resulting benzyl chlorides are treated with cyanide and hydrolyzed to yield 2-(2-aminoethyl)phenylacetic acid derivs. Thermal cyclization yields the corresponding lactams. Hydride reduction of these lactams furnishes the substituted 2,3,4,5-tetrahydro-1H-3-benzazepines which may be methylated on N by H₂CO and H.

IT 37015-25-1P 37015-26-2P 37015-27-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 37015-25-1 CAPLUS

CN 2H-3-Benzazepin-2-one, 6-bromo-1,3,4,5-tetrahydro-7,8,9-trimethoxy- (CA INDEX NAME)



RN 37015-26-2 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-6,7,8-trimethoxy- (CA INDEX NAME)



RN 37015-27-3 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-6,7,8-trimethoxy-, hydrochloride (1:1) (CA INDEX NAME)

10/598,302



● HCl

OS.CITING REF COUNT:

2

THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)

L27 ANSWER 101 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1972:153628 CAPLUS

DOCUMENT NUMBER: 76:153628

ORIGINAL REFERENCE NO.: 76:25036h,25037a

TITLE: 1,2,4,5-Tetrahydro-3H-3-benzazepines as analgesics and antagonists of narcotics

PATENT ASSIGNEE(S): Wallace and Tiernan, Inc.

SOURCE: Brit., 42 pp.

CODEN: BRXXAA

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1268243		19720322	GB 1969-12844	19690311
CA 974989			CA	
US 3719669		19730306	US	19720327
PRIORITY APPLN. INFO.:			US 1968-711897	19680311

GI For diagram(s), see printed CA Issue.


AB H-3-Benzazepines (I, R was usually 7- or 8-MeO or 7-OH; R1 was, e.g., H, alkyl, cycloalkylmethyl, substituted phenethyl, p-MeC6H4SO2, a cetoxyalkyl; R2 = H3 Me), useful as analgesics, anticholinergics, antihistamines, and antagonists of narcotics, were prepared Thus, 50 g 4-methoxy-o-benzenediacetamide (II) was reduced by borane in THF at 10° to give 28 g I (R = 7-MeO, R1 = R2 = H), analyzed as the maleate. II was prepared from 3,4-dimethylphenol by methylation, oxidation to 4-methoxyphthalic acid, formation of the anhydride, reduction to 4-methoxy-o-xylene- α,α' -diol, dibromination of the diol, conversion to the dinitrile, and cyclization to the imide. Pharmacol. test results were given.

IT 36134-42-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 36134-42-6 CAPLUS

CN 1H-3-Benzazepin-1-one, 2,3,4,5-tetrahydro-9-methoxy-4-methyl-3-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 3

THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)

L27 ANSWER 102 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1971:524960 CAPLUS

DOCUMENT NUMBER: 75:124960

ORIGINAL REFERENCE NO.: 75:19729a,19732a

TITLE: Flash photolysis of N-chloroacetyl-m-tyramine

AUTHOR(S): Yonemitsu, Osamu; Naruto, Shunji; Kanamaru, Nobuaki;
Kimura, Katsumi

CORPORATE SOURCE: Fac. Pharm. Sci., Hokkaido Univ., Sapporo, Japan

SOURCE: Journal of the American Chemical Society (1971),
93(16), 4053-5

CODEN: JACSAT; ISSN: 0002-7863

DOCUMENT TYPE: Journal

LANGUAGE: English


AB The flash photolysis of N-chloroacetyl-m-tyramine (I) in aqueous solution (not degassed) afforded a transient absorption spectrum which consists of 2 groups with different intensities and lifetimes. The weak bands at 380, 386, and 412 nm ($\tau = 200\text{--}400\ \mu\text{sec}$), which were also observed in the photolysis of N-acetyl-m-tyramine, correspond with the spectrum of the phenoxy radical. The strong bands at 322 and 330 nm decay according to 1st-order kinetics ($\tau = 530\ \mu\text{sec}$ in neutral solution, $\tau = 140\ \mu\text{sec}$ in alkaline solution) and are attributed to the 2,4-dienone (1,2,4,5,9,9a-hexahydro-3H-benzazepine-2,9-dione (II), which is an intermediate of the photocyclization of I to 9-hydroxy-1,2,4,5-tetrahydro-3H-3-benzazepin-2-one (III). In conclusion, the photocyclization of I may be initiated by an electron transfer from the aromatic system to the chloroacetamide group, followed by ortho-cyclization to II, which aromatizes to yield III.

IT 34014-41-0P

RL: FORM (Formation, nonpreparative); PREP (Preparation)
(formation of, in photolysis of chloroacetyltyramine)

RN 34014-41-0 CAPLUS

CN 2H-3-Benzazepin-2-one, 1,3,4,5-tetrahydro-9-hydroxy- (CA INDEX NAME)



L27 ANSWER 103 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1970:531172 CAPLUS

DOCUMENT NUMBER: 73:131172

ORIGINAL REFERENCE NO.: 73:21377a,21380a

TITLE: Photocyclizations of pharmacodynamic amines. V.

Unusual rearrangements of the mescaline skeleton

AUTHOR(S): Yonemitsu, Osamu; Nakai, Hideo; Kanaoka, Yuichi;

Karle, Isabella L.; Witkop, Bernhard

CORPORATE SOURCE: Fac. Pharm. Sci., Hokkaido Univ., Sapporo, Japan

SOURCE: Journal of the American Chemical Society (1970),

92(19), 5691-700

CODEN: JACSAT; ISSN: 0002-7863

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 73:131172

GI For diagram(s), see printed CA Issue.

AB Irradiation of N-chloroacetylmescaline 3,4,5-(MeO)3C6H2CH2CH2NHCOCH2Cl, in aqueous

solution or in water-ethanol gave 10%

7,8,9-trimethoxy-1,2,4,5-tetrahydro-3H-3-benzazepin-2-one (I) and 35%

7-hydroxy-1,9,10-trimethoxy-4-azabicyclo[5.2.2]undeca-8,-10-dien-3-one

(II) in addition to 10-20% starting material and >1% N-acetylmescaline.

Photocyclization in anhydrous methanol gave 20% recovered starting material,

and, in addition to 11% II, a new compound,

11,12-dimethoxy-2-oxa-6-azabicyclo[7.3.1]trideca-1(13),9,11-trien-5-one

(III) in >2% yield. The racemic photoproduct II, which crystallizes in

the orthorhombic space group Aba2, was elucidated by the symbolic addition

procedure which was applied to this space group for the first time. The

nonplanar spatial orientation of the 3 MeO groups of II in the crystal,

and probably also in solution, resembles that of the trimethoxyphenyl moiety

of reserpine. On refluxing in glacial HOAc II underwent a novel

fragmentation reaction and aromatized to a mixture of 35%

N-acetoxymethyl-2,6-dimethoxy-4-acetoxymethylphenylacetamide and 34%

2,6-dimethoxy-4-acetoxymethylphenylacetamide, whose structures were

clarified by degradation and interconversion reactions. In MeOH-HCl at

20° photoproduct II underwent a new type of transannular aldol

condensation to yield 1,8,8-trimethoxy-2,6-dioxo-4-(2-

aminoethyl)bicyclo[3.2.1]oct-3-ene, which was elucidated as the

perchlorate by the symbolic addition procedure. The mechanism of this

unusual rearrangement was studied by the use of HCl in ethanol and CD3OD.


IT 23137-72-6P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)

RN 23137-72-6 CAPLUS

CN 2H-3-Benzazepin-2-one, 1,3,4,5-tetrahydro-7,8,9-trimethoxy- (CA INDEX NAME)



L27 ANSWER 104 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1970:509589 CAPLUS

DOCUMENT NUMBER: 73:109589

ORIGINAL REFERENCE NO.: 73:17839a,17842a

TITLE: Photocyclization of pharmacodynamic amines. IV.

Novel heterocycles from

N-chloroacetyl-3,4-dimethoxyphenethylamine

AUTHOR(S): Yonemitsu, Osamu; Okuno, Yohmei; Kanaoka, Yuichi;

Witkop, Bernhard

CORPORATE SOURCE: Fac. Pharm. Sci., Hokkaido Univ., Sapporo, Japan

SOURCE: Journal of the American Chemical Society (1970),

92(19), 5686-90

CODEN: JACSAT; ISSN: 0002-7863

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 73:109589

AB Irradiation of N-chloroacetyl-3,4-dimethoxyphenethylamine in aqueous ethanol with

a high-pressure Hg lamp gave 27% 7,8-and 6%

8,9-dimethoxy-1,2,4,5-tetrahydro-3H-3-benzazepin-2-one of which the latter was hydrolyzed and lactonized by 48% HBr to

4-(β -aminoethyl)-7-hydroxy-2,3-dihydrobenzofuran-2-one and the formerto 2-(β -aminoethyl)-4,5-dihydroxyphenylacetic acid, characterized as

the Et ester. A deepseated photorearrangement gave 11%

1,2,5a,7b-tetrahydro-5a,5b-dimethoxy-5bH-cyclobuta[1,4]cyclobuta

[1,2,3-gh]pyrrolizin-4(5H)-one which easily aromatized on warming with

Al₂O₃ in toluene to the tricyclic lactam of

6-methoxy-2,3-dihydroindole-7-acetic acid and on esterification opened up

to form Me 4,5-dimethoxy-7-azatricyclo[4.3.0.0^{1,4}]non-2-ene-5-acetate,

reconvertible to starting material by base. Photolysis in THF gave the

ten-membered lactam (11% yield), 12-methoxy-2-oxa-6-azabicyclo[7.3.1]-

trideca-1(13),9,11-trien-5-one which with 6.0N HCl at 20° underwent

an unusually facile transannular Bischler-Napieralski reaction to yield

9-methoxy-2,3,5,6-tetrahydropyrano[2,3,4-ij]-isoquinoline. These unusual

photocyclizations are discussed in terms of intramol, transfer of energy

from an excited aromatic singlet state to the C-Cl bond.


IT 20925-65-9P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)

RN 20925-65-9 CAPLUS

CN 2H-3-Benzazepin-2-one, 1,3,4,5-tetrahydro-8,9-dimethoxy- (CA INDEX NAME)



OS.CITING REF COUNT: 2

THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)

L27 ANSWER 105 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1969:461186 CAPLUS

DOCUMENT NUMBER: 71:61186

ORIGINAL REFERENCE NO.: 71:11255a,11258a

TITLE: Photocyclizations of pharmacodynamic amines. III.
Three-dimensional structure of
7-hydroxy-1,9,10-trimethoxy-4-azabicyclo[5.2.2]undeca-
8,10-dien-3-one from mescaline

AUTHOR(S): Yonemitsu, Osamu; Nakai, H.; Kanaoka, Yuichi; Karle,
Isabella L.; Witkop, Bernhard

CORPORATE SOURCE: Fac. Pharm. Sci., Hokkaido Univ., Sapporo, Japan

SOURCE: Journal of the American Chemical Society (1969),
91(16), 4591-3

CODEN: JACSAT; ISSN: 0002-7863

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 71:61186

GI For diagram(s), see printed CA Issue.


AB A mixture of .apprx.33% title bicycloundecadienone I and .apprx.10% II is
prepared by the photolysis of the mescaline. I is treated with HCl(MeOH) to
give III. X-ray data and bond lengths and angles for I are given; the
9-membered ring formed from C(1)-C(9) is in a boat conformation.

IT 23137-72-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 23137-72-6 CAPLUS

CN 2H-3-Benzazepin-2-one, 1,3,4,5-tetrahydro-7,8,9-trimethoxy- (CA INDEX
NAME)



L27 ANSWER 106 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1969:11554 CAPLUS

DOCUMENT NUMBER: 70:11554

ORIGINAL REFERENCE NO.: 70:2159a,2162a

TITLE: Photocyclizations of pharmacodynamic amines. II.
X-ray analysis of a noncentrosymmetric tetracyclic indoleAUTHOR(S): Yonemitsu, Osamu; Okuno, Yohmei; Kanaoka, Yuichi;
Karle, Isabella L.; Witkop, Bernhard

CORPORATE SOURCE: Fac. Pharm. Sci., Hokkaido Univ., Sapporo, Japan

SOURCE: Journal of the American Chemical Society (1968),
90(23), 6522-3

CODEN: JACSAT; ISSN: 0002-7863

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 70:11554

GI For diagram(s), see printed CA Issue.


AB Two novel photocyclizations of 3,4,-MeOC₆H₃-(CH₂)₂NHCOCH₂Cl (I), the
catatonic compound implied as a metabolite in schizophrenia, are described.
Irradiation of I in aqueous EtOH gives the isomeric benzazepines, II (R = H,R' =
OMe) and II (R = OMe, R' = H), along with a 10-12% yield of III. Irradiation
of I in tetrahydrofuran, on the other hand, gave the products described
above along with IV as the major product. Several reactions of the
products are described.

IT 20925-65-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 20925-65-9 CAPLUS

CN 2H-3-Benzazepin-2-one, 1,3,4,5-tetrahydro-8,9-dimethoxy- (CA INDEX NAME)

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L27 ANSWER 107 OF 107 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1968:87523 CAPLUS

DOCUMENT NUMBER: 68:87523

ORIGINAL REFERENCE NO.: 68:16907a,16910a

TITLE: Photocyclizations of tyrosines, tyramines, catechol amines, and normescaline

AUTHOR(S): Yonemitsu, Osamu; Tokuyama, Takashi; Chaykovsky, Michael; Witkop, Bernhard

CORPORATE SOURCE: Natl. Inst. of Arthritis and Metab. Diseases, Natl. Insts. of Health Bethesda, Bethesda, MD, USA

SOURCE: Journal of the American Chemical Society (1968), 90(3), 776-84

CODEN: JACSAT; ISSN: 0002-7863

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 68:87523

GI For diagram(s), see printed CA Issue.


AB N-Chloroacetyl-m-tyramine and m-tyrosine on irradiation in aqueous solution are photocyclized to 7-hydroxy-1,2,4,5-tetrahydro-3H-3-benzazepin-2-one and its 4-carboxy derivative (I) resp., which are methylated to the 7-methoxy-(II) and 7-methoxy-4-carbomethoxy derivative II is reduced to 7-methoxy-1,2,4,5-tetrahydro-3H-3-benzazepine by diborane in tetrahydrofuran. N-Chloroacetyl-p-O-methyltyramine and p-O-methyl-L-tyrosine on irradiation in aqueous solution undergo a deepseated photolytic rearrangement to yield 7-formyl-1,2,5,6-tetrahydro-3H-pyrrolo[1,2-a]azepin-3-one and L-5-carboxy-7-formyl-1,2,5,6-tetrahydro-3H-pyrrolo[1,2-a]azepin-3-one (III). The structure of III, an asym. mol., was determined by x-ray crystallography of the Me ester without the benefit of a heavy atom. N-Chloroacetyl-3,4-dihydroxyphenethylamine undergoes photocyclization with ring closure into the two positions para and ortho to the m-hydroxy group. After acetylation the crystalline photocyclization products were N-acetyl-7,8-diacetoxy-1,2,4,5-tetrahydro-3H-3-benzazepin-2-one and N-acetyl-8,9-diacetoxy-1,2,4,5-tetrahydro-3H-3-benzazepin-2-one. N-Chloroacetyl-3-hydroxy-4,5-dimethoxyphenethylamine, a derivative of normescaline, on irradiation gave a single product, the anhalonidine analog 7,8-dimethoxy-9-hydroxy-1,2,4,5-tetrahydro-3H-3-benzazepin-2-one, resulting from photocyclization into the position ortho to the phenolic hydroxyl. N-Chloroacetyl-, N-bromoacetyl-, and N-iodoacetylmescalines in preliminary photocyclization attempts were converted to N-acetylmescaline. N-Chloroacetyl-3,5-dibromotyrosine on irradiation gave no identifiable products. 17 references.

IT 17639-61-1

RL: PRP (Properties)
(nuclear magnetic resonance of)


RN 17639-61-1 CAPLUS

CN 2H-3-Benzazepin-2-one, 3-acetyl-9-(acetyloxy)-1,3,4,5-tetrahydro-7,8-dimethoxy- (CA INDEX NAME)




10/598,302

IT 17639-54-2P 17639-56-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and N.M.R. of)
RN 17639-54-2 CAPLUS
CN 2H-3-Benzazepin-2-one, 3-acetyl-8,9-bis(acetyloxy)-1,3,4,5-tetrahydro-
(CA INDEX NAME)




RN 17639-56-4 CAPLUS
CN 2H-3-Benzazepin-2-one, 1,3,4,5-tetrahydro-9-hydroxy-7,8-dimethoxy- (CA
INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)

10/598,302


L20 ANSWER 729 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN
RN 73942-94-6 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1H-3-Benzazepine-7,8-diol, 6-[(4-chlorophenyl)thio]-2,3,4,5-tetrahydro-3-methyl- (CA INDEX NAME)
MF C17 H18 Cl N O2 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302


L20 ANSWER 700 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN
RN 775535-88-1 REGISTRY
ED Entered STN: 07 Nov 2004
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-methyl-6-(2-propen-1-ylthio)- (CA
INDEX NAME)
OTHER CA INDEX NAMES:
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-methyl-6-(2-propenylthio)- (9CI)
MF C14 H19 N S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302


L20 ANSWER 675 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN
RN 864252-46-0 REGISTRY
ED Entered STN: 30 Sep 2005
CN 1H-3-Benzazepin-6-amine, 7-chloro-N-[[4-(1,1-dimethylethyl)phenyl]methyl]-
2,3,4,5-tetrahydro- (CA INDEX NAME)
MF C21 H27 Cl N2
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302


L20 ANSWER 685 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN
RN 864251-76-3 REGISTRY
ED Entered STN: 30 Sep 2005
CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-[3-(methylthio)propoxy]-
(CA INDEX NAME)
MF C14 H20 Cl N O S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302


L20 ANSWER 695 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN
RN 787509-42-6 REGISTRY
ED Entered STN: 23 Nov 2004
CN 1H-3-Benzazepin-7-ol, 2,3,4,5-tetrahydro-6-(methylsulfonyl)- (CA INDEX
NAME)
MF C11 H15 N O3 S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302


L20 ANSWER 686 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN
RN 864251-70-7 REGISTRY
ED Entered STN: 30 Sep 2005
CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-(3-pyridinylmethoxy)- (CA
INDEX NAME)
MF C16 H17 Cl N2 O
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302


L20 ANSWER 687 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN
RN 864251-68-3 REGISTRY
ED Entered STN: 30 Sep 2005
CN 1H-3-Benzazepine, 7-chloro-2,3,4,5-tetrahydro-6-(2-pyridinylmethoxy)- (CA
INDEX NAME)
MF C16 H17 Cl N2 O
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302

L20 ANSWER 688 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN
RN 864251-60-5 REGISTRY
ED Entered STN: 30 Sep 2005
CN 1H-3-Benzazepine, 7-chloro-6-[(4-fluorophenyl)methoxy]-2,3,4,5-tetrahydro-
(CA INDEX NAME)
MF C17 H17 Cl F N O
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302

L20 ANSWER 689 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN

RN 864251-58-1 REGISTRY

ED Entered STN: 30 Sep 2005

CN 1H-3-Benzazepine, 6-(3,3-dimethyl-1-butyn-1-yl)-7-fluoro-2,3,4,5-tetrahydro- (CA INDEX NAME)


OTHER CA INDEX NAMES:

CN 1H-3-Benzazepine, 6-(3,3-dimethyl-1-butynyl)-7-fluoro-2,3,4,5-tetrahydro- (9CI)

MF C16 H20 F N

CI COM


SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302


L20 ANSWER 690 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN
RN 864251-56-9 REGISTRY
ED Entered STN: 30 Sep 2005
CN 1H-3-Benzazepine, 6-(3,3-dimethyl-1-butyn-1-yl)-2,3,4,5-tetrahydro- (CA
INDEX NAME)
OTHER CA INDEX NAMES:
CN 1H-3-Benzazepine, 6-(3,3-dimethyl-1-butynyl)-2,3,4,5-tetrahydro- (9CI)
MF C16 H21 N
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302


L20 ANSWER 691 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN
RN 791730-05-7 REGISTRY
ED Entered STN: 02 Dec 2004
CN 1H-3-Benzazepine-7,8-diol, 6-(ethylthio)-2,3,4,5-tetrahydro-1-phenyl- (CA
INDEX NAME)
MF C18 H21 N O2 S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302


L20 ANSWER 692 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN
RN 790179-42-9 REGISTRY
ED Entered STN: 28 Nov 2004
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-6-nitro- (CA INDEX NAME)
MF C11 H14 N2 O3
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302

L20 ANSWER 693 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN
RN 789440-83-1 REGISTRY
ED Entered STN: 26 Nov 2004
CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-6-(methylsulfonyl)-1-phenyl-
(CA INDEX NAME)
MF C17 H19 N O4 S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302

L20 ANSWER 694 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN

RN 788774-20-9 REGISTRY

ED Entered STN: 25 Nov 2004

CN 3H-3-Benzazepine-7,8-diol, 1,2,4,5-tetrahydro-3-(2-hydroxyethyl)-6-(phenylthio)- (CA INDEX NAME)


OTHER CA INDEX NAMES:

CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-3-(2-hydroxyethyl)-6-(phenylthio)- (9CI)

MF C18 H21 N O3 S

CI COM


SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302


L20 ANSWER 696 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN
RN 785728-24-7 REGISTRY
ED Entered STN: 21 Nov 2004
CN 1H-3-Benzazepine-6,7,8-triol, 2,3,4,5-tetrahydro-1-phenyl- (CA INDEX
NAME)
MF C16 H17 N O3
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302


L20 ANSWER 697 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN
RN 781565-14-8 REGISTRY
ED Entered STN: 15 Nov 2004
CN 1H-3-Benzazepine-7,8-diol, 6-(ethylthio)-2,3,4,5-tetrahydro- (CA INDEX
NAME)
MF C12 H17 N O2 S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302


L20 ANSWER 698 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN
RN 780701-87-3 REGISTRY
ED Entered STN: 14 Nov 2004
CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-6-[(1-methylethyl)thio]-1-phenyl- (CA INDEX NAME)
MF C19 H23 N O2 S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302

L20 ANSWER 699 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN
RN 776276-77-8 REGISTRY
ED Entered STN: 08 Nov 2004
CN Benzamide, 4-(1,1-dimethylethyl)-2-methoxy-N-(2,3,4,5-tetrahydro-3-methyl-
1H-3-benzazepin-6-yl)- (CA INDEX NAME)
MF C23 H30 N2 O2
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302

L20 ANSWER 701 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN

RN 769069-77-4 REGISTRY

ED Entered STN: 25 Oct 2004

CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-6-(phenylthio)-3-(2-propen-1-yl)- (CA INDEX NAME)


OTHER CA INDEX NAMES:

CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-6-(phenylthio)-3-(2-propenyl)- (9CI)

MF C19 H21 N O2 S

CI COM


SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302


L20 ANSWER 702 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN
RN 767580-38-1 REGISTRY
ED Entered STN: 22 Oct 2004
CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-6-[(1-methylethyl)thio]-
(CA INDEX NAME)
MF C13 H19 N O2 S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302


L20 ANSWER 703 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN
RN 767578-90-5 REGISTRY
ED Entered STN: 22 Oct 2004
CN 1H-3-Benzazepine-6,7-diol, 9-chloro-2,3,4,5-tetrahydro-5-phenyl- (CA
INDEX NAME)
MF C16 H16 Cl N O2
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302


L20 ANSWER 704 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN
RN 765220-86-8 REGISTRY
ED Entered STN: 18 Oct 2004
CN 1H-3-Benzazepin-6-amine, 2,3,4,5-tetrahydro-3-methyl-9-(phenylthio)- (CA
INDEX NAME)
MF C17 H20 N2 S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302


L20 ANSWER 705 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN
RN 760892-96-4 REGISTRY
ED Entered STN: 11 Oct 2004
CN 1H-3-Benzazepine-7,8-diol, 9-(ethylthio)-2,3,4,5-tetrahydro-1-phenyl- (CA
INDEX NAME)
MF C18 H21 N O2 S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302


L20 ANSWER 706 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN
RN 756765-88-5 REGISTRY
ED Entered STN: 04 Oct 2004
CN 1H-3-Benzazepine-7,8-diol, 6-(butylthio)-2,3,4,5-tetrahydro-1-phenyl- (CA
INDEX NAME)
MF C20 H25 N O2 S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302


L20 ANSWER 707 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN
RN 756426-71-8 REGISTRY
ED Entered STN: 03 Oct 2004
CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-6-(phenylthio)- (CA INDEX
NAME)
MF C16 H17 N O2 S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302


L20 ANSWER 708 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN
RN 753401-75-1 REGISTRY
ED Entered STN: 28 Sep 2004
CN 1H-3-Benzazepine-7,8-diol, 6-(2-furanylthio)-2,3,4,5-tetrahydro-3-methyl-
(CA INDEX NAME)
MF C15 H17 N O3 S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302


L20 ANSWER 709 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN
RN 752929-24-1 REGISTRY
ED Entered STN: 27 Sep 2004
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-8,9-dimethoxy-1-phenyl- (CA INDEX
NAME)
MF C18 H21 N O2
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302


L20 ANSWER 710 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN
RN 752153-27-8 REGISTRY
ED Entered STN: 26 Sep 2004
CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-6-(methylsulfinyl)-1-phenyl-
(CA INDEX NAME)
MF C17 H19 N O3 S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302


L20 ANSWER 711 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN
RN 751426-14-9 REGISTRY
ED Entered STN: 24 Sep 2004
CN 1H-3-Benzazepine-6,7-diol, 2,3,4,5-tetrahydro-5-phenyl- (CA INDEX NAME)
MF C16 H17 N O2
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302


L20 ANSWER 712 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN
RN 743373-78-6 REGISTRY
ED Entered STN: 12 Sep 2004
CN 1H-3-Benzazepin-6-amine, 9-[(4-fluorophenyl)thio]-2,3,4,5-tetrahydro-3-methyl- (CA INDEX NAME)
MF C17 H19 F N2 S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302


L20 ANSWER 713 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN
RN 742664-14-8 REGISTRY
ED Entered STN: 12 Sep 2004
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-3-methyl-6-(phenylthio)-
(CA INDEX NAME)
MF C18 H21 N O S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302


L20 ANSWER 714 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN
RN 737731-98-5 REGISTRY
ED Entered STN: 02 Sep 2004
CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(2-phenylethoxy)-
(CA INDEX NAME)
MF C19 H22 Cl N O
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302

L20 ANSWER 715 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN
RN 737721-14-1 REGISTRY
ED Entered STN: 02 Sep 2004
CN 1H-3-Benzazepin-6-ol, 2,3,4,5-tetrahydro-3-methyl-8-(methylsulfonyl)- (CA
INDEX NAME)
MF C12 H17 N O3 S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302

L20 ANSWER 716 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN

RN 734487-27-5 REGISTRY

ED Entered STN: 27 Aug 2004

CN 1H-3-Benzazepine-7,8-diol, 6-(cyclohexylthio)-2,3,4,5-tetrahydro-3-methyl-, 7,8-diacetate (CA INDEX NAME)


OTHER CA INDEX NAMES:

CN 1H-3-Benzazepine-7,8-diol, 6-(cyclohexylthio)-2,3,4,5-tetrahydro-3-methyl-, diacetate (ester) (9CI)

MF C21 H29 N O4 S

CI COM


SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302


L20 ANSWER 717 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN
RN 716307-62-9 REGISTRY
ED Entered STN: 25 Jul 2004
CN 1H-3-Benzazepin-6-ol, 2,3,4,5-tetrahydro-5-phenyl- (CA INDEX NAME)
MF C16 H17 N O
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302


L20 ANSWER 718 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN
RN 714188-21-3 REGISTRY
ED Entered STN: 21 Jul 2004
CN 1H-3-Benzazepine-7,8-diol, 9-(butylthio)-2,3,4,5-tetrahydro-1-phenyl- (CA
INDEX NAME)
MF C20 H25 N O2 S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302


L20 ANSWER 719 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN
RN 710271-40-2 REGISTRY
ED Entered STN: 14 Jul 2004
CN 1H-3-Benzazepine, 6-chloro-9-[(4-fluorophenyl)thio]-2,3,4,5-tetrahydro-3-methyl- (CA INDEX NAME)
MF C17 H17 Cl F N S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302


L20 ANSWER 720 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN
RN 708966-44-3 REGISTRY
ED Entered STN: 12 Jul 2004
CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-9-[(1-methylethyl)thio]-1-phenyl- (CA INDEX NAME)
MF C19 H23 N O2 S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302

L20 ANSWER 721 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN
RN 699528-14-8 REGISTRY
ED Entered STN: 25 Jun 2004
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-6-(methylthio)-1-(2-thienyl)- (CA
INDEX NAME)
MF C15 H17 N S2
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302

L20 ANSWER 722 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN

RN 689732-75-0 REGISTRY

ED Entered STN: 04 Jun 2004

CN 1H-3-Benzazepin-7-ol, 2,3,4,5-tetrahydro-8-methoxy-3-methyl-9-(phenylthio)-
, 7-acetate (CA INDEX NAME)


OTHER CA INDEX NAMES:

CN 1H-3-Benzazepin-7-ol, 2,3,4,5-tetrahydro-8-methoxy-3-methyl-9-(phenylthio)-
, acetate (ester) (9CI)

MF C20 H23 N O3 S

CI COM


SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302


L20 ANSWER 723 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN
RN 409327-22-6 REGISTRY
ED Entered STN: 01 May 2002
CN Ethanone, 1-(8-bromo-1,2,4,5-tetrahydro-9-methoxy-1-phenyl-3H-3-benzazepin-3-yl)-2,2,2-trifluoro- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1H-3-Benzazepine, 8-bromo-2,3,4,5-tetrahydro-9-methoxy-1-phenyl-3-(trifluoroacetyl)- (9CI)
MF C19 H17 Br F3 N O2
SR Reaction Database



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302

L20 ANSWER 724 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN
RN 408337-79-1 REGISTRY
ED Entered STN: 26 Apr 2002
CN Ethanone, 2,2,2-trifluoro-1-[1,2,4,5-tetrahydro-9-methoxy-1-phenyl-8-(trifluoromethyl)-3H-3-benzazepin-3-yl]- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-9-methoxy-1-phenyl-3-(trifluoroacetyl)-8-(trifluoromethyl)- (9CI)
MF C20 H17 F6 N O2
SR Reaction Database



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302

L20 ANSWER 725 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN

RN 408337-73-5 REGISTRY

ED Entered STN: 26 Apr 2002


CN Ethanone, 2,2,2-trifluoro-1-[1,2,4,5-tetrahydro-9-hydroxy-1-phenyl-8-(trifluoromethyl)-3H-3-benzazepin-3-yl]- (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 1H-3-Benzazepin-6-ol, 2,3,4,5-tetrahydro-5-phenyl-3-(trifluoroacetyl)-7-(trifluoromethyl)- (9CI)

MF C19 H15 F6 N O2

SR Reaction Database




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302

L20 ANSWER 726 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN
RN 237065-98-4 REGISTRY
ED Entered STN: 03 Sep 1999
CN 1,2-Propanediol, 3-[4-[3-[[3-[(9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-6-yl)oxy]propyl]thio]-2-hydroxypropoxy]butoxy]- (CA INDEX NAME)
MF C24 H40 Cl N O6 S
CI COM
SR CA

PAGE 1-A




PAGE 1-B

— OH

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302

L20 ANSWER 727 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN
RN 149299-31-0 REGISTRY
ED Entered STN: 13 Aug 1993
CN 1H-3-Benzazepine, 6-chloro-9-[(2,3-dihydro-1,4-benzodioxin-2-yl)methoxy]-
2,3,4,5-tetrahydro-3-methyl- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1,4-Benzodioxin, 1H-3-benzazepine deriv.
MF C20 H22 Cl N O3
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,302

L20 ANSWER 728 OF 729 REGISTRY COPYRIGHT 2010 ACS on STN

RN 73942-98-0 REGISTRY

ED Entered STN: 16 Nov 1984


CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-3-methyl-6-(phenylthio)-,
7,8-diacetate (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-3-methyl-6-(phenylthio)-,
diacetate (ester) (9CI)

MF C21 H23 N O4 S

CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT